WO2024112492A1 - Compositions comprising antibody cleaving enzymes and method of using the same - Google Patents
Compositions comprising antibody cleaving enzymes and method of using the same Download PDFInfo
- Publication number
- WO2024112492A1 WO2024112492A1 PCT/US2023/078407 US2023078407W WO2024112492A1 WO 2024112492 A1 WO2024112492 A1 WO 2024112492A1 US 2023078407 W US2023078407 W US 2023078407W WO 2024112492 A1 WO2024112492 A1 WO 2024112492A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- disclosed
- igm
- sequence
- nucleic acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 102000004190 Enzymes Human genes 0.000 title claims description 532
- 108090000790 Enzymes Proteins 0.000 title claims description 532
- 150000007523 nucleic acids Chemical class 0.000 claims description 384
- 102000039446 nucleic acids Human genes 0.000 claims description 303
- 108020004707 nucleic acids Proteins 0.000 claims description 303
- 230000000694 effects Effects 0.000 claims description 268
- 108091005804 Peptidases Proteins 0.000 claims description 252
- 239000004365 Protease Substances 0.000 claims description 252
- 239000013598 vector Substances 0.000 claims description 136
- 241000282414 Homo sapiens Species 0.000 claims description 124
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 81
- 230000014509 gene expression Effects 0.000 claims description 66
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 210000000056 organ Anatomy 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 108700019146 Transgenes Proteins 0.000 claims description 28
- 230000004913 activation Effects 0.000 claims description 25
- 230000024203 complement activation Effects 0.000 claims description 20
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 208000023275 Autoimmune disease Diseases 0.000 claims description 15
- 230000009467 reduction Effects 0.000 claims description 14
- 238000001415 gene therapy Methods 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 11
- 230000001052 transient effect Effects 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 230000001976 improved effect Effects 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000005847 immunogenicity Effects 0.000 claims description 5
- 238000009256 replacement therapy Methods 0.000 claims description 5
- 230000003292 diminished effect Effects 0.000 claims description 4
- 238000002641 enzyme replacement therapy Methods 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 9
- 238000001727 in vivo Methods 0.000 abstract description 5
- 229940088598 enzyme Drugs 0.000 description 512
- 229940027941 immunoglobulin g Drugs 0.000 description 245
- 102000035195 Peptidases Human genes 0.000 description 243
- 235000019419 proteases Nutrition 0.000 description 243
- 239000012634 fragment Substances 0.000 description 140
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 102
- 239000008194 pharmaceutical composition Substances 0.000 description 75
- 201000010099 disease Diseases 0.000 description 53
- 208000035475 disorder Diseases 0.000 description 49
- 208000026350 Inborn Genetic disease Diseases 0.000 description 42
- 208000016361 genetic disease Diseases 0.000 description 42
- 210000003719 b-lymphocyte Anatomy 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 35
- 125000003729 nucleotide group Chemical group 0.000 description 32
- -1 kits Substances 0.000 description 31
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
- 239000002773 nucleotide Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 239000000427 antigen Substances 0.000 description 25
- 108020004705 Codon Proteins 0.000 description 24
- 238000011282 treatment Methods 0.000 description 24
- 239000003623 enhancer Substances 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 238000003776 cleavage reaction Methods 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 230000007017 scission Effects 0.000 description 18
- 108010009685 Cholinergic Receptors Proteins 0.000 description 17
- 102000034337 acetylcholine receptors Human genes 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 239000007850 fluorescent dye Substances 0.000 description 16
- 238000003119 immunoblot Methods 0.000 description 16
- 230000006872 improvement Effects 0.000 description 16
- 241000125945 Protoparvovirus Species 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 241000282472 Canis lupus familiaris Species 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 241000701022 Cytomegalovirus Species 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 230000004727 humoral immunity Effects 0.000 description 11
- 101710136329 IgM protease Proteins 0.000 description 10
- 230000000977 initiatory effect Effects 0.000 description 10
- 239000004055 small Interfering RNA Substances 0.000 description 10
- 108091006146 Channels Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 108020004566 Transfer RNA Proteins 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 239000002679 microRNA Substances 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000013607 AAV vector Substances 0.000 description 8
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 238000012384 transportation and delivery Methods 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 241000288906 Primates Species 0.000 description 7
- 210000000234 capsid Anatomy 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 108091027963 non-coding RNA Proteins 0.000 description 7
- 102000042567 non-coding RNA Human genes 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 108700010070 Codon Usage Proteins 0.000 description 6
- 108010021466 Mutant Proteins Proteins 0.000 description 6
- 102000008300 Mutant Proteins Human genes 0.000 description 6
- 108091005461 Nucleic proteins Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 6
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 230000006058 immune tolerance Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 238000002203 pretreatment Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 5
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 5
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 5
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 238000012230 antisense oligonucleotides Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000013401 experimental design Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 108091070501 miRNA Proteins 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 229960002930 sirolimus Drugs 0.000 description 5
- 230000010415 tropism Effects 0.000 description 5
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 4
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 4
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 4
- 101710201279 Biotin carboxyl carrier protein Proteins 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241000282560 Macaca mulatta Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100037385 Phosphoglycerate mutase 2 Human genes 0.000 description 4
- 101710093483 Phosphoglycerate mutase 2 Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000039471 Small Nuclear RNA Human genes 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 3
- 102100024642 ATP-binding cassette sub-family C member 9 Human genes 0.000 description 3
- 108050008988 ATP-binding cassette subfamily C member 9 Proteins 0.000 description 3
- 102100036818 Ankyrin-2 Human genes 0.000 description 3
- 101710191052 Ankyrin-2 Proteins 0.000 description 3
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 108010059081 Cathepsin A Proteins 0.000 description 3
- 102000005572 Cathepsin A Human genes 0.000 description 3
- 102000002734 Collagen Type VI Human genes 0.000 description 3
- 108010043741 Collagen Type VI Proteins 0.000 description 3
- 108010002947 Connectin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 102100038199 Desmoplakin Human genes 0.000 description 3
- 108091000074 Desmoplakin Proteins 0.000 description 3
- 102000004168 Dysferlin Human genes 0.000 description 3
- 108090000620 Dysferlin Proteins 0.000 description 3
- 102100024108 Dystrophin Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100031509 Fibrillin-1 Human genes 0.000 description 3
- 108010030229 Fibrillin-1 Proteins 0.000 description 3
- 102100031510 Fibrillin-2 Human genes 0.000 description 3
- 108010030242 Fibrillin-2 Proteins 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000986621 Homo sapiens ATP-binding cassette sub-family C member 6 Proteins 0.000 description 3
- 101001027628 Homo sapiens Kinesin-like protein KIF21A Proteins 0.000 description 3
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 description 3
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 3
- 101000825933 Homo sapiens Structural maintenance of chromosomes flexible hinge domain-containing protein 1 Proteins 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 102100037688 Kinesin-like protein KIF21A Human genes 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 102100036639 Myosin-11 Human genes 0.000 description 3
- 101710115164 Myosin-11 Proteins 0.000 description 3
- 102100038319 Myosin-6 Human genes 0.000 description 3
- 101710204027 Myosin-6 Proteins 0.000 description 3
- 102100038934 Myosin-7 Human genes 0.000 description 3
- 101710204029 Myosin-7 Proteins 0.000 description 3
- 102100034434 Nebulin Human genes 0.000 description 3
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 description 3
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 3
- 102100030477 Plectin Human genes 0.000 description 3
- 108010054050 Plectin Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100020824 Serine-protein kinase ATM Human genes 0.000 description 3
- 102100023105 Sialin Human genes 0.000 description 3
- 101710105284 Sialin Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 102100022770 Structural maintenance of chromosomes flexible hinge domain-containing protein 1 Human genes 0.000 description 3
- 102100026260 Titin Human genes 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000010001 cellular homeostasis Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000007688 immunotoxicity Effects 0.000 description 3
- 231100000386 immunotoxicity Toxicity 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000010120 metabolic dysregulation Effects 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 108010054130 nebulin Proteins 0.000 description 3
- 108010049224 perlecan Proteins 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XQTLDIFVVHJORV-UHFFFAOYSA-N tecnazene Chemical compound [O-][N+](=O)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl XQTLDIFVVHJORV-UHFFFAOYSA-N 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- PURMPUDWXOWORS-SKNVOMKLSA-N (2r,3s,4s,5r)-2,3,4-trihydroxy-6-oxo-5-sulfooxyhexanoic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](OS(O)(=O)=O)C=O PURMPUDWXOWORS-SKNVOMKLSA-N 0.000 description 2
- HCHFRAXBELVCGG-JYFOCSDGSA-N (2z,3z)-2,3-bis[(4-methoxyphenyl)methylidene]butanedinitrile Chemical compound C1=CC(OC)=CC=C1\C=C(/C#N)\C(\C#N)=C\C1=CC=C(OC)C=C1 HCHFRAXBELVCGG-JYFOCSDGSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102100039791 43 kDa receptor-associated protein of the synapse Human genes 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 102100040084 A-kinase anchor protein 9 Human genes 0.000 description 2
- 101710109922 A-kinase anchor protein 9 Proteins 0.000 description 2
- 102100032123 AMP deaminase 1 Human genes 0.000 description 2
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 2
- 102100032922 ATP-dependent 6-phosphofructokinase, muscle type Human genes 0.000 description 2
- 102100040963 Acetylcholine receptor subunit epsilon Human genes 0.000 description 2
- 102100029271 Acetylcholinesterase collagenic tail peptide Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 101710168746 Ankyrin repeat and LEM domain-containing protein 1 Proteins 0.000 description 2
- 102000000326 Anoctamin-5 Human genes 0.000 description 2
- 108050008799 Anoctamin-5 Proteins 0.000 description 2
- 101100328883 Arabidopsis thaliana COL1 gene Proteins 0.000 description 2
- 102100022146 Arylsulfatase A Human genes 0.000 description 2
- 102100031491 Arylsulfatase B Human genes 0.000 description 2
- 108010023546 Aspartylglucosylaminase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100022440 Battenin Human genes 0.000 description 2
- 102100034732 Beta-1,3-glucuronyltransferase LARGE1 Human genes 0.000 description 2
- 101710093792 Beta-1,3-glucuronyltransferase LARGE1 Proteins 0.000 description 2
- 102100033849 CCHC-type zinc finger nucleic acid binding protein Human genes 0.000 description 2
- 101710116319 CCHC-type zinc finger nucleic acid binding protein Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100025580 Calmodulin-1 Human genes 0.000 description 2
- 101710164735 Calmodulin-1 Proteins 0.000 description 2
- 102100025579 Calmodulin-2 Human genes 0.000 description 2
- 101710164734 Calmodulin-2 Proteins 0.000 description 2
- 102100032539 Calpain-3 Human genes 0.000 description 2
- 108030001375 Calpain-3 Proteins 0.000 description 2
- 102100038613 Calreticulin-3 Human genes 0.000 description 2
- 101710160266 Calreticulin-3 Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 2
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000004171 Cathepsin K Human genes 0.000 description 2
- 108090000625 Cathepsin K Proteins 0.000 description 2
- 102000003904 Caveolin 3 Human genes 0.000 description 2
- 108090000268 Caveolin 3 Proteins 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 2
- 102100023457 Chloride channel protein 1 Human genes 0.000 description 2
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108091028075 Circular RNA Proteins 0.000 description 2
- 102100023470 Cobalamin trafficking protein CblD Human genes 0.000 description 2
- 101710103565 Cobalamin trafficking protein CblD Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000012432 Collagen Type V Human genes 0.000 description 2
- 108010022514 Collagen Type V Proteins 0.000 description 2
- 102100034976 Cystathionine beta-synthase Human genes 0.000 description 2
- 108010073644 Cystathionine beta-synthase Proteins 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 102100031620 Cysteine and glycine-rich protein 3 Human genes 0.000 description 2
- 102100031515 D-ribitol-5-phosphate cytidylyltransferase Human genes 0.000 description 2
- 108010093818 D-ribitol-5-phosphate cytidylyltransferase Proteins 0.000 description 2
- 102100034690 Delta(14)-sterol reductase LBR Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102100036912 Desmin Human genes 0.000 description 2
- 108010044052 Desmin Proteins 0.000 description 2
- 102100040481 Desmocollin-2 Human genes 0.000 description 2
- 101710157873 Desmocollin-2 Proteins 0.000 description 2
- 102000005707 Desmoglein 2 Human genes 0.000 description 2
- 108010045583 Desmoglein 2 Proteins 0.000 description 2
- 102100037713 Down syndrome cell adhesion molecule Human genes 0.000 description 2
- 108010044191 Dynamin II Proteins 0.000 description 2
- 102100021238 Dynamin-2 Human genes 0.000 description 2
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 2
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 2
- 102100038651 Four and a half LIM domains protein 1 Human genes 0.000 description 2
- 102000003869 Frataxin Human genes 0.000 description 2
- 108090000217 Frataxin Proteins 0.000 description 2
- 102100021237 G protein-activated inward rectifier potassium channel 4 Human genes 0.000 description 2
- 102100023364 Ganglioside GM2 activator Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 2
- 102100039684 Glucose-6-phosphate exchanger SLC37A4 Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100039264 Glycogen [starch] synthase, liver Human genes 0.000 description 2
- 102100039262 Glycogen [starch] synthase, muscle Human genes 0.000 description 2
- 102100029481 Glycogen phosphorylase, liver form Human genes 0.000 description 2
- 102100029492 Glycogen phosphorylase, muscle form Human genes 0.000 description 2
- 101710141659 Glycogen synthase 2 Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 108020004996 Heterogeneous Nuclear RNA Proteins 0.000 description 2
- 102000016871 Hexosaminidase A Human genes 0.000 description 2
- 108010053317 Hexosaminidase A Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108010090007 Homeobox Protein Nkx-2.5 Proteins 0.000 description 2
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000744504 Homo sapiens 43 kDa receptor-associated protein of the synapse Proteins 0.000 description 2
- 101000775844 Homo sapiens AMP deaminase 1 Proteins 0.000 description 2
- 101000760602 Homo sapiens ATP-binding cassette sub-family D member 1 Proteins 0.000 description 2
- 101000730838 Homo sapiens ATP-dependent 6-phosphofructokinase, muscle type Proteins 0.000 description 2
- 101000965233 Homo sapiens Acetylcholine receptor subunit epsilon Proteins 0.000 description 2
- 101000770471 Homo sapiens Acetylcholinesterase collagenic tail peptide Proteins 0.000 description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
- 101000906651 Homo sapiens Chloride channel protein 1 Proteins 0.000 description 2
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 description 2
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 2
- 101001031607 Homo sapiens Four and a half LIM domains protein 1 Proteins 0.000 description 2
- 101000614712 Homo sapiens G protein-activated inward rectifier potassium channel 4 Proteins 0.000 description 2
- 101000685969 Homo sapiens Ganglioside GM2 activator Proteins 0.000 description 2
- 101000930910 Homo sapiens Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 2
- 101000886173 Homo sapiens Glucose-6-phosphate exchanger SLC37A4 Proteins 0.000 description 2
- 101000700616 Homo sapiens Glycogen phosphorylase, liver form Proteins 0.000 description 2
- 101000700475 Homo sapiens Glycogen phosphorylase, muscle form Proteins 0.000 description 2
- 101000944277 Homo sapiens Inward rectifier potassium channel 2 Proteins 0.000 description 2
- 101001023021 Homo sapiens LIM domain-binding protein 3 Proteins 0.000 description 2
- 101000575454 Homo sapiens Major facilitator superfamily domain-containing protein 8 Proteins 0.000 description 2
- 101000584208 Homo sapiens Myosin light chain kinase 2, skeletal/cardiac muscle Proteins 0.000 description 2
- 101000958744 Homo sapiens Myosin-7B Proteins 0.000 description 2
- 101001066305 Homo sapiens N-acetylgalactosamine-6-sulfatase Proteins 0.000 description 2
- 101000829992 Homo sapiens N-acetylglucosamine-6-sulfatase Proteins 0.000 description 2
- 101000604411 Homo sapiens NADH-ubiquinone oxidoreductase chain 1 Proteins 0.000 description 2
- 101000598279 Homo sapiens NADH-ubiquinone oxidoreductase chain 5 Proteins 0.000 description 2
- 101000637240 Homo sapiens Neurite extension and migration factor Proteins 0.000 description 2
- 101000637249 Homo sapiens Nexilin Proteins 0.000 description 2
- 101000731078 Homo sapiens Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Proteins 0.000 description 2
- 101000945272 Homo sapiens Phosphorylase b kinase regulatory subunit alpha, liver isoform Proteins 0.000 description 2
- 101000945267 Homo sapiens Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform Proteins 0.000 description 2
- 101000609211 Homo sapiens Polyadenylate-binding protein 2 Proteins 0.000 description 2
- 101001032038 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Proteins 0.000 description 2
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 2
- 101000845685 Homo sapiens Protein Dok-7 Proteins 0.000 description 2
- 101001094684 Homo sapiens Protein O-mannosyl-transferase 2 Proteins 0.000 description 2
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
- 101000936731 Homo sapiens Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Proteins 0.000 description 2
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 101001123859 Homo sapiens Sialidase-1 Proteins 0.000 description 2
- 101001034303 Homo sapiens Solute carrier family 2, facilitated glucose transporter member 10 Proteins 0.000 description 2
- 101000597193 Homo sapiens Telethonin Proteins 0.000 description 2
- 101000837639 Homo sapiens Thyroxine-binding globulin Proteins 0.000 description 2
- 102000030513 Homogentisate 1,2-Dioxygenase Human genes 0.000 description 2
- 108700023439 Homogentisate 1,2-dioxygenases Proteins 0.000 description 2
- 102100039283 Hyaluronidase-1 Human genes 0.000 description 2
- 101710199679 Hyaluronidase-1 Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 102000004627 Iduronidase Human genes 0.000 description 2
- 108010003381 Iduronidase Proteins 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100028799 Inner nuclear membrane protein Man1 Human genes 0.000 description 2
- 101710087161 Inner nuclear membrane protein Man1 Proteins 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- 102100023915 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 101800001691 Inter-alpha-trypsin inhibitor light chain Proteins 0.000 description 2
- 102100033114 Inward rectifier potassium channel 2 Human genes 0.000 description 2
- 102000012322 Junction plakoglobin Human genes 0.000 description 2
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 2
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 description 2
- 102100035112 LIM domain-binding protein 3 Human genes 0.000 description 2
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010021101 Lamin Type B Proteins 0.000 description 2
- 102100022743 Laminin subunit alpha-4 Human genes 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 2
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 2
- 102100025613 Major facilitator superfamily domain-containing protein 8 Human genes 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000001696 Mannosidases Human genes 0.000 description 2
- 108010054377 Mannosidases Proteins 0.000 description 2
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 2
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 description 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- 102100026502 Mucolipin-1 Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102100021970 Myc box-dependent-interacting protein 1 Human genes 0.000 description 2
- 101710146921 Myc box-dependent-interacting protein 1 Proteins 0.000 description 2
- 102100026786 Myopalladin Human genes 0.000 description 2
- 101710189520 Myopalladin Proteins 0.000 description 2
- 102100030971 Myosin light chain 3 Human genes 0.000 description 2
- 101710193416 Myosin light chain 3 Proteins 0.000 description 2
- 102100030788 Myosin light chain kinase 2, skeletal/cardiac muscle Human genes 0.000 description 2
- 101710101143 Myosin light polypeptide 6 Proteins 0.000 description 2
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 2
- 102100038322 Myosin-7B Human genes 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 2
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 2
- 102100038900 Myozenin-2 Human genes 0.000 description 2
- 101710132256 Myozenin-2 Proteins 0.000 description 2
- 102100021003 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase Human genes 0.000 description 2
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 2
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 2
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 description 2
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 2
- 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 2
- 102100033341 N-acetylmannosamine kinase Human genes 0.000 description 2
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 description 2
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 description 2
- 102100038625 NADH-ubiquinone oxidoreductase chain 1 Human genes 0.000 description 2
- 102100036971 NADH-ubiquinone oxidoreductase chain 5 Human genes 0.000 description 2
- 102100031810 Neurite extension and migration factor Human genes 0.000 description 2
- 102100031801 Nexilin Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100031686 Paired mesoderm homeobox protein 2A Human genes 0.000 description 2
- 101710187404 Paired mesoderm homeobox protein 2A Proteins 0.000 description 2
- 102000005327 Palmitoyl protein thioesterase Human genes 0.000 description 2
- 108020002591 Palmitoyl protein thioesterase Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 2
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 2
- 102100032391 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Human genes 0.000 description 2
- 102100033548 Phosphorylase b kinase regulatory subunit alpha, liver isoform Human genes 0.000 description 2
- 102100033547 Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform Human genes 0.000 description 2
- 108010057275 Plakophilins Proteins 0.000 description 2
- 102000003753 Plakophilins Human genes 0.000 description 2
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 2
- 102100038718 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Human genes 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 102100026531 Prelamin-A/C Human genes 0.000 description 2
- 102100032859 Protein AMBP Human genes 0.000 description 2
- 102100031135 Protein Dok-7 Human genes 0.000 description 2
- 102100028655 Protein O-mannose kinase Human genes 0.000 description 2
- 101710086532 Protein O-mannose kinase Proteins 0.000 description 2
- 102100028120 Protein O-mannosyl-transferase 1 Human genes 0.000 description 2
- 101710093787 Protein O-mannosyl-transferase 1 Proteins 0.000 description 2
- 102100035490 Protein O-mannosyl-transferase 2 Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 102100031774 Ribitol 5-phosphate transferase FKRP Human genes 0.000 description 2
- 101710087595 Ribitol 5-phosphate transferase FKRP Proteins 0.000 description 2
- 102100031754 Ribitol-5-phosphate transferase FKTN Human genes 0.000 description 2
- 101710087566 Ribitol-5-phosphate transferase FKTN Proteins 0.000 description 2
- 102100035179 Ribitol-5-phosphate xylosyltransferase 1 Human genes 0.000 description 2
- 101710161553 Ribitol-5-phosphate xylosyltransferase 1 Proteins 0.000 description 2
- 108010083379 Sarcoglycans Proteins 0.000 description 2
- 102000006308 Sarcoglycans Human genes 0.000 description 2
- 102100027697 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Human genes 0.000 description 2
- 101710166136 Selenocysteine insertion sequence-binding protein 2 Proteins 0.000 description 2
- 102100026077 Selenocysteine insertion sequence-binding protein 2 Human genes 0.000 description 2
- 102100023781 Selenoprotein N Human genes 0.000 description 2
- 101710095024 Selenoprotein N Proteins 0.000 description 2
- 102100021119 Serine protease HTRA1 Human genes 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- 102100028760 Sialidase-1 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100037190 Sodium-dependent neutral amino acid transporter B(0)AT1 Human genes 0.000 description 2
- 101710168080 Sodium-dependent neutral amino acid transporter B(0)AT1 Proteins 0.000 description 2
- 108010038615 Solute Carrier Family 22 Member 5 Proteins 0.000 description 2
- 102100039670 Solute carrier family 2, facilitated glucose transporter member 10 Human genes 0.000 description 2
- 102100036924 Solute carrier family 22 member 5 Human genes 0.000 description 2
- 102000000019 Sterol Esterase Human genes 0.000 description 2
- 108010055297 Sterol Esterase Proteins 0.000 description 2
- 108090000532 Stromal Interaction Molecule 1 Proteins 0.000 description 2
- 102100035557 Stromal interaction molecule 1 Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009273 T-cell dependend antibody response Effects 0.000 description 2
- 102100026508 Tafazzin Human genes 0.000 description 2
- 101710175789 Tafazzin Proteins 0.000 description 2
- 102100035155 Telethonin Human genes 0.000 description 2
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 102100028709 Thyroxine-binding globulin Human genes 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 102100033530 Transmembrane protein 43 Human genes 0.000 description 2
- 101710106890 Transmembrane protein 43 Proteins 0.000 description 2
- 102000009190 Transthyretin Human genes 0.000 description 2
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 description 2
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 description 2
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 description 2
- 101710128188 Tropomyosin alpha-1 chain Proteins 0.000 description 2
- 102100033080 Tropomyosin alpha-3 chain Human genes 0.000 description 2
- 101710091952 Tropomyosin alpha-3 chain Proteins 0.000 description 2
- 101710186379 Tropomyosin-1 Proteins 0.000 description 2
- 102000013534 Troponin C Human genes 0.000 description 2
- 102000004987 Troponin T Human genes 0.000 description 2
- 108090001108 Troponin T Proteins 0.000 description 2
- 102100038413 UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase Human genes 0.000 description 2
- 108010024501 UDPacetylglucosamine-dolichyl-phosphate acetylglucosamine-1-phosphate transferase Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 102100038983 Xylosyltransferase 1 Human genes 0.000 description 2
- 108050007995 Xylosyltransferase 1 Proteins 0.000 description 2
- 102100032728 Xylosyltransferase 2 Human genes 0.000 description 2
- 101710199598 Xylosyltransferase 2 Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 108010023942 cysteine and glycine-rich protein 3 Proteins 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000005045 desmin Anatomy 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000695 excitation spectrum Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 108010084448 gamma Catenin Proteins 0.000 description 2
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006057 immunotolerant effect Effects 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000017730 intein-mediated protein splicing Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
- 108010012212 junctophilin Proteins 0.000 description 2
- 102000019028 junctophilin Human genes 0.000 description 2
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108010022838 lamin B receptor Proteins 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108010065781 myosin light chain 2 Proteins 0.000 description 2
- 108010059725 myosin-binding protein C Proteins 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108010059929 phospholamban Proteins 0.000 description 2
- 102000005681 phospholamban Human genes 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 2
- 108010011110 polyarginine Proteins 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- WMLBMYGMIFJTCS-HUROMRQRSA-N (2r,3s,5r)-2-[(9-phenylxanthen-9-yl)oxymethyl]-5-purin-9-yloxolan-3-ol Chemical compound C([C@H]1O[C@H](C[C@@H]1O)N1C2=NC=NC=C2N=C1)OC1(C2=CC=CC=C2OC2=CC=CC=C21)C1=CC=CC=C1 WMLBMYGMIFJTCS-HUROMRQRSA-N 0.000 description 1
- WDVIDPRACNGFPP-QWRGUYRKSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WDVIDPRACNGFPP-QWRGUYRKSA-N 0.000 description 1
- QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 description 1
- 102100028734 1,4-alpha-glucan-branching enzyme Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102100038028 1-phosphatidylinositol 3-phosphate 5-kinase Human genes 0.000 description 1
- 102100030492 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 Human genes 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 102100036563 26S proteasome regulatory subunit 8 Human genes 0.000 description 1
- 108700036240 26S proteasome regulatory subunit 8 Proteins 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102100024626 5'-AMP-activated protein kinase subunit gamma-2 Human genes 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 108010011122 A Kinase Anchor Proteins Proteins 0.000 description 1
- 102000014022 A Kinase Anchor Proteins Human genes 0.000 description 1
- 102100032290 A disintegrin and metalloproteinase with thrombospondin motifs 13 Human genes 0.000 description 1
- 108091005670 ADAMTS13 Proteins 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 102100024053 AP-4 complex accessory subunit RUSC2 Human genes 0.000 description 1
- 102100024408 AT-hook DNA-binding motif-containing protein 1 Human genes 0.000 description 1
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 description 1
- 102100034571 AT-rich interactive domain-containing protein 1B Human genes 0.000 description 1
- 102100023157 AT-rich interactive domain-containing protein 2 Human genes 0.000 description 1
- 102100036618 ATP-binding cassette sub-family A member 13 Human genes 0.000 description 1
- 102100033618 ATP-binding cassette sub-family A member 2 Human genes 0.000 description 1
- 102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 description 1
- 102100024645 ATP-binding cassette sub-family C member 8 Human genes 0.000 description 1
- 102100036450 ATP-dependent RNA helicase TDRD9 Human genes 0.000 description 1
- 101150020330 ATRX gene Proteins 0.000 description 1
- 102100022117 Abnormal spindle-like microcephaly-associated protein Human genes 0.000 description 1
- 102100022729 Acetylcholine receptor subunit delta Human genes 0.000 description 1
- 108020005296 Acid Ceramidase Proteins 0.000 description 1
- 102100024005 Acid ceramidase Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 241000649047 Adeno-associated virus 12 Species 0.000 description 1
- 241000300529 Adeno-associated virus 13 Species 0.000 description 1
- 102100032157 Adenylate cyclase type 10 Human genes 0.000 description 1
- 102100036799 Adhesion G-protein coupled receptor V1 Human genes 0.000 description 1
- 101710096099 Adhesion G-protein coupled receptor V1 Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100040026 Agrin Human genes 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 102100033806 Alpha-protein kinase 3 Human genes 0.000 description 1
- 102100040191 Alpha-tectorin Human genes 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102100040894 Amylo-alpha-1,6-glucosidase Human genes 0.000 description 1
- 102100034614 Ankyrin repeat domain-containing protein 11 Human genes 0.000 description 1
- 102100034280 Ankyrin repeat domain-containing protein 26 Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 102100040124 Apoptosis-inducing factor 1, mitochondrial Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100028449 Arginine-glutamic acid dipeptide repeats protein Human genes 0.000 description 1
- 101000690509 Aspergillus oryzae (strain ATCC 42149 / RIB 40) Alpha-glucosidase Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100021247 BCL-6 corepressor Human genes 0.000 description 1
- 102100021256 BCL-6 corepressor-like protein 1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 108091005625 BRD4 Proteins 0.000 description 1
- 229940124291 BTK inhibitor Drugs 0.000 description 1
- 101710199232 Battenin Proteins 0.000 description 1
- 102100031500 Beta-1,4-glucuronyltransferase 1 Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100030686 Beta-sarcoglycan Human genes 0.000 description 1
- 102100035631 Bloom syndrome protein Human genes 0.000 description 1
- 108091009167 Bloom syndrome protein Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 description 1
- 102100025399 Breast cancer type 2 susceptibility protein Human genes 0.000 description 1
- 102100028573 Brefeldin A-inhibited guanine nucleotide-exchange protein 2 Human genes 0.000 description 1
- 102100027310 Bromodomain adjacent to zinc finger domain protein 1A Human genes 0.000 description 1
- 102100021574 Bromodomain adjacent to zinc finger domain protein 2B Human genes 0.000 description 1
- 102100029833 Bromodomain and WD repeat-containing protein 3 Human genes 0.000 description 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 102100025903 C-Jun-amino-terminal kinase-interacting protein 3 Human genes 0.000 description 1
- 102100032955 C2 domain-containing protein 3 Human genes 0.000 description 1
- 102100024881 C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 Human genes 0.000 description 1
- 102100022361 CAAX prenyl protease 1 homolog Human genes 0.000 description 1
- 102000014817 CACNA1A Human genes 0.000 description 1
- 102000014819 CACNA1B Human genes 0.000 description 1
- 102000014816 CACNA1D Human genes 0.000 description 1
- 102000014811 CACNA1E Human genes 0.000 description 1
- 102000014812 CACNA1F Human genes 0.000 description 1
- 102000014837 CACNA1G Human genes 0.000 description 1
- 102000014835 CACNA1H Human genes 0.000 description 1
- 102100028737 CAP-Gly domain-containing linker protein 1 Human genes 0.000 description 1
- 102100031024 CCR4-NOT transcription complex subunit 1 Human genes 0.000 description 1
- 102100038451 CDK5 regulatory subunit-associated protein 2 Human genes 0.000 description 1
- 102100021975 CREB-binding protein Human genes 0.000 description 1
- 102100025659 Cadherin EGF LAG seven-pass G-type receptor 1 Human genes 0.000 description 1
- 102100022509 Cadherin-23 Human genes 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102100036293 Calcium-binding mitochondrial carrier protein SCaMC-3 Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102100029876 Capping protein, Arp2/3 and myosin-I linker protein 2 Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 1
- 102100037677 Cell surface hyaluronidase Human genes 0.000 description 1
- 102100023344 Centromere protein F Human genes 0.000 description 1
- 102100023441 Centromere protein J Human genes 0.000 description 1
- 102100025832 Centromere-associated protein E Human genes 0.000 description 1
- 102100023309 Centrosomal protein of 152 kDa Human genes 0.000 description 1
- 101710181192 Centrosomal protein of 152 kDa Proteins 0.000 description 1
- 102100036180 Centrosomal protein of 164 kDa Human genes 0.000 description 1
- 101710131445 Centrosomal protein of 164 kDa Proteins 0.000 description 1
- 102100035673 Centrosomal protein of 290 kDa Human genes 0.000 description 1
- 101710198317 Centrosomal protein of 290 kDa Proteins 0.000 description 1
- 102100039219 Centrosome-associated protein CEP250 Human genes 0.000 description 1
- 101710110151 Centrosome-associated protein CEP250 Proteins 0.000 description 1
- 101000654316 Centruroides limpidus Beta-toxin Cll2 Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 102100033619 Cholesterol transporter ABCA5 Human genes 0.000 description 1
- 108010018888 Choline kinase Proteins 0.000 description 1
- 102100031065 Choline kinase alpha Human genes 0.000 description 1
- 102100031082 Choline/ethanolamine kinase Human genes 0.000 description 1
- 102100031235 Chromodomain-helicase-DNA-binding protein 1 Human genes 0.000 description 1
- 102100031266 Chromodomain-helicase-DNA-binding protein 3 Human genes 0.000 description 1
- 102100038214 Chromodomain-helicase-DNA-binding protein 4 Human genes 0.000 description 1
- 102100038215 Chromodomain-helicase-DNA-binding protein 7 Human genes 0.000 description 1
- 102100038165 Chromodomain-helicase-DNA-binding protein 8 Human genes 0.000 description 1
- 102100023331 Cilia- and flagella-associated protein 43 Human genes 0.000 description 1
- 102100023327 Cilia- and flagella-associated protein 44 Human genes 0.000 description 1
- 102100033687 Cilia- and flagella-associated protein 65 Human genes 0.000 description 1
- 102100026328 Ciliogenesis and planar polarity effector 1 Human genes 0.000 description 1
- 102100026127 Clathrin heavy chain 1 Human genes 0.000 description 1
- 102100038641 Cleavage and polyadenylation specificity factor subunit 1 Human genes 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 102100024079 Coiled-coil and C2 domain-containing protein 2A Human genes 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102100029136 Collagen alpha-1(II) chain Human genes 0.000 description 1
- 102100022145 Collagen alpha-1(IV) chain Human genes 0.000 description 1
- 102100024335 Collagen alpha-1(VII) chain Human genes 0.000 description 1
- 102100033825 Collagen alpha-1(XI) chain Human genes 0.000 description 1
- 102100027442 Collagen alpha-1(XII) chain Human genes 0.000 description 1
- 102100028256 Collagen alpha-1(XVII) chain Human genes 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 102100031544 Collagen alpha-1(XXVII) chain Human genes 0.000 description 1
- 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 description 1
- 102100033885 Collagen alpha-2(XI) chain Human genes 0.000 description 1
- 102100033780 Collagen alpha-3(IV) chain Human genes 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 102100033775 Collagen alpha-5(IV) chain Human genes 0.000 description 1
- 102100033773 Collagen alpha-6(IV) chain Human genes 0.000 description 1
- 108091026815 Competing endogenous RNA (CeRNA) Proteins 0.000 description 1
- 102100033843 Condensin complex subunit 1 Human genes 0.000 description 1
- 102100032978 Condensin-2 complex subunit D3 Human genes 0.000 description 1
- 102100040501 Contactin-associated protein 1 Human genes 0.000 description 1
- 108010022637 Copper-Transporting ATPases Proteins 0.000 description 1
- 102100027587 Copper-transporting ATPase 1 Human genes 0.000 description 1
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 description 1
- 102100031096 Cubilin Human genes 0.000 description 1
- 102100025522 Cullin-7 Human genes 0.000 description 1
- 102100038114 Cyclin-dependent kinase 13 Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 102100031089 Cystinosin Human genes 0.000 description 1
- 101710092486 Cystinosin Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100031635 Cytoplasmic dynein 1 heavy chain 1 Human genes 0.000 description 1
- 102100037147 Cytoplasmic dynein 2 heavy chain 1 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 102100031867 DNA excision repair protein ERCC-6 Human genes 0.000 description 1
- 102100021603 DNA excision repair protein ERCC-6-like 2 Human genes 0.000 description 1
- 102100028849 DNA mismatch repair protein Mlh3 Human genes 0.000 description 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 1
- 102100022307 DNA polymerase alpha catalytic subunit Human genes 0.000 description 1
- 102100028216 DNA polymerase zeta catalytic subunit Human genes 0.000 description 1
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 1
- 102100031593 DNA-directed RNA polymerase I subunit RPA1 Human genes 0.000 description 1
- 102100021429 DNA-directed RNA polymerase II subunit RPB1 Human genes 0.000 description 1
- 102100024452 DNA-directed RNA polymerase III subunit RPC1 Human genes 0.000 description 1
- 102100031597 Dedicator of cytokinesis protein 2 Human genes 0.000 description 1
- 102100031604 Dedicator of cytokinesis protein 3 Human genes 0.000 description 1
- 102100024354 Dedicator of cytokinesis protein 6 Human genes 0.000 description 1
- 102100024351 Dedicator of cytokinesis protein 7 Human genes 0.000 description 1
- 102100024350 Dedicator of cytokinesis protein 8 Human genes 0.000 description 1
- 102100021790 Delta-sarcoglycan Human genes 0.000 description 1
- 101001117086 Dictyostelium discoideum cAMP/cGMP-dependent 3',5'-cAMP/cGMP phosphodiesterase A Proteins 0.000 description 1
- KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 description 1
- 102100037923 Disco-interacting protein 2 homolog B Human genes 0.000 description 1
- 102100035347 DmX-like protein 2 Human genes 0.000 description 1
- 108010083068 Dual Oxidases Proteins 0.000 description 1
- 102100021217 Dual oxidase 2 Human genes 0.000 description 1
- 102100024821 Dynamin-binding protein Human genes 0.000 description 1
- 102100032244 Dynein axonemal heavy chain 1 Human genes 0.000 description 1
- 102100032300 Dynein axonemal heavy chain 11 Human genes 0.000 description 1
- 102100032297 Dynein axonemal heavy chain 17 Human genes 0.000 description 1
- 102100032245 Dynein axonemal heavy chain 2 Human genes 0.000 description 1
- 102100031648 Dynein axonemal heavy chain 5 Human genes 0.000 description 1
- 102100031647 Dynein axonemal heavy chain 7 Human genes 0.000 description 1
- 102100031637 Dynein axonemal heavy chain 8 Human genes 0.000 description 1
- 102100031636 Dynein axonemal heavy chain 9 Human genes 0.000 description 1
- 102100032249 Dystonin Human genes 0.000 description 1
- 102100025682 Dystroglycan 1 Human genes 0.000 description 1
- 108010071885 Dystroglycans Proteins 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102100038912 E3 SUMO-protein ligase RanBP2 Human genes 0.000 description 1
- 102100034675 E3 ubiquitin-protein ligase HECW2 Human genes 0.000 description 1
- 102100034745 E3 ubiquitin-protein ligase HERC2 Human genes 0.000 description 1
- 102100034893 E3 ubiquitin-protein ligase HUWE1 Human genes 0.000 description 1
- 102100022409 E3 ubiquitin-protein ligase LNX Human genes 0.000 description 1
- 102100027418 E3 ubiquitin-protein ligase RNF213 Human genes 0.000 description 1
- 102100028093 E3 ubiquitin-protein ligase TRIP12 Human genes 0.000 description 1
- 102100023226 Early growth response protein 1 Human genes 0.000 description 1
- 102100030281 Ectopic P granules protein 5 homolog Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100034239 Emerin Human genes 0.000 description 1
- HCHFRAXBELVCGG-UHFFFAOYSA-N Emerin Natural products C1=CC(OC)=CC=C1C=C(C#N)C(C#N)=CC1=CC=C(OC)C=C1 HCHFRAXBELVCGG-UHFFFAOYSA-N 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100039254 Exophilin-5 Human genes 0.000 description 1
- 102100037122 Extracellular matrix organizing protein FRAS1 Human genes 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 102100035449 FRAS1-related extracellular matrix protein 1 Human genes 0.000 description 1
- 102100035441 FRAS1-related extracellular matrix protein 2 Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000009095 Fanconi Anemia Complementation Group A protein Human genes 0.000 description 1
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 description 1
- 102000013601 Fanconi Anemia Complementation Group D2 protein Human genes 0.000 description 1
- 108010026653 Fanconi Anemia Complementation Group D2 protein Proteins 0.000 description 1
- 102100034552 Fanconi anemia group M protein Human genes 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 102100032596 Fibrocystin Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 102100027625 Fibrous sheath-interacting protein 2 Human genes 0.000 description 1
- 102100037009 Filaggrin-2 Human genes 0.000 description 1
- 102100026561 Filamin-A Human genes 0.000 description 1
- 102100026559 Filamin-B Human genes 0.000 description 1
- 102100026560 Filamin-C Human genes 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 102100028924 Formin-2 Human genes 0.000 description 1
- 102100028875 Formylglycine-generating enzyme Human genes 0.000 description 1
- 101710192607 Formylglycine-generating enzyme Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 102100024114 G2/mitotic-specific cyclin-B3 Human genes 0.000 description 1
- 102100022688 GATOR complex protein DEPDC5 Human genes 0.000 description 1
- 102100023930 GREB1-like protein Human genes 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 102100033414 Gamma-tubulin complex component 6 Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102100037412 Germinal-center associated nuclear protein Human genes 0.000 description 1
- 101710194542 Germinal-center associated nuclear protein Proteins 0.000 description 1
- 102100036769 Girdin Human genes 0.000 description 1
- 102100036621 Glucosylceramide transporter ABCA12 Human genes 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 1
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
- 102100027978 Glutamine-rich protein 2 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710141660 Glycogen synthase 1 Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102100027675 Guanine nucleotide exchange factor subunit RIC1 Human genes 0.000 description 1
- 102100034154 Guanine nucleotide-binding protein G(i) subunit alpha-2 Human genes 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 102100031880 Helicase SRCAP Human genes 0.000 description 1
- 102100028893 Hemicentin-1 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102100033071 Histone acetyltransferase KAT6A Human genes 0.000 description 1
- 102100033070 Histone acetyltransferase KAT6B Human genes 0.000 description 1
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 1
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 1
- 102100022102 Histone-lysine N-methyltransferase 2B Human genes 0.000 description 1
- 102100027755 Histone-lysine N-methyltransferase 2C Human genes 0.000 description 1
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 description 1
- 102100026265 Histone-lysine N-methyltransferase ASH1L Human genes 0.000 description 1
- 102100029234 Histone-lysine N-methyltransferase NSD2 Human genes 0.000 description 1
- 102100029768 Histone-lysine N-methyltransferase SETD1A Human genes 0.000 description 1
- 102100030095 Histone-lysine N-methyltransferase SETD1B Human genes 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 102100027711 Histone-lysine N-methyltransferase SETD5 Human genes 0.000 description 1
- 102100029239 Histone-lysine N-methyltransferase, H3 lysine-36 specific Human genes 0.000 description 1
- 102100030234 Homeobox protein cut-like 1 Human genes 0.000 description 1
- 101001058479 Homo sapiens 1,4-alpha-glucan-branching enzyme Proteins 0.000 description 1
- 101001126442 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 Proteins 0.000 description 1
- 101000760987 Homo sapiens 5'-AMP-activated protein kinase subunit gamma-2 Proteins 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101000690059 Homo sapiens AP-4 complex accessory subunit RUSC2 Proteins 0.000 description 1
- 101000833502 Homo sapiens AT-hook DNA-binding motif-containing protein 1 Proteins 0.000 description 1
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 description 1
- 101000924255 Homo sapiens AT-rich interactive domain-containing protein 1B Proteins 0.000 description 1
- 101000685261 Homo sapiens AT-rich interactive domain-containing protein 2 Proteins 0.000 description 1
- 101000929660 Homo sapiens ATP-binding cassette sub-family A member 13 Proteins 0.000 description 1
- 101000801645 Homo sapiens ATP-binding cassette sub-family A member 2 Proteins 0.000 description 1
- 101000760570 Homo sapiens ATP-binding cassette sub-family C member 8 Proteins 0.000 description 1
- 101000713950 Homo sapiens ATP-dependent RNA helicase TDRD9 Proteins 0.000 description 1
- 101000900939 Homo sapiens Abnormal spindle-like microcephaly-associated protein Proteins 0.000 description 1
- 101000678765 Homo sapiens Acetylcholine receptor subunit delta Proteins 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000775498 Homo sapiens Adenylate cyclase type 10 Proteins 0.000 description 1
- 101000959594 Homo sapiens Agrin Proteins 0.000 description 1
- 101000779572 Homo sapiens Alpha-protein kinase 3 Proteins 0.000 description 1
- 101000889766 Homo sapiens Alpha-tectorin Proteins 0.000 description 1
- 101000893559 Homo sapiens Amylo-alpha-1,6-glucosidase Proteins 0.000 description 1
- 101000924476 Homo sapiens Ankyrin repeat domain-containing protein 11 Proteins 0.000 description 1
- 101000780116 Homo sapiens Ankyrin repeat domain-containing protein 26 Proteins 0.000 description 1
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 1
- 101001061654 Homo sapiens Arginine-glutamic acid dipeptide repeats protein Proteins 0.000 description 1
- 101000952934 Homo sapiens Atrial natriuretic peptide-converting enzyme Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000894688 Homo sapiens BCL-6 corepressor-like protein 1 Proteins 0.000 description 1
- 101100165236 Homo sapiens BCOR gene Proteins 0.000 description 1
- 101000729794 Homo sapiens Beta-1,4-glucuronyltransferase 1 Proteins 0.000 description 1
- 101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 description 1
- 101000703495 Homo sapiens Beta-sarcoglycan Proteins 0.000 description 1
- 101000695920 Homo sapiens Brefeldin A-inhibited guanine nucleotide-exchange protein 2 Proteins 0.000 description 1
- 101000937778 Homo sapiens Bromodomain adjacent to zinc finger domain protein 1A Proteins 0.000 description 1
- 101000971143 Homo sapiens Bromodomain adjacent to zinc finger domain protein 2B Proteins 0.000 description 1
- 101000794050 Homo sapiens Bromodomain and WD repeat-containing protein 3 Proteins 0.000 description 1
- 101001076874 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 3 Proteins 0.000 description 1
- 101000867970 Homo sapiens C2 domain-containing protein 3 Proteins 0.000 description 1
- 101000909150 Homo sapiens C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 Proteins 0.000 description 1
- 101000824531 Homo sapiens CAAX prenyl protease 1 homolog Proteins 0.000 description 1
- 101000767052 Homo sapiens CAP-Gly domain-containing linker protein 1 Proteins 0.000 description 1
- 101000919672 Homo sapiens CCR4-NOT transcription complex subunit 1 Proteins 0.000 description 1
- 101000882873 Homo sapiens CDK5 regulatory subunit-associated protein 2 Proteins 0.000 description 1
- 101000990005 Homo sapiens CLIP-associating protein 1 Proteins 0.000 description 1
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 description 1
- 101000914155 Homo sapiens Cadherin EGF LAG seven-pass G-type receptor 1 Proteins 0.000 description 1
- 101000899442 Homo sapiens Cadherin-23 Proteins 0.000 description 1
- 101000793825 Homo sapiens Capping protein, Arp2/3 and myosin-I linker protein 2 Proteins 0.000 description 1
- 101000855412 Homo sapiens Carbamoyl-phosphate synthase [ammonia], mitochondrial Proteins 0.000 description 1
- 101001028831 Homo sapiens Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 1
- 101000880605 Homo sapiens Cell surface hyaluronidase Proteins 0.000 description 1
- 101000907941 Homo sapiens Centromere protein F Proteins 0.000 description 1
- 101000907924 Homo sapiens Centromere protein J Proteins 0.000 description 1
- 101000914247 Homo sapiens Centromere-associated protein E Proteins 0.000 description 1
- 101000851684 Homo sapiens Chimeric ERCC6-PGBD3 protein Proteins 0.000 description 1
- 101000801660 Homo sapiens Cholesterol transporter ABCA5 Proteins 0.000 description 1
- 101000777313 Homo sapiens Choline/ethanolamine kinase Proteins 0.000 description 1
- 101000777047 Homo sapiens Chromodomain-helicase-DNA-binding protein 1 Proteins 0.000 description 1
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 description 1
- 101000777071 Homo sapiens Chromodomain-helicase-DNA-binding protein 3 Proteins 0.000 description 1
- 101000883749 Homo sapiens Chromodomain-helicase-DNA-binding protein 4 Proteins 0.000 description 1
- 101000883739 Homo sapiens Chromodomain-helicase-DNA-binding protein 7 Proteins 0.000 description 1
- 101000883545 Homo sapiens Chromodomain-helicase-DNA-binding protein 8 Proteins 0.000 description 1
- 101000907999 Homo sapiens Cilia- and flagella-associated protein 43 Proteins 0.000 description 1
- 101000907982 Homo sapiens Cilia- and flagella-associated protein 44 Proteins 0.000 description 1
- 101000944485 Homo sapiens Cilia- and flagella-associated protein 65 Proteins 0.000 description 1
- 101000855375 Homo sapiens Ciliogenesis and planar polarity effector 1 Proteins 0.000 description 1
- 101000912851 Homo sapiens Clathrin heavy chain 1 Proteins 0.000 description 1
- 101000957603 Homo sapiens Cleavage and polyadenylation specificity factor subunit 1 Proteins 0.000 description 1
- 101000910414 Homo sapiens Coiled-coil and C2 domain-containing protein 2A Proteins 0.000 description 1
- 101000771163 Homo sapiens Collagen alpha-1(II) chain Proteins 0.000 description 1
- 101000901150 Homo sapiens Collagen alpha-1(IV) chain Proteins 0.000 description 1
- 101000909498 Homo sapiens Collagen alpha-1(VII) chain Proteins 0.000 description 1
- 101000710623 Homo sapiens Collagen alpha-1(XI) chain Proteins 0.000 description 1
- 101000861874 Homo sapiens Collagen alpha-1(XII) chain Proteins 0.000 description 1
- 101000860679 Homo sapiens Collagen alpha-1(XVII) chain Proteins 0.000 description 1
- 101000940068 Homo sapiens Collagen alpha-1(XVIII) chain Proteins 0.000 description 1
- 101000940372 Homo sapiens Collagen alpha-1(XXVII) chain Proteins 0.000 description 1
- 101000710876 Homo sapiens Collagen alpha-2(IV) chain Proteins 0.000 description 1
- 101000710619 Homo sapiens Collagen alpha-2(XI) chain Proteins 0.000 description 1
- 101000710873 Homo sapiens Collagen alpha-3(IV) chain Proteins 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101000710886 Homo sapiens Collagen alpha-5(IV) chain Proteins 0.000 description 1
- 101000710885 Homo sapiens Collagen alpha-6(IV) chain Proteins 0.000 description 1
- 101000710846 Homo sapiens Condensin complex subunit 1 Proteins 0.000 description 1
- 101000942612 Homo sapiens Condensin-2 complex subunit D3 Proteins 0.000 description 1
- 101000749872 Homo sapiens Contactin-associated protein 1 Proteins 0.000 description 1
- 101000936280 Homo sapiens Copper-transporting ATPase 2 Proteins 0.000 description 1
- 101000922080 Homo sapiens Cubilin Proteins 0.000 description 1
- 101000856425 Homo sapiens Cullin-7 Proteins 0.000 description 1
- 101000884348 Homo sapiens Cyclin-dependent kinase 13 Proteins 0.000 description 1
- 101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 1
- 101000866326 Homo sapiens Cytoplasmic dynein 1 heavy chain 1 Proteins 0.000 description 1
- 101000881344 Homo sapiens Cytoplasmic dynein 2 heavy chain 1 Proteins 0.000 description 1
- 101000920783 Homo sapiens DNA excision repair protein ERCC-6 Proteins 0.000 description 1
- 101000898683 Homo sapiens DNA excision repair protein ERCC-6-like 2 Proteins 0.000 description 1
- 101000577867 Homo sapiens DNA mismatch repair protein Mlh3 Proteins 0.000 description 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 1
- 101000902558 Homo sapiens DNA polymerase alpha catalytic subunit Proteins 0.000 description 1
- 101000579381 Homo sapiens DNA polymerase zeta catalytic subunit Proteins 0.000 description 1
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 1
- 101000729474 Homo sapiens DNA-directed RNA polymerase I subunit RPA1 Proteins 0.000 description 1
- 101001106401 Homo sapiens DNA-directed RNA polymerase II subunit RPB1 Proteins 0.000 description 1
- 101000689002 Homo sapiens DNA-directed RNA polymerase III subunit RPC1 Proteins 0.000 description 1
- 101000866237 Homo sapiens Dedicator of cytokinesis protein 2 Proteins 0.000 description 1
- 101000866238 Homo sapiens Dedicator of cytokinesis protein 3 Proteins 0.000 description 1
- 101001052950 Homo sapiens Dedicator of cytokinesis protein 6 Proteins 0.000 description 1
- 101001052952 Homo sapiens Dedicator of cytokinesis protein 7 Proteins 0.000 description 1
- 101001052946 Homo sapiens Dedicator of cytokinesis protein 8 Proteins 0.000 description 1
- 101001053992 Homo sapiens Deleted in lung and esophageal cancer protein 1 Proteins 0.000 description 1
- 101000616408 Homo sapiens Delta-sarcoglycan Proteins 0.000 description 1
- 101000805871 Homo sapiens Disco-interacting protein 2 homolog B Proteins 0.000 description 1
- 101000804534 Homo sapiens DmX-like protein 2 Proteins 0.000 description 1
- 101000909230 Homo sapiens Dynamin-binding protein Proteins 0.000 description 1
- 101001016198 Homo sapiens Dynein axonemal heavy chain 1 Proteins 0.000 description 1
- 101001016208 Homo sapiens Dynein axonemal heavy chain 11 Proteins 0.000 description 1
- 101001016203 Homo sapiens Dynein axonemal heavy chain 17 Proteins 0.000 description 1
- 101001016199 Homo sapiens Dynein axonemal heavy chain 2 Proteins 0.000 description 1
- 101000866368 Homo sapiens Dynein axonemal heavy chain 5 Proteins 0.000 description 1
- 101000866372 Homo sapiens Dynein axonemal heavy chain 7 Proteins 0.000 description 1
- 101000866323 Homo sapiens Dynein axonemal heavy chain 8 Proteins 0.000 description 1
- 101000866325 Homo sapiens Dynein axonemal heavy chain 9 Proteins 0.000 description 1
- 101000966403 Homo sapiens Dynein light chain 1, cytoplasmic Proteins 0.000 description 1
- 101001016186 Homo sapiens Dystonin Proteins 0.000 description 1
- 101000872871 Homo sapiens E3 ubiquitin-protein ligase HECW2 Proteins 0.000 description 1
- 101000872516 Homo sapiens E3 ubiquitin-protein ligase HERC2 Proteins 0.000 description 1
- 101001019732 Homo sapiens E3 ubiquitin-protein ligase HUWE1 Proteins 0.000 description 1
- 101000620132 Homo sapiens E3 ubiquitin-protein ligase LNX Proteins 0.000 description 1
- 101000650316 Homo sapiens E3 ubiquitin-protein ligase RNF213 Proteins 0.000 description 1
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 1
- 101000938359 Homo sapiens Ectopic P granules protein 5 homolog Proteins 0.000 description 1
- 101001010541 Homo sapiens Electron transfer flavoprotein subunit alpha, mitochondrial Proteins 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- 101000813263 Homo sapiens Exophilin-5 Proteins 0.000 description 1
- 101001029168 Homo sapiens Extracellular matrix organizing protein FRAS1 Proteins 0.000 description 1
- 101000877896 Homo sapiens FRAS1-related extracellular matrix protein 1 Proteins 0.000 description 1
- 101000877894 Homo sapiens FRAS1-related extracellular matrix protein 2 Proteins 0.000 description 1
- 101000848187 Homo sapiens Fanconi anemia group M protein Proteins 0.000 description 1
- 101000827746 Homo sapiens Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 101000730595 Homo sapiens Fibrocystin Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000862369 Homo sapiens Fibrous sheath-interacting protein 2 Proteins 0.000 description 1
- 101000917159 Homo sapiens Filaggrin Proteins 0.000 description 1
- 101000878281 Homo sapiens Filaggrin-2 Proteins 0.000 description 1
- 101000913549 Homo sapiens Filamin-A Proteins 0.000 description 1
- 101000913551 Homo sapiens Filamin-B Proteins 0.000 description 1
- 101000913557 Homo sapiens Filamin-C Proteins 0.000 description 1
- 101001059398 Homo sapiens Formin-2 Proteins 0.000 description 1
- 101000910528 Homo sapiens G2/mitotic-specific cyclin-B3 Proteins 0.000 description 1
- 101001044724 Homo sapiens GATOR complex protein DEPDC5 Proteins 0.000 description 1
- 101000904872 Homo sapiens GREB1-like protein Proteins 0.000 description 1
- 101000926908 Homo sapiens Gamma-tubulin complex component 6 Proteins 0.000 description 1
- 101001071367 Homo sapiens Girdin Proteins 0.000 description 1
- 101000929652 Homo sapiens Glucosylceramide transporter ABCA12 Proteins 0.000 description 1
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 description 1
- 101000972850 Homo sapiens Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 description 1
- 101000972840 Homo sapiens Glutamate receptor ionotropic, NMDA 2D Proteins 0.000 description 1
- 101001060579 Homo sapiens Glutamine-rich protein 2 Proteins 0.000 description 1
- 101000581349 Homo sapiens Guanine nucleotide exchange factor subunit RIC1 Proteins 0.000 description 1
- 101001070508 Homo sapiens Guanine nucleotide-binding protein G(i) subunit alpha-2 Proteins 0.000 description 1
- 101000704158 Homo sapiens Helicase SRCAP Proteins 0.000 description 1
- 101000839060 Homo sapiens Hemicentin-1 Proteins 0.000 description 1
- 101000944179 Homo sapiens Histone acetyltransferase KAT6A Proteins 0.000 description 1
- 101000944174 Homo sapiens Histone acetyltransferase KAT6B Proteins 0.000 description 1
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 description 1
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 1
- 101001045848 Homo sapiens Histone-lysine N-methyltransferase 2B Proteins 0.000 description 1
- 101001008892 Homo sapiens Histone-lysine N-methyltransferase 2C Proteins 0.000 description 1
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 description 1
- 101000785963 Homo sapiens Histone-lysine N-methyltransferase ASH1L Proteins 0.000 description 1
- 101000634048 Homo sapiens Histone-lysine N-methyltransferase NSD2 Proteins 0.000 description 1
- 101000865038 Homo sapiens Histone-lysine N-methyltransferase SETD1A Proteins 0.000 description 1
- 101000864672 Homo sapiens Histone-lysine N-methyltransferase SETD1B Proteins 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101000650669 Homo sapiens Histone-lysine N-methyltransferase SETD5 Proteins 0.000 description 1
- 101000634050 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-36 specific Proteins 0.000 description 1
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 1
- 101001037204 Homo sapiens Hydrocephalus-inducing protein homolog Proteins 0.000 description 1
- 101001077647 Homo sapiens IQ motif and SEC7 domain-containing protein 2 Proteins 0.000 description 1
- 101001008896 Homo sapiens Inactive histone-lysine N-methyltransferase 2E Proteins 0.000 description 1
- 101000889893 Homo sapiens Inactive serine/threonine-protein kinase TEX14 Proteins 0.000 description 1
- 101000975428 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 1 Proteins 0.000 description 1
- 101000975421 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 2 Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001053790 Homo sapiens Integrator complex subunit 1 Proteins 0.000 description 1
- 101001015006 Homo sapiens Integrin beta-4 Proteins 0.000 description 1
- 101000960200 Homo sapiens Intraflagellar transport protein 140 homolog Proteins 0.000 description 1
- 101000960114 Homo sapiens Intraflagellar transport protein 172 homolog Proteins 0.000 description 1
- 101000834851 Homo sapiens KICSTOR complex protein SZT2 Proteins 0.000 description 1
- 101001046985 Homo sapiens KN motif and ankyrin repeat domain-containing protein 1 Proteins 0.000 description 1
- 101001050038 Homo sapiens Kalirin Proteins 0.000 description 1
- 101000975939 Homo sapiens Kinase D-interacting substrate of 220 kDa Proteins 0.000 description 1
- 101001008949 Homo sapiens Kinesin-like protein KIF14 Proteins 0.000 description 1
- 101000971638 Homo sapiens Kinesin-like protein KIF1A Proteins 0.000 description 1
- 101000971697 Homo sapiens Kinesin-like protein KIF1B Proteins 0.000 description 1
- 101001027602 Homo sapiens Kinesin-like protein KIF26B Proteins 0.000 description 1
- 101001006787 Homo sapiens Kinesin-like protein KIF7 Proteins 0.000 description 1
- 101000971521 Homo sapiens Kinetochore scaffold 1 Proteins 0.000 description 1
- 101000972489 Homo sapiens Laminin subunit alpha-1 Proteins 0.000 description 1
- 101000972488 Homo sapiens Laminin subunit alpha-4 Proteins 0.000 description 1
- 101001008527 Homo sapiens Laminin subunit alpha-5 Proteins 0.000 description 1
- 101001008568 Homo sapiens Laminin subunit beta-1 Proteins 0.000 description 1
- 101001008558 Homo sapiens Laminin subunit beta-2 Proteins 0.000 description 1
- 101000946306 Homo sapiens Laminin subunit gamma-1 Proteins 0.000 description 1
- 101001023261 Homo sapiens Laminin subunit gamma-3 Proteins 0.000 description 1
- 101001054649 Homo sapiens Latent-transforming growth factor beta-binding protein 2 Proteins 0.000 description 1
- 101001054646 Homo sapiens Latent-transforming growth factor beta-binding protein 3 Proteins 0.000 description 1
- 101000978212 Homo sapiens Latent-transforming growth factor beta-binding protein 4 Proteins 0.000 description 1
- 101000966742 Homo sapiens Leucine-rich PPR motif-containing protein, mitochondrial Proteins 0.000 description 1
- 101000941877 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 101001017764 Homo sapiens Lipopolysaccharide-responsive and beige-like anchor protein Proteins 0.000 description 1
- 101001043562 Homo sapiens Low-density lipoprotein receptor-related protein 2 Proteins 0.000 description 1
- 101001043598 Homo sapiens Low-density lipoprotein receptor-related protein 4 Proteins 0.000 description 1
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 1
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 description 1
- 101000614020 Homo sapiens Lysine-specific demethylase 3B Proteins 0.000 description 1
- 101001088883 Homo sapiens Lysine-specific demethylase 5B Proteins 0.000 description 1
- 101001088887 Homo sapiens Lysine-specific demethylase 5C Proteins 0.000 description 1
- 101001025967 Homo sapiens Lysine-specific demethylase 6A Proteins 0.000 description 1
- 101001025971 Homo sapiens Lysine-specific demethylase 6B Proteins 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 101001059644 Homo sapiens MAP kinase-activating death domain protein Proteins 0.000 description 1
- 101000614988 Homo sapiens Mediator of RNA polymerase II transcription subunit 12 Proteins 0.000 description 1
- 101001017597 Homo sapiens Mediator of RNA polymerase II transcription subunit 12-like protein Proteins 0.000 description 1
- 101001055427 Homo sapiens Mediator of RNA polymerase II transcription subunit 13 Proteins 0.000 description 1
- 101001017592 Homo sapiens Mediator of RNA polymerase II transcription subunit 13-like Proteins 0.000 description 1
- 101001019117 Homo sapiens Mediator of RNA polymerase II transcription subunit 23 Proteins 0.000 description 1
- 101000578932 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Proteins 0.000 description 1
- 101001116314 Homo sapiens Methionine synthase reductase Proteins 0.000 description 1
- 101000615498 Homo sapiens Methyl-CpG-binding domain protein 5 Proteins 0.000 description 1
- 101000653369 Homo sapiens Methylcytosine dioxygenase TET3 Proteins 0.000 description 1
- 101000578920 Homo sapiens Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 Proteins 0.000 description 1
- 101000957756 Homo sapiens Microtubule-associated protein RP/EB family member 2 Proteins 0.000 description 1
- 101001018259 Homo sapiens Microtubule-associated serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 description 1
- 101000969697 Homo sapiens Multiple PDZ domain protein Proteins 0.000 description 1
- 101000955249 Homo sapiens Multiple epidermal growth factor-like domains protein 8 Proteins 0.000 description 1
- 101001022780 Homo sapiens Myosin light chain kinase, smooth muscle Proteins 0.000 description 1
- 101001000109 Homo sapiens Myosin-10 Proteins 0.000 description 1
- 101000588964 Homo sapiens Myosin-14 Proteins 0.000 description 1
- 101000958753 Homo sapiens Myosin-2 Proteins 0.000 description 1
- 101000958751 Homo sapiens Myosin-3 Proteins 0.000 description 1
- 101001030228 Homo sapiens Myosin-8 Proteins 0.000 description 1
- 101001030232 Homo sapiens Myosin-9 Proteins 0.000 description 1
- 101000635935 Homo sapiens Myosin-IIIa Proteins 0.000 description 1
- 101001116514 Homo sapiens Myotubularin-related protein 13 Proteins 0.000 description 1
- 101001072477 Homo sapiens N-acetylglucosamine-1-phosphotransferase subunit gamma Proteins 0.000 description 1
- 101001072470 Homo sapiens N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Proteins 0.000 description 1
- 101000983292 Homo sapiens N-fatty-acyl-amino acid synthase/hydrolase PM20D1 Proteins 0.000 description 1
- 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 description 1
- 101000962088 Homo sapiens NBAS subunit of NRZ tethering complex Proteins 0.000 description 1
- 101000624947 Homo sapiens Nesprin-1 Proteins 0.000 description 1
- 101001108436 Homo sapiens Neurexin-1 Proteins 0.000 description 1
- 101001108433 Homo sapiens Neurexin-1-beta Proteins 0.000 description 1
- 101000969961 Homo sapiens Neurexin-3 Proteins 0.000 description 1
- 101000969963 Homo sapiens Neurexin-3-beta Proteins 0.000 description 1
- 101000962041 Homo sapiens Neurobeachin Proteins 0.000 description 1
- 101000962052 Homo sapiens Neurobeachin-like protein 2 Proteins 0.000 description 1
- 101001023793 Homo sapiens Neurofascin Proteins 0.000 description 1
- 101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 description 1
- 101001108932 Homo sapiens Nuclear pore complex protein Nup155 Proteins 0.000 description 1
- 101000589749 Homo sapiens Nuclear pore complex protein Nup205 Proteins 0.000 description 1
- 101001108862 Homo sapiens Nucleoporin NUP188 Proteins 0.000 description 1
- 101000934489 Homo sapiens Nucleosome-remodeling factor subunit BPTF Proteins 0.000 description 1
- 101000585675 Homo sapiens Obscurin Proteins 0.000 description 1
- 101000992104 Homo sapiens Obscurin-like protein 1 Proteins 0.000 description 1
- 101001134169 Homo sapiens Otoferlin Proteins 0.000 description 1
- 101001134207 Homo sapiens Otogelin Proteins 0.000 description 1
- 101001134210 Homo sapiens Otogelin-like protein Proteins 0.000 description 1
- 101000854060 Homo sapiens Oxygen-regulated protein 1 Proteins 0.000 description 1
- 101100174573 Homo sapiens PIKFYVE gene Proteins 0.000 description 1
- 101001135199 Homo sapiens Partitioning defective 3 homolog Proteins 0.000 description 1
- 101001129178 Homo sapiens Patatin-like phospholipase domain-containing protein 6 Proteins 0.000 description 1
- 101001095085 Homo sapiens Periaxin Proteins 0.000 description 1
- 101001117010 Homo sapiens Pericentrin Proteins 0.000 description 1
- 101001131990 Homo sapiens Peroxidasin homolog Proteins 0.000 description 1
- 101000619708 Homo sapiens Peroxiredoxin-6 Proteins 0.000 description 1
- 101001038051 Homo sapiens Phlorizin hydrolase Proteins 0.000 description 1
- 101001001516 Homo sapiens Phosphatidylinositol 4-kinase alpha Proteins 0.000 description 1
- 101000721642 Homo sapiens Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Proteins 0.000 description 1
- 101000591234 Homo sapiens Phosphatidylinositol phosphatase PTPRQ Proteins 0.000 description 1
- 101000801640 Homo sapiens Phospholipid-transporting ATPase ABCA3 Proteins 0.000 description 1
- 101001129789 Homo sapiens Piezo-type mechanosensitive ion channel component 1 Proteins 0.000 description 1
- 101001129788 Homo sapiens Piezo-type mechanosensitive ion channel component 2 Proteins 0.000 description 1
- 101000730606 Homo sapiens Pleckstrin homology domain-containing family G member 2 Proteins 0.000 description 1
- 101001066701 Homo sapiens Pogo transposable element with ZNF domain Proteins 0.000 description 1
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 description 1
- 101000730580 Homo sapiens Polycystic kidney disease protein 1-like 1 Proteins 0.000 description 1
- 101001074444 Homo sapiens Polycystin-1 Proteins 0.000 description 1
- 101000772905 Homo sapiens Polyubiquitin-B Proteins 0.000 description 1
- 101000974726 Homo sapiens Potassium voltage-gated channel subfamily E member 1 Proteins 0.000 description 1
- 101000974720 Homo sapiens Potassium voltage-gated channel subfamily E member 2 Proteins 0.000 description 1
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
- 101001105683 Homo sapiens Pre-mRNA-processing-splicing factor 8 Proteins 0.000 description 1
- 101000843497 Homo sapiens Probable ATP-dependent DNA helicase HFM1 Proteins 0.000 description 1
- 101000872514 Homo sapiens Probable E3 ubiquitin-protein ligase HERC1 Proteins 0.000 description 1
- 101001028703 Homo sapiens Probable JmjC domain-containing histone demethylation protein 2C Proteins 0.000 description 1
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 description 1
- 101000836337 Homo sapiens Probable helicase senataxin Proteins 0.000 description 1
- 101000808592 Homo sapiens Probable ubiquitin carboxyl-terminal hydrolase FAF-X Proteins 0.000 description 1
- 101000619116 Homo sapiens Proline-rich protein 12 Proteins 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 1
- 101000956094 Homo sapiens Protein Daple Proteins 0.000 description 1
- 101000652433 Homo sapiens Protein SON Proteins 0.000 description 1
- 101000825428 Homo sapiens Protein Shroom4 Proteins 0.000 description 1
- 101000657326 Homo sapiens Protein TANC2 Proteins 0.000 description 1
- 101000726148 Homo sapiens Protein crumbs homolog 1 Proteins 0.000 description 1
- 101001028804 Homo sapiens Protein eyes shut homolog Proteins 0.000 description 1
- 101000609959 Homo sapiens Protein piccolo Proteins 0.000 description 1
- 101000601770 Homo sapiens Protein polybromo-1 Proteins 0.000 description 1
- 101000841715 Homo sapiens Protein unc-80 homolog Proteins 0.000 description 1
- 101001123332 Homo sapiens Proteoglycan 4 Proteins 0.000 description 1
- 101000824318 Homo sapiens Protocadherin Fat 1 Proteins 0.000 description 1
- 101000848199 Homo sapiens Protocadherin Fat 4 Proteins 0.000 description 1
- 101001072259 Homo sapiens Protocadherin-15 Proteins 0.000 description 1
- 101001072237 Homo sapiens Protocadherin-16 Proteins 0.000 description 1
- 101000728107 Homo sapiens Putative Polycomb group protein ASXL2 Proteins 0.000 description 1
- 101000728110 Homo sapiens Putative Polycomb group protein ASXL3 Proteins 0.000 description 1
- 101001112424 Homo sapiens RB1-inducible coiled-coil protein 1 Proteins 0.000 description 1
- 101000712814 Homo sapiens Rab3 GTPase-activating protein non-catalytic subunit Proteins 0.000 description 1
- 101000665509 Homo sapiens Ral GTPase-activating protein subunit alpha-1 Proteins 0.000 description 1
- 101000641879 Homo sapiens Ras/Rap GTPase-activating protein SynGAP Proteins 0.000 description 1
- 101000606545 Homo sapiens Receptor-type tyrosine-protein phosphatase F Proteins 0.000 description 1
- 101000591236 Homo sapiens Receptor-type tyrosine-protein phosphatase R Proteins 0.000 description 1
- 101000606506 Homo sapiens Receptor-type tyrosine-protein phosphatase eta Proteins 0.000 description 1
- 101001074528 Homo sapiens Regulating synaptic membrane exocytosis protein 1 Proteins 0.000 description 1
- 101001074548 Homo sapiens Regulating synaptic membrane exocytosis protein 2 Proteins 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 101000854044 Homo sapiens Retinitis pigmentosa 1-like 1 protein Proteins 0.000 description 1
- 101001075563 Homo sapiens Rho GTPase-activating protein 31 Proteins 0.000 description 1
- 101001106322 Homo sapiens Rho GTPase-activating protein 7 Proteins 0.000 description 1
- 101000927778 Homo sapiens Rho guanine nucleotide exchange factor 10 Proteins 0.000 description 1
- 101000731730 Homo sapiens Rho guanine nucleotide exchange factor 18 Proteins 0.000 description 1
- 101000657452 Homo sapiens Rotatin Proteins 0.000 description 1
- 101000650694 Homo sapiens Roundabout homolog 1 Proteins 0.000 description 1
- 101000650697 Homo sapiens Roundabout homolog 2 Proteins 0.000 description 1
- 101000650588 Homo sapiens Roundabout homolog 3 Proteins 0.000 description 1
- 101000693903 Homo sapiens S phase cyclin A-associated protein in the endoplasmic reticulum Proteins 0.000 description 1
- 101000654718 Homo sapiens SET-binding protein Proteins 0.000 description 1
- 101000641122 Homo sapiens Sacsin Proteins 0.000 description 1
- 101000628575 Homo sapiens Serine/threonine-protein kinase 19 Proteins 0.000 description 1
- 101000770770 Homo sapiens Serine/threonine-protein kinase WNK1 Proteins 0.000 description 1
- 101000836849 Homo sapiens Signal-induced proliferation-associated 1-like protein 3 Proteins 0.000 description 1
- 101000651890 Homo sapiens Slit homolog 2 protein Proteins 0.000 description 1
- 101000651893 Homo sapiens Slit homolog 3 protein Proteins 0.000 description 1
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 1
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 description 1
- 101000640020 Homo sapiens Sodium channel protein type 11 subunit alpha Proteins 0.000 description 1
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 description 1
- 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 description 1
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 description 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 1
- 101000962322 Homo sapiens Sodium leak channel NALCN Proteins 0.000 description 1
- 101000823931 Homo sapiens Spatacsin Proteins 0.000 description 1
- 101000881267 Homo sapiens Spectrin alpha chain, erythrocytic 1 Proteins 0.000 description 1
- 101000704203 Homo sapiens Spectrin alpha chain, non-erythrocytic 1 Proteins 0.000 description 1
- 101000881247 Homo sapiens Spectrin beta chain, erythrocytic Proteins 0.000 description 1
- 101000704198 Homo sapiens Spectrin beta chain, non-erythrocytic 2 Proteins 0.000 description 1
- 101000704196 Homo sapiens Spectrin beta chain, non-erythrocytic 4 Proteins 0.000 description 1
- 101000702102 Homo sapiens Sperm flagellar protein 2 Proteins 0.000 description 1
- 101000585180 Homo sapiens Stereocilin Proteins 0.000 description 1
- 101000641015 Homo sapiens Sterile alpha motif domain-containing protein 9 Proteins 0.000 description 1
- 101000822540 Homo sapiens Sterile alpha motif domain-containing protein 9-like Proteins 0.000 description 1
- 101000861263 Homo sapiens Steroid 21-hydroxylase Proteins 0.000 description 1
- 101000651178 Homo sapiens Striated muscle preferentially expressed protein kinase Proteins 0.000 description 1
- 101000702606 Homo sapiens Structure-specific endonuclease subunit SLX4 Proteins 0.000 description 1
- 101000630720 Homo sapiens Supervillin Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000800113 Homo sapiens THO complex subunit 2 Proteins 0.000 description 1
- 101000662997 Homo sapiens TRAF2 and NCK-interacting protein kinase Proteins 0.000 description 1
- 101000713234 Homo sapiens TRIO and F-actin-binding protein Proteins 0.000 description 1
- 101000835705 Homo sapiens Tectonin beta-propeller repeat-containing protein 2 Proteins 0.000 description 1
- 101000837130 Homo sapiens Tenascin-R Proteins 0.000 description 1
- 101000626163 Homo sapiens Tenascin-X Proteins 0.000 description 1
- 101000800616 Homo sapiens Teneurin-3 Proteins 0.000 description 1
- 101000666331 Homo sapiens Teneurin-4 Proteins 0.000 description 1
- 101000596845 Homo sapiens Testis-expressed protein 15 Proteins 0.000 description 1
- 101000633680 Homo sapiens Tetratricopeptide repeat protein 37 Proteins 0.000 description 1
- 101000893741 Homo sapiens Tissue alpha-L-fucosidase Proteins 0.000 description 1
- 101000638427 Homo sapiens Tonsoku-like protein Proteins 0.000 description 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 1
- 101000800583 Homo sapiens Transcription factor 20 Proteins 0.000 description 1
- 101000723923 Homo sapiens Transcription factor HIVEP2 Proteins 0.000 description 1
- 101000933296 Homo sapiens Transcription factor TFIIIB component B'' homolog Proteins 0.000 description 1
- 101000596093 Homo sapiens Transcription initiation factor TFIID subunit 1 Proteins 0.000 description 1
- 101001074042 Homo sapiens Transcriptional activator GLI3 Proteins 0.000 description 1
- 101000796673 Homo sapiens Transformation/transcription domain-associated protein Proteins 0.000 description 1
- 101000844510 Homo sapiens Transient receptor potential cation channel subfamily M member 1 Proteins 0.000 description 1
- 101000844519 Homo sapiens Transient receptor potential cation channel subfamily M member 6 Proteins 0.000 description 1
- 101000844518 Homo sapiens Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
- 101000662961 Homo sapiens Transmembrane protein 94 Proteins 0.000 description 1
- 101000891326 Homo sapiens Treacle protein Proteins 0.000 description 1
- 101000611192 Homo sapiens Trinucleotide repeat-containing gene 6B protein Proteins 0.000 description 1
- 101000649014 Homo sapiens Triple functional domain protein Proteins 0.000 description 1
- 101000851334 Homo sapiens Troponin I, cardiac muscle Proteins 0.000 description 1
- 101000795659 Homo sapiens Tuberin Proteins 0.000 description 1
- 101001087412 Homo sapiens Tyrosine-protein phosphatase non-receptor type 18 Proteins 0.000 description 1
- 101001135585 Homo sapiens Tyrosine-protein phosphatase non-receptor type 23 Proteins 0.000 description 1
- 101000659545 Homo sapiens U5 small nuclear ribonucleoprotein 200 kDa helicase Proteins 0.000 description 1
- 101000697888 Homo sapiens UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2 Proteins 0.000 description 1
- 101000958729 Homo sapiens Unconventional myosin-IXa Proteins 0.000 description 1
- 101000583031 Homo sapiens Unconventional myosin-Va Proteins 0.000 description 1
- 101000582993 Homo sapiens Unconventional myosin-Vb Proteins 0.000 description 1
- 101000585635 Homo sapiens Unconventional myosin-XV Proteins 0.000 description 1
- 101001030226 Homo sapiens Unconventional myosin-XVIIIb Proteins 0.000 description 1
- 101000805941 Homo sapiens Usherin Proteins 0.000 description 1
- 101000667092 Homo sapiens Vacuolar protein sorting-associated protein 13A Proteins 0.000 description 1
- 101000667110 Homo sapiens Vacuolar protein sorting-associated protein 13B Proteins 0.000 description 1
- 101000667104 Homo sapiens Vacuolar protein sorting-associated protein 13C Proteins 0.000 description 1
- 101000667116 Homo sapiens Vacuolar protein sorting-associated protein 13D Proteins 0.000 description 1
- 101000860430 Homo sapiens Versican core protein Proteins 0.000 description 1
- 101000867817 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1D Proteins 0.000 description 1
- 101000867848 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1F Proteins 0.000 description 1
- 101000935123 Homo sapiens Voltage-dependent N-type calcium channel subunit alpha-1B Proteins 0.000 description 1
- 101000935117 Homo sapiens Voltage-dependent P/Q-type calcium channel subunit alpha-1A Proteins 0.000 description 1
- 101000867844 Homo sapiens Voltage-dependent R-type calcium channel subunit alpha-1E Proteins 0.000 description 1
- 101000867850 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1G Proteins 0.000 description 1
- 101000932804 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1H Proteins 0.000 description 1
- 101000771662 Homo sapiens WD repeat and FYVE domain-containing protein 3 Proteins 0.000 description 1
- 101000667300 Homo sapiens WD repeat-containing protein 19 Proteins 0.000 description 1
- 101000771618 Homo sapiens WD repeat-containing protein 62 Proteins 0.000 description 1
- 101000666077 Homo sapiens WD repeat-containing protein 81 Proteins 0.000 description 1
- 101000804798 Homo sapiens Werner syndrome ATP-dependent helicase Proteins 0.000 description 1
- 101000785721 Homo sapiens Zinc finger FYVE domain-containing protein 26 Proteins 0.000 description 1
- 101000744860 Homo sapiens Zinc finger homeobox protein 2 Proteins 0.000 description 1
- 101000759236 Homo sapiens Zinc finger protein 142 Proteins 0.000 description 1
- 101000723902 Homo sapiens Zinc finger protein 292 Proteins 0.000 description 1
- 101000760227 Homo sapiens Zinc finger protein 335 Proteins 0.000 description 1
- 101000723920 Homo sapiens Zinc finger protein 40 Proteins 0.000 description 1
- 101000964701 Homo sapiens Zinc finger protein 407 Proteins 0.000 description 1
- 101000782483 Homo sapiens Zinc finger protein 462 Proteins 0.000 description 1
- 101000915642 Homo sapiens Zinc finger protein 469 Proteins 0.000 description 1
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 description 1
- 108010027310 Host Cell Factor C1 Proteins 0.000 description 1
- 102100030355 Host cell factor 1 Human genes 0.000 description 1
- 102100040204 Hydrocephalus-inducing protein homolog Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101150009156 IGSF1 gene Proteins 0.000 description 1
- 229940124790 IL-6 inhibitor Drugs 0.000 description 1
- 102100025141 IQ motif and SEC7 domain-containing protein 2 Human genes 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102100022514 Immunoglobulin superfamily member 1 Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100027767 Inactive histone-lysine N-methyltransferase 2E Human genes 0.000 description 1
- 102100040173 Inactive serine/threonine-protein kinase TEX14 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100024039 Inositol 1,4,5-trisphosphate receptor type 1 Human genes 0.000 description 1
- 102100024037 Inositol 1,4,5-trisphosphate receptor type 2 Human genes 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102100024061 Integrator complex subunit 1 Human genes 0.000 description 1
- 102100033000 Integrin beta-4 Human genes 0.000 description 1
- 102100039927 Intraflagellar transport protein 140 homolog Human genes 0.000 description 1
- 102100039929 Intraflagellar transport protein 172 homolog Human genes 0.000 description 1
- 108010011185 KCNQ1 Potassium Channel Proteins 0.000 description 1
- 101710036322 KIAA0586 Proteins 0.000 description 1
- 101710024993 KIAA1109 Proteins 0.000 description 1
- 101710029140 KIAA1549 Proteins 0.000 description 1
- 102100026895 KICSTOR complex protein SZT2 Human genes 0.000 description 1
- 102100022891 KN motif and ankyrin repeat domain-containing protein 1 Human genes 0.000 description 1
- 102100023093 Kalirin Human genes 0.000 description 1
- 102100023924 Kinase D-interacting substrate of 220 kDa Human genes 0.000 description 1
- 102100027631 Kinesin-like protein KIF14 Human genes 0.000 description 1
- 102100021527 Kinesin-like protein KIF1A Human genes 0.000 description 1
- 102100021524 Kinesin-like protein KIF1B Human genes 0.000 description 1
- 102100037692 Kinesin-like protein KIF26B Human genes 0.000 description 1
- 102100027929 Kinesin-like protein KIF7 Human genes 0.000 description 1
- 102100021464 Kinetochore scaffold 1 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102100022746 Laminin subunit alpha-1 Human genes 0.000 description 1
- 102100027450 Laminin subunit alpha-5 Human genes 0.000 description 1
- 102100027448 Laminin subunit beta-1 Human genes 0.000 description 1
- 102100027454 Laminin subunit beta-2 Human genes 0.000 description 1
- 102100035158 Laminin subunit gamma-3 Human genes 0.000 description 1
- 102100027017 Latent-transforming growth factor beta-binding protein 2 Human genes 0.000 description 1
- 102100023757 Latent-transforming growth factor beta-binding protein 4 Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- 102100040589 Leucine-rich PPR motif-containing protein, mitochondrial Human genes 0.000 description 1
- 102100032656 Leucine-rich repeat serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 102100033353 Lipopolysaccharide-responsive and beige-like anchor protein Human genes 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 1
- 102100021918 Low-density lipoprotein receptor-related protein 4 Human genes 0.000 description 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 1
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102100040582 Lysine-specific demethylase 3B Human genes 0.000 description 1
- 102100033247 Lysine-specific demethylase 5B Human genes 0.000 description 1
- 102100033249 Lysine-specific demethylase 5C Human genes 0.000 description 1
- 102100037462 Lysine-specific demethylase 6A Human genes 0.000 description 1
- 102100037461 Lysine-specific demethylase 6B Human genes 0.000 description 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 102100028822 MAP kinase-activating death domain protein Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102100021070 Mediator of RNA polymerase II transcription subunit 12 Human genes 0.000 description 1
- 102100034160 Mediator of RNA polymerase II transcription subunit 12-like protein Human genes 0.000 description 1
- 102100026161 Mediator of RNA polymerase II transcription subunit 13 Human genes 0.000 description 1
- 102100034164 Mediator of RNA polymerase II transcription subunit 13-like Human genes 0.000 description 1
- 102100034771 Mediator of RNA polymerase II transcription subunit 23 Human genes 0.000 description 1
- 102100028328 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Human genes 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 101710163328 Methionine synthase Proteins 0.000 description 1
- 102100031551 Methionine synthase Human genes 0.000 description 1
- 102100024614 Methionine synthase reductase Human genes 0.000 description 1
- 102100021292 Methyl-CpG-binding domain protein 5 Human genes 0.000 description 1
- 102100030812 Methylcytosine dioxygenase TET3 Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100028322 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 Human genes 0.000 description 1
- 108090001040 Microtubule-associated protein 1B Proteins 0.000 description 1
- 102000004866 Microtubule-associated protein 1B Human genes 0.000 description 1
- 102100033268 Microtubule-associated serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 101150097381 Mtor gene Proteins 0.000 description 1
- 108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 description 1
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 1
- 102100038990 Multiple epidermal growth factor-like domains protein 8 Human genes 0.000 description 1
- 101100129193 Mus musculus Man2b1 gene Proteins 0.000 description 1
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 1
- 101600105505 Mus musculus Vascular endothelial growth factor C (isoform 1) Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 108010009047 Myosin VIIa Proteins 0.000 description 1
- 102000026889 Myosin VIIa Human genes 0.000 description 1
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 1
- 102100036640 Myosin-10 Human genes 0.000 description 1
- 102100038303 Myosin-2 Human genes 0.000 description 1
- 102100038317 Myosin-3 Human genes 0.000 description 1
- 102100038891 Myosin-8 Human genes 0.000 description 1
- 102100038938 Myosin-9 Human genes 0.000 description 1
- 102100030743 Myosin-IIIa Human genes 0.000 description 1
- 102000004128 Myotubularin Human genes 0.000 description 1
- 108090000697 Myotubularin Proteins 0.000 description 1
- 102100024960 Myotubularin-related protein 13 Human genes 0.000 description 1
- 102100036713 N-acetylglucosamine-1-phosphotransferase subunit gamma Human genes 0.000 description 1
- 102100036710 N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Human genes 0.000 description 1
- 101710202061 N-acetyltransferase Proteins 0.000 description 1
- 108010029147 N-acylmannosamine kinase Proteins 0.000 description 1
- 102100026873 N-fatty-acyl-amino acid synthase/hydrolase PM20D1 Human genes 0.000 description 1
- 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 description 1
- 102100039210 NBAS subunit of NRZ tethering complex Human genes 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 102100023306 Nesprin-1 Human genes 0.000 description 1
- 102100021582 Neurexin-1-beta Human genes 0.000 description 1
- 102100021310 Neurexin-3 Human genes 0.000 description 1
- 102100039234 Neurobeachin Human genes 0.000 description 1
- 102100039235 Neurobeachin-like protein 2 Human genes 0.000 description 1
- 102100035414 Neurofascin Human genes 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102100021713 Nuclear nucleic acid-binding protein C1D Human genes 0.000 description 1
- 102100021512 Nuclear pore complex protein Nup155 Human genes 0.000 description 1
- 102100032226 Nuclear pore complex protein Nup205 Human genes 0.000 description 1
- 102100021530 Nucleoporin NUP188 Human genes 0.000 description 1
- 102100025062 Nucleosome-remodeling factor subunit BPTF Human genes 0.000 description 1
- 102100030127 Obscurin Human genes 0.000 description 1
- 102100031914 Obscurin-like protein 1 Human genes 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102100034198 Otoferlin Human genes 0.000 description 1
- 102100034205 Otogelin Human genes 0.000 description 1
- 102100034206 Otogelin-like protein Human genes 0.000 description 1
- 102100030275 PH-interacting protein Human genes 0.000 description 1
- 101710119304 PH-interacting protein Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102100033496 Partitioning defective 3 homolog Human genes 0.000 description 1
- 102100031254 Patatin-like phospholipase domain-containing protein 6 Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102100024315 Pericentrin Human genes 0.000 description 1
- 102100034601 Peroxidasin homolog Human genes 0.000 description 1
- 102100022239 Peroxiredoxin-6 Human genes 0.000 description 1
- UQVKZNNCIHJZLS-UHFFFAOYSA-N PhIP Chemical compound C1=C2N(C)C(N)=NC2=NC=C1C1=CC=CC=C1 UQVKZNNCIHJZLS-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100040402 Phlorizin hydrolase Human genes 0.000 description 1
- 102100036161 Phosphatidylinositol 4-kinase alpha Human genes 0.000 description 1
- 102100025058 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Human genes 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102100030384 Phospholipid phosphatase-related protein type 2 Human genes 0.000 description 1
- 102100033623 Phospholipid-transporting ATPase ABCA3 Human genes 0.000 description 1
- 108010064071 Phosphorylase Kinase Proteins 0.000 description 1
- 102000014750 Phosphorylase Kinase Human genes 0.000 description 1
- 102100031693 Piezo-type mechanosensitive ion channel component 1 Human genes 0.000 description 1
- 102100031694 Piezo-type mechanosensitive ion channel component 2 Human genes 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 102100032594 Pleckstrin homology domain-containing family G member 2 Human genes 0.000 description 1
- 102100034345 Pogo transposable element with ZNF domain Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 description 1
- 102100032580 Polycystic kidney disease protein 1-like 1 Human genes 0.000 description 1
- 102100036143 Polycystin-1 Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102100022755 Potassium voltage-gated channel subfamily E member 1 Human genes 0.000 description 1
- 102100022752 Potassium voltage-gated channel subfamily E member 2 Human genes 0.000 description 1
- 101710163354 Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
- 102100037444 Potassium voltage-gated channel subfamily KQT member 1 Human genes 0.000 description 1
- 102100021231 Pre-mRNA-processing-splicing factor 8 Human genes 0.000 description 1
- 102100030730 Probable ATP-dependent DNA helicase HFM1 Human genes 0.000 description 1
- 102100034747 Probable E3 ubiquitin-protein ligase HERC1 Human genes 0.000 description 1
- 102100021191 Probable G-protein coupled receptor 179 Human genes 0.000 description 1
- 108091011158 Probable G-protein coupled receptor 179 Proteins 0.000 description 1
- 102100037169 Probable JmjC domain-containing histone demethylation protein 2C Human genes 0.000 description 1
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 description 1
- 102100027178 Probable helicase senataxin Human genes 0.000 description 1
- 101710113072 Probable methionine synthase Proteins 0.000 description 1
- 102100038603 Probable ubiquitin carboxyl-terminal hydrolase FAF-X Human genes 0.000 description 1
- 102100022637 Proline-rich protein 12 Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102100038589 Protein Daple Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100030232 Protein SON Human genes 0.000 description 1
- 102100028545 Protein TALPID3 Human genes 0.000 description 1
- 102100034784 Protein TANC2 Human genes 0.000 description 1
- 102100027331 Protein crumbs homolog 1 Human genes 0.000 description 1
- 102100037166 Protein eyes shut homolog Human genes 0.000 description 1
- 102100039154 Protein piccolo Human genes 0.000 description 1
- 102100037516 Protein polybromo-1 Human genes 0.000 description 1
- 102100029475 Protein unc-80 homolog Human genes 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100022095 Protocadherin Fat 1 Human genes 0.000 description 1
- 102100034547 Protocadherin Fat 4 Human genes 0.000 description 1
- 102100036382 Protocadherin-15 Human genes 0.000 description 1
- 102100036393 Protocadherin-16 Human genes 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 101000984527 Pseudomonas putida Benzene 1,2-dioxygenase system ferredoxin subunit Proteins 0.000 description 1
- 101000984526 Pseudomonas putida Benzene 1,2-dioxygenase system ferredoxin-NAD(+) reductase component Proteins 0.000 description 1
- 102100029750 Putative Polycomb group protein ASXL2 Human genes 0.000 description 1
- 102100029749 Putative Polycomb group protein ASXL3 Human genes 0.000 description 1
- 102100023588 RB1-inducible coiled-coil protein 1 Human genes 0.000 description 1
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 1
- 102100033185 Rab3 GTPase-activating protein non-catalytic subunit Human genes 0.000 description 1
- 102100038202 Ral GTPase-activating protein subunit alpha-1 Human genes 0.000 description 1
- 102100033428 Ras/Rap GTPase-activating protein SynGAP Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000832669 Rattus norvegicus Probable alcohol sulfotransferase Proteins 0.000 description 1
- 102100039663 Receptor-type tyrosine-protein phosphatase F Human genes 0.000 description 1
- 102100034101 Receptor-type tyrosine-protein phosphatase R Human genes 0.000 description 1
- 102100039808 Receptor-type tyrosine-protein phosphatase eta Human genes 0.000 description 1
- 102000043322 Reelin Human genes 0.000 description 1
- 108700038365 Reelin Proteins 0.000 description 1
- 102100036240 Regulating synaptic membrane exocytosis protein 1 Human genes 0.000 description 1
- 102100036266 Regulating synaptic membrane exocytosis protein 2 Human genes 0.000 description 1
- 101150057388 Reln gene Proteins 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 102100035670 Retinitis pigmentosa 1-like 1 protein Human genes 0.000 description 1
- 102100020890 Rho GTPase-activating protein 31 Human genes 0.000 description 1
- 102100021446 Rho GTPase-activating protein 7 Human genes 0.000 description 1
- 102100033203 Rho guanine nucleotide exchange factor 10 Human genes 0.000 description 1
- 102100032432 Rho guanine nucleotide exchange factor 18 Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 102100034742 Rotatin Human genes 0.000 description 1
- 102100027702 Roundabout homolog 1 Human genes 0.000 description 1
- 102100027739 Roundabout homolog 2 Human genes 0.000 description 1
- 102100027488 Roundabout homolog 3 Human genes 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 102100027219 S phase cyclin A-associated protein in the endoplasmic reticulum Human genes 0.000 description 1
- 102100032741 SET-binding protein Human genes 0.000 description 1
- 102100030680 SH3 and multiple ankyrin repeat domains protein 2 Human genes 0.000 description 1
- 102100030681 SH3 and multiple ankyrin repeat domains protein 3 Human genes 0.000 description 1
- 101710101741 SH3 and multiple ankyrin repeat domains protein 3 Proteins 0.000 description 1
- 101710067890 SHANK2 Proteins 0.000 description 1
- 108091006464 SLC25A23 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 101001128051 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L3 Proteins 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- 102100034272 Sacsin Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710192761 Serine-type anaerobic sulfatase-maturating enzyme Proteins 0.000 description 1
- 102100026757 Serine/threonine-protein kinase 19 Human genes 0.000 description 1
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102100027099 Signal-induced proliferation-associated 1-like protein 3 Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 102100027339 Slit homolog 3 protein Human genes 0.000 description 1
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 description 1
- 102100033974 Sodium channel protein type 11 subunit alpha Human genes 0.000 description 1
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 description 1
- 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 description 1
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 description 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 1
- 102100039242 Sodium leak channel NALCN Human genes 0.000 description 1
- 102100022077 Spatacsin Human genes 0.000 description 1
- 102100037608 Spectrin alpha chain, erythrocytic 1 Human genes 0.000 description 1
- 102100031874 Spectrin alpha chain, non-erythrocytic 1 Human genes 0.000 description 1
- 102100037613 Spectrin beta chain, erythrocytic Human genes 0.000 description 1
- 102100031864 Spectrin beta chain, non-erythrocytic 2 Human genes 0.000 description 1
- 102100031882 Spectrin beta chain, non-erythrocytic 4 Human genes 0.000 description 1
- 102100030317 Sperm flagellar protein 2 Human genes 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100029924 Stereocilin Human genes 0.000 description 1
- 102100034291 Sterile alpha motif domain-containing protein 9 Human genes 0.000 description 1
- 102100022459 Sterile alpha motif domain-containing protein 9-like Human genes 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 102100027659 Striated muscle preferentially expressed protein kinase Human genes 0.000 description 1
- 102100031003 Structure-specific endonuclease subunit SLX4 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100026344 Supervillin Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000004402 Syntrophin Human genes 0.000 description 1
- 108090000916 Syntrophin Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100033491 THO complex subunit 2 Human genes 0.000 description 1
- 102100037671 TRAF2 and NCK-interacting protein kinase Human genes 0.000 description 1
- 102100036855 TRIO and F-actin-binding protein Human genes 0.000 description 1
- 108091007076 TRIP12 Proteins 0.000 description 1
- 102000003617 TRPM1 Human genes 0.000 description 1
- 102000003608 TRPM6 Human genes 0.000 description 1
- 102000003611 TRPM7 Human genes 0.000 description 1
- 102100026312 Tectonin beta-propeller repeat-containing protein 2 Human genes 0.000 description 1
- 102100028644 Tenascin-R Human genes 0.000 description 1
- 102100024549 Tenascin-X Human genes 0.000 description 1
- 102100033191 Teneurin-3 Human genes 0.000 description 1
- 102100038123 Teneurin-4 Human genes 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 102100035116 Testis-expressed protein 15 Human genes 0.000 description 1
- 102100029210 Tetratricopeptide repeat protein 37 Human genes 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 102100040526 Tissue alpha-L-fucosidase Human genes 0.000 description 1
- 102100031224 Tonsoku-like protein Human genes 0.000 description 1
- 102100031027 Transcription activator BRG1 Human genes 0.000 description 1
- 102100033142 Transcription factor 20 Human genes 0.000 description 1
- 102100028438 Transcription factor HIVEP2 Human genes 0.000 description 1
- 102100035222 Transcription initiation factor TFIID subunit 1 Human genes 0.000 description 1
- 102100035559 Transcriptional activator GLI3 Human genes 0.000 description 1
- 102100032762 Transformation/transcription domain-associated protein Human genes 0.000 description 1
- 102100037621 Transmembrane protein 94 Human genes 0.000 description 1
- 102100025378 Transmembrane protein KIAA1109 Human genes 0.000 description 1
- 102100040421 Treacle protein Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100040244 Trinucleotide repeat-containing gene 6B protein Human genes 0.000 description 1
- 102100028101 Triple functional domain protein Human genes 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100031638 Tuberin Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100033018 Tyrosine-protein phosphatase non-receptor type 18 Human genes 0.000 description 1
- 102100033137 Tyrosine-protein phosphatase non-receptor type 23 Human genes 0.000 description 1
- 102100036230 U5 small nuclear ribonucleoprotein 200 kDa helicase Human genes 0.000 description 1
- 102000003441 UBR1 Human genes 0.000 description 1
- 101150118716 UBR1 gene Proteins 0.000 description 1
- 102100027958 UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2 Human genes 0.000 description 1
- 102100022865 UPF0606 protein KIAA1549 Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102100038307 Unconventional myosin-IXa Human genes 0.000 description 1
- 102100030409 Unconventional myosin-Va Human genes 0.000 description 1
- 102100030366 Unconventional myosin-Vb Human genes 0.000 description 1
- 102100029836 Unconventional myosin-XV Human genes 0.000 description 1
- 102100038892 Unconventional myosin-XVIIIb Human genes 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 102100037930 Usherin Human genes 0.000 description 1
- 101150045640 VWF gene Proteins 0.000 description 1
- 102100039114 Vacuolar protein sorting-associated protein 13A Human genes 0.000 description 1
- 102100039113 Vacuolar protein sorting-associated protein 13B Human genes 0.000 description 1
- 102100039112 Vacuolar protein sorting-associated protein 13C Human genes 0.000 description 1
- 102100039110 Vacuolar protein sorting-associated protein 13D Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 102100028437 Versican core protein Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102100029465 WD repeat and FYVE domain-containing protein 3 Human genes 0.000 description 1
- 102100039744 WD repeat-containing protein 19 Human genes 0.000 description 1
- 102100029478 WD repeat-containing protein 62 Human genes 0.000 description 1
- 102100038087 WD repeat-containing protein 81 Human genes 0.000 description 1
- 102100035336 Werner syndrome ATP-dependent helicase Human genes 0.000 description 1
- 108091007416 X-inactive specific transcript Proteins 0.000 description 1
- 102000056014 X-linked Nuclear Human genes 0.000 description 1
- 108700042462 X-linked Nuclear Proteins 0.000 description 1
- 108091035715 XIST (gene) Proteins 0.000 description 1
- 108010088665 Zinc Finger Protein Gli2 Proteins 0.000 description 1
- 102100026419 Zinc finger FYVE domain-containing protein 26 Human genes 0.000 description 1
- 102100040033 Zinc finger homeobox protein 2 Human genes 0.000 description 1
- 102100023392 Zinc finger protein 142 Human genes 0.000 description 1
- 102100028431 Zinc finger protein 292 Human genes 0.000 description 1
- 102100024773 Zinc finger protein 335 Human genes 0.000 description 1
- 102100028440 Zinc finger protein 40 Human genes 0.000 description 1
- 102100040832 Zinc finger protein 407 Human genes 0.000 description 1
- 102100035849 Zinc finger protein 462 Human genes 0.000 description 1
- 102100029042 Zinc finger protein 469 Human genes 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- 101710151579 Zinc metalloproteinase Proteins 0.000 description 1
- ZPCCSZFPOXBNDL-ZSTSFXQOSA-N [(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2r,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoe Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 ZPCCSZFPOXBNDL-ZSTSFXQOSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- KYHUYMLIVQFXRI-UHFFFAOYSA-N didemnin B Natural products CC1OC(=O)C(CC=2C=CC(OC)=CC=2)N(C)C(=O)C2CCCN2C(=O)C(CC(C)C)NC(=O)C(C)C(=O)C(C(C)C)OC(=O)CC(O)C(C(C)CC)NC(=O)C1NC(=O)C(CC(C)C)N(C)C(=O)C1CCCN1C(=O)C(C)O KYHUYMLIVQFXRI-UHFFFAOYSA-N 0.000 description 1
- 108010061297 didemnins Proteins 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 102000009061 dystrobrevin Human genes 0.000 description 1
- 108010074202 dystrobrevin Proteins 0.000 description 1
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 description 1
- 101150004703 eIF3i gene Proteins 0.000 description 1
- 108010056197 emerin Proteins 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 108010017007 glucose-regulated proteins Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 101150028578 grp78 gene Proteins 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000047965 human UBB Human genes 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229950005015 inebilizumab Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010008094 laminin alpha 3 Proteins 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- 210000004160 naive b lymphocyte Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 108010062219 ran-binding protein 2 Proteins 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 108091023025 thyroid hormone binding Proteins 0.000 description 1
- 102000028501 thyroid hormone-binding Human genes 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
Definitions
- Monomeric IgM is the first antibody to emerge as the B cell antigen receptor (BCR) on the surface of B cells followed by secreted pentameric IgM from plasma cells.
- BCR B cell antigen receptor
- Class switching upon B cell activation generates different isotypes or subtypes of IgG, which constitute the most abundant, secreted class of antibodies (Engels N, et al. (2016) Immunol Rev. 283: 150-160). Due to the highly diverse BCR repertoire, recognition of self-antigens can sometimes lead to the generation of harmful IgG and IgM autoantibodies leading to autoimmune disease (Suurmond J, et al. (2015) J Clin Invest. 125:2194-2202).
- HLAs human leukocyte antigens expressed on the surface of cells in a transplanted organ
- HLAs human leukocyte antigens
- AAV recombinant adeno-associated viruses
- Another pathophysiological manifestation of autoantibodies in the context of autoimmune disease, organ transplantation or gene therapies is the activation of the complement cascade and lytic components thereof, which can lead to significant tissue damage (Goldberg BS, et al. (2020) Immunol Cell Biol. 98:305-317; Grafals M, et al. (2019) Front Immunol. 10:2380; West C, et al. (2023) Hum Gene Ther. 34:554-566; Smith CJ, et al. (2022) Front Immunol. 13:999-1021).
- IgG and IgM levels can have profound implications in the development of therapeutic modalities with broad clinical impact.
- FIG. 1A - FIG. 1H show structural model and in vitro characterization of a human IgM cleaving enzyme.
- FIG. 1A shows a representative structural model of the core domain of cysteine protease candidates with active site in orange.
- FIG. IB confirms the protein expression system and IgM-cleaving assay, we used a known porcine IgM protease from Streptococcus Suis (Idessuis) that is known to cleave porcine IgM, but not human IgM.
- Immunoblot analyses showing the banding patterns of IgM from human sera following treatment with multiple candidate proteins. A cleavage band was observed for protein candidate protein 2 and 6, hereinafter referred to as IceM and IceM2, respectively.
- FIG. 1C is a cartoon schematic illustrating predicted cleavage site motif and IgM cleavage product (CP) molecular weights.
- FIG. ID shows a structural docking analysis of IceM in complex with human IgM heavy 7 chain (HC) with active site in orange.
- FIG. IE is an SDS-PAGE gel showing recombinant IceM (41.6 kDa) expression and punfication with BSA loading control.
- FIG. IF shows an SDS-PAGE gel of purified human IgM, IceM, or IgM treated with 10 pg mL' 1 IceM for 1 hr at 37 °C.
- FIG. 1G shows a concentration curve for IceM enzymatic activity in human sera.
- FIG. 1J show an immunoblot analyses showing the banding patterns of IgM, IgA, IgD, IgE, or IgG from human sera (FIG. 1H) and IgM from sera across species (FIG. II) treated with PBS or 10 pg mL" 1 IceM for 1 hr at 37 °C. indicates full length HC (IgM, ⁇ 73 kDa; IgG, ⁇ 53 kDa; IgA, ⁇ 55 kDa IgE, ⁇ 73 kDa; IgD, ⁇ 63 kDa) and arrows indicate cleavage products.
- FIG. 1J shows an alignment of IgM sequences from multiple species with the predicted human and NHP cleavage site residues (SEQ ID NO: 110) indicated in the red box. Error bars denote mean ⁇ standard deviation. All experiments were completed in at least biological triplicate. Analyses were performed with GraphPad Prism version 9.5 with P values less than 0.05 being significant.
- FIG. 2A - FIG. 2C show structural modeling and analyses of IceM contact residues.
- FIG. 2A shows structural models showing IdeS with residues in contact with human IgG shown in red.
- FIG. 2B - FIG. 2C show structural models showing IgM cleaving enzymes IceM (FIG. 2B) and IceM 2 (FIG. 2C) with residues in contact with human IgM shown in red.
- FIG. 3A - FIG. 3C show optimizing linkers for a recombinant IceM fusion protein.
- FIG. 3A top
- FIG. 3A show' structural modeling of IceM fusion proteins with three different linkers (rigid linker, flexible linker 1, and flexible linker 2 with corresponding linker amino acid sequence beneath the structure. Models are colored by pLDDT.
- FIG. 3A bottom
- FIG. 3A show' immunoblot analyses for His-tagged fusion protein expression.
- the fusion protein with the rigid linker, hereinafter termed IceMG showed the best expression and was chosen for further evaluation.
- FIG. 3B show' a structural model of the dual cleaving enzyme IceMG.
- FIG. 3C shows structural docking analysis of IceMG in complex with human IgM (gray) and human IgG (green) heavy chain with active site in red.
- FIG. 4A - FIG. 4H show in vitro characterization of a human IgM and IgG cleaving enzyme IceMG.
- FIG. 4A shows aSDS-PAGE gel showing recombinant IceMG (70.4 kDa) expression and purification with BSA loading control.
- FIG.4B shows a SDS-PAGE gel of purified human IgM. IceMG, or IgM treated with 10 pg mL" 1 IceMG for 1 hr at 37 °C.
- FIG. 4C shows a schematic illustrating predicted IgG cleavage products (CP).
- FIG. 4D shows a SDS- PAGE gel of purified human IgG, IceMG, or IgG treated w'ith 10 pg mL" 1 IceMG for 1 hr at 37 °C.
- FIG. 4E and FIG. 4F shows a concentration curve for IceMG enzymatic activity on IgM (FIG. 4E) or IgG (FIG. 4F) in human sera.
- FIG. 4G shows immunoblot analyses showing the banding patterns of IgM, IgG, IgA, IgE, or IgD from human sera and IgM or IgG from sera across species treated with PBS or 10 pg mL" 1 IceMG for 1 hr at 37 °C.
- IgG cleavage site residues for each IgG subtype IgGl (SEQ ID NO: 115), IgG2 (SEQ ID NO: 116), IgG3 (SEQ ID NO: 117), and IgG4 (SEQ ID NO: 118). *indicates full length HC and arrows indicate cleavage products. Error bars denote mean ⁇ standard deviation. All experiments were completed in at least biological triplicate. Analyses were performed with GraphPad Prism version 9.5 with P values less than 0.05 being significant.
- FIG. 5A - FIG. 5G show an in vitro assessment of recombinant IceM and IceMG on B cells.
- FIG. 5A shows immunoblot analysis of Daudi cells treated with recombinant 10 pg mL" 1 IceM for 1 hr at 37 °C.
- FIG. 5B show' immunofluorescent staining of surface-bound IgM on Daudi cells.
- FIG. 5C show representative plots for flow cytometric analysis of IgM surface expression on Daudi cells following treatment with PBS or IceM at 1 hr. Data are gated to analyze the IgM + (FITC + ) cohort.
- FIG. 5D show the quantitation of percent IgM + Daudi cells.
- FIG. 5A shows immunoblot analysis of Daudi cells treated with recombinant 10 pg mL" 1 IceM for 1 hr at 37 °C.
- FIG. 5B show' immunofluorescent staining of surface-bound IgM on Daudi cells.
- FIGS. 5E are representative plots for flow' cytometric analysis of IgM surface expression on CD 19+ B Cells (BCR) following treatment with PBS, IceM, or IceMG at 1 hr, 12 hr, and 24 hr post-treatment. Data are gated on live cells and then CD19 + (APC + ) to analyze the IgM + (FITC + ) cohort.
- FIG. 5F shows the quantitation of percent IgM + B cells from (FIG. 5A).
- FIG. 5G shows dose curve for IceM enzymatic activity on B cells treated for 1 hr at 37 °C. Error bars denote mean ⁇ standard deviation. All experiments were completed in at least biological triplicate.
- FIG. 6A - FIG. 6C shows the in vitro assessment of recombinant IceM and IceMG complement activation.
- FIG. 6A show- the illustration of AAV 9- or platelet factor-based complement activation assay.
- FIG. 6B and FIG. 6C show ELISA based quantitation of C3a levels in human sera treated with PBS or 10 pg mL' 1 IceM for 1 hr at 37 °C to cleave IgM followed by incubation with AAV9 (FIG. 6B) or PF4/Heparin complexes (FIG. 6C). Error bars denote mean ⁇ standard deviation. All experiments were completed in at least biological triplicate. Statistical significance was determined using one-way ANOVA. Analyses were performed with GraphPad Prism version 9.5 with P values less than 0.05 being significant.
- FIG. 7A - FIG. 7N show the in vivo assessment of recombinant IceM and IceMG in passively immunized mice.
- FIG. 7A show an overview' of experimental design for mouse study.
- FIG. 7B - FIG. 7E show immunoblots for circulating human IgM in mice treated with PBS of IceM at the dose indicated.
- FIG. 7F - FIG. 71 show immunoblots for circulating human IgM (top panel) or IgG (bottom panel) in mice treated with PBS of IceM at the dose indicated.
- Five mice (numbered 1-5) w ere tested per cohort with human serum (Hu) included as a positive control.
- FIG. 7J show' an overview' of experimental design for AAV mouse study.
- Luciferase expression was evaluated 21 days post injection in heart and liver tissue for AAV8 (FIG. 7K and FIG. 7L) and AAV9 (FIG. 7M and FIG. 7N). Luciferase expression levels were normalized for total tissue protein concentration and represented as log relative luminescence units per gram of tissue (log RLU/g tissue).
- FIG.8A- FIG.8H show- the Tn vivo assessment of recombinant IceM in rhesus macaques.
- FIG. 8A show an overview of experimental design for IceM nonhuman primate study.
- FIG. 8B and FIG. 8C show immunoblot analyses of His-tagged IceM (41.6 kDa) from NHP N303 (FIG. SB) and NHP M741 (FIG. 8C) at various time intervals following IceM administration.
- FIG. 8D and FIG. 8E show' immunoblots for circulating IgM in animals treated with IceM. Treatment days indicated in red.
- FIG. 8F shows the quantification of uncleaved IgM and cleavage product bands from immunoblots in FIG. 8G and FIG.
- FIG. 9A - FIG. 9H show the in vivo assessment 1 of recombinant IceMG on circulating IgM in rhesus macaques.
- FIG. 9A show overview of experimental design for IceMG nonhuman primate study 1.
- FIG. 9B FIG. 9D (top) show the immunoblot analyses of His-tagged IceMG (70.4 kDa) from animals 49873 (FIG. 9B), 49813 (FIG. 9C), and 499682 (FIG. 9D) at various time intervals following IceMG administration.
- FIG. 9D (bottom) show the immunoblots for circulating IgM in animals treated with IceMG at the dose indicated.
- FIG. 9E - FIG. 9G show the quantitation of IgM immunoblots from FIG. 9B - FIG. 9D.
- FIG. 9H shows the ELISA based quantitation of C3a levels in sera from NHPs in FIG. 9B - FIG. 9D following treatment with AAV9 to elicit complement activation, indicates full-length HC and arrows indicate cleavage products.
- FIG. 10A - FIG. 10G shows the in vivo assessment 2 of recombinant IceMG on circulating IgM in rhesus macaques.
- FIG. 10A show the overview of experimental design for IceMG nonhuman primate study 2 using animals 36725, 37662, 35788, 38131, 38718, 38721.
- FIG. 10B - FIG. 10D show immunoblot analyses for circulating IgM (FIG. 10B - FIG. 10D) in animals treated with IceMG at the dose indicated.
- FIG. 10E - FIG. 10G show the quantitation of IgM immunoblots from FIG. 10B - FIG. 10D. * indicates full-length HC and arrows indicate cleavage products.
- FIG. 11A - FIG. 11F show the in vivo assessment of recombinant IceMG on circulating IgG in rhesus macaques.
- FIG. 11A - FIG. 11F show immunoblots for circulating IgG in animals treated with IceMG at the dose indicated for nonhuman primate study 1 (FIG. 11A - FIG. HC) or nonhuman primate study 2 (FIG. HD - FIG. HF). *indicates full-length HC and arrows indicate cleavage products.
- Disclosed herein is a recombinant enzyme having IgM specific protease activity.
- a recombinant enz me having IgG specific protease activity 7 .
- an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and having IgM specific protease activity and/or IgG specific protease activity.
- a recombinant enzy me that can bind to and cleave at one or more sequences set forth in SEQ ID NO: 111 - SEQ ID NO: 118 in an IgG molecule and at the sequence set forth in SEQ ID NO: 110 in an IgM molecule.
- Disclosed herein is an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
- an isolated nucleic acid molecule encoding any disclosed recombinant enzy me.
- a codon-optimized isolated nucleic acid molecule encoding any disclosed recombinant enzyme.
- an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92.
- Disclosed herein is an isolated nucleic acid molecule encoding the recombinant enzyme having the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
- a vector comprising a nucleic acid sequence encoding the recombinant enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
- a vector comprising a nucleic acid sequence comprising the sequence of any one of SEQ ID NO: 47 - SEQ ID NO: 92 or a fragment thereof.
- IgM immunoglobulin M
- IgG immunoglobulin G
- IgM immunoglobulin M
- the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
- Disclosed herein is a method of reducing the level of circulating intact IgM and/or IgG and IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence of any one of SEQ ID NO: 01 - SEQ ID NO:46.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
- a method of reducing and/or minimizing an immune response in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
- Disclosed herein is a method reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity, and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity.
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
- compositions compounds, kits, capsules, containers, and/or methods thereof. It is to be understood that the inventive aspects of which are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, a further aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent '‘about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as ‘'about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
- references in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed.
- X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
- a disclosed method can optionally comprise one or more additional steps, such as, for example, repeating an administering step or altering an administering step.
- isolated refers to a nucleic acid molecule or a nucleic acid sequence that has been substantially separated, produced apart from, or purified away from other biological components in the cell or tissue of an organism in which the component occurs, such as other cells, chromosomal and extrachromosomal DNA and RNA, and proteins.
- Nucleic acids and proteins that have been “isolated” include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids and proteins.
- Isolated IceM, IceM2, IceM Full, IceM2 Full, IceM Mid, IceM Lead, IceM2 Lead, Ice MG, IceMG2, IceMG Optilinkerl, IceMG2 Optilinkerl, IceMG-Optimlinker2, and IceMG-Optinlinker3 can be at least 50% pure, such as at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 100% pure.
- the term “subject” refers to the target of administration, e.g., a human being.
- the term “subject” also includes domesticated animals (e.g., cats, dogs, etc.), livestock (e.g. , cattle, horses, pigs, sheep, goats, etc.), and laboratory' animals (e.g. , mouse, rabbit, rat, guinea pig, fruit fly, etc.).
- the subject of the herein disclosed methods can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian.
- the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, or rodent.
- the term does not denote a particular age or sex, and thus, adult and child subjects, as well as fetuses, whether male or female, are intended to be covered.
- a subject can be a human patient.
- a subject can have a disease or disorder, be suspected of having a disease or disorder, or be at risk of developing a disease or disorder (e.g., a genetic disease or disorder).
- a subject can have an AD or AIF disease and/or disorder.
- a subject can be in need of one or more transplanted organs. In an aspect, a subject can have received one or more transplanted organs. In an aspect, a subject can have received one or more transplanted organs. In an aspect, a subject can be in need of gene therapy, can be receiving gene therapy, or can have received gene therapy.
- the term “diagnosed” means having been subj ected to an examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof, or by one or more of the disclosed methods.
- diagnosisd with a disease or disorder means having been subjected to an examination by a person of skill, for example, a physician, and found to have a condition (such as a genetic disease or disorder) that can be treated by one or more of the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof, or by one or more of the disclosed methods.
- a condition such as a genetic disease or disorder
- “suspected of having a disease or disorder” can mean having been subjected to an examination by a person of skill, for example, a physician, and found to have a condition (such as a genetic disease or disorder) that can likely be treated by one or more of the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof, or by one or more of the disclosed methods.
- an examination can be physical, can involve various tests (e.g., blood tests, genotyping, biopsies, etc.) and assays (e.g., enzymatic assay), or a combination thereof.
- a “patient” refers to a subject afflicted with a disease or disorder (e.g., a genetic disease or disorder).
- a patient can refer to a subject that has been diagnosed with or is suspected of having a disease or disorder.
- a patient can refer to a subject that has been diagnosed with or is suspected of having a disease or disorder and is seeking treatment or receiving treatment for a disease or disorder.
- a patient can have an AD or AIF disease and/or disorder.
- a patient can be in need of one or more transplanted organs.
- a patient can have received one or more transplanted organs.
- a patient can have received one or more transplanted organs.
- a patient can be in need of gene therapy, can be receiving gene therapy, or can have received gene therapy.
- the phrase "‘identified to be in need of treatment for a disease or disorder,” or the like, refers to selection of a subject based upon need for treatment of the disease or disorder.
- a subject can be identified as having a need for treatment of a disease or disorder (e.g., a genetic disease or disorder, an AD, an AIF disease, transplanted organs) based upon an earlier diagnosis by a person of skill and thereafter subjected to treatment for the genetic disease or disorder.
- the identification can be performed by a person different from the person making the diagnosis.
- the administration can be performed by one who performed the diagnosis.
- B lymphocytes As discussed herein, humoral immunity is mediated by circulating proteins called antibodies, which are produced by B lymphocytes.
- Antibodies exist either as membrane-bound antibodies on the surface of B lymphocytes that function as receptors for the antigen or as secreted antibodies that reside in the circulation, tissues, and mucosal sites to neutralize toxins, prevent the entry and spread of pathogens, and eliminate microbes.
- the activation of B lymphocytes is initiated by the specific recognition of antigens by the surface Ig receptors of these cells. Activation leads to proliferation of antigen-specific cells and their differentiation in cooperation with Th cells, generating memory B lymphocytes and antibody-secreting plasma cells.
- T-dependent antibody response' T-dependent antibody response'
- TDARs antibody responses to multivalent nonproteinic antigens with repeating determinants, such as polysaccharides, some lipids, and nucleic acids, do not involve antigen-specific helper T lymphocytes and are called ‘T-independent antibody responses.’
- TDARs plasma cells or their precursors migrate from germinal centers in the peripheral lymphoid organs, where they are produced, to the bone marrow, where they live for many years and ensure specific protection against microbes for long periods of time.
- immune response refers to the body’s response to foreign agents and infections organisms and includes (i) the body’s innate or non-specific immune system and (ii) the body's adaptive or specific immune system (including B cells, cytotoxic T cells, and helper T cells).
- body's adaptive or specific immune system including B cells, cytotoxic T cells, and helper T cells.
- ‘'primary and secondary antibody responses” to protein antigens differ qualitatively and quantitatively. Primary responses result from the activation of naive B lymphocytes that have not been previously stimulated by the antigen, whereas a secondary' immune response is elicited when the same antigen stimulates antigen-specific memory B lymphocytes.
- the main isotype is IgG instead of IgM, and antibody affinity is much greater.
- the various forms of antibodies (Ig) possess a number of effector functions to engage the antigen. Microbes, tumor cells, or foreign proteins can express several types of antigens and multiple copies of these antigens. If the microbial antigen to which an antibody is directed is associated with the toxic portion of a molecule, then the antibody can neutralize the toxin.
- neutralizing antibodies are frequently a problem in the therapeutic application of biotechnolog -derived recombinant proteins as neutralizing antibodies can become a rate-limiting step during preclinical testing because animals may perceive the recombinant protein, especially when humanized, as non-self.
- IgM and IgG can function to opsonize some microbes independent of complement activation in an antigen-dependent fashion because macrophages and neutrophils have receptors on their surface, which recognize the constant region of Ig (Fc receptors, FcRs).
- FcRs also play a maj or role in the ability' of IgG to participate in a process known as ‘antibody-dependent cellular cytotoxicity,’ whereby antigen-specific antibody attaches via FcRs to certain types of cells, including NK. cells, enabling these cells to attach intimately to the target cell and trigger cell death.
- FcRs are also the primary effector mechanism for IgE, which is the principal immune defense against certain types of parasitic infections (most notably, helminths) and is produced primarily by the external immune system along secretory surfaces. IgE binds to FcR on the surface of mast cells and basophils. Once bound to FcR, IgE can sen e as an antigen-specific receptor to trigger the release of proinflammatory factors, including vasoactive amines (e.g., histamine) and products of the arachidonic cascade (e.g., leucotrienes and prostaglandins). Systemic immunity is mediated by IgM and IgG, the latter being the major form of Ig found in the blood.
- vasoactive amines e.g., histamine
- arachidonic cascade e.g., leucotrienes and prostaglandins
- AD autoimmune disease
- IgA and IgE inflammatory bowel syndrome
- AD occurs when adaptive immune cells lose their ability to maintain self-tolerance of human cells. As a result, the immune system begins attacking healthy tissues as though they were infectious agents. Some ADs are organ-specific, whereas others can affect multiple parts of the body. Recurrent fever and chronic inflammation can be attributed to autoimmune disease. However, many possible symptoms are unique to AD, including hair loss, dry mouth, temperature sensitivity’, muscle weakness, reproductive issues, and more. A variety of conditions including environment, hormones, injury', infection, and genes can all play a role in initiating autoimmunity.
- AD Alzheimer's disease
- AIF Autoinflammatory
- diseases only involve the innate immune system. AIFs occur when innate immune cells are activated without an infection or injury being present. This mishap kickstarts the release of cytokines and other immune responses, causing fever and inflammation. Recurring episodes of high fever are the primary' symptom of AIF. Similar to some autoimmune diseases, autoinflammatory symptoms can be widespread, affecting the joints, gastrointestinal tract, skin, eyes, and internal organs.
- a "regulatory element” can refer to promoters, enhancers, internal ribosomal entry' sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences).
- Regulatory elements can include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory' sequences).
- inhibiting mean to diminish or decrease an activity, level, response, condition, severity, disease, or other biological parameter (such as the level of circulating IgG and/or circulating IgM or the level of surface-bound IgM on B cells). This can include, but is not limited to, the complete ablation of the activity', level, response, condition, severity', disease, or other biological parameter (such as the level of circulating IgG and/or IgM or the level of surface-bound IgM on B cells).
- the inhibition or reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of reduction in between as compared to native or control levels.
- the inhibition or reduction can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% as compared to native or control levels.
- the inhibition or reduction can be 0-25%, 25-50%, 50-75%, or 75- 100% as compared to native or control levels.
- a native or control level can be a predisease or pre-disorder level.
- treat or “treating’’ or “treatment” include palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
- the terms cover any treatment of a subject, including a mammal (e.g., a human), and includes: (i) preventing the undesired physiological change, disease, pathological condition, or disorder from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the physiological change, disease, pathological condition, or disorder, i.e., arresting its development; or (iii) relieving the physiological change, disease, pathological condition, or disorder, i.e., causing regression of the disease.
- a mammal e.g., a human
- treating a disease or disorder can reduce the severity of an established a disease or disorder in a subject by l%-100% as compared to a control (such as, for example, an individual not having a genetic disease or disorder).
- treating can refer to a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of a disease or disorder (such as a genetic disease or disorder).
- treating a disease or disorder can reduce one or more symptoms of a disease or disorder in a subject by 1 %-l 00% as compared to a control (such as, for example, an individual not having a genetic disease or disorder).
- treating can refer to 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% reduction of one or more symptoms of an established a disease or disorder.
- treatment does not necessarily refer to a cure or complete ablation or eradication of a disease or disorder.
- treatment can refer to a cure or complete ablation or eradication of a disease or disorder.
- the term “prevent” or “preventing” or “prevention” refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. It is understood that where reduce, inhibit, or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed. In an aspect, preventing a disease or disorder having chromatin deregulation and/or chromatin dysregulation is intended.
- prevent also refer to prophylactic or preventative measures for protecting or precluding a subject (e.g., an individual) not having a given a disease or disorder (such as a genetic disease or disorder) or related complication from progressing to that complication.
- a subject e.g., an individual
- a disease or disorder such as a genetic disease or disorder
- related complication from progressing to that complication.
- administering and “administration” refer to any method of providing one or more of the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof to a subject.
- Such methods include, but are not limited to, the following: oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, in utero administration, intrahepatic administration, intravaginal administration, ophthalmic administration, intraaural administration, otic administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-CSF administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can also include hepatic intra-arterial administration or administration through the hepatic portal vein (HPV).
- HPV hepatic portal vein
- Administration of a disclosed enzy me, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical composition, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed small molecule, a disclosed endonuclease, a disclosed oligonucleotide, and/or a disclosed RNA therapeutic can comprise administration directly into the CNS or the PNS. Administration can be continuous or intermittent. Administration can comprise a combination of one or more route.
- the skilled person can determine an efficacious dose, an efficacious schedule, and an efficacious route of administration for the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof to treat or prevent a disease or disorder (such as genetic disease or disorder).
- the skilled person can also alter, change, or modify an aspect of an administering step to improve efficacy of the disclosed enzymes, the disclosed recombinant enzy mes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof.
- determining the amount is meant both an absolute quantification of a particular analyte (e.g., level of IgG and/or IgM) or a determination of the relative abundance of a particular analyte (e.g., level of IgG and/or IgM compared to a control / reference level).
- the phrase includes both direct or indirect measurements of abundance or both.
- IdeZ is a cysteine protease that inactivates IgG antibodies by cleaving IgG at the lower hinge region of the heavy chain producing one F(ab’)? and one homodimeric Fc fragment.
- a pharmaceutical carrier refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
- suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- a pharmaceutical carrier employed can be a solid, liquid, or gas.
- examples of solid carriers can include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
- examples of liquid carriers can include sugar syrup, peanut oil, olive oil, and water.
- examples of gaseous carriers can include carbon dioxide and nitrogen.
- oral liquid preparations such as suspensions, elixirs and solutions
- carriers such as starches, sugars, microcry stalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like
- oral solid preparations such as powders, capsules and tablets.
- tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
- tablets can be coated by standard aqueous or nonaqueous techniques.
- Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
- These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
- Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like.
- Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption.
- Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polygly colide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial -retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use.
- Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
- the term '‘excipient” refers to an inert substance which is commonly used as a diluent, vehicle, preservative, binder, or stabilizing agent, and includes, but is not limited to, proteins (e.g., serum albumin, etc.), amino acids (e.g., aspartic acid, glutamic acid, lysine, arginine, glycine, histidine, etc.), fatty acids and phospholipids (e.g., alkyl sulfonates, caprylate, etc.), surfactants (e.g., SDS, polysorbate, nonionic surfactant, etc.), saccharides (e.g., sucrose, maltose, trehalose, etc.) and polyols (e.g., mannitol, sorbitol, etc.). See, also, for reference. Remington’s Pharmaceutical Sciences, (1990) Mack Publishing Co., Easton, Pa., which is fatty acids and phospholipids (
- “concurrently” means (1) simultaneously in time, or (2) at different times during the course of a common treatment schedule.
- contacting refers to bringing one or more of the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof together with a target area or intended target area (e.g. a cleavage site on IgG (SEQ ID NO: 111 - SEQ ID NO: 118) and/or IgM (SEQ ID NO: 110)) in such a manner that the one or more of the disclosed isolated nucleic acid molecules, disclosed vectors, disclosed pharmaceutical formulations, or a combination thereof exert an effect on the intended target or targeted area either directly or indirectly.
- a target area or intended target area e.g. a cleavage site on IgG (SEQ ID NO: 111 - SEQ ID NO: 118) and/or IgM (SEQ ID NO: 110)
- a target area can comprise one or more cells, and in an aspect, one or more cells can be in a subject.
- a target area or intended target area can be one or more of a subject’s organs (e.g., lungs, heart, liver, kidney, brain, etc.).
- a target area or intended target area can be any organ, tissue, or cells that are affected by a disease or disorder (such as a genetic disease or disorder).
- determining can refer to measuring or ascertaining the presence and severity of a disease or disorder, such as, for example, a genetic disease or disorder.
- Methods and techniques used to determine the presence and/or severity of a disease or disorder are ty pically known to the medical arts.
- the art is familiar with the ways to identify and/or diagnose the presence, severity, or both of a disease or disorder (such as, for example, a genetic disease or disorder).
- “effective amount'’ and “amount effective” can refer to an amount that is sufficient to achieve the desired result such as, for example, the treatment and/or prevention of a disease or disorder (e.g., a genetic disease or disorder) or a suspected disease or disorder.
- the terms “effective amount” and “amount effective” can refer to an amount that is sufficient to achieve the desired an effect on an undesired condition (e.g., a disease or disorder).
- a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects.
- “therapeutically effective amount” means an amount of a disclosed enzy me, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation; that (i) treats the particular disease, condition, or disorder (e.g., a genetic disease or disorder), (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder e.g., a genetic disease or disorder), or (iii) delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein (e.g., a genetic disease or disorder).
- a genetic disease or disorder e.g., a genetic disease or disorder
- attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder e.g., a genetic disease or disorder
- delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein e.g., a genetic disease or disorder.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety' of factors including the disorder being treated and the severity of the disorder; the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, disclosed vectors, disclosed pharmaceutical formulations employed; the disclosed methods employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the disclosed isolated nucleic acid molecules, disclosed vectors, or disclosed pharmaceutical formulations employed; the duration of the treatment; drugs used in combination or coincidental with the disclosed isolated nucleic acid molecules, disclosed vectors, or disclosed pharmaceutical formulations employed, and other like factors well known in the medical arts.
- the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, disclosed vectors, or disclosed pharmaceutical formulations at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, a single dose of the disclosed isolated nucleic acid molecules, disclosed vectors, or disclosed pharmaceutical formulations can contain such amounts or submultiples thereof to make up the daily dose.
- the dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days.
- a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition, such as, for example, a disease or disorder due to a missing, deficient, and/or mutant protein or enzyme.
- RNA therapeutics can refer to the use of oligonucleotides to target RNA. RNA therapeutics can offer the promise of uniquely targeting the precise nucleic acids involved in a particular disease with greater specificity, improved potency, and decreased toxicity. This could be particularly powerful for genetic diseases where it is most advantageous to aim for the RNA as opposed to the protein.
- a therapeutic RNA can comprise one or more expression sequences.
- expression sequences can comprise an RNAi, shRNA, mRNA, non-coding RNA (ncRNA), an antisense such as an antisense RNA, miRNA, morpholino oligonucleotide, peptide-nucleic acid (PNA) or ssDNA (with natural, and modified nucleotides, including but not limited to, LNA, BNA, 2’-O-Me-RNA, 2 -MEO-RNA, 2'-F-RNA), or analog or conjugate thereof.
- an antisense such as an antisense RNA, miRNA, morpholino oligonucleotide, peptide-nucleic acid (PNA) or ssDNA (with natural, and modified nucleotides, including but not limited to, LNA, BNA, 2’-O-Me-RNA, 2 -MEO-RNA, 2'-F-RNA, or analog or conjugate thereof.
- a disclosed therapeutic RNA can comprise one or more long non-coding RNA (IncRNA), such as, for example, along intergenic non-coding RNA (lincRNA), pre-transcript, pre-miRNA, pre-mRNA, competing endogenous RNA (ceRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), pseudo-gene, rRNA, or tRNA.
- ncRNA can be piwi-interacting RNA (piRNA), primary miRNA (pri-miRNA), or premature miRNA (pre-miRNA).
- a disclosed therapeutic RNA or an RNA therapeutic can comprise antisense oligonucleotides (ASOs) that inhibit mRNA translation, oligonucleotides that function via RNA interference (RNAi) pathway, RNA molecules that behave like enzymes (ribozymes), RNA oligonucleotides that bind to proteins and other cellular molecules, and ASOs that bind to mRNA and form a structure that is recognized by RNase H resulting in cleavage of the mRNA target.
- RNA therapeutics can comprise RNAi and ASOs that inhibit mRNA translation.
- RNAi operates sequence specifically and post-transcriptionally by activating ribonucleases which, along with other enzymes and complexes, coordinately degrade the RNA after the original RNA target has been cut into smaller pieces while antisense oligonucleotides bind to their target nucleic acid via Watson-Crick base pairing, and inhibit or alter gene expression via steric hindrance, splicing alterations, initiation of target degradation, or other events.
- peptide As used herein, “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds.
- a protein must contain at least two amino acids and there is no limitation on the maximum number of amino acids that can comprise a protein’s sequence.
- peptide can refer to a short chain of amino acids including, for example, natural peptides, recombinant peptides, synthetic peptides, or any combination thereof.
- Proteins and peptides can include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, and fusion proteins, among others.
- nucleic acid or "oligonucleotide” or “polynucleotide” as used herein means at least two nucleotides covalently linked together.
- the depiction of a single strand can also define the sequence of the complementary strand.
- a nucleic acid can encompass the complementary strand of a depicted single strand.
- Many variants of a nucleic acid can be used for the same purpose as a given nucleic acid.
- a nucleic acid can encompass substantially identical nucleic acids and complements thereof.
- a single strand can provide a probe that can hybridize to a target sequence under stringent hybridization conditions.
- a nucleic acid can encompass a probe that hybridizes under stringent hybridization conditions.
- a nucleic acid can be single-stranded, or double-stranded, or can contain portions of both double-stranded and single-stranded sequence.
- the nucleic acid can be DNA, both genomic and cDN A, RN A, or a hybrid, where the nucleic acid can contain combinations of deoxy ribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine and isoguanine.
- Nucleic acids can be obtained by chemical synthesis methods or by recombinant methods.
- nucleic acid can refer to RNA or DNA that is linear or branched, single or double stranded, or a hybrid thereof.
- the term can encompass RNA/DNA hybrids.
- less common bases such as inosine, 5- methylcytosine, 6-methyladenine. hypoxanthine and others can also be used for antisense, dsRNA, and ribozyme pairing.
- polynucleotides that contain C-5 propyne analogues of uridine and cytidine have been shown to bind RNA with high affinity and to be potent antisense inhibitors of gene expression.
- Other modifications, such as modification to the phosphodiester backbone, or the 2'-hy droxy in the ribose sugar group of the RNA can also be made.
- a “polynucleotide” is a sequence of nucleotide bases, and may be RNA, DNA, or DNA- RNA hybrid sequences (including both naturally occurring and non-naturally occurring nucleotides).
- a "fragment” or "portion” of a nucleotide sequence can be understood to mean a nucleotide sequence of reduced length relative (e.g., reduced by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more nucleotides) to a reference nucleic acid or nucleotide sequence and comprising, consisting essentially of, or consisting of a nucleotide sequence of contiguous nucleotides identical or almost identical (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical) to the reference nucleic acid or nucleotide sequence.
- nucleic acid fragment or portion can be. where appropriate, included in a larger polynucleotide of which it is a constituent.
- a fragment or portion of a nucleotide sequence or nucleic acid sequence can comprise the sequence encoding an exon having one or more mutations.
- a “fragment’' or “portion” of an amino acid sequence can be understood to mean an amino acid sequence of reduced length relative (e.g., reduced by 1, 2. 3, 4, 5. 6, 7, 8. 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more ammo acids) to a reference amino acid sequence and comprising, consisting essentially of, or consisting of an amino acid sequence of contiguous amino acids identical or almost identical (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical) to the reference amino acid sequence.
- Such an amino acid fragment or portion according to the disclosure can be, where appropriate, included in a larger amino acid sequence of which it is a
- “Complement” or “complementary” as used herein means a nucleic acid can mean Watson-Crick (e.g., A-T/U and C-G) or Hoogsteen base pairing between nucleotides or nucleotide analogs of nucleic acid molecules. “Complementarity” refers to a property shared between two nucleic acid sequences, such that when they are aligned antiparallel to each other, the nucleotide bases at each position will be complementary.
- operably linked means that expression of a gene or a transgene is under the control of a promoter with which it is spatially connected.
- a promoter can be positioned 5’ (upstream) or 3’ (downstream) of a gene under its control.
- the distance between the promoter and a gene can be approximately the same as the distance between that promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variation in this distance can be accommodated without loss of promoter function.
- promoter or “promoters” are known to the art. Depending on the level and tissue-specific expression desired, a variety of promoter elements can be used. A promoter can be tissue-specific or ubiquitous and can be constitutive or inducible, depending on the pattern of the gene expression desired. A promoter can be native (endogenous) or foreign (exogenous) and can be a natural or a synthetic sequence. By foreign or exogenous, it is intended that the transcriptional initiation region is not found in the wild-type host into which the transcriptional initiation region is introduced.
- tissue-specific promoters are known to the art and include, but are not limited to, neuron-specific promoters, muscle-specific promoters, liver-specific promoters, skeletal musclespecific promoters, and heart-specific promoters.
- Liver-specific promoters are known to the art and include, but are not limited to, the thyroxin binding globulin (TBG) promoter, the al-microglobulin/bikunin enhancer/thyroid hormone-binding globulin promoter, the human albumin (hALB) promoter, the thyroid hormone- binding globulin promoter, the a- 1 -anti -trypsin promoter, the bovine albumin (bAlb) promoter, the murine albumin (mAlb) promoter, the human al -antitrypsin (hAAT) promoter, the ApoEhAAT promoter comprising the ApoE enhancer and the hAAT promoter, the transthyretin (TTR) promoter, the liver fatty acid binding protein promoter, the hepatitis B virus (HBV) promoter, the DC172 promoter comprising the hAAT promoter and the al -microglobulin enhancer, the DC 190 promoter comprising
- a liver specific promoter can comprise about 845-bp and comprise the thyroid hormone-binding globulin promoter sequences (2382 to 13), two copies of al-microglobulin/bikunin enhancer sequences (22,804 through 22,704), and a 71-bp leader sequence as described by Ill CR, et al. (1997).
- Ubiquitous/constitutive promoters include, but are not limited to, a CMV major immediate-early enhancer/chicken beta-actin promoter, a cytomegalovirus (CMV) major immediate-early promoter, an Elongation Factor 1-a (EFl-a) promoter, a simian vacuolating virus 40 (SV40) promoter, an AmpR promoter, a PyK promoter, a human ubiquitin C gene (Ubc) promoter, a MFG promoter, a human beta actin promoter, a CAG promoter, a EGR1 promoter, a FerH promoter, a FerL promoter, a GRP78 promoter, a GRP94 promoter, a HSP70 promoter, a 0-kin promoter, a murine phosphoglycerate kinase (mPGK.) or human PGK (hPGK) promoter, a
- CMV CMV major immediate-ear
- an “inducible promoter” refers to a promoter that can be regulated bypositive or negative control.
- Factors that can regulate an inducible promoter include, but are not limited to, chemical agents (e g., the metallothionein promoter or a hormone inducible promoter), temperature, and light.
- the term “seroty pe” is a distinction used to refer to an AAV having a capsid that is serologically distinct from other AAV serotypes. Serologic distinctiveness can be determined by the lack of cross-reactivity between antibodies to one AAV as compared to another AAV. Such cross-reactivity differences are usually due to differences in capsid protein sequences/antigenic determinants (e.g., due to VP1, VP2, and/or VP3 sequence differences of AAV serotypes).
- “tropism’’ refers to the specificity of an AAV capsid protein present in an AAV viral particle, for infecting a particular type of cell or tissue.
- the tropism of an AAV capsid for a particular type of cell or tissue may be determined by measuring the ability of AAV vector particles comprising the hybrid AAV capsid protein to infect or to transduce a particular type of cell or tissue, using standard assays that are well-known in the art such as those disclosed in the examples of the present application.
- the term “liver tropism” or “hepatic tropism” refers to the tropism for liver or hepatic tissue and cells, including hepatocytes.
- sequence identity and “sequence similarity” can be determined by alignment of two peptide or two nucleotide sequences using global or local alignment algorithms. Sequences may then be referred to as “substantially identical” or “essentially similar” when they are optimally aligned. For example, sequence similarity or identity can be determined by searching against databases such as FASTA, BLAST, etc., but hits should be retrieved and aligned pairwise to compare sequence identity.
- Two proteins or two protein domains, or two nucleic acid sequences can have “substantial sequence identity” if the percentage sequence identity is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more, preferably 90%, 95%, 98%, 99% or more.
- Such sequences are also referred to as “variants” herein, e.g., other variants of a missing, deficient, and/or mutant protein or enzyme. It should be understood that sequence with substantial sequence identity do not necessarily have the same length and may differ in length. For example, sequences that have the same nucleotide sequence but of which one has additional nucleotides on the 3’- and/or 5’-side are 100% identical.
- a “heterologous” or a “recombinant” nucleotide or amino acid sequence as used interchangeably herein can refer to a nucleotide or an amino acid sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring nucleotide or amino acid sequence.
- homologues Different nucleic acids or proteins having homology' can be referred to as “homologues”.
- the term homologue includes homologous sequences from the same and other species and orthologous sequences from the same and other species.
- “Homology” refers to the level of similarity' betw een two or more nucleic acid and/or amino acid sequences in terms of percent of positional identity (i.e., sequence similarity or identity). Homology' also refers to the concept of similar functional properties among different nucleic acids or proteins.
- the disclosed compositions and disclosed methods can comprise homologues to the disclosed nucleotide sequences and/or disclosed polypeptide sequences.
- Orthologous can refer to homologous nucleotide sequences and/or amino acid sequences in different species that arose from a common ancestral gene during speciation.
- a homologue of a disclosed nucleotide sequence or a disclosed polypeptide can have substantial sequence identity (e.g., at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and/or 100%) to a disclosed nucleotide sequence or a disclosed polypeptide.
- codon optimization can refer to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing one or more codons or more of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence.
- Various species exhibit particular bias for certain codons of a particular amino acid.
- genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the “Codon Usage Database.” Many methods and software tools for codon optimization have been reported previously . (See, for example, genomes .urv.es/ OPTIMIZER/) .
- a codon is a sequence of three nucleotides that encodes for a specific amino acid in the synthesis of a protein.
- the amino acid Leucine can be encoded with six synonymous codons CUU, CUC, CUA, CUG, UUA and UUG whereas Cysteine can be encoded with two codons UGU and UGC.
- 2 of the 20 amino acids can be encoded with 1 codon, 9 with 2 codons, 1 with 3 codons, 5 with 4 codons and 3 with 6 codons leading to 61 essential codons.
- Codon degeneracy leads to many possible ways of encoding a protein, e.g. a typical 375-amino acid protein in humans can be potentially encoded by 10207 different codon sequences. All possible encodings and resulting sequences are not equally likely to be observed in nature; however, as some synonymous codons are more frequently used than others in encoding a particular amino acid in a particular organism. This phenomenon is called ‘codon usage bias’ or ‘codon bias’.
- Leucine is encoded 39.5% of the time with codon CUG in Homo sapiens, whereas the same codon is used 11.1% of the same amino acid’s encoding in Saccharomyces cerevisiae (Nakamura et al., 2000).
- immune tolerance refers to a state of unresponsiveness or blunted response of the immune system to substances (e.g., protein replacement therapy, enzyme replacement therapy, recombinant product, a transplanted organ, a vector protein, etc.) that have the capacity to elicit an immune response in a subject.
- Immune tolerance is induced by prior exposure to a specific antigen. Immune tolerance can be determined in a subject by measuring antibodies against a particular antigen (such as, for example, to an HLA on a transplanted organ, an enzy me or therapeutic protein as part of replacement therapy, a viral vector, an AAV capsid protein).
- immune tolerance can be established by having IgG antibody titers of less than or equal to about 12,000, 11,500, 11,000. 10.500, 10,000, 9,500. 9,000, 8,500, 8,000, 7.500, 7,000, 6.500, or 6,000 following gene therapy (such as the administration of the transgene encoding, for example, a missing, deficient, and/or mutant protein or enzyme), protein replacement therapy, enzyme replacement therapy, or a recombinant product.
- antibodies can mitigate AAV infection through multiple mechanisms by binding to AAV capsids and blocking critical steps in transduction such as cell surface attachment and uptake, endosomal escape, productive trafficking to the nucleus, or uncoating as well as promoting AAV opsonization by phagocytic cells, thereby mediating their rapid clearance from the circulation.
- AAV capsids For example, in humans, serological studies reveal a high prevalence of NAbs in the worldwide population, with about 67% of people having antibodies against AAV1, 72% against AAV2, and approximately 40% against AAV serotypes 5 through 9.
- Vector immunogenicity represents a major challenge in re-administration of AAV vectors.
- partial self-complementary 7 parvovirus e.g., a disclosed AAV
- plasmid vectors encoding the parvovirus genomes e.g., a disclosed AAV particles including such genomes.
- a plasmid vector comprising a nucleotide sequence encoding a disclosed parvovirus genome such as for example, a disclosed AAV.
- a partial self-complementary' parvovirus genome including a payload construct, parvovirus ITRs flanking the payload construct, and a self-complementary region flanking one of the ITRs.
- a self-complementary 7 region can comprise a nucleotide sequence that is complementary 7 to the payload construct.
- a disclosed self- complementary region can have a length that is less the entire length of the pay load construct.
- a disclosed self-complementary 7 region of a disclosed parvovirus genome can comprise a minimum length, while still having a length that is less the entire length of the payload construct.
- a disclosed self-complementary region can comprise at least 50 bases in length, at least 100 bases in length, at least 200 in length, at least 300 bases in length, at least 400 bases in length, at least 500 bases in length, at least 600 bases in length, at least 700 bases in length, at least 800 bases in length, at least 900 bases in length, or at least 1,000 bases in length.
- a “self-complementary parvovirus genome” can be a single stranded polynucleotide having, in the 5’ to 3’ direction, a first parvovirus ITR sequence, a heterologous sequence (e.g., payload construct comprising, for example, a desired gene), a second parvovirus ITR sequence, a second heterologous sequence, wherein the second heterologous sequence is complementary to the first heterologous sequence, and a third parvovirus ITR sequence.
- a heterologous sequence e.g., payload construct comprising, for example, a desired gene
- a "partial self-complementary genome” does not include three parvovirus ITRs and the second heterologous sequence that is complementary to the first heterologous sequence has a length that is less than the entire length of the first heterologous sequence (e.g., payload construct).
- a partial self-complementary genome is a single stranded polynucleotide having, in the 5’ to 3’ direction or the 3’ to 5’ direction, a first parvovirus ITR sequence, a heterologous sequence (e.g., payload construct), a second parvovirus ITR sequence, and a self-complementary region that is complementary to a portion of the heterologous sequence and has a length that is less than the entire length the heterologous sequence.
- a heterologous sequence e.g., payload construct
- immune-modulating refers to the ability of a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a disclosed agent to alter (modulate) one or more aspects of the immune system.
- the immune system functions to protect the organism from infection and from foreign antigens by cellular and humoral mechanisms involving lymphocytes, macrophages, and other antigen-presenting cells that regulate each other by means of multiple cell-cell interactions and by elaborating soluble factors, including lymphokines and antibodies, that have autocrine, paracrine, and endocrine effects on immune cells.
- immune modulator refers to an agent that is capable of adjusting a given immune response to a desired level (e.g., as in immunopotentiation, immunosuppression, or induction of immunologic tolerance).
- immune modulators include but are not limited to, a disclosed immune modulator can comprise aspirin, azathioprine, belimumab, betamethasone dipropionate, betamethasone valerate, bortezomib, bredinin, cyazathioprine, cyclophosphamide, cyclosporine, deoxyspergualin, didemnin B, fluocinolone acetonide, folinic acid, ibuprofen.
- a disclosed immune modulator can comprise aspirin, azathioprine, belimumab, betamethasone dipropionate, betamethasone valerate, bortezomib, bredinin, cyazathioprine, cyclophosphamide, cyclosporine, deoxyspergualin, didemnin B, fluocinolone acetonide, folinic acid, ibuprofen.
- IL6 inhibitors such as sarilumab indomethacin, inebilizumab, intravenous gamma globulin (IVIG), methotrexate, methylprednisolone, mycophenolate mofetil, naproxen, prednisolone, prednisone, prednisolone indomethacin, rapamycin, rituximab, sirolimus, sulindac, synthetic vaccine particles containing rapamycin (SVP-Rapamycin or ImmTOR), thalidomide, tocilizumab, tolmetin, triamcinolone acetonide.
- IVIG intravenous gamma globulin
- methotrexate methotrexate
- methylprednisolone mycophenolate mofetil
- naproxen prednisolone
- prednisone prednisolone indomethacin
- rapamycin rituxima
- a disclosed immune modulator can comprise one or more Treg (regulatory T cells) infusions (e.g., antigen specific Treg cells to AAV).
- a disclosed immune modulator can be bortezomib or SVP-Rapamycin.
- an immune modulator can be administered by any suitable route of administration including, but not limited to, in utero, intra-CSF, intrathecally, intravenously, subcutaneously, trans dermally, intradermally, intramuscularly, orally, trans cutaneously, intraperitoneally (IP), or intravaginally.
- a disclosed immune modulator can be administered using a combination of routes.
- Administration can also include hepatic intra-arterial administration or administration through the hepatic portal vein (HPV).
- Administration of an immune modulator can be continuous or intermittent, and administration can comprise a combination of one or more routes.
- immunotoleranf refers to unresponsiveness to an antigen (e.g., a vector, a therapeutic protein, a transgene product, etc.).
- An immunotolerant promoter can reduce, ameliorate, or prevent transgene-induced immune responses that can be associated with gene therapy.
- Assays known in the art to measure immune responses such as immunohistochemical detection of cytotoxic T cell responses, can be used to determine whether one or more promoters can confer immunotolerant properties.
- package insert is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products.
- the term “in combination” in the context of the administration of other therapies includes the use of more than one therapy (e.g., drug therapy).
- Administration “in combination with” one or more further therapeutic agents includes simultaneous (e.g.. concurrent) and consecutive administration in any order.
- the use of the term “in combination” does not restrict the order in which therapies are administered to a subject.
- a first therapy e.g., a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof
- a first therapy may be administered prior to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks), concurrently, or after (e.g., 1 minute.
- a second therapy e.g., gene therapy, enzyme replacement therapy, protein replacement therapy, recombinant product
- a disease or disorder such as a genetic disease or disorder
- these and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds cannot be explicitly disclosed, each is specifically contemplated and described herein.
- Disclosed herein is an enzy me having IgM specific protease activity.
- an enzyme having IgG specific protease activity is an enzyme having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme having IgM specific protease activity is a recombinant enzyme having IgG specific protease activity.
- a recombinant enzyme having IgM specific protease activity and IgG specific protease activity Disclosed herein is a fusion protein having IgM specific protease activity and IgG specific protease activity.
- an enzy me comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
- an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and having IgM specific protease activity and/or IgG specific protease activity.
- Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:01. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:04. [0098] Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:07. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO: 10. Disclosed herein is an enzy me comprising the sequence set forth in SEQ ID NO: 13.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 02 or SEQ IDNO:03 and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity’ to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO: 05 or SEQ IDNO:06 and having IgM specific protease activity'.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity 7 , or at least 90% identity 7 to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity 7 to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 and having IgM specific protease activity.
- a recombinant enzy me comprising the sequence set forth in SEQ ID NO:11 or SEQ ID NO: 12 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity’ to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 and having IgM specific protease activity.
- a recombinant enzy me comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof and having IgM specific protease activity.
- a linker can comprise a flexible linker or a rigid linker.
- a disclosed linker can comprise the sequence of any one of SEQ ID NO:94 - SEQ ID NO: 104.
- a disclosed linker can comprise the sequence of SEQ ID NO: 96.
- a disclosed linker can be a rigid linker.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18.
- a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NQ:20 or SEQ ID NO:21 and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 and having IgM specific protease activity’ and IgG specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23.
- a recombinant enzyme com rising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:24. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:27. Disclosed herein is an enzy me comprising the sequence set forth in SEQ ID NO:30. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:33. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO: 36.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%. at least 70%. at least 80%.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzy me comprising the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29.
- a recombinant enzyme comprising a sequence having at least 50%. at least 60%. at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof.
- a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof and having IgM specific protease activity 7 .
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 31 or SEQ ID NO:32 and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzy me comprising the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35.
- a recombinant enzyme comprising a sequence having at least 50%. at least 60%. at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof.
- a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 34 or SEQ ID NO:35 and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof and having IgM specific protease activity 7 .
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 37 or SEQ IDNO:38 and having IgM specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof and having IgM specific protease activity.
- a recombinant enzy me comprising the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41.
- a recombinant enzyme comprising a sequence having at least 50%. at least 60%. at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof.
- a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity’ to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 and having IgM specific protease activity and IgG specific protease activity 7 .
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a disclosed recombinant enzy me can have IgM specific protease activity'.
- a disclosed recombinant enzyme can cleave the IgM the heavy chain at the interdomain region between constant domains CLL2 and Cp3.
- a disclosed recombinant enzyme can cleave human IgM.
- a disclosed recombinant enzyme can cleave non-human primate IgM.
- a disclosed recombinant enzy me does not cleave non-human IgM.
- a disclosed recombinant enzyme does not cleave dog IgM, pig IgM, and mouse IgM.
- a disclosed IgM specific recombinant enzyme does not cleave human IgA, IgD, IgE, IgG, or any combination thereof.
- a disclosed recombinant enzyme can have a binding domain specific for IgM.
- a disclosed recombinant enzy me can cleave IgM between position 350 and position IgM (for example, the substrate).
- a disclosed recombinant enzyme can have a binding domain capable of specifically binding to one or more amino acid residues 355 through 360 of IgM.
- a disclosed recombinant enzyme can have an affinity for human IgM.
- a disclosed IgM can be cleaved at SEQ ID NO: 110.
- a disclosed IgM can be cleaved at the sequence comprising 355D, 356T. 357A, 3581, 359R. and 360V.
- a disclosed IgM can be cleaved at position 355 through position 360 of SEQ ID NO: 105.
- a disclosed recombinant enzyme can have IgG and IgM specific protease activity.
- a disclosed recombinant enzyme can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3 and can cleave the IgG below the hinge region.
- a disclosed recombinant enzyme can cleave the IgG below the hinge region, thereby yielding Ftab'h and Fc fragments.
- a disclosed recombinant enzyme can cleave the IgG separating the Cp2 and Cp3 domains from the Cpl domain.
- a disclosed recombinant enzyme can cleave human IgG and human IgM.
- a disclosed recombinant enz me can cleave non-human primate IgG and non-human primate IgM.
- a disclosed recombinant enzyme having IgG and IgM protease activity does not cleave IgA, IgD, IgE, or any combination thereof.
- a disclosed recombinant enzyme having IgG and IgM protease activity does not cleave non-human IgM or non-human IgG.
- a disclosed recombinant enzyme having IgG and IgM protease activity does not cleave dog IgM, pig IgM, and mouse IgM, or dog IgG, pig IgG, or mouse IgG.
- a disclosed recombinant enzyme can have a binding domain capable of specifically binding to the sequence of SEQ ID NO: 111, SEQ ID NO:112, SEQ ID NO: 113, SEQ ID NO: 114, or any combination thereof.
- a disclosed recombinant enzyme can have a binding domain capable of specifically binding to the sequence of SEQ ID NO: 1 15, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
- a disclosed recombinant enzyme can cleave IgG at amino acid residues 109 through 124 of the IgG of SEQ ID NO: 106, residues 106 through 120 of the IgG of SEQ ID NO: 107, residues 156 through 171 of the IgG of SEQ ID NO: 108. residues 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof.
- a disclosed recombinant enzyme can cleave IgG at amino acid residues 116 through 122 of the IgG of SEQ ID NO: 106, residues 112 through 118 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108, residues 113 through 119 oflgG of SEQ ID NO: 109, or any combination thereof.
- a disclosed recombinant enzyme can cleave one or more IgG molecules at SEQ ID NO: 115, SEQ ID NO: 1 16, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
- a disclosed recombinant enzy me can be specific for IgM and IgG, can cleave IgM between position 355 and position 360 of SEQ ID NO: 105, and can cleave at residues 116 through 122 of the IgG of SEQ ID NO: 106, residues 112 through 118 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108, and residues 113 through 119 of IgG of SEQ ID NO: 109.
- a disclosed recombinant enzyme can be specific for IgM and IgG can recognize and cleave SEQ ID NO: 110 in IgM and cleave SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117. SEQ ID NO: 118 in IgG
- a disclosed recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in a subject. In an aspect, a disclosed recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject. In an aspect, a disclosed recombinant enzyme can cleave and/or degrade circulating IgM and/or IgM and IgG in a subject.
- a disclosed recombinant enzyme can transiently clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject, or can transiently cleave and/or degrade circulating IgM and/or IgM and IgG in a subject.
- a disclosed recombinant enzyme can reduce and/or diminish the level of circulating IgM and/or IgG and IgM levels in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM levels in a subject.
- a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
- a disclosed recombinant enzyme can block and/or minimize activation of the complement cascade. In an aspect, a disclosed recombinant enzyme can block and/or minimize activation of the formation of the Cl complex and/or C3 complex. In an aspect, a disclosed recombinant enzyme can block and/or minimize activation of the classical complement pathway. In an aspect, a disclosed recombinant enzyme can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
- a disclosed recombinant enzyme can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells.
- the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient.
- a disclosed recombinant enzyme can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells.
- a disclosed recombinant enzyme can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
- a disclosed recombinant enzyme can reduce and/or minimize vector mediated immunotoxicity in a subject.
- a disclosed recombinant enzyme can enable and/or allow vector re-dosing in a subject.
- a disclosed recombinant enzyme can reduce and/or minimize transgene immunogenicity in a subject.
- a disclosed recombinant enzyme can improve and/or enhance transgene efficacy and/or expression in a subj ect.
- a disclosed recombinant enzyme can improve and/or enhance transgene efficacy and/or expression in a subject.
- improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%. 60%. 70%. 80%. 90%. 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed recombinant enzymes).
- the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40- 50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed recombinant enzymes).
- a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed recombinant enzymes).
- an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed recombinant enzymes).
- an improvement and/or enhancement can be a partial or incomplete restoration.
- an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wild-type or control level.
- a disclosed recombinant enzyme can decrease and/or minimize the severity’ of a rejection event of the one or more transplanted organs. In an aspect, a disclosed recombinant enzyme can prevent the rejection of the one or more transplanted organs. In an aspect, a disclosed rej ection event can be classified a hyperacute rej ection event, an acute rej ection event, or a chronic rejection event. In an aspect, following the administration and/or delivery of a disclosed recombinant enzyme, the one or more transplanted organs are not rejected by the subject.
- the viability’ of one or more transplanted organs can be improved and/or increased.
- the functionality' of one or more transplanted organs can be improved and/or increased.
- the functionality of one or more transplanted organs is not decreased and/or diminished.
- a disclosed recombinant enzyme can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
- a disclosed enzyme can be used to modulate humoral immunity in a subject.
- modulating humoral immunity in a subject can be an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject's humoral immunity.
- a disclosed enzyme can comprise one or more labels and/or tags.
- a disclosed label and/or a tag can comprise a fluorescent label and/or a tag.
- a disclosed label and/or a tag can comprise a carboxy -terminal label and/or tag or an amino-terminal label and/or tag.
- a disclosed label and/or a tag can comprise a carboxy -terminal fluorescent label and/or tag or an amino-terminal fluorescent label and/or tag.
- a disclosed label and/or tag can comprise an ALFA tag, an AviTag, a C tag, a Calmodulin-tag, an iCapTag (intein Capture Tag), a polyglutamate tag, a polyarginine tag, an E tag, a FLAG tag, a HA tag, a His tag, a Myc tag, a NE tag, a RholD4 tag, a S tag, a SBP tag, a Softag 1, a Softag 3, a Spot tag, a Strep tag, a T7 tag, a TC tag, a Ty tag, a V5 tag.
- VSV-tag an Xpress tag, an Isopeptag, a Spy tag, a SnoopTag, a SnoopTagJr, a DogTag, a SdyTag, a BCCP (Biotin Carboxyl Carrier Protein), a glutathione-S-transferase tag, a green fluorescent protein tag, a Halo tag, a SNAP -tag, a CLIP tag, a HUH tag, a maltose binding protein tag, a Nus tag, a thioredoxin tag, a Fc tag, a Designed Intrinsically Disordered tags containing disorder promoting amino acids, a Carbohydrate Recognition Domain or CRDSAT tag, a HiBiT-tag, or any combination thereof.
- BCCP Biotin Carboxyl Carrier Protein
- glutathione-S-transferase tag a green fluorescent protein tag
- Halo tag a SNAP -tag
- CLIP tag a
- a disclosed label and/or a tag can comprise a fluorescent label or a fluorescent tag.
- a disclosed fluorescent label or disclosed fluorophore can comprise enhanced green fluorescent protein (EGFP), mEmerald, enhanced yellow fluorescent protein (EYFP), mApple, TdTomato, mCherry, miRFP670. any known fluorescent label or tag, or any combination thereof.
- a disclosed fluorescent label or disclosed fluorophore can comprise any fluorescent label or fluorophore that is amendable to analysis via flow cytometry.
- a pair of disclosed fluorescent labels or disclosed fluorophores can comprise any pair of fluorescent labels or fluorophores that is amendable to analysis via flow cytometry and have excitation and emission spectra that can be isolated or separated from each other, thereby enabling the interrogation of the docking interactions.
- Fluorophores and fluorescent labels are known in the art.
- a disclosed enzy me or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg body weight to about 100 mg/kg body w eight.
- a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
- Disclosed herein is a recombinant enzy me comprising the sequence of SEQ ID NO:119.
- a recombinant enzy me encoded by the codon-optimized nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161.
- a recombinant enzyme encoded by a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity 7 to the codon-optimized sequence of SEQ ID NO: 160 or SEQ ID NO: 161.
- a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121.
- a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 119.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity 7 to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a recombinant enzyme comprising the sequence of SEQ ID NO: 119 and having human and non-human primate IgG specific protease activity.
- a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121 and having human and non-human primate IgG specific protease activity.
- a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159 and having human and non-human primate IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity 7 to the sequence of SEQ ID NO: 119 and having human and non-human primate IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity 7 to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121 and having human and non-human primate IgG specific protease activity.
- a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159 and having human and non-human primate IgG specific protease activity.
- a recombinant enzyme encoded by the codon-optimized nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161 and having human and non-human primate IgG specific protease activity.
- a recombinant enzyme encoded by a nucleic acid sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the codon-optimized nucleic acid sequence of SEQ ID NO: 1 0 or SEQ ID NO: 161 and having human and non-human primate IgG specific protease activity.
- Disclosed herein is an isolated nucleic acid molecule encoding any disclosed enzyme. Disclosed herein is an isolated nucleic acid molecule encoding any disclosed recombinant enzyme. Disclosed herein is an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO: 92.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:01. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:24. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:47. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:70.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:04. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:27. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:50. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:73.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:07. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:30. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:53. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:76.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 10. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:33. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:56. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:79.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 13. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:36. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:59. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:82.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 16. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:39. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:62. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:85. [0146] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 19.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:42. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:65. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:88. [0147] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03.
- an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO: 02 or SEQ ID NO:03.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 and having IgM specific protease activity'.
- an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof and having IgM specific protease activity 7 .
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26.
- Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:48 or SEQ ID NO: 49. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:71 or SEQ ID NO:72.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%.
- an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 and having IgM specific protease activity'.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 and having IgM specific protease activity 7 .
- Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity' to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof and having IgM specific protease activity'.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29.
- Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:51 or SEQ ID NO: 52. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:74 or SEQ ID NO:75.
- an isolated nucleic acid molecule encoding the enzyme comprising the recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity 7 , or at least 90% identity 7 to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme comprising the recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof and having IgM specific protease activity 7 .
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%. at least 70%. at least 80%.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:54 or SEQ ID NO:55. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:77 or SEQ ID NO: 78.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12.
- an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity 7 , or at least 90% identity to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity 7 to the sequence set forth in SEQ ID NO:11 or SEQ ID NO: 12 and having IgM specific protease activity 7 .
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof and having IgM specific protease activity 7 .
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity 7 to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35.
- an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:57 or SEQ ID NO: 58.
- Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 80 or SEQ ID NO: 81. [0151] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity’ to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 and having IgM specific protease activity.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity’ to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof and having IgM specific protease activity 7 .
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:60 or SEQ ID NO:61. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:83 or SEQ ID NO:84.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%. at least 60%. at least 70%, at least 80% identity 7 , or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41.
- an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:63 or SEQ ID NO:64.
- an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:86 or SEQ ID NO:87.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21.
- an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 20 or SEQ ID NO:21.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NQ:20 or SEQ ID NO:21 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:2I and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity 7 to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44.
- an isolated nucleic acid molecule comprising the sequence set forth in SEQ IDNO:66 or SEQ ID NO:67.
- an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 89 or SEQ ID NO:90.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23.
- an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 22 or SEQ ID NO:23.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme compnsing the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46.
- an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:68 or SEQ ID NO:69.
- an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:91 or SEQ ID NO:92.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:24. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:27. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:30. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me having the sequence set forth in SEQ ID NO:33. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:36.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:39. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:42.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26.
- an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme having sequence having at least 50%, at least 60%. at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof and having IgM specific protease activity.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity', or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof and having IgM specific protease activity.
- nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof and having IgM specific protease activity.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32.
- an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzy me having the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof and having IgM specific protease activity.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35.
- an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity 7 , or at least 90% identity 7 to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof and having IgM specific protease activity.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%.
- an isolated nucleic acid molecule encoding the enzy me having the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof and having IgM specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof and having IgM specific protease activity.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity’ to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%.
- nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof and having IgM specific protease activity' and IgG specific protease activity.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44.
- an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity 7 , or at least 90% identity 7 to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44.
- an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity 7 to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 and having IgM specific protease activity and IgG specific protease activity 7 .
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity 7 , or at least 90% identity to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46.
- an isolated nucleic acid molecule encoding the enz me having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof.
- an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 and having IgM specific protease activity and IgG specific protease activity.
- an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
- a disclosed isolated nucleic acid molecule can comprise the nucleic acid sequence for one or more labels and/or tags.
- a disclosed label and/or a tag can comprise a fluorescent label and/or a tag.
- a disclosed label and/or a tag can comprise a carboxy -terminal label and/or tag or an amino-terminal label and/or tag.
- a disclosed label and/or a tag can comprise a carboxy-terminal fluorescent label and/or tag or an aminoterminal fluorescent label and/or tag.
- a disclosed label and/or tag can comprise an ALFA tag, an AviTag, a C tag, a Calmodulin-tag, an iCapTag (intein Capture Tag), a poly glutamate tag, a polyarginine tag, an E tag, a FLAG tag, a HA tag, a His tag, a Myc tag, a NE tag, a RholD4 tag, a S tag, a SBP tag, a Softag 1, a Softag 3, a Spot tag, a Strep tag, a T7 tag, a TC tag, a Ty tag, a V5 tag, a VSV-tag, an Xpress tag.
- an Isopeptag a Spy tag. a SnoopTag. a SnoopTagJr. a DogTag. a SdyTag, a BCCP (Biotin Carboxyl Carrier Protein), a glutathione-S-transferase tag, a green fluorescent protein tag, a Halo tag, a SNAP-tag, a CLIP tag, a HUH tag, a maltose binding protein tag, a Nus tag, a thioredoxin tag, a Fc tag, a Designed Intrinsically Disordered tags containing disorder promoting amino acids, a Carbohydrate Recognition Domain or CRDSAT tag, a HiBiT-tag. or any combination thereof.
- a disclosed label and/or a tag can comprise a fluorescent label or a fluorescent tag.
- a disclosed fluorescent label or disclosed fluorophore can comprise enhanced green fluorescent protein (EGFP), mEmerald. enhanced yellow fluorescent protein (EYFP), mApple, TdTomato, mCherry, miRFP670, any known fluorescent label or tag, or any combination thereof.
- a disclosed fluorescent label or disclosed fluorophore can comprise any fluorescent label or fluorophore that is amendable to analysis via flow cytometry 7 .
- a pair of disclosed fluorescent labels or disclosed fluorophores can comprise any pair of fluorescent labels or fluorophores that is amendable to analysis via flow cytometry and have excitation and emission spectra that can be isolated or separated from each other, thereby enabling the interrogation of interactions.
- Fluorophores and fluorescent labels are known in the art.
- a disclosed encoded recombinant enzyme can have IgM specific protease activity.
- a disclosed encoded recombinant enzyme can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3.
- a disclosed encoded recombinant enzyme can cleave human IgM.
- a disclosed encoded enzyme can cleave non-human primate IgM.
- a disclosed encoded recombinant enzyme does not cleave non-human IgM.
- a disclosed encoded recombinant enzyme does not cleave dog IgM, pig IgM, and mouse IgM.
- a disclosed encoded IgM specific recombinant enzyme does not cleave human IgA, IgD, IgE, IgG, or any combination thereof.
- a disclosed encoded recombinant enzy me can have a binding domain specific for IgM.
- a disclosed encoded recombinant enzyme can cleave IgM between position 350 and position 365 of SEQ ID NO: 105.
- SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate).
- a disclosed encoded recombinant enzy me can have a binding domain capable of specifically binding to one or more amino acid residues 355 through 360 of IgM.
- a disclosed encoded recombinant enzyme can have an affinity for human IgM.
- a disclosed IgM can be cleaved at SEQ ID NO: 110. In an aspect, a disclosed IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, a disclosed IgM can be cleaved at position 355 through position 360 of SEQ ID NO: 105.
- a disclosed encoded recombinant enzyme can have IgG and IgM specific protease activity.
- a disclosed encoded recombinant enzyme can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3 and can cleave the IgG below the hinge region.
- a disclosed encoded recombinant enzyme can cleave the IgG below the hinge region, thereby yielding Ftab’fi and Fc fragments.
- a disclosed encoded recombinant enzyme can cleave the IgG separating the Cp2 and Cp3 domains from the Cpl domain.
- a disclosed encoded recombinant enzyme can cleave human IgG and human IgM. In an aspect, a disclosed encoded recombinant enzyme can cleave non-human primate IgG and non-human primate IgM. In an aspect, a disclosed encoded recombinant enzyme having IgG and IgM protease activity does not cleave IgA, IgD, IgE, or any combination thereof. In an aspect, a disclosed encoded recombinant enzyme having IgG and IgM protease activity does not cleave non-human IgM or non-human IgG.
- a disclosed encoded recombinant enzyme having IgG and IgM protease activity does not cleave dog IgM, pig IgM, and mouse IgM, or dog IgG, pig IgG, or mouse IgG.
- a disclosed encoded recombinant enzyme can have a binding domain capable of specifically binding to the sequence of SEQ ID NO:111, SEQ ID NO: 112, SEQ ID NO:113, SEQ ID NO: 114, or any combination thereof.
- a disclosed encoded recombinant enzyme can have a binding domain capable of specifically binding to the sequence of SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
- a disclosed encoded recombinant enzy me can cleave IgG at amino acid residues 109 through 124 of the IgG of SEQ ID NO: 106, residues 106 through 120 of the IgG of SEQ ID NO: 107, residues 156 through 171 of the IgG of SEQ ID NO: 108, residues 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof.
- a disclosed encoded recombinant enzyme can cleave IgG at amino acid residues 116 through 122 of the IgG of SEQ ID NO: 106, residues 112 through 118 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108. residues 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof.
- a disclosed encoded recombinant enzyme can cleave one or more IgG molecules at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
- a disclosed encoded recombinant enzyme can be specific for IgM and IgG, can cleave IgM between position 355 and position 360 of SEQ ID NO: 105, and can cleave at residues 116 through 122 of the IgG of SEQ ID NO: 106, residues 112 through 118 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108, and residues 113 through 119 of IgG of SEQ ID NO: 109.
- a disclosed encoded recombinant enzyme can be specific for IgM and IgG can recognize and cleave SEQ ID NO: 1 10 in IgM and cleave SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118 m IgG
- a disclosed encoded recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in a subject. In an aspect, a disclosed recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject. In an aspect, a disclosed recombinant enzyme can cleave and/or degrade circulating IgM and/or IgM and IgG in a subject.
- a disclosed recombinant enzyme can transiently clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject, or can transiently cleave and/or degrade circulating IgM and/or IgM and IgG in a subject.
- a disclosed recombinant enzyme can reduce and/or diminish the level of circulating IgM and/or IgM and IgG levels in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgM and IgG levels in a subject.
- a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
- a disclosed encoded enzy me can block and/or minimize activation of the complement cascade.
- a disclosed encoded enzyme can block and/or minimize activation of the formation of the Cl complex and/or C3 complex.
- a disclosed encoded enzyme can block and/or minimize activation of the classical complement pathway.
- a disclosed encoded enz me can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
- a disclosed encoded enzyme can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells.
- the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient.
- a disclosed encoded enzyme can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells.
- a disclosed encoded enzyme can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
- a disclosed encoded enzyme can reduce and/or minimize vector mediated immunotoxicity in a subject.
- a disclosed encoded enzyme can enable and/or allow vector re-dosing in a subject.
- a disclosed encoded enzyme can reduce and/or minimize transgene immunogenicity in a subject.
- a disclosed encoded enzyme can improve and/or enhance transgene efficacy and/or expression in a subject.
- a disclosed nucleic acid molecule can improve and/or enhance transgene efficacy and/or expression in a subject.
- a disclosed nucleic acid molecule can improve and/or enhance transgene efficacy and/or expression in a subject.
- improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more a disclosed nucleic acid molecules).
- the amount of improvement and/or enhancement can be 10-20%, 20- 30%. 30-40%, 40-50%, 50-60%. 60-70%, 70-80%, 80-90%. or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more a disclosed nucleic acid molecule).
- an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more a disclosed nucleic acid molecules).
- an improvement and/or enhancement can be a partial or incomplete restoration.
- an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wildtype or control level.
- a disclosed nucleic acid molecule and/or a disclosed nucleic acid sequence can be CpG depleted and codon-optimized for expression in a human cell.
- CpG- free can mean completely free of CpGs or partially free of CpGs.
- CpG-free can mean “CpG-depleted”.
- CpG-depleted can mean “CpG-free'’.
- CpG- depleted can mean completely depleted of CpGs or partially depleted of CpGs.
- CpG-free can mean “CpG-optimized” for a desired and/or ideal expression level. CpG depletion and/or optimization is know n to the skilled person in the art.
- a “codon-optimized” gene can be a gene having its frequency of codon usage designed to mimic the frequency of preferred codon usage of the host cell (i.e.. a human cell or a human subject).
- a disclosed nucleic acid molecule and/or a disclosed nucleic acid sequence can be codon-optimized, either wholly or in part. Because any one amino acid (except for methionine and tryptophan) is encoded by several codons, the sequence of the nucleic acid molecule can be changed without changing the encoded amino acid.
- a disclosed nucleic acid sequence can be codon-optimized for expression in a human cell or a human organ or one or more human cells or one or more human organs. In an aspect, a disclosed nucleic acid sequence can be codon-optimized for expression in a human subject.
- a disclosed codon-optimized nucleic acid sequence can comprise SEQ ID NO:48.
- a disclosed nucleic acid sequence can encode the protein or a portion thereof (such as, for example, Exon 1 or Exon 4, etc.) associated with the following genes: ABCA1, ABCA12, ABCA13, ABCA2, ABCA3, ABCA4, ABCA5, ABCC1, ABCC2, ABCC6, ABCC8, ABCC9, AC AN, ADAMTS13, ADCY10, ADGRV1, AGL.
- AGRN AGRN, AHDC1, ALK, ALMS 1, ALPK3, ALS2, ANAPC 1, ANK.1, ANK2, ANKA, ANKRD11, ANKRD26, APC, APC2, APOB, ARFGEF2, ARHGAP31, ARHGEF10, ARHGEF18, ARID1A, ARID1B, ARID2, ASH1L, ASPM, ASXL1, ASXL2, ASXL3, ATM, ATP7A, ATP7B, ATR, ATRX, BAZ1A, BAZ2B, BCOR.
- DMXL2 DNAH1, DNAH11, DNAH17, DNAH2, DNAH5, DNAH7, DNAH8, DNAH9, DNMBP, DNMT1, DOCK2, DOCK3, DOCK6, DOCK7, DOCK8, DSCAM, DSP, DST, DUOX2, DYNC1H1, DYNC2H1, DYSF, EIF2AK4, EP300, EPG5, ERCC6, ERCC6L2, EXPH5, EYS, F5, F8, FANCA, FANCD2, FANCM, FAT1, FAT4, FBN1, FBN2, FLG, FLG2, FLNA, FLNB, FLNC, FLT4, FMN2, FN1, FRAS1, FREM1, FREM2, FSIP2, FYC01, GLI2, GLI3, GPR179, GREB1L, GRIN2A, GRIN2B, GRIN2D, HCFC1, HECW2, HERC1, HERC2, HFM1, HIVEP1, HIVEP2, HMCN1, HSPG2,
- NPHP4 NRXN1, NRXN3, NSD1, NSD2, NUP155, NUP188, NUP205, OBSCN, OBSL1, OTOF, OTOG, OTOGL, PARD3, PBRM1, PCDH15, PCLO, PCNT, PHIP, PI4KA, PIEZO1, PIEZO2, PIK3C2A, PIKFYVE, PKD1, PKD1L1, PKHD1, PLCE1, PLEC.
- PNPLA6, POGZ POLA1, POLE, POLR1A, POLR2A, POLR3A, PRG4.
- PRKDC PRKDC.
- PRPF8 PRR12, PRX, PTCHI, PTPN23, PTPRF, PTPRJ, PTPRQ, PXDN, QRICH2, RAB3GAP2, RAIL RALGAPA1, RANBP2, RB1CC1, RELN, RERE, REV3L, RIC1, RIMS1, RIMS2, RNF213, ROBO1, ROBO2, ROBO3, ROS 1, RP1, RP1L1, RTTN, RUSC2, RYR1, RYR2, SACS, SAMD9, SAMD9L, SBF2, SCAPER, SCN10A, SCN11A, SCN1A, SCN2A.
- TECTA TECTA, TENM3, TENM4, TET3, TEX14, TEX15. TG, THOC2.
- TMEM94 TNC. TNIK, TNR, TNRC6B, TNXB, TOGARAMI, TONSL, TRIO, TRIOBP, TRIP1 1 , TRIP12, TRPM1 , TRPM6, TRPM7, TRRAP, TSC2, TTC37, TTN, TUBGCP6, UBR1, UNC80, USH2A, USP9X, VCAN, VPS13A, VPS13B, VPS13C, VPS13D, VWF, WDFY3, WDR19, WDR62, WDR81, WNK1, WRN, ZFHX2, ZFYVE26. ZNF142, ZNF292, ZNF335. ZNF407, ZNF462, ZNF469. or a portion thereof.
- a disclosed nucleic acid sequence can encode a gene or a portion thereof (e.g., a specific exon such as an exon having a mutation) with a gene product that is directly or indirectly linked to one or more genetic diseases.
- dystrophin including mini- and micro-dystrophins (DMD); titin (TTN); titin cap (TCAP) a- sarcoglycan (SGCA), P-sarcoglycan (SGCB), y-sarcoglycan (SGCG) or 8-sarcoglycan (SGCD); alpha- 1 -antitrypsin (Al-AT); myosin heavy chain 6 (MYH6); myosin heavy chain 7 (MYH7); myosin heavy chain 11 (MYH11); myosin light chain 2 (ML2); myosin light chain 3 (ML3); myosin light chain kinase 2 (MYLK2); myosin binding protein C (MYBPC3); desmin (DES); dynamin 2 (DNM2); laminin a2 (LAMA2); lamin A/C (LMNA); lamin B (LMNB); lamin B receptor (LAMA2); lamin A/C (LM
- a disclosed nucleic acid sequence can encode an RNA.
- a disclosed encoded RNA can comprise ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), micro RNA (miRNA), Piwd-interacting RNA (piRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), singe guide RNA (sgRNA), non-coding RNA (ncRNA), long non-coding RNA (IncRNA), 7SL, Xist, short enhancer RNA (eRNA), circular RNA, intergenic RNA, or any combination thereof.
- rRNA ribosomal RNA
- tRNA transfer RNA
- hnRNA heterogeneous nuclear RNA
- snRNA small nuclear RNA
- snoRNA small nucleolar RNA
- miRNA micro RNA
- piRNA Piwd-interacting RNA
- a disclosed encoded RNA can comprise IncRNA, siRNA, shRNA, sgRNA, circular RNA, snoRNA, miRNA, or any combination thereof.
- a disclosed encoded RNA can comprise a functional non-coding RNA element.
- a disclosed nucleic acid molecule can comprise the sequence for one or more regulatory elements.
- a disclosed regulatory element can be a promoter, an enhancer, an internal ribosomal entry site (IRES), or another expression control element (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences).
- Regulatory elements can include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences).
- a disclosed promoter can be tissue-specific or ubiquitous and can be constitutive or inducible, depending on the pattern of the gene expression desired.
- a promoter can be native or foreign and can be a natural or a synthetic sequence. By foreign, it is intended that the transcriptional initiation region is not found in the w ild-type host into which the transcriptional initiation region is introduced.
- a disclosed promoter can be a promoter/enhancer.
- a disclosed promoter can be an endogenous promoter.
- a disclosed endogenous promoter can be an endogenous promoter/enhancer.
- a disclosed endogenous promoter or a disclosed endogenous promoter/enhancer can generally be obtained from anon-coding region upstream of a transcription initiation site of a gene of interest.
- a disclosed endogenous promoter or a disclosed endogenous promoter/enhancer can be used for constitutive and efficient expression of a disclosed gene.
- a disclosed promoter can be a CMV promoter or a CMV promoter/enhancer. CMV promoters and CMV promoters/enhancers are well known to the art.
- a disclosed promoter can be any eukaryotic RNA polymerase II promoter.
- a disclosed nucleic acid molecule can be in an expression cassette.
- Expression cassettes are know n to the art and can comprise a promoter sequence, an open reading frame (for the transgene of interest), and a 3’ UTR (typically containing a polyA in eukaryotes).
- a disclosed isolated nucleic acid molecule can restore one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation.
- a disclosed isolated nucleic acid molecule can restore the functionality and/or structural integrity 7 of a missing, deficient, and/or mutant protein or enzy me.
- a disclosed isolated nucleic acid molecule upon expression, can decrease and/or minimize the severity' of a rejection event of the one or more transplanted organs. In an aspect, upon expression, a disclosed isolated nucleic acid molecule can prevent the rejection of the one or more transplanted organs. In an aspect, a disclosed rejection event can be classified a hyperacute rejection event, an acute rejection event, or a chronic rejection event. In an aspect, upon expression, a disclosed isolated nucleic acid molecule, the one or more transplanted organs are not rejected by' the subject. In an aspect, upon expression, a disclosed isolated nucleic acid molecule, the viability 7 of one or more transplanted organs can be improved and/or increased.
- a disclosed isolated nucleic acid molecule upon expression, a disclosed isolated nucleic acid molecule, the functionality of one or more transplanted organs can be improved and/or increased. In an aspect, upon expression, a disclosed isolated nucleic acid molecule, the functionality of one or more transplanted organs is not decreased and/or diminished. In an aspect, a disclosed encoded recombinant enzyme can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
- Disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzyme of SEQ ID NO: 119.
- an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzyme of any 7 one of SEQ ID NO: 120 - SEQ ID NO: 121.
- an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzyme of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzyme of SEQ ID NO: 119, which has IgG specific protease activity.
- an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzy me of any one of SEQ ID NO: 120 - SEQ ID NO: 121, which has IgG specific protease activity’.
- an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzyme of any one of SEQ ID NO: 122 - SEQ ID NO: 159, which has IgG specific protease activity 7 .
- nucleic acid molecule encoding a recombinant enzyme comprising the nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161.
- a nucleic acid sequence encoding a recombinant enzyme and having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity 7 to the nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161.
- a nucleic acid sequence encoding a recombinant enzyme having human and non-human primate IgG specific protease activity and having the nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161.
- a recombinant enzyme encoded by a nucleic acid sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity 7 to the codon-optimized nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161 and having human and non-human primate IgG specific protease activity.
- an expression cassette comprising a disclosed nucleic acid sequence.
- an expression cassette comprising an isolated nucleic acid molecule encoding any disclosed enzyme.
- an expression cassette comprising an isolated nucleic acid molecule encoding any disclosed recombinant enzyme.
- an expression cassette comprising an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92.
- an expression cassette comprising an isolated nucleic acid molecule comprising the sequence of SEQ ID NO: 160 or SEQ ID NO: 161.
- Disclosed herein is a vector comprising a disclosed isolated nucleic acid molecule.
- a vector comprising one or more disclosed isolated nucleic acid molecules Disclosed herein is a vector comprising a disclosed isolated nucleic acid molecule have IgM specific protease activity 7 .
- a vector comprising a disclosed isolated nucleic acid molecule having IgM and IgG specific protease activity Disclosed herein is a vector comprising a disclosed isolated nucleic acid molecule having IgM specific protease activity.
- a vector comprising a disclosed isolated nucleic acid molecule have IgM and IgG specific protease activity 7 .
- a vector comprising a nucleic acid sequence encoding the enzyme of any one of SEQ ID NO: 01 - SEQ ID NO: 46 or a fragment thereof.
- a vector comprising a nucleic acid sequence encoding the recombinant enzyme of any one of SEQ ID NO:02, SEQ ID NO:03, SEQ ID NO:05, SEQ ID NO:06, SEQ ID NO:08, SEQ ID NO: 09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:21.
- SEQ ID NO:22 SEQ ID NO 23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29.
- SEQ ID NO:31 SEQ ID NO:32.
- SEQ ID NO:34 SEQ ID NO 35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO 41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, and SEQ ID NO:46.
- a vector comprising a nucleic acid sequence encoding the enzyme of any one of SEQ ID NO:01, SEQ ID NO:04, SEQ ID NO:07, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:39, and SEQ ID NO:42.
- a vector comprising a disclosed expression cassette.
- a vector comprising a nucleic acid sequence comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92 or a fragment thereof.
- a vector comprising a nucleic acid sequence of any one of SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO 52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO 58, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:72.
- SEQ ID NO:74 SEQ ID NO 75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:81.
- a vector comprising a nucleic acid sequence of any one of SEQ ID NO:01, SEQ ID NO:47, SEQ ID NO:50, SEQ ID NO:53, SEQ ID NO:56, SEQ ID NO:59, SEQ ID NO:62, SEQ ID NO:65, SEQ ID NO:70, SEQ ID NO 73, SEQ ID NO:76, SEQ ID NO:79, and SEQ ID NO:82.
- a vector comprising a nucleic acid sequence comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92 or a fragment thereof.
- a vector comprising a nucleic acid sequence of any one of SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55.
- SEQ ID NO:66 SEQ ID NO:67.
- a vector comprising a nucleic acid sequence of any one of SEQ ID NO:01, SEQ ID NO:47.
- SEQ ID NO:50 SEQ ID NO:53, SEQ ID NO:56, SEQ ID NO:59, SEQ ID NO:62, SEQ ID NO:65, SEQ ID NO:70, SEQ ID NO:73, SEQ ID NO:76, SEQ ID NO:79, and SEQ ID NO:82.
- a vector comprising a nucleic acid sequence encoding the recombinant enzyme of SEQ ID NO: 119.
- a vector comprising a nucleic acid sequence encoding the recombinant enzyme of SEQ ID NO: 120 or SEQ ID NO: 121.
- a vector comprising a nucleic acid sequence encoding the recombinant enzyme of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a vector comprising a nucleic acid sequence encoding the recombinant enzyme of SEQ ID NO: 119 or a fragment thereof.
- a vector comprising a nucleic acid sequence encoding the recombinant enzyme of SEQ ID NO: 120 or SEQ ID NO: 121 or a fragment thereof.
- a vector comprising a nucleic acid sequence encoding the recombinant enzyme of any one of SEQ ID NO: 122 - SEQ ID NO: 159 or a fragment thereof.
- a vector comprising a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161.
- a vector comprising a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161 or a fragment thereof.
- a disclosed vector can restore one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation.
- a disclosed vector can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 10 vg/kg to about 2 x 10 14 vg/kg.
- IV intravenous
- a disclosed vector can be administered at a dose of about 1 x 10 11 to about 8 x 10 13 vg/kg or about 1 x 10 12 to about 8 x 10 13 vg/kg.
- a disclosed vector can be administered at a dose of about 1 x 10 13 to about 6 x 10 13 vg/kg.
- a disclosed vector can be administered at a dose of at least about 1 x 10 10 , at least about 5 x 10 10 .
- a disclosed vector can be administered at a dose of no more than about 1 x 10 10 , no more than about 5 x 10 10 , no more than about 1 x 10 11 , no more than about 5 x 10 11 , no more than about 1 x 10 12 , no more than about 5 x 10 12 , no more than about 1 x 10 13 , at least about 5 x 10 13 , or at least about 1 x 10 14 vg/kg.
- a disclosed vector can be administered at a dose of no more than about 1 x 10 10 , no more than about 5 x 10 10 , no more than about 1 x 10 11 , no more than about 5 x 10 11 , no more than about 1 x 10 12 , no more than about 5 x 10 12 , no more than about 1 x 10 13 .
- a disclosed vector can be administered at a dose of about 1 x 10 12 vg/kg. In an aspect, a disclosed vector can be administered at a dose of about 1 x 10 11 vg/kg. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 12 vg per subject total to about 1 x 10 17 vg per subject total.
- IV intravenous
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 12 vg per subject total, about 1 x 10 13 vg per subject total, about 1 x 10 14 vg per subject total, about 1 x 10 15 vg per subject total, about 1 x 10 16 vg per subject total, or about 1 x 10 17 vg per subject total.
- a disclosed vector can be administered in a single dose, or in multiple doses (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses) as needed for the desired therapeutic results.
- a therapeutically effective amount of disclosed vector can comprise a range determined by a skilled person.
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 12 vg per subj ect total to about 1 x 10 17 vg per subject total.
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 12 vg per subject total, about 1 x 10 13 vg per subject total, about 1 x 10 14 vg per subject total, about 1 x 10 15 vg per subject total, about 1 x 10 16 vg per subject total, or about 1 x 10 17 vg per subject total.
- a disclosed nucleic acid sequence can have a coding sequence that is less than about 4.5 kilobases.
- a disclosed vector can be a viral vector or a non-viral vector.
- a disclosed non-viral vector can be a polymer-based vector, a peptide-based vector, a lipid nanoparticle, a solid lipid nanoparticle, or a cationic lipid-based vector.
- a disclosed vector can comprise exosomes, extracellular vesicles, and virus like particles.
- a disclosed viral vector can be an adenovirus vector, an AAV vector, a herpes simplex virus vector, a retrovirus vector, a lentivirus vector, and alphavirus vector, a Flavivirus vector, a rhabdovirus vector, a measles virus vector, a Newcastle disease viral vector, a poxvirus vector, or a picomavirus vector.
- a disclosed viral vector can be an adeno-associated virus (AAV) vector
- AAV vector can include naturally isolated serotypes including, but not limited to, AAV1, AAV2, AAV3 (including 3a and 3b), AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV9, AAV10, AAVrhlO, AAV11, AAV12, AAV13, AAVrh39, AAVrh43, AAVcy.7 as well as bovine AAV, caprine AAV, canine AAV, equine AAV, ovine AAV, avian AAV, primate AAV, non-primate AAV, and any other virus classified by the International Committee on Taxonomy of Viruses (ICTV) as an AAV.
- ICTV International Committee on Taxonomy of Viruses
- an AAV capsid can be a chimera either created by capsid evolution or by rational capsid engineering from a naturally isolated AAV variants to capture desirable serotype features such as enhanced or specific tissue tropism and/or a host immune response escape.
- Naturally isolated AAV variants include, but not limited to, AAV-DJ, AAV-HAE1, AAV-HAE2, AAVM41, AAV- 1829.
- a disclosed AAV vector can be AAV-Rh74 or a related variant (e.g., capsid variants like RHM4-1).
- a disclosed AAV vector can be AAV 8.
- a disclosed AAV vector can be AAVhum.8.
- a disclosed AAV vector can be a self-complementary AAV as disclosed herein.
- a disclosed vector can comprise one or more promoters operably linked to a disclosed transgene and/or a disclosed nucleic acid sequence.
- a disclosed promoter can be positioned 5’ (upstream) or 3’ (downstream) of a disclosed transgene and/or a disclosed nucleic acid sequence under its control. As is known in the art, variation in this distance can be accommodated without loss of promoter function.
- a disclosed vector can further comprise one or more regulatory elements.
- a disclosed “‘regulatory element” can refer to promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences).
- regulatory elements are discussed infra and can include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences).
- a disclosed promoter for the one or more disclosed isolated nucleic acid molecules can be tissue-specific or ubiquitous and can be constitutive or inducible, depending on the pattern of the gene expression desired.
- a promoter can be native or foreign and can be a natural or a synthetic sequence. By foreign, it is intended that the transcriptional initiation region is not found in the wild-type host into which the transcriptional initiation region is introduced.
- a disclosed promoter can be a promoter/enhancer.
- a disclosed promoter for the one or more disclosed isolated nucleic acid molecules can be an endogenous promoter.
- a disclosed endogenous promoter can be an endogenous promoter/enhancer.
- a disclosed endogenous promoter or a disclosed endogenous promoter/enhancer can generally be obtained from a non-coding region upstream of a transcription initiation site of a gene of interest.
- a disclosed endogenous promoter or a disclosed endogenous promoter/enhancer can be used for constitutive and efficient expression of a disclosed gene.
- a disclosed promoter for the one or more disclosed isolated nucleic acid molecules can be a CMV promoter or a CMV promoter/enhancer. CMV promoters and CMV promoters/enhancers are well known to the art.
- a disclosed promoter can be any eukaryotic RNA polymerase II promoter.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme having IgM specific protease activity.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave the IgM the heavy chain at the interdomain region betw een constant domains Cp2 and Cp3.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave human IgM.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave non-human primate IgM.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzy me that does not cleave non-human IgM.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that does not cleave dog IgM, pig IgM, and mouse IgM.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed IgM specific recombinant enzyme that does not cleave human IgA, IgD, IgE, IgG, or any combination thereof.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have a binding domain specific for IgM.
- a disclosed recombinant enzyme can cleave IgM between position 350 and position 365 of SEQ ID NO: 105.
- SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate).
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have a binding domain capable of specifically binding to one or more amino acid residues 355 through 360 of IgM.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have an affinity for human IgM.
- a disclosed IgM can be cleaved at SEQ ID NO: 110.
- a disclosed IgM can be cleaved at the sequence comprising 355D. 356T, 357A. 3581. 359R, and 360V.
- a disclosed IgM can be cleaved at position 355 through position 360 of SEQ ID NO: 105.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have IgG and IgM specific protease activity.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3 and can cleave the IgG below the hinge region.
- a disclosed recombinant enzyme can cleave the IgG below the hinge region, thereby yielding F(ab’)2 and Fc fragments.
- a disclosed recombinant enzyme can cleave the IgG separating the Cp2 and Cp3 domains from the Cpl domain.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave human IgG and human IgM.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave non- human primate IgG and non-human primate IgM.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme having IgG and IgM protease activity' does not cleave IgA, IgD, IgE, or any combination thereof.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme having IgG and IgM protease activity does not cleave non-human IgM or non-human IgG.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme having IgG and IgM protease activity that does not cleave dog IgM, pig IgM, and mouse IgM, or dog IgG, pig IgG, or mouse IgG.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have a binding domain capable of specifically binding to the sequence of SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO: 114, or any combination thereof.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have a binding domain capable of specifically binding to the sequence of SEQ ID NO: 115.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave IgG at amino acid residues 109 through 124 of the IgG of SEQ ID NO: 106, residues 106 through 120 of the IgG of SEQ ID NO:107, residues 156 through 171 of the IgG of SEQ ID NO: 108, residues 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave IgG at amino acid residues 116 through 122 of the IgG of SEQ ID NO: 106, residues 112 through 118 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108, residues 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof.
- a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave one or more IgG molecules at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO:118, or any combination thereof.
- a disclosed encoded recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in a subject.
- a disclosed recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject.
- a disclosed recombinant enz me can cleave and/or degrade circulating IgM and/or IgM and IgG in a subject.
- a disclosed recombinant enzyme can transiently clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject, or can transiently cleave and/or degrade circulating IgM and/or IgM and IgG in a subject.
- a disclosed recombinant enzyme can reduce and/or diminish the level of circulating IgM and/or IgM and IgG levels in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgM and IgG levels in a subject.
- a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
- a disclosed vector can block and/or minimize activation of the complement cascade.
- a disclosed vector can block and/or minimize activation of the formation of the C 1 complex and/or C3 complex.
- a disclosed vector can block and/or minimize activation of the classical complement pathway.
- a disclosed vector can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
- a disclosed vector can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells.
- the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient.
- a disclosed vector can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells. In an aspect, a disclosed vector can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
- a disclosed vector can decrease and/or minimize the severity of a rejection event of the one or more transplanted organs. In an aspect a disclosed vector can prevent the rejection of the one or more transplanted organs. In an aspect, a disclosed rejection event can be classified a hyperacute rejection event, an acute rejection event, or a chronic rejection event. In an aspect, following the administration and/or delivery of a disclosed vector, the one or more transplanted organs are not rejected by the subject. In an aspect, following the administration and/or delivery of a disclosed vector, the viability of one or more transplanted organs can be improved and/or increased.
- the functionality of one or more transplanted organs can be improved and/or increased.
- the functionality 7 of one or more transplanted organs is not decreased and/or diminished.
- a disclosed recombinant enzyme can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
- a disclosed vector can reduce and/or minimize vector mediated immunotoxicity 7 in a subject. In an aspect, a disclosed vector can reduce and/or minimize transgene immunogenicity in a subject.
- a disclosed vector can be used to modulate humoral immunity in a subject.
- modulating humoral immunity in a subject can be an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject’s humoral immunity 7 .
- a disclosed vector can enable and/or allow vector re-dosing in a subject.
- a disclosed vector can improve and/or enhance transgene efficacy and/or expression in a subject.
- a disclosed vector can improve and/or enhance transgene efficacy and/or expression in a subject.
- a disclosed vector can improve and/or enhance transgene efficacy and/or expression in a subject.
- improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed vectors).
- the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed vectors).
- a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed vectors).
- an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed vectors).
- an improvement and/or enhancement can be a partial or incomplete restoration.
- an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wild-type or control level.
- Disclosed herein is a pharmaceutical formulation comprising a disclosed enzyme. Disclosed herein is a pharmaceutical formulation comprising a disclosed enzyme and one or more pharmaceutically acceptable carriers and/or excipients. Disclosed herein is a pharmaceutical formulation comprising a disclosed recombinant enzyme. Disclosed herein is a pharmaceutical formulation comprising a disclosed recombinant enzyme and one or more pharmaceutically acceptable carriers and/or excipients. Disclosed herein is a pharmaceutical formulation comprising a disclosed vector. Disclosed herein is a pharmaceutical formulation comprising a disclosed vector and one or more pharmaceutically acceptable carriers and/or excipients. Disclosed herein is a pharmaceutical formulation comprising an enzyme having IgM specific protease activity.
- Disclosed herein is a pharmaceutical formulation comprising an enzyme having IgG specific protease activity.
- a pharmaceutical formulation comprising an enzyme having IgM specific protease activity and IgG specific protease activity.
- a pharmaceutical formulation comprising a recombinant enzyme having IgG specific protease activity.
- Disclosed herein is a pharmaceutical formulation comprising a recombinant enz me having IgM specific protease activity and IgG specific protease activity.
- a pharmaceutical formulation comprising a fusion protein having IgM specific protease activity and IgG specific protease activity.
- a pharmaceutical formulation comprising an enzy me comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
- a pharmaceutical formulation comprising an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and having IgM specific protease activity and/or IgG specific protease activity.
- a pharmaceutical formulation comprising a disclosed recombinant enzyme having human or non-human primate IgM specific protease activity and a disclosed recombinant enzyme having human or non-human primate IgG specific protease activity.
- a pharmaceutical formulation comprising the recombinant enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and the recombinant enzyme comprising the sequence of SEQ ID NO: 119.
- Disclosed herein is a pharmaceutical formulation comprising the recombinant enzyme comprising the sequence of any one of SEQ ID NO: 01 - SEQ ID NO:46 and the recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121.
- a pharmaceutical formulation comprising the recombinant enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and the recombinant enzy me comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a pharmaceutical formulation comprising a recombinant enzyme comprising the sequence of SEQ ID NO: 119.
- Disclosed herein is a pharmaceutical formulation comprising a recombinant enzy me comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121.
- a pharmaceutical formulation comprising a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 119.
- a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121.
- a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a pharmaceutical formulation comprising a recombinant enzyme comprising the sequence of SEQ ID NO: 119 and having human and non-human primate IgG specific protease activity.
- a pharmaceutical formulation comprising a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121 and having human and non- human primate IgG specific protease activity.
- a pharmaceutical formulation comprising a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159 and having human and non-human primate IgG specific protease activity.
- a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 119 and having human and non-human primate IgG specific protease activity.
- a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121 and having human and non-human primate IgG specific protease activity.
- a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159 and having human and non-human primate IgG specific protease activity.
- Disclosed herein is a pharmaceutical formulation comprising a disclosed isolated nucleic acid molecule.
- a pharmaceutical formulation comprising a disclosed isolated nucleic acid molecule and one or more pharmaceutically acceptable carriers and/or excipients.
- a pharmaceutical formulation comprising an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92.
- a pharmaceutical formulation comprising an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92 and one or more pharmaceutically acceptable carriers and/or excipients.
- a pharmaceutical formulation comprising an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO: 160 or SEQ ID NO: 161.
- a pharmaceutical formulation comprising an isolated nucleic acid molecule comprising the sequence of SEQ ID NO: 160 or SEQ ID NO: 161 and one or more pharmaceutically acceptable carriers and/or excipients.
- a disclosed pharmaceutical formulation can restore one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation. In an aspect, a disclosed pharmaceutical formulation can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
- a disclosed pharmaceutical formulation can have IgM specific protease activity.
- a disclosed pharmaceutical formulation can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3.
- a disclosed recombinant enzyme can cleave human IgM.
- a disclosed pharmaceutical formulation can cleave non-human primate IgM.
- a disclosed pharmaceutical formulation does not cleave non-human IgM.
- a disclosed pharmaceutical formulation does not cleave dog IgM, pig IgM, and mouse IgM.
- a disclosed IgM specific pharmaceutical formulation does not cleave human IgA, IgD, IgE, IgG, or any combination thereof.
- a disclosed pharmaceutical formulation can have a binding domain specific for IgM.
- a disclosed pharmaceutical formulation can cleave IgM between position 350 and position 365 of SEQ ID NO: 105.
- SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate).
- a disclosed pharmaceutical formulation can have a binding domain capable of specifically binding to one or more amino acid residues 355 through 360 of IgM.
- a disclosed pharmaceutical formulation can have an affinity for human IgM.
- a disclosed IgM can be cleaved at SEQ ID NO: 110.
- a disclosed IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, a disclosed IgM can be cleaved at position 355 through position 360 of SEQ ID NO: 105.
- a disclosed pharmaceutical formulation can have IgG and IgM specific protease activity.
- a disclosed pharmaceutical formulation can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3 and can cleave the IgG below the hinge region.
- a disclosed pharmaceutical formulation can cleave the IgG below the hinge region, thereby yielding Ffab'E and Fc fragments.
- a disclosed pharmaceutical formulation can cleave the IgG separating the Cp2 and Cp3 domains from the Cpl domain.
- a disclosed pharmaceutical formulation can cleave human IgG and human IgM.
- a disclosed pharmaceutical formulation e can cleave non-human primate IgG and non-human primate IgM.
- a disclosed pharmaceutical formulation having IgG and IgM protease activity does not cleave IgA, IgD, IgE, or any combination thereof.
- a disclosed pharmaceutical formulation having IgG and IgM protease activity does not cleave non- human IgM or non-human IgG.
- a disclosed pharmaceutical formulation having IgG and IgM protease activity does not cleave dog IgM. pig IgM. and mouse IgM, or dog IgG, pig IgG, or mouse IgG.
- a disclosed pharmaceutical formulation can have a binding domain capable of specifically binding to the sequence of SEQ ID NO:111, SEQ ID NO: 112, SEQ ID NO:113, SEQ ID NO: 114. or any combination thereof.
- disclosed pharmaceutical formulation can have a binding domain capable of specifically binding to the sequence of SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
- disclosed pharmaceutical formulation can cleave IgG at amino acid residues 109 through 124 of the IgG of SEQ ID NO: 106, residues 106 through 120 of the IgG of SEQ ID NO: 107, residues 156 through 171 of the IgG of SEQ ID NO: 108, residues 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof.
- a disclosed pharmaceutical formulation can cleave IgG at amino acid residues 116 through 122 of the IgG of SEQ ID NO:106, residues 112 through 119 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108, residues 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof.
- a disclosed pharmaceutical formulation can cleave one or more IgG molecules at SEQ ID NO:115, SEQ ID NO: 116, SEQ ID NO:117, SEQ ID NO:118, or any combination thereof.
- a disclosed pharmaceutical formulation can clear and/or remove IgM and/or IgG and IgM from circulation in a subject.
- a disclosed recombinant enzyme can cleave and/or degrade circulating IgM and/or IgG and IgM in a subject.
- disclosed pharmaceutical formulation can transiently clear and/or remove IgM and/or IgG and IgM from circulation in a subject, or can transiently cleave and/or degrade circulating IgM and/or IgG and IgM in a subject.
- disclosed pharmaceutical formulation can reduce and/or diminish the level of circulating IgM and/or IgG and IgM levels in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM levels in a subject.
- a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
- a disclosed pharmaceutical formulation can block and/or minimize activation of the complement cascade. In an aspect, a disclosed pharmaceutical formulation can block and/or minimize activation of the formation of the Cl complex and/or C3 complex. In an aspect, a disclosed pharmaceutical formulation can block and/or minimize activation of the classical complement pathway. In an aspect, a disclosed pharmaceutical formulation can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
- a disclosed pharmaceutical formulation can remove and/or cleave surfacebound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells.
- the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient.
- a disclosed pharmaceutical formulation can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells.
- a disclosed pharmaceutical formulation me can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
- a disclosed pharmaceutical formulation can reduce and/or minimize vector mediated immunotoxicity in a subject.
- a disclosed pharmaceutical formulation can enable and/or allow vector re-dosing in a subject.
- a disclosed pharmaceutical formulation can reduce and/or minimize transgene immunogenicity in a subject.
- a disclosed pharmaceutical formulation can improve and/or enhance transgene efficacy and/or expression in a subject.
- improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed pharmaceutical formulations).
- the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed pharmaceutical formulations).
- a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed pharmaceutical formulations).
- an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed pharmaceutical formulations).
- an improvement and/or enhancement can be a partial or incomplete restoration.
- an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wild-type or control level.
- a disclosed pharmaceutical formulation can comprise (i) one or more active agents, (ii) biologically active agents, (iii) one or more pharmaceutically active agents, (iv) one or more immune-based therapeutic agents, (v) one or more clinically approved agents, or (vi) a combination thereof.
- a disclosed composition can comprise one or more immune modulators.
- a disclosed composition can comprise one or more proteasome inhibitors.
- a disclosed composition can comprise one or more immunosuppressives or immunosuppressive agents.
- an immunosuppressive agent can be anti-thymocyte globulin (ATG), cyclosporine (CSP), mycophenolate mofetil (MMF), or a combination thereof.
- a disclosed formulation can comprise an anaplerotic agent (such as, for example, C7 compounds like triheptanoin or MCT).
- a pharmaceutical formulation can decrease and/or minimize the severity of a rejection event of the one or more transplanted organs.
- a pharmaceutical formulation can prevent the rejection of the one or more transplanted organs.
- a disclosed rejection event can be classified a hyperacute rejection event, an acute rejection event, or a chronic rejection event.
- following administration of a disclosed pharmaceutical formulation a disclosed isolated nucleic acid molecule, the one or more transplanted organs are not rejected by the subject.
- the viability of one or more transplanted organs can be improved and/or increased.
- any disclosed pharmaceutical formulation can comprise one or more excipients and/or pharmaceutically acceptable carriers. Excipients and/or pharmaceutically acceptable carriers are known to the art and are discussed supra.
- a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg body weight to about 100 mg/kg body weight.
- a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
- plasmid comprising one or more disclosed isolated nucleic acid molecules.
- plasmid comprising one or more disclosed vectors.
- plasmids used in methods of making a disclosed composition such as, for example, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. Plasmids and using plasmids are known to the art.
- a plasmid comprising the sequence set forth in any one of SEQ ID NO:93 or a fragment thereof.
- a plasmid comprising a sequence having at least 40%, 50%, 60%, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to the sequence set forth in SEQ ID NO:93 or a fragment thereof.
- a plasmid comprising a sequence having at least 40%-60%, at least 60%-80%, at least 80%-90%, or at least 90%-100% identity to the sequence set forth in SEQ ID NO:93 or a fragment thereof.
- a plasmid comprising a nucleic acid sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO: 92.
- a plasmid comprising a nucleic acid molecule that, upon expression, can generate an enzyme comprising the sequence of any one of SEQ ID NO: 01 - SEQ ID NO: 46.
- a plasmid comprising a nucleic acid sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- a plasmid comprising a nucleic acid molecule that, upon expression, can generate an enzyme comprising the sequence of any one of SEQ ID NO: 119 - SEQ ID NO: 121.
- cells comprising a disclosed isolated nucleic acid molecule, a disclosed vector, and/or a disclosed plasmid.
- cells transduced by one or more disclosed viral vectors Disclosed herein are cells transduced by one or more disclosed recombinant viral vectors.
- cells transfected with one or more disclosed isolated nucleic acid molecules In an aspect, a disclosed cell has been transfected or disclosed cells have been transfected with one or more nucleic acid sequences having the sequence set forth in SEQ ID NO 93.
- Disclosed herein are cells that have been transfected by a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO: 92. Disclosed herein are cells that generate a disclosed enzyme or a disclosed recombinant enzyme for harvesting and purification. Disclosed herein are cells that generate an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 for harvesting and purification.
- cells that, upon expression of the nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92, can generate an enzyme comprising the sequence of any one of SEQ ID NO: 01 - SEQ ID NO:46 for harvesting and purification.
- Disclosed herein are cells that have been transfected by a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- cells that generate a disclosed enzyme or a disclosed recombinant enz me for harvesting and purification Disclosed herein are cells that generate an enzy me comprising the sequence of any one of SEQ ID NO: 119 - SEQ ID NO: 121 for harvesting and purification.
- a disclosed cell or disclosed cells can be humanized. Techniques to achieve transfection and transduction are known to the art and using transfected or transduced cells are known to the art.
- disclosed herein are human immortalized cells lines transduced by one or more disclosed viral vectors or transfected with one or more disclosed isolated nucleic acids or disclosed plasmids.
- transgenic animals are known to the art as are the techniques to generate transgenic animals.
- IgM immunoglobulin M
- a method of cleaving immunoglobulin M comprising contacting one or more IgM molecules with one or more disclosed enzymes or disclosed recombinant enzymes.
- a method of cleaving immunoglobulin M comprising contacting one or more IgM molecules with one or more disclosed nucleic acid molecules.
- a method of cleaving immunoglobulin M comprising contacting one or more IgM molecules with one or more disclosed vectors.
- Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with one or more disclosed pharmaceutical formulations.
- a method of cleaving immunoglobulin M (IgM) the method comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15.
- a method of cleaving immunoglobulin M (IgM) the method comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in any one of SEQ ID NO:24 - SEQ ID NO:38.
- Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03.
- a method of cleaving immunoglobulin M (IgM) the method comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06.
- Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09.
- IgM immunoglobulin M
- a method of cleaving immunoglobulin M comprising contacting one or more IgM molecules with an enzy me comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12.
- a method of cleaving immunoglobulin M comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15.
- IgM immunoglobulin M
- a method of cleaving immunoglobulin M comprising contacting one or more IgM molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61.
- a method of cleaving immunoglobulin M comprising contacting one or more IgM molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in any one of SEQ ID NO:70 - SEQ ID NO:84.
- a method of cleaving immunoglobulin M (IgM) is disclosed herein.
- the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO:48 or SEQ ID NO:49.
- a method of cleaving immunoglobulin M (IgM) the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO:51 or SEQ ID NO:52.
- a method of cleaving immunoglobulin M (IgM) the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO:54 or SEQ ID NO:55.
- IgM immunoglobulin M
- a method of cleaving immunoglobulin M comprising contacting one or more IgM molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58.
- a method of cleaving immunoglobulin M comprising contacting one or more IgM molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO: 60 or SEQ ID NO:61.
- a method of cleaving immunoglobulin G comprising contacting one or more IgG molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO: 160 - SEQ ID NO: 161.
- a method of cleaving immunoglobulin G comprising contacting one or more IgG molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- Disclosed herein is a method of cleaving immunoglobulin G (IgG), the method comprising contacting one or more IgG molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- a method of cleaving immunoglobulin G (IgG) the method comprising contacting one or more IgG molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- Disclosed herein is a method of cleaving immunoglobulin G (IgG), the method comprising contacting one or more IgG molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- a method of cleaving immunoglobulin G (IgG) the method comprising contacting one or more IgG molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- IgG immunoglobulin G
- the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed enzymes or disclosed recombinant enzy mes.
- a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG) the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed nucleic acid molecules.
- Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed vectors.
- a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG) the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed pharmaceutical formulations.
- Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with an enzy me comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23.
- a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG) the method comprising contacting one or more IgM molecules and IgG molecules with an enzy me comprising the sequence set forth in any one of SEQ ID NO: 39 - SEQ ID NO:46.
- Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with an enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18.
- a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG) the method comprising contacting one or more IgM molecules and IgG molecules with an enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21.
- Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with an enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23.
- a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG) the method comprising contacting one or more IgM molecules and IgG molecules with an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46.
- IgM immunoglobulin M
- IgG immunoglobulin G
- Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:62 - SEQ ID NO:69.
- a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG) the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO: 85 - SEQ ID NO:92.
- Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:63 or SEQ ID NO:64.
- a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG) the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:66 or SEQ ID NO:67.
- Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:68 or SEQ ID NO:69.
- a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG) the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 86 or SEQ ID NO: 87.
- Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 89 or SEQ ID NQ:90.
- a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG) the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:91 or SEQ ID NO:92.
- the IgM molecule and/or the IgG molecule that is cleaved can be in the sera of a subject. In an aspect, the IgM molecule and/or the IgG molecule that is cleaved can be circulating in a subject. In an aspect, a disclosed IgM molecule and/or the IgG molecule can be neutralizing against an exogenously administered protein. In an aspect, a disclosed IgM molecule and/or the IgG molecule can be neutralizing against enzyme replacement therapy or protein replacement therapy or recombinant product. In an aspect, a disclosed IgM molecule and/or the IgG molecule can be neutralizing against a non-viral vector or a viral vector.
- a disclosed IgM molecule and/or the IgG molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein).
- a disclosed method can further comprise diagnosing a subject as being in need of one or more disclosed enzymes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed IgM molecule and/or the IgG molecule can be neutralizing against one or more transplanted organs.
- a disclosed method can decrease and/or can minimize the severity’ of a rejection event of the one or more transplanted organs.
- a disclosed method can prevent the rejection of the one or more transplanted organs.
- a disclosed rejection event can be classified ahyperacute rejection event, an acute rejection event, or a chronic rejection event.
- a disclosed method can reduce the risk of rejection of the one or more transplanted organs.
- a disclosed method can reduce or diminish the subject's need for long-term immunosuppression.
- a disclosed method can improve and/or increase the viability of one or more transplanted organs. In an aspect, a disclosed method can improve and/or increase the functionality of one or more transplanted organs. In an aspect, a disclosed method does not decrease and/or diminish the functionality of one or more transplanted organs. In an aspect, a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
- a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800).
- HSAT high sustained antibody titer
- a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- HSAT high sustained antibody titer
- a disclosed HSAT can be reduced and/or eliminated.
- a subject can be re-dosed.
- a subject can be re-dosed with one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- a disclosed method can comprise modifying one or more of the disclosed steps.
- modifying one or more of steps of a disclosed method can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method.
- a method can be altered by changing the amount of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof administered to a subj ect.
- a disclosed method can further comprise measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
- a disclosed method of cleaving IgM and/or IgG can clear and/or remove IgM and/or IgG from circulation in a subject.
- a disclosed method of cleaving IgM and/or IgG can leave and/or degrade circulating IgM and/or IgG in a subject.
- a disclosed method can transiently clear and/or remove IgM and/or IgG from circulation in a subject, or can transiently cleave and/or degrade circulating IgM and/or IgG in a subject.
- a disclosed method of cleaving IgM and/or IgG can reduce and/or diminish the level of circulating IgM and/or IgG levels in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG levels in a subject.
- a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
- a disclosed method of cleaving IgM and/or IgG can block and/or minimize activation of the complement cascade. In an aspect, a disclosed method of cleaving IgM and/or IgG can block and/or minimize activation of the formation of the Cl complex and/or C3 complex. In an aspect, a disclosed method of cleaving IgM and/or IgG can block and/or minimize activation of the classical complement pathway. In an aspect, a disclosed method can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
- a disclosed method of cleaving IgM and/or IgG can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells.
- the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient.
- a disclosed method of cleaving IgM and/or IgG can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells.
- a disclosed method can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
- a disclosed method of cleaving IgM and/or IgG can reduce and/or minimize vector mediated immunotoxicity in a subject. In an aspect, a disclosed method of cleaving IgM and/or IgG can enable and/or allow vector re-dosing in a subject.
- a disclosed method of cleaving IgM and/or IgG can modulate humoral immunity in a subject.
- modulating humoral immunity in a subject can be an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject's humoral immunity.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein.
- the intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
- a disclosed method of cleaving IgM and/or IgG can reduce and/or minimize transgene immunogenicity in a subject. In an aspect, a disclosed method of cleaving IgM and/or IgG can improve and/or enhance transgene efficacy and/or expression in a subject.
- improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%.
- an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wildtype or control level.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered prior to, concurrent, or after the delivery and/or administration of enz me replacement therapy, protein replacement, gene therapy, a recombinant product, or any combination thereof.
- a disclosed method of cleaving IgM and/or IgG can further comprise reducing and/or minimizing vector-mediated immunotoxicity and/or transgene immunogenicity (e.g., the ability to induce specific immunity).
- vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the efficacy of the recombinant product encoded by the transgene.
- vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with gene therapy, enzyme replacement therapy, protein replacement, recombinant product, or any combination thereof.
- IgM can be cleaved in the heavy chain at the interdomain region between constant domains Cp2 and Cp3.
- IgM can be cleaved between position 350 and position 365 of SEQ ID NO: 105.
- SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate).
- IgM can be cleaved between positions 355 through 360 of IgM.
- IgM can be cleaved at SEQ ID NO: 110.
- IgM can be cleaved at the sequence comprising 355D, 356T, 357 A, 3581, 359R, and 360V. In an aspect IgM can be cleaved at position 355 through position 360 of the IgM of SEQ ID NO: 105. In an aspect, IgG can be cleaved below the hinge region, thereby yielding F(ab’)2 and Fc fragments. In an aspect, IgG can be cleaved to separate the Cu2 and Cp3 domains from the Cpl domain. In an aspect, IgG can be cleaved at SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 1 13, SEQ ID NO: 114.
- IgG can be cleaved at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 1 17, SEQ ID NO: 118, or any combination thereof.
- IgG can be cleaved at positions 109 through 124 of the IgG of SEQ ID NO: 106, positions 106 through 120 of the IgG of SEQ ID NO: 107, positions 156 through 171 ofthe lgG of SEQ ID NO: 108, positions 106 through 121 of lgG of SEQ ID NO: 109, or any combination thereof.
- IgG can be cleaved at positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107, positions 163 through 169 of the IgG of SEQ ID NO: 108, positions 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof.
- IgG can be cleaved SEQ ID NO: 115. SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
- IgM immunoglobulin M
- IgG immunoglobulin G
- IgM immunoglobulin M
- IgG immunoglobulin G
- the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
- IgM immunoglobulin M
- IgG immunoglobulin G
- the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 11 or SEQ ID NO: 12 and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
- IgM immunoglobulin M
- IgG immunoglobulin G
- the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 11 or SEQ ID NO: 12 and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 1 19.
- IgM immunoglobulin M
- IgG immunoglobulin G
- the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 14 or SEQ ID NO: 15 and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
- IgM immunoglobulin M
- IgG immunoglobulin G
- the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 14 or SEQ ID NO: 15 and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO:119.
- a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 119.
- a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121.
- a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 119.
- a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121.
- a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a disclosed method can further comprise administering one or more times one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed method can further comprise measuring and/or determining a subject’s pre-treatment level of circulating IgG and/or IgM and/or a subject’s pre-treatment level of surface bound IgM. In an aspect, a disclosed method can further comprise measuring and/or determining one or more times a subject’s level of circulating IgG and/or IgM and/or a subject’s level of surface bound IgM (e.g., before, during, and after a disclosed administering step).
- a disclosed method can be performed using a singular disclosed enzyme having both IgG and IgM specific protease activity. In an aspect, a disclosed method can be performed using a disclosed enzyme having IgG specific protease activity and a disclosed enzyme having IgM specific protease activity.
- IgM immunoglobulin M
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed enzymes or disclosed recombinant enzymes.
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid molecules.
- a method of cleaving bound immunoglobulin M (IgM) the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed vectors.
- IgM immunoglobulin M
- a method of cleaving bound immunoglobulin M (IgM) comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed pharmaceutical formulations.
- a method of cleaving bound immunoglobulin M (IgM) comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15.
- IgM immunoglobulin M
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in any one of SEQ ID NO:24 - SEQ ID NO:38.
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03.
- IgM immunoglobulin M
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06.
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09.
- IgM immunoglobulin M
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12.
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15.
- IgM immunoglobulin M
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid molecules comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID N0:61.
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid molecules comprising the sequence set forth in any one of SEQ ID NO:70 - SEQ ID NO: 84.
- IgM immunoglobulin M
- the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO:48 or SEQ ID NO:49.
- a method of cleaving bound immunoglobulin M (IgM) the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO:51 or SEQ ID NO:52.
- IgM immunoglobulin M
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO:54 or SEQ ID NO:55.
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58.
- IgM immunoglobulin M
- the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO:60 or SEQ ID NO:61.
- IgM immunoglobulin M
- a method of cleaving bound immunoglobulin M (IgM) comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23.
- a method of cleaving bound immunoglobulin M (IgM) the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46.
- IgM immunoglobulin M
- a method of cleaving bound immunoglobulin M (IgM) comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO:18.
- a method of cleaving bound immunoglobulin M (IgM) the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21.
- IgM immunoglobulin M
- the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23.
- a method of cleaving bound immunoglobulin M (IgM) comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46.
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:62- SEQ ID NO:69.
- a method of cleaving bound immunoglobulin M (IgM)
- the method comprising contacting one or more IgM molecules bound to the surface of B cells with a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:85 - SEQ ID NO:92.
- a method of cleaving bound immunoglobulin M (IgM) is disclosed herein.
- IgM immunoglobulin M
- IgM immunoglobulin M
- the method comprising contacting one or more IgM molecules bound to the surface of B cells w ith a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:68 or SEQ ID NO:69.
- a method of cleaving bound immunoglobulin M (IgM) comprising contacting one or more IgM molecules bound to the surface of B cells with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:86 or SEQ ID NO:87.
- IgM immunoglobulin M
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 89 or SEQ ID NQ:90.
- a method of cleaving bound immunoglobulin M comprising contacting one or more IgM molecules bound to the surface of B cells with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:91 or SEQ ID NO:92.
- disclosed B cells can be in the sera of a subject. In an aspect, disclosed B cells can be circulating in a subject.
- a disclosed surface-bound IgM molecule can be neutralizing against an exogenously administered protein. In an aspect, a disclosed surface-bound IgM molecule can be neutralizing against enzy me replacement therapy or protein replacement therapy or recombinant product. In an aspect, a disclosed surface-bound IgM molecule can be neutralizing against a non- viral vector or a viral vector. In an aspect, a disclosed surface-bound IgM molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector. For example, in an aspect, a disclosed surface-bound IgM molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein).
- a viral vector capsid protein e.g., an AAV capsid protein
- a disclosed method can further comprise diagnosing a subject as being in need of one or more disclosed enzymes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed surface-bound IgM molecule can be neutralizing against one or more transplanted organs.
- a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
- a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800).
- HSAT high sustained antibody titer
- a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- HSAT high sustained antibody titer
- a disclosed HSAT can be reduced and/or eliminated.
- a subject after the reduction and/or elimination of one or more HS ATs, a subject can be re-dosed.
- a subject can be re-dosed with one or more exogenously administered proteins or enzy mes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- a disclosed method can further comprise measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
- a disclosed method of cleaving surface-bound IgM can clear and/or remove IgM from circulation in a subject.
- a disclosed method of cleaving surface-bound IgM can cleave and/or degrade circulating IgM in a subject.
- a disclosed method of cleaving surface-bound IgM can transiently clear and/or remove IgM from circulation in a subject, or can transiently cleave and/or degrade circulating IgM in a subject.
- a disclosed method of cleaving surface-bound IgM can reduce and/or diminish the level of circulating IgM levels in a subj ect, or can transiently 7 reduce and/or diminish the level of circulating IgM levels in a subject.
- a disclosed method can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
- a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
- a disclosed method of cleaving surface-bound IgM can block and/or minimize activation of the complement cascade. In an aspect, a disclosed method of cleaving surface-bound IgM can block and/or minimize activation of the formation of the C 1 complex and/or C3 complex. In an aspect, a disclosed method of cleaving surface-bound IgM can block and/or minimize activation of the classical complement pathway.
- a disclosed method of cleaving surface-bound IgM can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
- a disclosed method of cleaving surface-bound IgM can reduce and/or minimize vector mediated immunotoxicity in a subject.
- a disclosed method of cleaving surface-bound IgM can enable and/or allow vector re-dosing in a subject.
- a disclosed method of cleaving surface-bound IgM can enable and/or allow re-dosing of one or more disclosed enzymes or recombinant enzy mes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof in a subject.
- a disclosed method of cleaving surface-bound IgM can reduce and/or minimize transgene immunogenicity in a subject.
- a disclosed method of cleaving surface-bound IgM can improve and/or enhance transgene efficacy and/or expression in a subject.
- improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%.
- a pre-treatment level prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- a pre-treatment level prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- an improvement and/or enhancement can be a partial or incomplete restoration.
- an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wildtype or control level.
- a disclosed method of cleaving surface-bound IgM can modulate humoral immunity in a subj ect.
- modulating humoral immunity' in a subject can be an increase in the functionality of the subject's humoral immunity, or can be a decrease in the functional of the subject’s humoral immunity.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein.
- the intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
- a disclosed method can comprise administering to a subject in need thereof a theoretically effectively amount of one or more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body weight.
- a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
- a subject can have or can be suspected of having one of more disclosed autoimmune diseases and/or disorders, one or more autoinflammatory diseases and/or disorders, one or more inflammatory diseases and
- a disclosed autoimmune disease and/or disorder can be celiac disease, diabetes mellitus type 1. Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, or any combination thereof.
- a disclosed autoinflammatory diseases and/or disorder can be Familial Mediterranean Fever (FMF), hyper IgD syndrome (HIDS), TNF receptor-associated periodic syndrome (TRAPS), cryopyrin associated periodic syndromes (CAPS), Blau syndrome, pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome (PAPA), or any combination thereof.
- FMF Familial Mediterranean Fever
- HIDS hyper IgD syndrome
- TRAPS TNF receptor-associated periodic syndrome
- CAS cryopyrin associated periodic syndromes
- Blau syndrome pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome (PAPA), or any combination thereof.
- a disclosed inflammatory disease and/or disorder can be Encephalitis, Myelitis, Meningitis, Arachnoiditis, Neuritis, Dacryoadenitis, Scleritis, Episcleritis, Keratitis, Retinitis, Chorioretinitis, Blepharitis, Conjunctivitis, Uveitis, Otitis externa, Otitis media, Labyrinthitis, Mastoiditis, Carditis, Endocarditis, Myocarditis, Pericarditis, Vasculitis, Arteritis, Phlebitis, Capillaritis, Sinusitis, Rhinitis, Pharyngitis, Laryngitis Tracheitis, Bronchitis, Bronchiolitis, Pneumonitis, Pleuritis, Mediastinitis, Stomatitis, Gingivitis, Gingivostomatitis, Glossitis, Tonsillitis,
- Nephritis Glomerulonephritis, Pyelonephritis, Ureteritis, Cystitis, Urethritis, Oophoritis, Salpingitis, Endometritis, Parametritis, Cervicitis, Vaginitis, Vulvitis, Mastitis, Orchitis, Epididymitis, Prostatitis, Seminal vesiculitis.
- a subject can be in need of one or more organ transplants.
- a subj ect can have received one or more organ transplants.
- a disclosed organ transplant can comprise the heart, one or both kidneys, the liver, one or both lungs, the pancreas, part or all of the colon or the intestines, or any combination thereof.
- a subject can be in need of gene therapy, can have received gene therapy, or can be receiving gene therapy.
- a subj ect can be treated with gene therapy or can have a disease and/or disorder that can be treated with gene therapy.
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes.
- a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
- examples of such genetic diseases and/or disorders or diseases and/or disorders that can be treated with gene therapy include those discussed supra at Part VII(B)(2).
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes discussed supra at Part VII(B)(2).
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes discussed supra at Part VI(B)(2).
- a disclosed method of cleaving surface-bound IgM can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme delivered by gene therapy.
- a disclosed method of cleaving surface-bound IgM can comprise restoring one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation.
- restoring one or more aspect of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation comprises restoring the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
- restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise one or more of the following: (i) correcting cell starvation in one or more cell types; (ii) normalizing aspects of the autophagy’ pathway (such as, for example, correcting, preventing, reducing, and/or ameliorating autophagy); (iii) improving, enhancing, restoring, and/or preserving mitochondrial functionality and/or structural integrity; (iv) improving, enhancing, restoring, and/or preserving organelle functionality and/or structural integrity; (v) correcting enzyme dysregulation; (vi) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of the multi-systemic manifestations of a genetic disease or disorder; (vii) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of a genetic disease or disorder, or (viii) any combination thereof.
- restoring one or more aspects of cellular homeosta can comprise one or more of the following:
- restoring the activity and/or functionality of a missing, deficient, and/or mutant protein or enzyme can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of restoration when compared to a pre-existing level such as, for example, a pre-treatment level.
- the amount of restoration can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as, for example, a pre-treatment level.
- restoration can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having a missing, deficient, and/or mutant protein or enzyme).
- restoration can be a partial or incomplete restoration.
- restoration can be complete or near complete restoration such that the level of expression, activity, and/or functionality is similar to that of a wild-type or control level.
- a disclosed method of cleaving surface-bound IgM, techniques to monitor, measure, and/or assess the restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise qualitative (or subjective) means as well as quantitative (or objective) means. These means are known to the skilled person. For example, representative regulated variables and sensors relating to systemic homeostasis are provided below.
- contacting a cell can comprising methods known to the art.
- contacting can comprise administering to a subject one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
- administering can comprise intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intra-CSF, intrathecal, intraventricular, intrahepatic. hepatic intraarterial, hepatic portal vein (HPV), or in utero administration.
- a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via intra-CSF administration in combination with RNAi, antisense oligonucleotides, miRNA, one or more small molecules, one or more therapeutic agents, one or more proteasome inhibitors, one or more immune modulators, and/or a gene editing system.
- a disclosed composition, a disclosed enzy me or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via LNP administration.
- a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be concurrently and/or serially administered to a subject via multiple routes of administration.
- administering a disclosed nucleic acid molecule, a disclosed enzyme or disclosed recombinant enzyme, a disclosed vector, and/or a disclosed pharmaceutical formulation can comprise intravenous administration and intra-cistem magna (ICM) administration.
- ICM intra-cistem magna
- administering a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can comprise IV administration and intrathecal (ITH) administration.
- a disclosed method can employ multiple routes of administration to the subject.
- a disclosed method can employ a first route of administration that can be the same or different as a second and/or subsequent routes of administration.
- a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body weight.
- a disclosed enzyme or disclosed recombinant enzy me can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
- a therapeutically effective amount of disclosed vector can be delivered to a subject via intravenous (IV) administration and can comprise a range of about 1 x 10 10 vg/kg to about 2 x 10 14 vg/kg.
- IV intravenous
- a disclosed vector can be administered at a dose of about 1 x 10 11 vg/kg to about 8 x 10° vg/kg or about 1 x 10 12 vg/kg to about 8 x 10 13 vg/kg.
- a disclosed vector can be administered at a dose of about I x 10 13 vg/kg to about 6 x 10 13 vg/kg.
- a disclosed vector can be administered at a dose of at least about 1 x 10 10 vg/kg, at least about 5 x IO 10 vg/kg, at least about 1 x 10 11 vg/kg, at least about 5 x I0 11 vg/kg, at least about I x IO 12 vg/kg, at least about 5 x 10 12 vg/kg, at least about I x 10 13 vg/kg, at least about 5 x 10 13 vg/kg, or at least about I x 10 14 vg/kg.
- a disclosed vector can be administered at a dose of no more than about 1 x 10 10 vg/kg, no more than about 5 x 10 10 vg/kg, no more than about 1 x 10 11 vg/kg, no more than about 5 x 10 11 vg/kg, no more than about 1 x 10 12 vg/kg, no more than about 5 x 10 12 vg/kg, no more than about 1 x 10 13 vg/kg, no more than about 5 x 10 13 , or no more than about 1 x 10 14 vg/kg.
- a disclosed vector can be administered to a subject at a dose of about 1 x 10 12 vg/kg.
- a disclosed vector can be administered to a subject at a dose of about 1 x 10 11 vg/kg.
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 12 vg per subj ect total to about 1 x 10 17 vg per subject total.
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 12 vg per subject total, about 1 x 10 13 vg per subject total, about 1 x 10 14 vg per subject total, about 1 x 10 15 vg per subject total, about 1 x 10 16 vg per subject total, or about 1 x 10 17 vg per subject total.
- a disclosed vector can be administered in a single dose, or in multiple doses (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses) as needed for the desired therapeutic results.
- a disclosed method of cleaving surface-bound IgM can further comprise administering to the subject a therapeutically effective amount of a therapeutic agent.
- a therapeutic agent can be any disclosed agent that effects a desired clinical outcome.
- a disclosed method of cleaving surface-bound IgM can further comprise monitoring the subject for adverse effects. In an aspect, in the absence of adverse effects, the method can further comprise continuing to treat the subject. In an aspect, in the presence of adverse effects, the method can further comprise modifying the treating step.
- Methods of monitoring a subject’s well-being can include both subjective and objective criteria (and are discussed supra). Such methods are known to the skilled person.
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering to the subject a therapeutically effective amount of an agent that can correct one or more aspects of a dysregulated metabolic or enzymatic pathway.
- an agent can comprise an enzyme for enzyme replacement therapy.
- a disclosed enzyme can replace any enzyme in a dysregulated or dysfunctional metabolic or enzymatic pathway.
- a disclosed method can comprise replacing one or more enzymes in a dysregulated or dysfunctional metabolic pathway.
- a disclosed method of cleaving surface-bound IgM can further comprise administering one or more immune modulators.
- a disclosed immune modulator can be methotrexate, rituximab, intravenous gamma globulin, or bortezomib, or a combination thereof.
- a disclosed immune modulator can be bortezomib or SVP-Rapamycin.
- a disclosed immune modulator can be Tacrolimus.
- a disclosed immune modulator such as methotrexate can be administered at a transient low to high dose.
- a disclosed immune modulator can be administered at a dose of about 0.1 mg/kg body weight to about 0.6 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at a dose of about 0.4 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for 3 to 5 or greater cycles, with up to three days per cycle. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for a minimum of 3 cycles, with three days per cycle. In an aspect, a person skilled in the art can determine the appropriate number of cycles. In an aspect, a disclosed immune modulator can be administered as many times as necessary to achieve a desired clinical effect.
- a disclosed immune modulator can be administered orally about one hour before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered orally about one hour or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof.
- a disclosed method of cleaving surface-bound IgM can further comprise administering one or more proteasome inhibitors (e.g., bortezomib, carfilzomib, marizomib, ixazomib, and oprozomib).
- a proteasome inhibitor can be an agent that acts on plasma cells (e.g., daratumumab).
- an agent that acts on a plasma cell can be melphalan hydrochloride, melphalan, pamidronate disodium, carmustine, carfilzomib, carmustine, cyclophosphamide, daratumumab, doxorubicin hydrochloride liposome, doxorubicin hydrochloride liposome, elotuzumab, melphalan hydrochloride, panobinostat, ixazomib citrate, carfilzomib, lenalidomide, melphalan, melphalan hydrochloride, plerixafor, ixazomib citrate, pamidronate disodium, panobinostat, plerixafor, pomalidomide, pomalidomide, lenalidomide, selinexor, thalidomide, thalidomide, bortezomib, selinexor, zoledronic acid, or zoledron
- a disclosed method of cleaving surface-bound IgM can further comprise administering one or more proteasome inhibitors or agents that act on plasma cells prior to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation.
- a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells concurrently with administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation.
- a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells subsequent to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation.
- a disclosed method can further comprise administering one or more proteasome inhibitors more than 1 time.
- a disclosed method can comprise administering one or more proteasome inhibitors repeatedly over time.
- a disclosed method of cleaving surface-bound IgM can further comprise administering one or more immunosuppressive agents.
- an immunosuppressive agent can be, but is not limited to, azathioprine, methotrexate, sirolimus, anti -thymocyte globulin (ATG), cyclosporine (CSP), mycophenolate mofetil (MMF), steroids, or a combination thereof.
- a disclosed method can comprise administering one or more immunosuppressive agents more than 1 time.
- a disclosed method can comprise administering one or more one or more immunosuppressive agents repeatedly over time.
- a disclosed method can comprise administering a compound that targets or alters antigen presentation or humoral or cell mediated or innate immune responses.
- a disclosed method of cleaving surface-bound IgM can further comprise administering a compound that exerts a therapeutic effect against B cells and/or a compound that targets or alters antigen presentation or humoral or cell mediated immune response.
- a disclosed compound can be rituximab, methotrexate, intravenous gamma globulin, anti CD4 antibody, anti CD2, an anti-FcRN antibody, a BTK inhibitor, an anti-IGFIR antibody, a CD19 antibody (e.g., inebilizumab), an anti-IL6 antibody (e.g., tocilizumab), an antibody to CD40, an IL2 mutein, or a combination thereof.
- a disclosed method can further comprise administering lipid nanoparticles (LNPs).
- LNPs can be organ-targeted.
- LNPs can be liver-targeted or testes-targeted.
- mRNA therapy with LNP encapsulation for systemic delivery to a subject has the potential to restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzy me.
- a disclosed method of cleaving surface-bound IgM can further comprise plasmapheresis and immunosuppression.
- a disclosed method can comprise using immunosuppression to decrease the T cell, B cell, and /or plasma cell population, decrease the innate immune response, inflammatory response, and antibody levels in general.
- a disclosed method can comprise repeating a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzy me, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell mediated immune response.
- a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzy me, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation
- a disclosed method can comprise modifying one or more of the disclosed steps.
- modifying one or more of steps of a disclosed method can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method.
- a method can be altered by changing the amount of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof administered to a subject, or by changing the frequency of administration of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof to a subject, or by changing the duration of time one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof are administered to a subject.
- a disclosed method can be altered by changing the amount of one or more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject, or by changing the frequency of administration of one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject.
- a disclosed method can comprise concurrent administration of one or more of the following: one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, one or more disclosed therapeutic agents, one or more disclosed immune modulators, one or more disclosed proteasome inhibitors, one or more disclosed immunosuppressive agents, one or more disclosed compounds that exert therapeutic effect against B cells, one or more disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response, or any combination thereof.
- a disclosed immune modulator can be administered prior to or after the administration of a disclosed therapeutic agent.
- a disclosed method of cleaving surface-bound IgM can further comprise generating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed method of cleaving surface-bound IgM can further comprise generating a disclosed viral or non- viral vector.
- generating a disclosed viral vector can comprise generating an AAV vector or a recombinant AAV (such as those disclosed herein).
- a disclosed method of cleaving surface-bound IgM can further comprise validating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
- a disclosed method of cleaving surface-bound IgM can further comprise gene editing one or more relevant genes (such as, for example, a missing, deficient, and/or mutant protein or enzy me), wherein editing includes but is not limited to single gene knockout, loss of function screening of multiple genes at one, gene knockin, or a combination thereof.
- relevant genes such as, for example, a missing, deficient, and/or mutant protein or enzy me
- a disclosed method of cleaving surface-bound IgM can further comprise administering an oligonucleotide therapeutic agent.
- a disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA, noncoding RNA (ncRNA), an antisense molecule, miRNA, a morpholino, a peptide-nucleic acid (PNA), or an analog or conjugate thereof.
- a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi.
- a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable.
- a disclosed oligonucleotide therapeutic agent can comprise a CRISPR-based endonuclease.
- a disclosed endonuclease can be Cas9.
- a disclosed Cas9 can be from Staphylococcus aureus or Streptococcus pyogenes.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered one or more times.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered for the duration of the subject’s life, or for the duration of the subject's treatment with, for example, gene therapy, enzy me replacement therapy, protein replacement therapy, and/or recombinant product.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered every' 6 weeks, every' 2 months, every' 3 months, every' 6 months, every' year, year other year, every 3 years, every 5 years, or for any other period deemed necessary by a skilled clinician.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered prior to, concurrent, or after the delivery and/or administration of enzyme replacement therapy, protein replacement, gene therapy, recombinant product, or any combination thereof.
- a disclosed method of cleaving surface bound IgM can further comprise reducing and/or minimizing vector-mediated immunotoxicity' and/or transgene immunogenicity' (e.g., the ability to induce specific immunity).
- vector-mediated immunotoxicity' and/or transgene immunogenicity can decrease and/or reduce the efficacy of the recombinant product encoded by the transgene.
- vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability 7 and/or likelihood of re-dosing a subject with one or more disclosed enzymes or recombinant enzy mes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with gene therapy, enzyme replacement therapy, protein replacement, or any combination thereof.
- IgM can be cleaved in the heavy chain at the interdomain region between constant domains Cp2 and Cp3.
- IgM can be cleaved between position 350 and position 365 of SEQ ID NO: 105.
- SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate).
- IgM can be cleaved between positions 355 through 360 of IgM.
- IgM can be cleaved at SEQ ID NO: 1 10.
- IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, IgM can be cleaved at position 355 through position 360 of the IgM of SEQ ID NO: 105. In an aspect, IgG can be cleaved below the hinge region, thereby yielding F(ab’)2 and Fc fragments. In an aspect, IgG can be cleaved to separate the Cp2 and Cp3 domains from the Cpl domain.
- IgG can be cleaved at SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, or any combination thereof. In an aspect, IgG can be cleaved at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof. In an aspect, IgG can be cleaved at positions 109 through 124 of the IgG of SEQ ID NO: 106. positions 106 through 120 of the IgG of SEQ ID NO: 107.
- IgG can be cleaved at positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107, positions 163 through 169 ofthe lgG of SEQ ID NO: 108, positions 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof.
- IgG can be cleaved SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO:118, or any combination thereof.
- IgM immunoglobulin M
- IgM immunoglobulin M
- IgM immunoglobulin M
- IgM immunoglobulin M
- IgM immunoglobulin M
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 119. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80%. at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 1 19.
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121.
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a disclosed method can further comprise administering one or more times one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed method can further comprise measuring and/or determining a subject’s pre-treatment level of circulating IgG and/or IgM and/or a subject’s pre-treatment level of surface bound IgM. In an aspect, a disclosed method can further comprise measuring and/or determining one or more times a subject’s level of circulating IgG and/or IgM and/or a subject’s level of surface bound IgM (e.g., before, during, and after a disclosed administering step).
- a disclosed method can be performed using a singular disclosed enzyme having both IgG and IgM specific protease activity. In an aspect, a disclosed method can be performed using a disclosed enzyme having IgG specific protease activity and a disclosed enzyme having IgM specific protease activity.
- Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzy mes.
- a method of reducing the level of circulating intact IgM in the serum of a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules.
- Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors.
- Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations.
- a method of reducing the level of circulating intact IgM in the serum of a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15.
- Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:24 - SEQ ID NO:38.
- a method of reducing the level of circulating intact IgM in the serum of a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03.
- Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06.
- a method of reducing the level of circulating intact IgM in the serum of a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enz me comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09.
- Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12.
- a method of reducing the level of circulating intact IgM in the serum of a subject the method comprising administering to the subject in need thereof a therapeutically ⁇ effective amount of an enzy me comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO:15.
- Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 or SEQ ID NO:70 - SEQ ID NO:84.
- a method of reducing the level of circulating intact IgM in the serum of a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:60, or SEQ ID NO:61.
- a method of reducing the level of circulating intact IgM in the serum of a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:83, or SEQ ID NO:84.
- Disclosed herein is a method reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzymes.
- a method of reducing the level of circulating intact IgM and IgG in the serum of a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules.
- a method of reducing the level of circulating intact IgM and IgG in the serum of a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors.
- a method of reducing the level of circulating intact IgM and IgG in the serum of a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations.
- Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23.
- a method of reducing the level of circulating intact IgM and IgG in the serum of a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46.
- Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18.
- a method of reducing the level of circulating intact IgM and IgG in the serum of a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 .
- Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23.
- Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO: 62 - SEQ ID NO: 69 or SEQ ID NO: 85 - SEQ ID NO: 92.
- a method of reducing the level of circulating intact IgM and IgG in the serum of a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:63, SEQ ID NO:64.
- SEQ ID NO:66 SEQ ID NO:67, SEQ ID NO:68, or SEQ ID NO 69.
- a method of reducing the level of circulating intact IgM and IgG in the serum of a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90. SEQ ID NO:91, or SEQ ID NO:92.
- Disclosed herein is a method reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity', and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity.
- a method reducing the level of circulating intact IgM and IgG in the serum of a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity (such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15).
- one or more disclosed recombinant enzymes having IgG specific protease activity such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15).
- a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity 7 such as, for example, the enzyme of any one of SEQ ID NO: 119 - SEQ ID NO: 159.
- a method of reducing the level of circulating intact IgM and IgG in the serum of a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 and (ii) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- a method of reducing the level of circulating intact IgM and IgG in the serum of a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO: 14, or SEQ ID NO: 15, and (ii) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO: 119, SEQ ID NO: 120, or SEQ ID NO: 121.
- a disclosed IgM molecule can be neutralizing against an exogenously administered protein.
- a disclosed IgM molecule can be neutralizing against enzyme replacement therapy, protein replacement therapy , and/or recombinant product.
- a disclosed IgM molecule can be neutralizing against a non-viral vector or a viral vector.
- a disclosed IgM molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector.
- a disclosed IgM molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein).
- a disclosed method can further comprise diagnosing a subject as being in need of one or more disclosed enzymes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed IgM molecule can be neutralizing against one or more transplanted organs.
- a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
- a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800).
- HSAT high sustained antibody titer
- a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- HSAT high sustained antibody titer
- a disclosed HSAT can be reduced and/or eliminated.
- a subject can be re-dosed.
- a subject can be re-dosed with one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- a disclosed method can further comprise measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
- a disclosed method of reducing circulating levels of IgM and/or IgG and IgM can clear and/or remove IgM and/or IgG and IgM from circulation in a subject.
- a disclosed method can cleave and/or degrade circulating IgM and/or IgG and IgM in a subject.
- a disclosed method can cleave and/or degrade all or nearly all circulating IgM and/or IgG and IgM in a subject.
- a disclosed method can transiently clear and/or remove IgM and/or IgG and IgM from circulation in a subject, or can transiently cleave and/or degrade circulating IgM and/or IgG and IgM in a subject.
- a disclosed method can completely or nearly completely clear and/or remove IgM and/or IgG and IgM from circulation in a subject.
- a disclosed method can reduce and/or diminish the level of circulating IgM and/or IgG and IgM in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM in a subject.
- a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
- a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the complement cascade. In an aspect, a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the formation of the Cl complex and/or C3 complex. In an aspect, a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the classical complement pathway.
- a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
- a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can reduce and/or minimize vector mediated immunotoxicity in a subject.
- a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can enable and/or allow vector re-dosing in a subject.
- a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can enable and/or allow re-dosing of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof in a subject.
- a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells.
- the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient.
- a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells.
- a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can reduce and/or minimize transgene immunogenicity in a subject. In an aspect, a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can improve and/or enhance transgene efficacy and/or expression in a subject.
- improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%. 40-50%, 50-60%, 60-70%, 70-80%.
- an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wildtype or control level.
- a disclosed method reducing the level of circulating intact IgM or circulating intact IgM and IgG can modulate humoral immunity in a subject.
- modulating humoral immunity 7 in a subject can be an increase in the functionality 7 of the subject’s humoral immunity 7 , or can be a decrease in the functional of the subject’s humoral immunity.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein.
- the intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
- a disclosed method can comprise administering to a subject in need thereof a theoretically effectively amount of one or more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a subject can have or can be suspected of having one of more autoimmune diseases and/or disorders, one or more autoinfl ammatory diseases and/or disorders, one or more inflammatory’ diseases and/or disorders, or any combination thereof.
- Disclosed autoimmune diseases and/or disorders are known to the art and discussed supra.
- Disclosed autoinflammatory diseases and/or disorders are known to the art and discussed supra.
- Disclosed inflammatory' diseases and/or disorders are known to the art and discussed supra.
- a subject can be in need of one or more organ transplants.
- a subj ect can have received one or more organ transplants.
- a disclosed organ transplant can comprise the heart, one or both kidneys, the liver, one or both lungs, the pancreas, part or all of the colon or the intestines, or any combination thereof.
- a subject can be in need of gene therapy, can have received gene therapy, or can be receiving gene therapy.
- a subject can be treated with gene therapy or can have a disease and/or disorder that can be treated with gene therapy.
- a subject can have or be suspected of having a disclosed disease or disorder that can be treated with gene therapy.
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes.
- a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
- a disclosed gene therapy can comprise the delivery' and/or repair of one or more disclosed genes.
- a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy. Lentiviral gene therapy, or the combination thereof.
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes known to the art and discussed supra.
- a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the complement cascade. In an aspect, a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the formation of the Cl complex and/or C3 complex. In an aspect, a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the classical complement pathway.
- a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
- a disclosed method of reducing circulating levels of IgG or circulating intact IgM and IgG can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme delivered by gene therapy.
- a disclosed method of reducing circulating levels of IgG or circulating intact IgM and IgG can comprise restoring one or more aspects of cellular homeostasis and/or cellular functionality' and/or metabolic dysregulation.
- restoring one or more aspect of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation comprises restoring the functionality' and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
- restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise one or more of the following: (i) correcting cell starvation in one or more cell types; (ii) normalizing aspects of the autophagy pathway (such as, for example, correcting, preventing, reducing, and/or ameliorating autophagy); (iii) improving, enhancing, restoring, and/or preserving mitochondrial functionality and/or structural integrity; (iv) improving, enhancing, restoring, and/or preserving organelle functionality and/or structural integrity; (v) correcting enzyme dysregulation; (vi) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of the multi-systemic manifestations of a genetic disease or disorder; (vii) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of a genetic disease or disorder, or (viii) any combination thereof.
- restoring one or more aspects of cellular homeostas can comprise one or more of the following:
- restoring the activity and/or functionality of a missing, deficient, and/or mutant protein or enzyme can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of restoration when compared to a pre-existing level such as, for example, a pre-treatment level.
- the amount of restoration can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as, for example, a pre-treatment level.
- restoration can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having a missing, deficient, and/or mutant protein or enzyme).
- restoration can be a partial or incomplete restoration.
- restoration can be complete or near complete restoration such that the level of expression, activity, and/or functionality is similar to that of a wild-type or control level.
- techniques to monitor, measure, and/or assess the restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise qualitative (or subjective) means as well as quantitative (or objective) means. These means are known to the skilled person. For example, representative regulated variables and sensors relating to systemic homeostasis are discussed supra.
- contacting a cell can comprising methods known to the art.
- contacting can comprise administering to a subject one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
- administering can comprise intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intra-CSF, intrathecal, intraventricular, intrahepatic, hepatic intraarterial, hepatic portal vein (HPV), or in utero administration.
- a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via intra-CSF administration in combination with RNAi, antisense oligonucleotides, miRNA, one or more small molecules, one or more therapeutic agents, one or more proteasome inhibitors, one or more immune modulators, and/or a gene editing system.
- a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via LNP administration.
- a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be concurrently and/or serially administered to a subject via multiple routes of administration.
- administering a disclosed nucleic acid molecule, a disclosed vector, and/or a disclosed pharmaceutical formulation can comprise intravenous administration and intra-cistem magna (ICM) administration.
- ICM intra-cistem magna
- administering a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can comprise IV administration and intrathecal (ITH) administration.
- a disclosed method can employ multiple routes of administration to the subject.
- a disclosed method can employ a first route of administration that can be the same or different as a second and/or subsequent routes of administration.
- a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body weight.
- a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg. about 75 mg/kg. about 80 mg/kg. about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
- a therapeutically effective amount of disclosed vector can be delivered to a subject via intravenous (IV) administration and can comprise a range of about 1 x 10 10 vg/kg to about 2 x 10 14 vg/kg.
- IV intravenous
- a disclosed vector can be administered at a dose of about 1 x 10 11 vg/kg to about 8 x 10 13 vg/kg or about 1 x 10 12 vg/kg to about 8 x 10 13 vg/kg.
- a disclosed vector can be administered at a dose of about 1 x 10 13 vg/kg to about 6 x 10 13 vg/kg. In an aspect, a disclosed vector can be administered at a dose of at least about 1 x 10 10 vg/kg, at least about 5 x IO 10 vg/kg, at least about 1 x 10 11 vg/kg, at least about 5 x 10 11 vg/kg, at least about 1 x 10 12 vg/kg, at least about 5 x 10 12 vg/kg, at least about 1 x 10 13 vg/kg, at least about 5 x 10 13 vg/kg, or at least about 1 x 10 14 vg/kg.
- a disclosed vector can be administered at a dose of no more than about 1 x 10 10 vg/kg, no more than about 5 x 10 10 vg/kg. no more than about 1 x 10 11 vg/kg, no more than about 5 x 10 11 vg/kg. no more than about 1 x 10 12 vg/kg, no more than about 5 x 10 12 vg/kg, no more than about 1 x 10 13 vg/kg, no more than about 5 x 10 13 , or no more than about 1 x 10 14 vg/kg.
- a disclosed vector can be administered to a subject at a dose of about 1 x 10 12 vg/kg.
- a disclosed vector can be administered to a subject at a dose of about 1 x 10 11 vg/kg.
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 12 vg per subject total to about 1 x 10 17 vg per subject total.
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 12 vg per subject total, about 1 x 10 13 vg per subject total, about 1 x 10 14 vg per subject total, about 1 x 10 15 vg per subject total, about 1 x 10 16 vg per subject total, or about 1 x 10 17 vg per subject total.
- a disclosed vector can be administered in a single dose, or in multiple doses (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses) as needed for the desired therapeutic results.
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering to the subject a therapeutically effective amount of a therapeutic agent.
- a therapeutic agent can be any disclosed agent that effects a desired clinical outcome.
- In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise monitoring the subject for adverse effects. In an aspect, in the absence of adverse effects, the method can further comprise continuing to treat the subject. In an aspect, in the presence of adverse effects, the method can further comprise modifying the treating step. Methods of monitoring a subject’s well-being can include both subjective and objective criteria (and are discussed supra). Such methods are known to the skilled person.
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering to the subject a therapeutically effective amount of an agent that can correct one or more aspects of a dysregulated metabolic or enzymatic pathway.
- an agent can comprise an enzyme for enzyme replacement therapy.
- a disclosed enzyme can replace any enzyme in a dysregulated or dysfunctional metabolic or enzy matic pathway.
- a disclosed method can comprise replacing one or more enzymes in a dysregulated or dysfunctional metabolic pathway.
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering one or more immune modulators.
- a disclosed immune modulator can be methotrexate, rituximab, intravenous gamma globulin, or bortezomib, or a combination thereof.
- a disclosed immune modulator can be bortezomib or SVP-Rapamycin.
- a disclosed immune modulator can be Tacrolimus.
- a disclosed immune modulator such as methotrexate can be administered at a transient low to high dose.
- a disclosed immune modulator can be administered at a dose of about 0.1 mg/kg body weight to about 0.6 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at a dose of about 0.4 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for 3 to 5 or greater cycles, with up to three days per cycle. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body w eight for a minimum of 3 cycles, with three days per cycle. In an aspect, a person skilled in the art can determine the appropriate number of cycles. In an aspect, a disclosed immune modulator can be administered as many times as necessary to achieve a desired clinical effect.
- a disclosed immune modulator can be administered orally about one hour before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered orally about one hour or a few' days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof.
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering one or more proteasome inhibitors (e.g., bortezomib, carfilzomib, marizomib, ixazomib, and oprozomib).
- a proteasome inhibitor can be an agent that acts on plasma cells (e.g., daratumumab).
- an agent that acts on a plasma cell can be melphalan hydrochloride, melphalan, pamidronate disodium, carmustine, carfilzomib, carmustine, cyclophosphamide, daratumumab, doxorubicin hydrochloride liposome, doxorubicin hydrochloride liposome, elotuzumab, melphalan hydrochloride, panobinostat.
- ixazomib citrate carfilzomib, lenalidomide, melphalan, melphalan hydrochloride, plerixafor, ixazomib citrate, pamidronate disodium, panobinostat, plerixafor, pomalidomide, pomalidomide, lenalidomide, selinexor, thalidomide, thalidomide, bortezomib, selinexor, zoledronic acid, or zoledronic acid.
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering one or more proteasome inhibitors or agents that act on plasma cells prior to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation.
- a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells concurrently with administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation.
- a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells subsequent to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can further comprise administering one or more proteasome inhibitors more than 1 time. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors repeatedly over time.
- an immunosuppressive agent can be, but is not limited to, azathioprine, methotrexate, sirolimus, anti -thymocyte globulin (ATG), cyclosporine (CSP), my cophenolate mofetil (MMF), steroids, or a combination thereof.
- a disclosed method can comprise administering one or more immunosuppressive agents more than 1 time.
- a disclosed method can comprise administering one or more one or more immunosuppressive agents repeatedly over time.
- a disclosed method can comprise administering a compound that targets or alters antigen presentation or humoral or cell mediated or innate immune responses.
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering a compound that exerts a therapeutic effect against B cells and/or a compound that targets or alters antigen presentation or humoral or cell mediated immune response.
- a disclosed compound can be rituximab, methotrexate, intravenous gamma globulin, anti CD4 antibody, anti CD2, an anti-FcRN antibody, a BTK inhibitor, an anti-IGFIR antibody, a CD 19 antibody (e.g.. inebilizumab).
- an anti-IL6 antibody e.g., tocilizumab
- an antibody to CD40 e.g., an antibody to CD40
- an IL2 mutein e.g., an antigen specific Treg cells to AAV.
- Treg infusions that can be administered as a way to help with immune tolerance (e.g., antigen specific Treg cells to AAV).
- a disclosed method can further comprise administering lipid nanoparticles (LNPs).
- LNPs can be organ-targeted.
- LNPs can be liver-targeted or testes-targeted.
- mRNA therapy with LNP encapsulation for systemic delivery to a subject has the potential to restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise plasmapheresis and immunosuppression.
- a disclosed method can comprise using immunosuppression to decrease the T cell, B cell, and /or plasma cell population, decrease the innate immune response, inflammatory response, and antibody levels in general.
- a disclosed method can comprise repeating a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell mediated immune response.
- a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell
- a disclosed method can comprise modifying one or more of the disclosed steps.
- modifying one or more of steps of a disclosed method can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method.
- a method can be altered by changing the amount of one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof administered to a subject, or by changing the frequency of administration of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof to a subject, or by changing the duration of time one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof are administered to a
- a disclosed method can be altered by changing the amount of one or more disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject, or by changing the frequency of administration of one or more of the disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject.
- a disclosed method can comprise concurrent administration of one or more of the following: one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, one or more disclosed therapeutic agents, one or more disclosed immune modulators, one or more disclosed proteasome inhibitors, one or more disclosed immunosuppressive agents, one or more disclosed compounds that exert therapeutic effect against B cells, one or more disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response, or any combination thereof.
- a disclosed immune modulator can be administered prior to or after the administration of a disclosed therapeutic agent.
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise generating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise generating a disclosed viral or non-viral vector.
- generating a disclosed viral vector can comprise generating an AAV vector or a recombinant AAV (such as those disclosed herein).
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise gene editing one or more relevant genes (such as, for example, a missing, deficient, and/or mutant protein or enzyme), wherein editing includes but is not limited to single gene knockout, loss of function screening of multiple genes at one, gene knockin, or a combination thereof.
- relevant genes such as, for example, a missing, deficient, and/or mutant protein or enzyme
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering an oligonucleotide therapeutic agent.
- a disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA, non-coding RNA (ncRNA), an antisense molecule, miRNA, a morpholino, a peptide-nucleic acid (PNA), or an analog or conjugate thereof.
- a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi.
- a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable.
- a disclosed oligonucleotide therapeutic agent can comprise a CRISPR-based endonuclease.
- a disclosed endonuclease can be Cas9.
- a disclosed Cas9 can be from Staphylococcus aureus or Streptococcus pyogenes.
- a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise generating and/or validating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered one or more times.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered for the duration of the subject’s life, or for the duration of the subject’s treatment with, for example, gene therapy, enzyme replacement therapy, protein replacement therapy, and/or recombinant product.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered every 6 weeks, every’ 2 months, every 3 months, every 6 months, every year, year other year, every 3 years, every 5 years, or for any other period deemed necessary by a skilled clinician.
- a disclosed enzy me, a disclosed recombinant enzy me, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered prior to, concurrent, or after the delivery and/or administration of enzyme replacement therapy, protein replacement, gene therapy, a recombinant product, or any combination thereof.
- a disclosed method of circulating levels of IgM and/or IgG can further comprise reducing and/or minimizing vector-mediated immunotoxicity and/or transgene immunogenicity (e.g., the ability to induce specific immunity).
- vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the efficacy of the recombinant product encoded by the transgene.
- vector-mediated immunotoxicity and/or trans gene immunogenicity can decrease and/or reduce the ability and/or likelihood of redosing a subject with one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with gene therapy, enzyme replacement therapy, protein replacement, or any combination thereof.
- IgM can be cleaved in the heavy' chain at the interdomain region between constant domains Cp2 and Cp3.
- IgM can be cleaved between position 350 and position 365 of SEQ ID NO: 105.
- SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate).
- IgM can be cleaved between positions 355 through 360 of IgM.
- IgM can be cleaved at SEQ ID NO: 110.
- IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, IgM can be cleaved at position 355 through position 360 of the IgM of SEQ ID NO: 105. In an aspect, IgG can be cleaved below the hinge region, thereby yielding F(ab’)2 and Fc fragments. In an aspect, IgG can be cleaved to separate the CLI2 and Cp3 domains from the Cpl domain. In an aspect, IgG can be cleaved at SEQ ID NO:111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114.
- IgG can be cleaved at SEQ ID NO: 115. SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118. or any combination thereof. In an aspect, IgG can be cleaved at positions 109 through 124 of the IgG of SEQ ID NO: 106, positions 106 through 120 of the IgG of SEQ ID NO: 107, positions 156 through 171 of the IgG of SEQ ID NO: 108, positions 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof.
- IgG can be cleaved at positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107, positions 163 through 169 ofthe lgG of SEQ ID NO: 108, positions 113 through 119 of IgG of SEQ ID NO:109, or any combination thereof.
- IgG can be cleaved SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
- Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzy mes having IgM specific protease activity' and one or more disclosed enzymes having IgG specific protease activity.
- Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity' and one or more disclosed recombinant enzy mes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
- Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of any one of SEQ ID NO: 01 - SEQ ID NO:46 and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
- Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity' and one or more disclosed recombinant enzy mes comprising the sequence of SEQ ID NO: 119.
- Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed recombinant enzy mes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
- Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 11 or SEQ ID NO: 12 and one or more disclosed recombinant enzy mes comprising the sequence of SEQ ID NO: 119.
- Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 14 or SEQ ID NO: 15 and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 119.
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 119. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 119.
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity' to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121.
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a sequence having at least 50%. at least 60%. at least 70%. at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a disclosed method can further comprise administering one or more times one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed method can further comprise measuring and/or determining a subject’s pre-treatment level of circulating IgG and/or IgM and/or a subject’s pre-treatment level of surface bound IgM. In an aspect, a disclosed method can further comprise measuring and/or determining one or more times a subject’s level of circulating IgG and/or IgM and/or a subject’s level of surface bound IgM (e.g., before, during, and after a disclosed administering step).
- a disclosed method can be performed using a singular disclosed enzyme having both IgG and IgM specific protease activity. In an aspect, a disclosed method can be performed using a disclosed enzyme having IgG specific protease activity and a disclosed enzyme having IgM specific protease activity.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzymes.
- a method of inhibiting complement activation in a subj ect the method comprising administering to the subj ect in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules.
- a method of inhibiting complement activation in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations.
- a method of inhibiting complement activation in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15.
- a method of inhibiting complement activation in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:24 - SEQ ID NO:38.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03.
- a method of inhibiting complement activation in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12.
- a method of inhibiting complement activation in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15.
- a method of inhibiting complement activation in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 or SEQ ID NO:70 - SEQ ID NO:84.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:60, or SEQ ID NO:61 .
- a method of inhibiting complement activation in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:71.
- SEQ ID NO:72 SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:83, or SEQ ID NO:84.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity, and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity.
- a method of inhibiting complement activation in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity (such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15), and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity (such as, for example, the enzyme of any one of SEQ ID NO: 119 - SEQ ID NO: 159).
- IgG specific protease activity such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15
- a method of inhibiting complement activation in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity’ (such as, for example, the enzyme of SEQ ID NO: 11. SEQ ID NO: 12, SEQ ID NO: 14. or SEQ ID NO: 15), and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity' (such as, for example, the enzyme of SEQ ID NO: 119).
- a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity such as, for example, the enzyme of SEQ ID NO: 11.
- SEQ ID NO: 12, SEQ ID NO: 14. or SEQ ID NO: 15 such as, for example, the enzyme of SEQ ID NO: 11.
- a method of inhibiting complement activation in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 and (ii) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO:161.
- a method of inhibiting complement activation in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15, and (ii) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO: 119, SEQ ID NO: 120. or SEQ ID NO: 121.
- a method of inhibiting complement activation in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- a method of inhibiting complement activation in a subject comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzymes.
- a method of inhibiting complement activation in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors.
- a method of inhibiting complement activation in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23.
- a method of inhibiting complement activation in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18.
- a method of inhibiting complement activation in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21.
- Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23.
- a method of inhibiting complement activation in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:62 - SEQ ID NO:69 or SEQ ID NO:85 - SEQ ID NO:92.
- a method of inhibiting complement activation in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, or SEQ ID NO:69.
- a method of inhibiting complement activation in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, or SEQ ID NO:92.
- a disclosed method of inhibiting complement activation the formation of the C 1 complex and/or C3 complex can be blocked and/or minimized.
- the activation of the classical complement pathway can be blocked and/or minimized.
- a disclosed method can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
- a disclosed method of inhibiting complement activation can further comprise clearing and/or removing IgM from circulation in a subject.
- a disclosed method of inhibiting complement activation can further comprise cleaving and/or degrading circulating IgM in a subj ect. In an aspect, a disclosed method of inhibiting complement activation can further comprise cleaving and/or degrading all or nearly all circulating IgM in a subject. In an aspect, a disclosed method of inhibiting complement activation can further comprise transiently clearing and/or removing IgM from circulation in a subject, or transiently clearing and/or degrading circulating IgM in a subject. In an aspect, a disclosed method of inhibiting complement activation can further comprise completely or nearly completely clearing and/or removing IgM from circulation in a subj ect. In an aspect, a disclosed method of inhibiting complement activation can further comprise reducing and/or diminishing the level of circulating IgM in a subject, or transiently reducing and/or diminishing the level of circulating IgM in a subject.
- a disclosed method of inhibiting complement activation can further comprise clearing and/or removing IgM and/or IgG and IgM from circulation in a subject. In an aspect, a disclosed method of inhibiting complement activation can further comprise clearing and/or degrade circulating IgM and/or IgG and IgM in a subject. In an aspect, a disclosed method of inhibiting complement activation can further comprise cleaving and/or degrading all or nearly all circulating IgM and/or IgG and IgM in a subject.
- a disclosed method of inhibiting complement activation can further comprise transiently clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, or can transiently cleaving and/or degrading circulating IgM and/or IgG and IgM in a subject.
- a disclosed method of inhibiting complement activation can further comprise completely or nearly completely clearing and/or removing IgM and/or IgG and IgM from circulation in a subject.
- a disclosed method of inhibiting complement activation can further comprise reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM in a subject.
- a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against an exogenously administered protein.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against enzyme replacement therapy or protein replacement therapy or recombinant product.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a non-viral vector or a viral vector.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein).
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against one or more transplanted organs.
- a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
- a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800).
- HSAT high sustained antibody titer
- a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- HSAT high sustained antibody titer
- a disclosed HSAT can be reduced and/or eliminated.
- a subject can be re-dosed.
- a subject can be re-dosed with one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- a disclosed method can further comprise measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
- a disclosed method of inhibiting complement activation can enable and/or allow vector re-dosing in a subject.
- a disclosed method of inhibiting complement activation can enable and/or allow re-dosing of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof in a subj ect.
- a disclosed method of inhibiting complement activation can further comprise reducing and/or minimizing vector mediated immunotoxicity in a subject.
- a disclosed method of inhibiting complement activation can reduce and/or minimize transgene immunogenicity in a subject.
- a disclosed method of inhibiting complement activation can improve and/or enhance transgene efficacy and/or expression in a subject.
- improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40- 50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- a pre-treatment level prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- an improvement and/or enhancement can be a partial or incomplete restoration.
- an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wild-type or control level.
- a disclosed method inhibiting complement activation can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells.
- the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient.
- a disclosed method of inhibiting complement activation can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells.
- a disclosed method can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
- a disclosed method of inhibiting complement activation can modulate humoral immunity in a subject.
- modulating humoral immunity in a subject can be an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject’s humoral immunity.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein.
- the intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
- a disclosed method of inhibiting complement activation can comprise administering to a subject in need thereof a theoretically effectively amount of one or more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a subject can have or can be suspected of having one of more autoimmune diseases and/or disorders, one or more autoinfl ammatory diseases and/or disorders, one or more inflammatory' diseases and/or disorders, or any combination thereof.
- Disclosed autoimmune diseases and/or disorders are known to the art and discussed supra.
- Disclosed autoinflammatory diseases and/or disorders are known to the art and discussed supra.
- Disclosed inflammatory diseases and/or disorders are known to the art and discussed supra.
- a subject can be in need of one or more organ transplants.
- a subj ect can have received one or more organ transplants.
- a disclosed organ transplant can comprise the heart, one or both kidneys, the liver, one or both lungs, the pancreas, part or all of the colon or the intestines, or any combination thereof.
- a subject can be in need of gene therapy, can have received gene therapy, or can be receiving gene therapy.
- a subject can be treated with gene therapy or can have a disease and/or disorder that can be treated with gene therapy.
- a subject can have or be suspected of having a disclosed disease or disorder that can be treated with gene therapy.
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes.
- a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes.
- a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
- Genetic diseases and/or disorders or diseases and/or disorders that can be treated with gene therapy are known to the art and are discussed supra.
- a disclosed gene therapy can comprise the delivery' and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes known to the art and discussed supra.
- a disclosed method of inhibiting complement activation can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme delivered by gene therapy.
- a disclosed method of inhibiting complement activation can comprise restoring one or more aspects of cellular homeostasis and/or cellular functionality’ and/or metabolic dysregulation.
- restoring one or more aspect of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation comprises restoring the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
- restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise one or more of the following: (i) correcting cell starvation in one or more cell ty pes; (ii) normalizing aspects of the autophagy' pathway (such as, for example, correcting, preventing, reducing, and/or ameliorating autophagy); (iii) improving, enhancing, restoring, and/or preserving mitochondrial functionality and/or structural integrity; (iv) improving, enhancing, restoring, and/or preserving organelle functionality and/or structural integrity; (v) correcting enzyme dysregulation; (vi) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of the multi-systemic manifestations of a genetic disease or disorder; (vii) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of a genetic disease or disorder, or (viii) any combination thereof.
- restoring the activity and/or functionality of a missing, deficient, and/or mutant protein or enzyme can comprise a 10%, 20%, 30%, 40%, 50%, 60%. 70%. 80%, 90%, 100%, or any amount of restoration w'hen compared to a pre-existing level such as, for example, a pre-treatment level.
- the amount of restoration can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as, for example, a pre-treatment level.
- restoration can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having a missing, deficient, and/or mutant protein or enzyme).
- restoration can be a partial or incomplete restoration.
- restoration can be complete or near complete restoration such that the level of expression, activity, and/or functionality is similar to that of a wild-type or control level.
- techniques to monitor, measure, and/or assess the restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise qualitative (or subjective) means as well as quantitative (or objective) means. These means are known to the skilled person. For example, representative regulated variables and sensors relating to systemic homeostasis are discussed supra.
- contacting a cell can comprising methods known to the art.
- contacting can comprise administering to a subject one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
- administering can comprise intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intra-CSF, intrathecal, intraventricular, intrahepatic, hepatic intraarterial, hepatic portal vein (HPV), or in utero administration.
- a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via intra-CSF administration in combination with RNAi, antisense oligonucleotides, miRNA, one or more small molecules, one or more therapeutic agents, one or more proteasome inhibitors, one or more immune modulators, and/or a gene editing system.
- a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via LNP administration.
- a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be concurrently and/or serially administered to a subject via multiple routes of administration.
- administering a disclosed nucleic acid molecule, a disclosed enzyme or disclosed recombinant enzyme, a disclosed vector, and/or a disclosed pharmaceutical formulation can comprise intravenous administration and intra-cistem magna (ICM) administration.
- ICM intra-cistem magna
- administering a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can comprise IV administration and intrathecal (ITH) administration.
- a disclosed method can employ multiple routes of administration to the subject.
- a disclosed method can employ a first route of administration that can be the same or different as a second and/or subsequent routes of administration.
- a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body weight.
- a disclosed enzy me or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg. about 15 mg/kg, about 20 mg/kg, about 25 mg/kg. about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
- a therapeutically effective amount of disclosed vector can be delivered to a subject via intravenous (IV) administration and can comprise a range of about 1 x 10 10 vg/kg to about 2 x 10 14 vg/kg.
- IV intravenous
- a disclosed vector can be administered at a dose of about 1 x 10 11 vg/kg to about 8 x 10 13 vg/kg or about 1 x 10 12 vg/kg to about 8 x 10 13 vg/kg.
- a disclosed vector can be administered at a dose of about 1 x 10 13 vg/kg to about 6 x 10 13 vg/kg.
- a disclosed vector can be administered at a dose of at least about 1 x 10 10 vg/kg, at least about 5 x 10 10 vg/kg, at least about 1 x 10 11 vg/kg, at least about 5 x 10 11 vg/kg, at least about 1 x 10 12 vg/kg, at least about 5 x 10 12 vg/kg, at least about 1 x 10 13 vg/kg, at least about 5 x 10 13 vg/kg, or at least about I x 10 14 vg/kg.
- a disclosed vector can be administered at a dose of no more than about 1 x 10 10 vg/kg, no more than about 5 x 10 10 vg/kg, no more than about 1 x 10 11 vg/kg, no more than about 5 x 10 11 vg/kg, no more than about 1 x 10 12 vg/kg, no more than about 5 x 10 12 vg/kg, no more than about 1 x 10 13 vg/kg, no more than about 5 x 10 13 , or no more than about 1 x 10 14 vg/kg.
- a disclosed vector can be administered to a subject at a dose of about 1 x 10 12 vg/kg.
- a disclosed vector can be administered to a subject at a dose of about 1 x 10 11 vg/kg.
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 12 vg per subject total to about 1 x 10 17 vg per subject total.
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x I O 12 vg per subject total, about 1 x 10 13 vg per subject total, about 1 x 10 14 vg per subject total, about 1 x 10 15 vg per subject total, about 1 x 10 16 vg per subject total, or about 1 x 10 17 vg per subject total.
- a disclosed vector can be administered in a single dose, or in multiple doses (such as 2. 3, 4, 5. 6, 7, 8. 9 or 10 doses) as needed for the desired therapeutic results.
- a disclosed method of inhibiting complement activation can further comprise administering to the subject a therapeutically effective amount of a therapeutic agent.
- a therapeutic agent can be any disclosed agent that effects a desired clinical outcome.
- a disclosed method of inhibiting complement activation can further comprise monitoring the subject for adverse effects. In an aspect, in the absence of adverse effects, the method can further comprise continuing to treat the subject. In an aspect, in the presence of adverse effects, the method can further comprise modifying the treating step. Methods of monitoring a subject’s well-being can include both subjective and objective criteria (and are discussed supra). Such methods are known to the skilled person.
- a disclosed method of inhibiting complement activation can further comprise administering to the subject a therapeutically effective amount of an agent that can correct one or more aspects of a dysregulated metabolic or enzymatic pathway.
- an agent can comprise an enzyme for enzyme replacement therapy.
- a disclosed enzyme can replace any enzy me in a dysregulated or dysfunctional metabolic or enzymatic pathway.
- a disclosed method can comprise replacing one or more enzymes in a dysregulated or dysfunctional metabolic pathway.
- a disclosed method of inhibiting complement activation can further comprise administering one or more immune modulators.
- a disclosed immune modulator can be methotrexate, rituximab, intravenous gamma globulin, or bortezomib, or a combination thereof.
- a disclosed immune modulator can be bortezomib or SVP-Rapamycin.
- a disclosed immune modulator can be Tacrolimus.
- a disclosed immune modulator such as methotrexate can be administered at a transient low to high dose.
- a disclosed immune modulator can be administered at a dose of about 0.1 mg/kg body weight to about 0.6 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at a dose of about 0.4 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for 3 to 5 or greater cycles, with up to three days per cycle. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for a minimum of 3 cycles, with three days per cycle. In an aspect, a person skilled in the art can determine the appropriate number of cycles. In an aspect, a disclosed immune modulator can be administered as many times as necessary to achieve a desired clinical effect.
- a disclosed immune modulator can be administered orally about one hour before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered orally about one hour or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof.
- a disclosed method of inhibiting complement activation can further comprise administering one or more proteasome inhibitors (e.g., bortezomib, carfilzomib, marizomib, ixazomib, and oprozomib).
- a proteasome inhibitor can be an agent that acts on plasma cells (e.g.. daratumumab).
- an agent that acts on a plasma cell can be melphalan hydrochloride, melphalan, pamidronate disodium, carmustine, carfilzomib, carmustine, cyclophosphamide, daratumumab, doxorubicin hydrochloride liposome, doxorubicin hydrochloride liposome, elotuzumab, melphalan hydrochloride, panobinostat, ixazomib citrate, carfilzomib, lenalidomide, melphalan, melphalan hydrochloride, plerixafor, ixazomib citrate, pamidronate disodium, panobinostat, plerixafor, pomalidomide, pomalidomide, lenalidomide, selinexor, thalidomide, thalidomide, bortezomib, selinexor, zoledronic acid, or zoledron
- a disclosed method of inhibiting complement activation can further comprise administering one or more proteasome inhibitors or agents that act on plasma cells prior to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation.
- a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells concurrently with administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation.
- a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells subsequent to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation.
- a disclosed method can further comprise administering one or more proteasome inhibitors more than 1 time.
- a disclosed method can comprise administering one or more proteasome inhibitors repeatedly over time.
- a disclosed method of inhibiting complement activation can further comprise administering one or more immunosuppressive agents.
- an immunosuppressive agent can be, but is not limited to, azathioprine, methotrexate, sirolimus, anti -thymocyte globulin (ATG). cyclosporine (CSP), mycophenolate mofetil (MMF), steroids, or a combination thereof.
- a disclosed method can comprise administering one or more immunosuppressive agents more than 1 time.
- a disclosed method can comprise administering one or more one or more immunosuppressive agents repeatedly over time.
- a disclosed method can comprise administering a compound that targets or alters antigen presentation or humoral or cell mediated or innate immune responses.
- a disclosed method of inhibiting complement activation can further comprise administering a compound that exerts a therapeutic effect against B cells and/or a compound that targets or alters antigen presentation or humoral or cell mediated immune response.
- a disclosed compound can be rituximab, methotrexate, intravenous gamma globulin, anti CD4 antibody, anti CD2, an anti-FcRN antibody, a BTK inhibitor, an anti-IGFIR antibody, a CD19 antibody (e.g., inebilizumab), an anti-IL6 antibody (e.g., tocilizumab), an antibody to CD40, an IL2 mutein, or a combination thereof.
- a disclosed method can further comprise administering lipid nanoparticles (LNPs).
- LNPs can be organ-targeted.
- LNPs can be liver-targeted or testes-targeted.
- mRNA therapy with LNP encapsulation for systemic delivery to a subject has the potential to restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
- a disclosed method of inhibiting complement activation can further comprise plasmapheresis and immunosuppression.
- a disclosed method can comprise using immunosuppression to decrease the T cell, B cell, and /or plasma cell population, decrease the innate immune response, inflammatory response, and antibody levels in general.
- a disclosed method can comprise repeating a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell mediated immune response.
- a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell
- a disclosed method can comprise modifying one or more of the disclosed steps.
- modifying one or more of steps of a disclosed method can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method.
- a method can be altered by changing the amount of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof administered to a subject, or by changing the frequency of administration of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof to a subject, or by changing the duration of time one or more disclosed enzymes or recombinant enzy mes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof are administered to a
- a disclosed method can be altered by changing the amount of one or more disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject, or by changing the frequency of administration of one or more of the disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject.
- a disclosed method can comprise concurrent administration of one or more of the following: one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, one or more disclosed therapeutic agents, one or more disclosed immune modulators, one or more disclosed proteasome inhibitors, one or more disclosed immunosuppressive agents, one or more disclosed compounds that exert therapeutic effect against B cells, one or more disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response, or any combination thereof.
- a disclosed immune modulator can be administered prior to or after the administration of a disclosed therapeutic agent.
- a disclosed method of inhibiting complement activation can further comprise generating one or more disclosed enzy mes or disclosed recombinant enzy mes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed
- a disclosed method of inhibiting complement activation can further comprise validating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed method of inhibiting complement activation can further comprise generating a disclosed viral or non-viral vector.
- generating a disclosed viral vector can comprise generating an AAV vector or a recombinant AAV (such as those disclosed herein).
- a disclosed method of inhibiting complement activation can further comprise gene editing one or more relevant genes (such as, for example, a missing, deficient, and/or mutant protein or enzyme), wherein editing includes but is not limited to single gene knockout, loss of function screening of multiple genes at one, gene knockin, or a combination thereof.
- a disclosed method of inhibiting complement activation can further comprise administering an oligonucleotide therapeutic agent.
- a disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA, noncoding RNA (ncRNA), an antisense molecule, miRNA. a morpholino, a peptide-nucleic acid (PNA). or an analog or conjugate thereof.
- a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi.
- a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable.
- a disclosed oligonucleotide therapeutic agent can comprise a CRISPR-based endonuclease.
- a disclosed endonuclease can be Cas9.
- a disclosed Cas9 can be from Staphylococcus aureus or Streptococcus pyogenes.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered one or more times.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered for the duration of the subject’s life, or for the duration of the subject's treatment with, for example, gene therapy, enzyme replacement therapy, protein replacement therapy, and/or recombinant product.
- a disclosed enz me, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered every' 6 weeks, every' 2 months, every' 3 months, every' 6 months, every year, year other year, every 3 years, every 5 years, or for any other period deemed necessary by a skilled clinician.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered prior to, concurrent, or after the delivery and/or administration of enzyme replacement therapy, protein replacement, gene therapy, a recombinant product, or any combination thereof.
- a disclosed method of inhibiting complement activation can further comprise reducing and/or minimizing vector-mediated immunotoxicity' and/or transgene immunogenicity' (e.g., the ability to induce specific immunity).
- vector-mediated immunotoxicity’ and/or transgene immunogenicity can decrease and/or reduce the efficacy of the recombinant product encoded by the transgene.
- vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with gene therapy, enzyme replacement therapy, protein replacement, or any combination thereof.
- IgM can be cleaved in the heavy chain at the interdomain region between constant domains Cp2 and Cp3.
- IgM can be cleaved between position 350 and position 365 of SEQ ID NO: 105.
- SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate).
- IgM can be cleaved between positions 355 through 360 of IgM.
- IgM can be cleaved at SEQ ID NO:110.
- IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, IgM can be cleaved at position 355 through position 360 of the IgM of SEQ ID NO: 105. In an aspect, IgG can be cleaved below the hinge region, thereby yielding F(ab')z and Fc fragments. In an aspect. IgG can be cleaved to separate the Cp2 and Cp3 domains from the Cpl domain.
- IgG can be cleaved at SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO:113, SEQ ID NO:114, or any combination thereof. In an aspect, IgG can be cleaved at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
- IgG can be cleaved at positions 109 through 124 of the IgG of SEQ ID NO: 106, positions 106 through 120 of the IgG of SEQ ID NO: 107, positions 156 through 171 of the IgG of SEQ ID NO: 108, positions 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof.
- IgG can be cleaved at positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107, positions 163 through 169 of the IgG of SEQ ID NO: 108.
- IgG can be cleaved SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO:118, or any combination thereof.
- Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed enzymes having IgG specific protease activity 7 .
- Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
- Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
- Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 119.
- Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 1 19 - SEQ ID NO: 159.
- method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 11 or SEQ ID NO: 12 and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 119.
- Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 14 or SEQ ID NO: 15 and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 119.
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 119. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 1 19.
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identify to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121.
- a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identify to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
- a disclosed method can further comprise administering one or more times one or more disclosed enzymes or recombinant enzy mes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed method can further comprise measuring and/or determining a subject’s pre-treatment level of circulating IgG and/or IgM and/or a subject’s pre-treatment level of surface bound IgM. In an aspect, a disclosed method can further comprise measuring and/or determining one or more times a subject’s level of circulating IgG and/or IgM and/or a subject's level of surface bound IgM (e.g., before, during, and after a disclosed administering step).
- a disclosed method can be performed using a singular disclosed enzyme having both IgG and IgM specific protease activity. In an aspect, a disclosed method can be performed using a disclosed enzy me having IgG specific protease activity and a disclosed enzyme having IgM specific protease activity.
- Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any' combination thereof.
- a method of reducing and/or minimizing an immune response in a subject comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15 or SEQ ID NO:24 - SEQ ID NO:38.
- Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subj ect in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:02, SEQ ID NO:03, SEQ ID NO:05, SEQ ID NO:06, SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15.
- a method of reducing and/or minimizing an immune response in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID N0:61 or SEQ ID NO:70 - SEQ ID NO:84.
- a method of reducing and/or minimizing an immune response in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55. SEQ ID NO:57, SEQ ID NO:58. SEQ ID NO:60, or SEQ ID NO:61.
- a method of reducing and/or minimizing an immune response in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:74. SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:83, or SEQ ID NO:84.
- Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity, and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity.
- a method of reducing and/or minimizing an immune response in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity (such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO:12, SEQ ID NO: 14, or SEQ ID NO: 15), and (ii) a therapeutically effective amount of one or more disclosed recombinant enz mes having IgM specific protease activity (such as, for example, the enzyme of any one of SEQ ID NO: 119 - SEQ ID NO: 159).
- a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO:12, SEQ ID NO: 14, or SEQ ID NO:
- a method of reducing and/or minimizing an immune response in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity (such as, for example, the enzyme of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15). and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity (such as, for example, the enzyme of SEQ ID NO: 119).
- IgG specific protease activity such as, for example, the enzyme of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15
- a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity such as, for example, the enzyme of SEQ ID NO: 119.
- a method of reducing and/or minimizing an immune response in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 and (ii) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- a method of reducing and/or minimizing an immune response in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14. or SEQ ID NO: 15, and (ii) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO: 119, SEQ ID NO: 120, or SEQ ID NO: 121.
- a method of reducing and/or minimizing an immune response in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23 or SEQ ID NO:39 - SEQ ID NO:46.
- method of reducing and/or minimizing an immune response in a subject the method comprising administenng to the subj ect in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, or SEQ ID NO: 23.
- Disclosed herein is a method of reducing and/or minimizing an immune response, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed recombinant enzy mes having IgM specific protease activity, wherein following the administering step, the level of circulating IgM targeting a recombinant product is reduced when compared to a pre-administering step level.
- Disclosed herein is a method of reducing and/or minimizing an immune response, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity 7 , wherein following the administering step, the level of circulating IgG targeting a recombinant product is reduced when compared to a pre-administering step level.
- [051 1 ] Disclosed herein is a method of reducing and/or minimizing an immune response, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed recombinant enzy mes having IgM specific protease activity 7 and IgG specific protease activity, wherein following the administering step, the level of circulating IgM and IgG targeting a recombinant product is reduced when compared to a pre-administering step level.
- a method of reducing and/or minimizing an immune response comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity, one or more disclosed recombinant enzymes having IgM specific protease activity, one or more disclosed recombinant enzy me having both IgM and IgG specific protease activity, or any combination thereof wherein following the administering step, the level of circulating IgG and/or IgM targeting a recombinant product is reduced when compared to a pre-administering step level.
- a disclosed method can further comprise re-dosing the subject with the recombinant product.
- a disclosed recombinant product can comprise a vector or portion thereof.
- a disclosed recombinant product can comprise an encoded therapeutic protein or enzyme or an encoded gene product.
- a disclosed recombinant product can comprise a therapeutic protein or a therapeutic enzyme.
- a disclosed method can further comprise reducing and/or minimizes immunogenicity 7 in the subject to the recombinant product.
- a disclosed method can further comprise improving and/or enhancing transgene efficacy and/or expression in a subject.
- transgene efficacy and/or expression in the subject can be improved and/or enhanced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100% when compared to a pre-administering step level.
- the formation of the Cl complex and/or C3 complex can be blocked and/or minimized.
- the activation of the classical complement pathway can be blocked and/or minimized.
- a disclosed method of reducing and/or minimizing an immune response can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
- a disclosed method of reducing and/or minimizing an immune response can further comprise clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, can further comprise cleaving and/or degrading circulating IgM and/or IgG and IgM in a subject, can further comprise cleaving and/or degrading all or nearly all circulating IgM and/or IgG and IgM in a subject, or any combination thereof.
- a disclosed method of reducing and/or minimizing an immune response can further comprise transiently clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, or transiently clearing and/or degrading circulating IgM and/or IgG and IgM in a subject.
- a disclosed method of reducing and/or minimizing an immune response can further comprise completely or nearly completely clearing and/or removing IgM and/or IgG and IgM from circulation in a subject.
- a disclosed method of reducing and/or minimizing an immune response can further comprise reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, or transiently reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject.
- a disclosed method of reducing and/or minimizing an immune response can further comprise clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, completely or nearly completely clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, clearing and/or degrade circulating IgM and/or IgG and IgM in a subject, cleaving and/or degrading all or nearly all circulating IgM and/or IgG and IgM in a subject, or any combination thereof.
- a disclosed method of reducing and/or minimizing an immune response can further comprise transiently clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, or can transiently cleaving and/or degrading circulating IgM and/or IgG and IgM in a subject.
- a disclosed method of reducing and/or minimizing an immune response can further comprise reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM in a subject.
- a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against an exogenously administered protein. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against enzyme replacement therapy or protein replacement therapy. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a non-viral vector or a viral vector. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein).
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against any disclosed recombinant product..
- a disclosed method can further comprise diagnosing a subject as being in need of one or more disclosed enzymes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against one or more transplanted organs.
- a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
- a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800).
- HSAT high sustained antibody titer
- a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- HSAT high sustained antibody titer
- a disclosed HSAT can be reduced and/or eliminated.
- a subject can be re-dosed.
- a subject can be re-dosed with one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- a disclosed method can further comprise measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
- a disclosed method of reducing and/or minimizing an immune response can enable and/or allow vector re-dosing in a subject.
- a disclosed method of reducing and/or minimizing an immune response can enable and/or allow re-dosing of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof in a subj ect.
- a disclosed method of reducing and/or minimizing an immune response can reduce and/or minimize transgene immunogenicity in a subject, can improve and/or enhance transgene efficacy and/or expression in a subject, or the combination thereof.
- improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%. 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- a pre-treatment level prior to administering one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- a pre-treatment level prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- an improvement and/or enhancement can be a partial or incomplete restoration.
- an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wildtype or control level.
- a disclosed method of reducing and/or minimizing an immune response can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells, can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells, or the combination thereof.
- the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient.
- a disclosed method can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
- a disclosed method of reducing and/or minimizing an immune response can modulate humoral immunity in a subject.
- modulating humoral immunity in a subject can be an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject's humoral immunity.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein.
- the intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
- a disclosed method of reducing and/or minimizing an immune response can comprise administering to a subject in need thereof a theoretically effectively amount of one or more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a subject can have or can be suspected of having one of more autoimmune diseases and/or disorders, one or more autoinfl ammatory diseases and/or disorders, one or more inflammatory diseases and/or disorders, or any combination thereof.
- Disclosed autoimmune diseases and/or disorders are known to the art and discussed supra.
- Disclosed autoinflammatory diseases and/or disorders are know n to the art and discussed supra.
- Disclosed inflammatory diseases and/or disorders are known to the art and discussed supra.
- a subject can be in need of one or more organ transplants.
- a subj ect can have received one or more organ transplants.
- a disclosed organ transplant can comprise the heart, one or both kidneys, the liver, one or both lungs, the pancreas, part or all of the colon or the intestines, or any combination thereof.
- a subject can be in need of gene therapy, can have received gene therapy, or can be receiving gene therapy.
- a subject can be treated with gene therapy or can have a disease and/or disorder that can be treated with gene therapy.
- a subject can have or be suspected of having a disclosed disease or disorder that can be treated with gene therapy.
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes.
- a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes.
- a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes known to the art and discussed supra.
- a disclosed method of reducing and/or minimizing an immune response can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme delivered by gene therapy.
- a disclosed method of reducing and/or minimizing an immune response can further comprise restoring one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation.
- restoring one or more aspect of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation comprises restoring the functionality' and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
- restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise one or more of the following: (i) correcting cell starvation in one or more cell types; (ii) normalizing aspects of the autophagy' pathway (such as, for example, correcting, preventing, reducing, and/or ameliorating autophagy); (iii) improving, enhancing, restoring, and/or preserving mitochondrial functionality and/or structural integrity; (iv) improving, enhancing, restoring, and/or preserving organelle functionality and/or structural integrity; (v) correcting enzyme dysregulation; (vi) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of the multi-systemic manifestations of a genetic disease or disorder; (vii) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of a genetic disease or disorder, or (viii) any combination thereof.
- restoring one or more aspects of cellular homeosta can comprise one or more of the following:
- restoring the activity and/or functionality of a missing, deficient, and/or mutant protein or enzyme can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of restoration when compared to a pre-existing level such as, for example, a pre-treatment level.
- the amount of restoration can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%. 70-80%, 80-90%, or 90-100% more than a pre-existing level such as, for example, a pre-treatment level.
- restoration can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having a missing, deficient, and/or mutant protein or enzyme).
- restoration can be a partial or incomplete restoration.
- restoration can be complete or near complete restoration such that the level of expression, activity, and/or functionality is similar to that of a wild-type or control level.
- a disclosed method of reducing and/or minimizing an immune response can further comprise administering to the subject a therapeutically effective amount of an agent that can correct one or more aspects of a dysregulated metabolic or enzymatic pathway.
- an agent can comprise an enzyme for enzyme replacement therapy.
- a disclosed enzyme can replace any enzyme in a dysregulated or dysfunctional metabolic or enzymatic pathway.
- a disclosed method can comprise replacing one or more enzymes in a dysregulated or dysfunctional metabolic pathway.
- techniques to monitor, measure, and/or assess the restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise qualitative (or subjective) means as well as quantitative (or objective) means. These means are known to the skilled person. For example, representative regulated variables and sensors relating to systemic homeostasis are discussed supra.
- contacting a cell can comprising methods know n to the art. For example, contacting can comprise administering to a subject one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
- administering can comprise intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intra-CSF, intrathecal, intraventricular, intrahepatic, hepatic intraarterial, hepatic portal vein (HPV), or in utero administration.
- a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via intra-CSF administration in combination with RNAi, antisense oligonucleotides, miRNA, one or more small molecules, one or more therapeutic agents, one or more proteasome inhibitors, one or more immune modulators, and/or a gene editing system.
- a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via LNP administration.
- a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be concurrently and/or serially administered to a subject via multiple routes of administration.
- administering a disclosed nucleic acid molecule, a disclosed enzyme or disclosed recombinant enzyme, a disclosed vector, and/or a disclosed pharmaceutical formulation can comprise intravenous administration and intra-cistem magna (ICM) administration.
- ICM intra-cistem magna
- administering a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can comprise IV administration and intrathecal (ITH) administration.
- a disclosed method can employ multiple routes of administration to the subject.
- a disclosed method can employ a first route of administration that can be the same or different as a second and/or subsequent routes of administration.
- a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body weight.
- a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
- a therapeutically effective amount of disclosed vector can be delivered to a subject via intravenous (IV) administration and can comprise a range of about 1 x IO 10 vg/kg to about 2 x 10 14 vg/kg.
- IV intravenous
- a disclosed vector can be administered at a dose of about 1 x 10 11 vg/kg to about 8 x 10 13 vg/kg or about I x 10 12 vg/kg to about 8 x 10 13 vg/kg.
- a disclosed vector can be administered at a dose of about 1 x 10 13 vg/kg to about 6 x 10 13 vg/kg.
- a disclosed vector can be administered at a dose of at least about 1 x IO 10 vg/kg, at least about 5 x IO 10 vg/kg, at least about 1 x 10 11 vg/kg, at least about 5 x 10 11 vg/kg, at least about 1 x 10 12 vg/kg, at least about 5 x 10 12 vg/kg. at least about 1 x 10 13 vg/kg. at least about 5 x 10 13 vg/kg. or at least about 1 x 10 14 vg/kg.
- a disclosed vector can be administered at a dose of no more than about 1 x IO 10 vg/kg, no more than about 5 x IO 10 vg/kg, no more than about 1 x 10 11 vg/kg, no more than about 5 x 10 11 vg/kg, no more than about 1 x 10 12 vg/kg, no more than about 5 x 10 12 vg/kg, no more than about 1 x 10 13 vg/kg, no more than about 5 x 10 13 , or no more than about 1 x 10 14 vg/kg.
- a disclosed vector can be administered to a subject at a dose of about 1 x 10 12 vg/kg.
- a disclosed vector can be administered to a subject at a dose of about 1 x 10 11 vg/kg.
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 12 vg per subject total to about 1 x 10 17 vg per subject total.
- a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 10 12 vg per subject total, about 1 x 10 13 vg per subject total, about 1 x 10 14 vg per subject total, about 1 x 10 15 vg per subject total, about 1 x 10 16 vg per subject total, or about 1 x 10 17 vg per subject total.
- a disclosed vector can be administered in a single dose, or in multiple doses (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses) as needed for the desired therapeutic results.
- a disclosed method of reducing and/or minimizing an immune response can further comprise administering to the subject a therapeutically effective amount of a therapeutic agent.
- a therapeutic agent can be any disclosed agent that effects a desired clinical outcome.
- a disclosed method of reducing and/or minimizing an immune response can further comprise monitoring the subject for adverse effects.
- the method in the absence of adverse effects, can further comprise continuing to treat the subject.
- the method in the presence of adverse effects, can further comprise modifying the treating step.
- Methods of monitoring a subject’s well-being can include both subjective and objective criteria (and are discussed supra). Such methods are known to the skilled person.
- a disclosed method of reducing and/or minimizing an immune response can further comprise administering one or more immune modulators.
- a disclosed immune modulator can be methotrexate, rituximab, intravenous gamma globulin, or bortezomib, or a combination thereof.
- a disclosed immune modulator can be bortezomib or SVP- Rapamycin.
- a disclosed immune modulator can be Tacrolimus.
- a disclosed immune modulator such as methotrexate can be administered at a transient low to high dose.
- a disclosed immune modulator can be administered at a dose of about 0.
- a disclosed immune modulator can be administered at a dose of about 0.4 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for 3 to 5 or greater cycles, with up to three days per cycle. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for a minimum of 3 cycles, with three days per cycle. In an aspect, a person skilled in the art can determine the appropriate number of cycles. In an aspect, a disclosed immune modulator can be administered as many times as necessary’ to achieve a desired clinical effect.
- a disclosed immune modulator can be administered orally about one hour before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered orally about one hour or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof.
- a disclosed method of reducing and/or minimizing an immune response can further comprise administering one or more proteasome inhibitors (e.g., bortezomib, carfilzomib, marizomib, ixazomib, and oprozomib).
- a proteasome inhibitor can be an agent that acts on plasma cells (e.g., daratumumab).
- an agent that acts on a plasma cell can be melphalan hydrochloride, melphalan, pamidronate disodium, carmustine, carfilzomib, carmustine, cyclophosphamide, daratumumab, doxorubicin hydrochloride liposome, doxorubicin hydrochloride liposome, elotuzumab, melphalan hydrochloride, panobinostat, ixazomib citrate, carfilzomib, lenalidomide, melphalan, melphalan hydrochloride, plerixafor, ixazomib citrate, pamidronate disodium, panobinostat, plerixafor, pomalidomide, pomalidomide, lenalidomide, selinexor, thalidomide, thalidomide, bortezomib, selinexor, zoledronic acid, or zoledron
- a disclosed method of reducing and/or minimizing an immune response can further comprise administering one or more proteasome inhibitors or agents that act on plasma cells prior to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation.
- a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells concurrently with administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation.
- a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells subsequent to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation.
- a disclosed method can further comprise administering one or more proteasome inhibitors more than 1 time.
- a disclosed method can comprise administering one or more proteasome inhibitors repeatedly over time.
- a disclosed method of reducing and/or minimizing an immune response can further comprise administering one or more immunosuppressive agents.
- an immunosuppressive agent can be, but is not limited to, azathioprine, methotrexate, sirolimus, antithymocyte globulin (ATG), cyclosporine (CSP), mycophenolate mofetil (MMF), steroids, or a combination thereof.
- a disclosed method can comprise administering one or more immunosuppressive agents more than 1 time.
- a disclosed method can comprise administering one or more one or more immunosuppressive agents repeatedly over time.
- a disclosed method can comprise administering a compound that targets or alters antigen presentation or humoral or cell mediated or innate immune responses.
- a disclosed method of reducing and/or minimizing an immune response can further compnse administering a compound that exerts a therapeutic effect against B cells and/or a compound that targets or alters antigen presentation or humoral or cell mediated immune response.
- a disclosed compound can be rituximab, methotrexate, intravenous gamma globulin, anti CD4 antibody, anti CD2, an anti-FcRN antibody, a BTK inhibitor, an anti-IGFIR antibody, a CD19 antibody (e.g., inebilizumab), an anti-IL6 antibody (e.g..
- Treg infusions that can be administered as a way to help with immune tolerance (e.g., antigen specific Treg cells to AAV).
- a disclosed method can further comprise administering lipid nanoparticles (LNPs).
- LNPs can be organ-targeted.
- LNPs can be liver-targeted or testes-targeted.
- mRNA therapy with LNP encapsulation for systemic delivery 7 to a subject has the potential to restore the functionality and/or structural integrity' of a missing, deficient, and/or mutant protein or enzyme.
- a disclosed method of reducing and/or minimizing an immune response can further comprise plasmapheresis and immunosuppression.
- a disclosed method can comprise using immunosuppression to decrease the T cell, B cell, and /or plasma cell population, decrease the innate immune response, inflammatory response, and antibody levels in general.
- a disclosed method can comprise repeating a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell mediated immune response.
- a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell
- a disclosed method can comprise modifying one or more of the disclosed steps.
- modifying one or more of steps of a disclosed method can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method.
- a method can be altered by changing the amount of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof administered to a subject, or by changing the frequency of administration of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof to a subject, or by changing the duration of time one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof are administered to a subject.
- a disclosed method can be altered by changing the amount of one or more disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject, or by changing the frequency of administration of one or more of the disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject.
- a disclosed method can comprise concurrent administration of one or more of the following: one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, one or more disclosed therapeutic agents, one or more disclosed immune modulators, one or more disclosed proteasome inhibitors, one or more disclosed immunosuppressive agents, one or more disclosed compounds that exert therapeutic effect against B cells, one or more disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response, or any combination thereof.
- a disclosed immune modulator can be administered prior to or after the administration of a disclosed therapeutic agent.
- a disclosed method of reducing and/or minimizing an immune response can further comprise generating and/or validating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed method of reducing and/or minimizing an immune response can further comprise generating a disclosed viral or non-viral vector.
- generating a disclosed viral vector can comprise generating an AAV vector or a recombinant AAV (such as those disclosed herein).
- a disclosed method of reducing and/or minimizing an immune response can further comprise gene editing one or more relevant genes (such as. for example, a missing, deficient, and/or mutant protein or enzyme), wherein editing includes but is not limited to single gene knockout, loss of function screening of multiple genes at one, gene knockin, or a combination thereof.
- relevant genes such as. for example, a missing, deficient, and/or mutant protein or enzyme
- a disclosed method of reducing and/or minimizing an immune response can further comprise administering an oligonucleotide therapeutic agent.
- a disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA, non-coding RNA (ncRNA), an antisense molecule, miRNA, a morpholino, a peptide-nucleic acid (PNA), or an analog or conjugate thereof.
- a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi.
- a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable.
- a disclosed oligonucleotide therapeutic agent can comprise a CRISPR- based endonuclease.
- a disclosed endonuclease can be Cas9.
- a disclosed Cas9 can be from Staphylococcus aureus or Streptococcus pyogenes.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered one or more times.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered for the duration of the subject’s life, or for the duration of the subject's treatment with, for example, gene therapy, enzy me replacement therapy, protein replacement therapy, and/or recombinant product.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered every' 6 weeks, every' 2 months, every' 3 months, every' 6 months, every' year, year other year, every 3 years, every 5 years, or for any other period deemed necessary by a skilled clinician.
- a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered prior to, concurrent, or after the delivery and/or administration of enzyme replacement therapy, protein replacement, gene therapy, recombinant product, or any combination thereof.
- a disclosed method of reducing and/or minimizing an immune response can further comprise reducing and/or minimizing vector-mediated immunotoxicity' and/or transgene immunogenicity (e.g., the ability to induce specific immunity).
- vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the efficacy of the recombinant product encoded by the transgene.
- vector-mediated immunotoxicity' and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of redosing a subject with one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with gene therapy, enzyme replacement therapy, protein replacement, or any combination thereof.
- IgM can be cleaved in the heavy chain at the interdomain region between constant domains Cp2 and Cp3.
- IgM can be cleaved between position 350 and position 365 of SEQ ID NO: 105.
- SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate).
- IgM can be cleaved between positions 355 through 360 of IgM.
- IgM can be cleaved at SEQ ID NO: 110.
- IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, IgM can be cleaved at position 355 through position 360 of the IgM of SEQ ID NO: 105. In an aspect, IgG can be cleaved below the hinge region, thereby yielding F(ab’)z and Fc fragments. In an aspect, IgG can be cleaved to separate the Cp2 and Cp3 domains from the Cpl domain.
- IgG can be cleaved at SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, or any combination thereof. In an aspect, IgG can be cleaved at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
- IgG can be cleaved at positions 109 through 124 of the IgG of SEQ ID NO: 106, positions 106 through 120 of the IgG of SEQ ID NO: 107, positions 156 through 171 of the IgG of SEQ ID NO: 108, positions 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof.
- IgG can be cleaved at positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107.
- IgG can be cleaved SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
- a disclosed method can further comprise administering one or more times one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed method can further comprise measuring and/or determining a subject's pre-treatment level of circulating IgG and/or IgM and/or a subject’s pre-treatment level of surface bound IgM. In an aspect, a disclosed method can further comprise measuring and/or determining one or more times a subject’s level of circulating IgG and/or IgM and/or a subject’s level of surface bound IgM (e.g., before, during, and after a disclosed administering step).
- a disclosed method can be performed using a singular disclosed enzyme having both IgG and IgM specific protease activity. In an aspect, a disclosed method can be performed using a disclosed enzyme having IgG specific protease activity and a disclosed enzyme having IgM specific protease activity.
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzymes.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations.
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:24 - SEQ ID NO:38.
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03.
- method of improving and/or enhancing transgene efficacy and/or expression in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06.
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 08 or SEQ ID NO:09.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12.
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 or SEQ ID NO:70 - SEQ ID NO:84.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:60, or SEQ ID NO:61.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ IDNO:78.
- SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:83, or SEQ ID NO: 84 comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ IDNO:78.
- SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:83, or SEQ ID NO: 84 comprising administering to the subject in need thereof a therapeutically effective amount of a nu
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzy mes or disclosed recombinant enzymes.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors.
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subj ect in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations.
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46.
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21.
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression on in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 22 or SEQ ID NO:23.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO: 62 - SEQ ID NO: 69 or SEQ ID NO: 85 - SEQ ID NO: 92.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO 67, SEQ ID NO:68, or SEQ ID NO:69.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, or SEQ ID NO:92.
- Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity, and (ii) a therapeutically effective amount of one or more disclosed recombinant enzy mes having IgM specific protease activity.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity (such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15). and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity’ (such as, for example, the enzyme of any one of SEQ ID NO: 119 - SEQ ID NO: 159).
- IgG specific protease activity such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity’ (such as, for example, the enzyme of SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15), and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity (such as, for example, the enzyme of SEQ ID NO: 119).
- a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity such as, for example, the enzyme of SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15
- a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity such as,
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID N0:61 and (ii) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject comprising administering to the subject in need thereof (i) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO:11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15, and (ii) a therapeutically effective amount of the recombinant enzy me of SEQ ID NO: 119, SEQ ID NO: 120, or SEQ ID NO: 121.
- a method of improving and/or enhancing transgene efficacy and/or expression in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO 161.
- the formation of the Cl complex and/or C3 complex can be blocked and/or minimized.
- the activation of the classical complement pathway can be blocked and/or minimized.
- a disclosed method can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, can further comprise cleaving and/or degrading circulating IgM and/or IgG and IgM in a subject, can further comprise cleaving and/or degrading all or nearly all circulating IgM and/or IgG and IgM in a subject, or any combination thereof.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise transiently clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, or transiently clearing and/or degrading circulating IgM and/or IgG and IgM in a subject, can further comprise completely or nearly completely clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, can further comprise reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, or transiently reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, or any combination thereof.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, can further comprise clearing and/or degrade circulating IgM and/or IgG and IgM in a subject, can further comprise cleaving and/or degrading all or nearly all circulating IgM and/or IgG and IgM in a subject, can further comprise transiently clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, can further comprise transiently cleaving and/or degrading circulating IgM and IgM in a subject, or any combination thereof.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise completely or nearly completely clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, can further comprise reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, can further transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM in a subject, or any combination thereof.
- a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against an exogenously administered protein.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against enzyme replacement therapy or protein replacement therapy or recombinant product.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a non-viral vector or a viral vector.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein).
- a disclosed method can further comprise diagnosing a subject as being in need of one or more disclosed enzy mes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against one or more transplanted organs.
- a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
- a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800).
- a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- HSAT high sustained antibody titer
- a disclosed HSAT can be reduced and/or eliminated.
- a subject after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed.
- a subject can be re-dosed with one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
- a disclosed method can further compnse measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise reducing and/or minimizing vector mediated immunotoxicity in a subject.
- a disclosed method of inhibiting complement activation can reduce and/or minimize transgene immunogenicity in a subj ect.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can enable and/or allow vector re-dosing in a subject.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can enable and/or allow re-dosing of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof in a subject.
- a disclosed method of inhibiting complement activation can improve and/or enhance transgene efficacy and/or expression in a subject.
- improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- a pre-treatment level prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40- 50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- a pre-treatment level prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof).
- an improvement and/or enhancement can be a partial or incomplete restoration.
- an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wild-type or control level.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells.
- the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells.
- a disclosed method can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further modulate humoral immunity in a subject.
- modulating humoral immunity in a subject can be an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject’s humoral immunity.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy.
- intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein.
- the intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise administering to a subject in need thereof a theoretically effectively amount of one or more disclosed enzy mes or disclosed recombinant enzymes, one or more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
- a subject can have or can be suspected of having one of more autoimmune diseases and/or disorders, one or more autoinfl ammatory diseases and/or disorders, one or more inflammatory diseases and/or disorders, or any combination thereof.
- Disclosed autoimmune diseases and/or disorders are known to the art and discussed supra.
- Disclosed autoinflammatory diseases and/or disorders are known to the art and discussed supra.
- Disclosed inflammatory diseases and/or disorders are known to the art and discussed supra.
- a subject can be in need of one or more organ transplants.
- a subj ect can have received one or more organ transplants.
- a disclosed organ transplant can comprise the heart, one or both kidneys, the liver, one or both lungs, the pancreas, part or all of the colon or the intestines, or any combination thereof.
- a subject can be in need of gene therapy, can have received gene therapy, or can be receiving gene therapy.
- a subject can be treated with gene therapy or can have a disease and/or disorder that can be treated with gene therapy.
- a subject can have or be suspected of having a disclosed disease or disorder that can be treated with gene therapy.
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes.
- a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes.
- a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
- a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes known to the art and discussed supra.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme delivered by gene therapy.
- a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise restoring one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation.
- restoring one or more aspect of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation comprises restoring the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
- restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise one or more of the following: (i) correcting cell starvation in one or more cell types; (ii) normalizing aspects of the autophagy pathway (such as, for example, correcting, preventing, reducing, and/or ameliorating autophagy); (hi) improving, enhancing, restoring, and/or preserving mitochondrial functionality and/or structural integrity; (iv) improving, enhancing, restoring, and/or preserving organelle functionality and/or structural integrity; (v) correcting enzyme dysregulation; (vi) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of the multi- systemic manifestations of a genetic disease or disorder; (vii) re
- restoring the activity and/or functionality of a missing, deficient, and/or mutant protein or enzyme can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of restoration when compared to a pre-existing level such as, for example, a pre-treatment level.
- the amount of restoration can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%. 70-80%, 80-90%, or 90-100% more than a pre-existing level such as, for example, a pre-treatment level.
- restoration can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having a missing, deficient, and/or mutant protein or enzy me).
- restoration can be a partial or incomplete restoration.
- restoration can be complete or near complete restoration such that the level of expression, activity, and/or functionality is similar to that of a wild-type or control level.
- techniques to monitor, measure, and/or assess the restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise qualitative (or subjective) means as well as quantitative (or objective) means. These means are known to the skilled person. For example, representative regulated variables and sensors relating to systemic homeostasis are discussed supra.
- contacting a cell can comprising methods known to the art.
- contacting can comprise administering to a subject one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
- administering can comprise intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intra-CSF, intrathecal, intraventricular, intrahepatic, hepatic intraarterial, hepatic portal vein (HPV), or in utero administration.
- a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via intra-CSF administration in combination with RNAi, antisense oligonucleotides, miRNA, one or more small molecules, one or more therapeutic agents, one or more proteasome inhibitors, one or more immune modulators, and/or a gene editing system.
- a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via LNP administration.
- a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be concurrently and/or serially administered to a subject via multiple routes of administration.
- administering a disclosed nucleic acid molecule, a disclosed enzyme or disclosed recombinant enzyme, a disclosed vector, and/or a disclosed pharmaceutical formulation can comprise intravenous administration and intra-cistem magna (ICM) administration.
- administering a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can comprise IV administration and intrathecal (ITH) administration.
- a disclosed method can employ multiple routes of administration to the subject.
- a disclosed method can employ a first route of administration that can be the same or different as a second and/or subsequent routes of administration.
- a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body weight.
- a disclosed enzyme or disclosed recombinant enzy me can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg.
- a therapeutically effective amount of disclosed vector can be delivered to a subject via intravenous (IV) administration and can comprise a range of about 1 x 10 10 vg/kg to about 2 x 10 14 vg/kg.
- IV intravenous
- a disclosed vector can be administered at a dose of about 1 x 10 11 vg/kg to about 8 x 10 13 vg/kg or about 1 x 10 12 vg/kg to about 8 x 10 lj vg/kg.
- a disclosed vector can be administered at a dose of about 1 x 10 13 vg/kg to about 6 x 10 13 vg/kg. In an aspect, a disclosed vector can be administered at a dose of at least about 1 x IO 10 vg/kg, at least about 5 x IO 10 vg/kg, at least about 1 x 10 11 vg/kg, at least about 5 x 10 11 vg/kg, at least about 1 x 10 12 vg/kg, at least about 5 x 10 12 vg/kg, at least about 1 x 10 13 vg/kg, at least about 5 x 10 13 vg/kg, or at least about 1 x 10 14 vg/kg.
- a disclosed vector can be administered at a dose of no more than about 1 x IO 10 vg/kg, no more than about 5 x IO 10 vg/kg, no more than about 1 x 10 11 vg/kg, no more than about 5 x 10 11 vg/kg, no more than about 1 x 10 12 vg/kg, no more than about 5 x 10 12 vg/kg, no more than about 1 x 10 13 vg/kg, no more than about 5 x 10 13 , or no more than about 1 x 10 14 vg/kg.
- a disclosed vector can be administered to a subject at a dose of about 1 x 10 12 vg/kg.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed herein are compositions for cleaving antibodies and in vivo methods of using these compositions.
Description
COMPOSITIONS COMPRISING ANTIBODY CLEAVING ENZYMES AND METHODS OF USING THE SAME
I. CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional App. No. 63/421,996 filed 2 November 2022, U.S. Provisional App. No. 63/492,985 filed 29 March 2023, and U.S. Provisional App. No. 63/502,920 filed 17 May 2023, each of which is incorporated herein in its entirety.
II. STATEMENT REGARDING FEDERAL FUNDING
[0002] This invention was made with Government support under Federal Grant Nos. R01 HL089221, R01 Al 166969, and U19 AI131471 awarded by the National Institute of Health. The Federal Government has certain rights to this invention.
III. REFERENCE TO THE SEQUENCE LISTING
[0003] The Sequence Listing submitted 1 November 2023 as an XML file named “22-2060-WO- Sequence_Listing’‘, created on 31 October 2023 and having a size of 289 kilobytes is hereby incorporated by reference pursuant to 37 C.F.R. § 1.52(e)(5).
IV. BACKGROUND
[0004] Monomeric IgM is the first antibody to emerge as the B cell antigen receptor (BCR) on the surface of B cells followed by secreted pentameric IgM from plasma cells. Class switching upon B cell activation generates different isotypes or subtypes of IgG, which constitute the most abundant, secreted class of antibodies (Engels N, et al. (2018) Immunol Rev. 283: 150-160). Due to the highly diverse BCR repertoire, recognition of self-antigens can sometimes lead to the generation of harmful IgG and IgM autoantibodies leading to autoimmune disease (Suurmond J, et al. (2015) J Clin Invest. 125:2194-2202). Similarly, antibodies directed against human leukocyte antigens (HLAs) expressed on the surface of cells in a transplanted organ can lead to rejection (Choi AY, et al. (2021) Front Immunol. 12:694-763). . Further, while beneficial in the context of immunity against pathogens such as viruses, antibodies against viral vectors such as recombinant adeno-associated viruses (AAV) can preclude administration of gene therapies in prospective patients (Earley J, et al. (2023) Trends Biotechnol. 41 :836-845)). Another pathophysiological manifestation of autoantibodies in the context of autoimmune disease, organ transplantation or gene therapies is the activation of the complement cascade and lytic components thereof, which can lead to significant tissue damage (Goldberg BS, et al. (2020) Immunol Cell Biol. 98:305-317; Grafals M, et al. (2019) Front Immunol. 10:2380; West C, et al. (2023) Hum Gene Ther. 34:554-566; Smith CJ, et al. (2022) Front Immunol. 13:999-1021). Thus, understanding and manipulating IgG and IgM levels can have profound implications in the development of therapeutic modalities with broad clinical impact.
[0005] To this end, a wide range of approaches including plasmapheresis, B cell targeting agents, complement inhibitors, neonatal Fc receptor (FcRn) blocking agents and IgG degrading enzymes are being explored to modulate humoral immunity7 in autoimmune disease, organ transplant and gene therapy applications (Choi AY, et al. (2021) Front Immunol. 12:694-763; Lee DSW, et al. (2020) Nature Reviews Drug Discov. 20: 179-199; Zelek WM, et al. (2019) Mol Immunol. 114:341-352; Corti M, et al. (2014) Mol Ther Methods Clin Dev. 1 : 14033; Elmore ZC, et al. (2020) JCI Insight. 5(19):el39881; Leborgne C, et al. (2020) Nature Med. 26:1096-1101). Despite this spectrum of agents, strategies that directly address pathogenic IgM and IgG antibodies, which are key players in initiating immune dysfunction, are lacking.
[0006] Thus, there remains an urgent need to generate and characterize antibody-cleaving enzymes, and to develop therapeutics based on those antibody-cleaving enzymes.
V. BRIEF DESCRIPTION OF THE FIGURES
[0007] FIG. 1A - FIG. 1H show structural model and in vitro characterization of a human IgM cleaving enzyme. FIG. 1A shows a representative structural model of the core domain of cysteine protease candidates with active site in orange. FIG. IB confirms the protein expression system and IgM-cleaving assay, we used a known porcine IgM protease from Streptococcus Suis (Idessuis) that is known to cleave porcine IgM, but not human IgM. Immunoblot analyses showing the banding patterns of IgM from human sera following treatment with multiple candidate proteins. A cleavage band was observed for protein candidate protein 2 and 6, hereinafter referred to as IceM and IceM2, respectively. FIG. 1C is a cartoon schematic illustrating predicted cleavage site motif and IgM cleavage product (CP) molecular weights. FIG. ID shows a structural docking analysis of IceM in complex with human IgM heavy7 chain (HC) with active site in orange. FIG. IE is an SDS-PAGE gel showing recombinant IceM (41.6 kDa) expression and punfication with BSA loading control. FIG. IF shows an SDS-PAGE gel of purified human IgM, IceM, or IgM treated with 10 pg mL'1 IceM for 1 hr at 37 °C. FIG. 1G shows a concentration curve for IceM enzymatic activity in human sera. FIG. II and FIG. 1J show an immunoblot analyses showing the banding patterns of IgM, IgA, IgD, IgE, or IgG from human sera (FIG. 1H) and IgM from sera across species (FIG. II) treated with PBS or 10 pg mL"1 IceM for 1 hr at 37 °C. indicates full length HC (IgM, ~73 kDa; IgG, ~53 kDa; IgA, ~55 kDa IgE, ~73 kDa; IgD, ~63 kDa) and arrows indicate cleavage products. FIG. 1J shows an alignment of IgM sequences from multiple species with the predicted human and NHP cleavage site residues (SEQ ID NO: 110) indicated in the red box. Error bars denote mean ± standard deviation. All experiments were completed in at least biological triplicate. Analyses were performed with GraphPad Prism version 9.5 with P values less than 0.05 being significant.
[0008] FIG. 2A - FIG. 2C show structural modeling and analyses of IceM contact residues. FIG. 2A shows structural models showing IdeS with residues in contact with human IgG shown in red. FIG. 2B - FIG. 2C show structural models showing IgM cleaving enzymes IceM (FIG. 2B) and IceM 2 (FIG. 2C) with residues in contact with human IgM shown in red.
[0009] FIG. 3A - FIG. 3C show optimizing linkers for a recombinant IceM fusion protein. FIG. 3A (top) show' structural modeling of IceM fusion proteins with three different linkers (rigid linker, flexible linker 1, and flexible linker 2 with corresponding linker amino acid sequence beneath the structure. Models are colored by pLDDT. FIG. 3A (bottom) show' immunoblot analyses for His-tagged fusion protein expression. The fusion protein with the rigid linker, hereinafter termed IceMG, showed the best expression and was chosen for further evaluation. FIG. 3B show' a structural model of the dual cleaving enzyme IceMG. FIG. 3C shows structural docking analysis of IceMG in complex with human IgM (gray) and human IgG (green) heavy chain with active site in red.
[0010] FIG. 4A - FIG. 4H show in vitro characterization of a human IgM and IgG cleaving enzyme IceMG. FIG. 4A shows aSDS-PAGE gel showing recombinant IceMG (70.4 kDa) expression and purification with BSA loading control. FIG.4B shows a SDS-PAGE gel of purified human IgM. IceMG, or IgM treated with 10 pg mL"1 IceMG for 1 hr at 37 °C. FIG. 4C shows a schematic illustrating predicted IgG cleavage products (CP). FIG. 4D shows a SDS- PAGE gel of purified human IgG, IceMG, or IgG treated w'ith 10 pg mL"1 IceMG for 1 hr at 37 °C. FIG. 4E and FIG. 4F shows a concentration curve for IceMG enzymatic activity on IgM (FIG. 4E) or IgG (FIG. 4F) in human sera. FIG. 4G shows immunoblot analyses showing the banding patterns of IgM, IgG, IgA, IgE, or IgD from human sera and IgM or IgG from sera across species treated with PBS or 10 pg mL"1 IceMG for 1 hr at 37 °C. FIG. 4H show's IgG cleavage site residues for each IgG subtype IgGl (SEQ ID NO: 115), IgG2 (SEQ ID NO: 116), IgG3 (SEQ ID NO: 117), and IgG4 (SEQ ID NO: 118). *indicates full length HC and arrows indicate cleavage products. Error bars denote mean ± standard deviation. All experiments were completed in at least biological triplicate. Analyses were performed with GraphPad Prism version 9.5 with P values less than 0.05 being significant.
[0011] FIG. 5A - FIG. 5G show an in vitro assessment of recombinant IceM and IceMG on B cells. FIG. 5A shows immunoblot analysis of Daudi cells treated with recombinant 10 pg mL"1 IceM for 1 hr at 37 °C. FIG. 5B show' immunofluorescent staining of surface-bound IgM on Daudi cells. FIG. 5C show representative plots for flow cytometric analysis of IgM surface expression on Daudi cells following treatment with PBS or IceM at 1 hr. Data are gated to analyze the IgM+ (FITC+) cohort. FIG. 5D show the quantitation of percent IgM+ Daudi cells. FIG. 5E are representative plots for flow' cytometric analysis of IgM surface expression on CD 19+ B Cells
(BCR) following treatment with PBS, IceM, or IceMG at 1 hr, 12 hr, and 24 hr post-treatment. Data are gated on live cells and then CD19+ (APC+) to analyze the IgM+ (FITC+) cohort. FIG. 5F shows the quantitation of percent IgM+ B cells from (FIG. 5A). FIG. 5G shows dose curve for IceM enzymatic activity on B cells treated for 1 hr at 37 °C. Error bars denote mean ± standard deviation. All experiments were completed in at least biological triplicate. Statistical significance was determined using an unpaired two-tailed Student’s t-test (FIG. 5D) or two-way ANOVA with Sidak’s correction for multiple comparisons (FIG. 5F). Analyses were performed with GraphPad Prism version 9.5 with P values less than 0.05 being significant.
[0012] FIG. 6A - FIG. 6C shows the in vitro assessment of recombinant IceM and IceMG complement activation. FIG. 6A show- the the illustration of AAV 9- or platelet factor-based complement activation assay. FIG. 6B and FIG. 6C show ELISA based quantitation of C3a levels in human sera treated with PBS or 10 pg mL'1 IceM for 1 hr at 37 °C to cleave IgM followed by incubation with AAV9 (FIG. 6B) or PF4/Heparin complexes (FIG. 6C). Error bars denote mean ± standard deviation. All experiments were completed in at least biological triplicate. Statistical significance was determined using one-way ANOVA. Analyses were performed with GraphPad Prism version 9.5 with P values less than 0.05 being significant.
[0013] FIG. 7A - FIG. 7N show the in vivo assessment of recombinant IceM and IceMG in passively immunized mice. FIG. 7A show an overview' of experimental design for mouse study. FIG. 7B - FIG. 7E show immunoblots for circulating human IgM in mice treated with PBS of IceM at the dose indicated. FIG. 7F - FIG. 71 show immunoblots for circulating human IgM (top panel) or IgG (bottom panel) in mice treated with PBS of IceM at the dose indicated. Five mice (numbered 1-5) w ere tested per cohort with human serum (Hu) included as a positive control. FIG. 7J show' an overview' of experimental design for AAV mouse study. Luciferase expression was evaluated 21 days post injection in heart and liver tissue for AAV8 (FIG. 7K and FIG. 7L) and AAV9 (FIG. 7M and FIG. 7N). Luciferase expression levels were normalized for total tissue protein concentration and represented as log relative luminescence units per gram of tissue (log RLU/g tissue).
[0014] FIG.8A- FIG.8H show- the Tn vivo assessment of recombinant IceM in rhesus macaques. FIG. 8A show an overview of experimental design for IceM nonhuman primate study. FIG. 8B and FIG. 8C show immunoblot analyses of His-tagged IceM (41.6 kDa) from NHP N303 (FIG. SB) and NHP M741 (FIG. 8C) at various time intervals following IceM administration. FIG. 8D and FIG. 8E show' immunoblots for circulating IgM in animals treated with IceM. Treatment days indicated in red. FIG. 8F shows the quantification of uncleaved IgM and cleavage product bands from immunoblots in FIG. 8G and FIG. 8H. indicates full-length HC and arrows indicate cleavage products.
[0015] FIG. 9A - FIG. 9H show the in vivo assessment 1 of recombinant IceMG on circulating IgM in rhesus macaques. FIG. 9A show overview of experimental design for IceMG nonhuman primate study 1. FIG. 9B FIG. 9D (top) show the immunoblot analyses of His-tagged IceMG (70.4 kDa) from animals 49873 (FIG. 9B), 49813 (FIG. 9C), and 499682 (FIG. 9D) at various time intervals following IceMG administration. FIG. 9B - FIG. 9D (bottom) show the immunoblots for circulating IgM in animals treated with IceMG at the dose indicated. FIG. 9E - FIG. 9G show the quantitation of IgM immunoblots from FIG. 9B - FIG. 9D. FIG. 9H shows the ELISA based quantitation of C3a levels in sera from NHPs in FIG. 9B - FIG. 9D following treatment with AAV9 to elicit complement activation, indicates full-length HC and arrows indicate cleavage products.
[0016] FIG. 10A - FIG. 10G shows the in vivo assessment 2 of recombinant IceMG on circulating IgM in rhesus macaques. FIG. 10A show the overview of experimental design for IceMG nonhuman primate study 2 using animals 36725, 37662, 35788, 38131, 38718, 38721. FIG. 10B - FIG. 10D show immunoblot analyses for circulating IgM (FIG. 10B - FIG. 10D) in animals treated with IceMG at the dose indicated. FIG. 10E - FIG. 10G show the quantitation of IgM immunoblots from FIG. 10B - FIG. 10D. * indicates full-length HC and arrows indicate cleavage products.
[0017] FIG. 11A - FIG. 11F show the in vivo assessment of recombinant IceMG on circulating IgG in rhesus macaques. FIG. 11A - FIG. 11F) show immunoblots for circulating IgG in animals treated with IceMG at the dose indicated for nonhuman primate study 1 (FIG. 11A - FIG. HC) or nonhuman primate study 2 (FIG. HD - FIG. HF). *indicates full-length HC and arrows indicate cleavage products.
VI. BRIEF SUMMARY
[0018] Disclosed herein is a recombinant enzyme having IgM specific protease activity. Disclosed herein is a recombinant enz me having IgG specific protease activity7. Disclosed herein is a recombinant enzyme having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and having IgM specific protease activity and/or IgG specific protease activity.
[0019] Disclosed herein is a recombinant enzy me that can bind to and cleave at one or more sequences set forth in SEQ ID NO: 111 - SEQ ID NO: 118 in an IgG molecule and at the sequence set forth in SEQ ID NO: 110 in an IgM molecule.
[0020] Disclosed herein is an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46. Disclosed herein is an isolated nucleic acid molecule encoding any disclosed recombinant enzy me. Disclosed herein is a codon-optimized isolated nucleic acid molecule encoding any disclosed recombinant enzyme.
[0021] Disclosed herein is an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92. Disclosed herein is an isolated nucleic acid molecule encoding the recombinant enzyme having the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46. Disclosed herein is a vector comprising a nucleic acid sequence encoding the recombinant enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46. Disclosed herein is a vector comprising a nucleic acid sequence comprising the sequence of any one of SEQ ID NO: 47 - SEQ ID NO: 92 or a fragment thereof.
[0022] Disclosed herein is a method of cleaving immunoglobulin M (IgM) and/or IgM and immunoglobulin G (IgG) the method comprising contacting one or more IgM molecules with an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
[0023] Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
[0024] Disclosed herein is a method of reducing the level of circulating intact IgM and/or IgG and IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence of any one of SEQ ID NO: 01 - SEQ ID NO:46.
[0025] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46. Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
[0026] Disclosed herein is a method reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity, and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity.
[0027] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46.
VII. DETAILED DESCRIPTION
[0028] The present disclosure describes formulations, compounded compositions, kits, capsules, containers, and/or methods thereof. It is to be understood that the inventive aspects of which are
not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.
[0029] All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
A. Definitions
[0030] Before the present compounds, compositions, articles, systems, devices, and/or methods are disclosed and descnbed, it is to be understood that they are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.
[0031] This disclosure describes inventive concepts with reference to specific examples. However, the intent is to cover all modifications, equivalents, and alternatives of the inventive concepts that are consistent with this disclosure.
[0032] As used in the specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.
[0033] The phrase “consisting essentially of’ limits the scope of a claim to the recited components in a composition or the recited steps in a method as well as those that do not materially affect the basic and novel characteristic or characteristics of the claimed composition or claimed method. The phrase “consisting of’ excludes any component, step, or element that is not recited in the claim. The phrase “comprising” is synonymous with “including”, “containing”, or “characterized by”, and is inclusive or open-ended. “Comprising” does not exclude additional, unrecited components or steps.
[0034] As used herein, when referring to any numerical value, the term “about” means a value falling within a range that is ± 10% of the stated value.
[0035] Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, a further aspect includes from the one
particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent '‘about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as ‘'about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
[0036] References in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed. Thus, in a compound containing 2 parts by weight component X and 5 parts by weight component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
[0037] As used herein, the terms “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. In an aspect, a disclosed method can optionally comprise one or more additional steps, such as, for example, repeating an administering step or altering an administering step.
[0038] As used herein, “isolated” refers to a nucleic acid molecule or a nucleic acid sequence that has been substantially separated, produced apart from, or purified away from other biological components in the cell or tissue of an organism in which the component occurs, such as other cells, chromosomal and extrachromosomal DNA and RNA, and proteins. Nucleic acids and proteins that have been “isolated” include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids and proteins. Isolated IceM, IceM2, IceM Full, IceM2 Full, IceM Mid, IceM Lead, IceM2 Lead, Ice MG, IceMG2, IceMG Optilinkerl, IceMG2 Optilinkerl, IceMG-Optimlinker2, and IceMG-Optinlinker3 can be at least 50% pure, such as at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 100% pure.
[0039] As used herein, the term “subject” refers to the target of administration, e.g., a human being. The term “subject” also includes domesticated animals (e.g., cats, dogs, etc.), livestock (e.g. , cattle, horses, pigs, sheep, goats, etc.), and laboratory' animals (e.g. , mouse, rabbit, rat, guinea pig, fruit fly, etc.). Thus, the subject of the herein disclosed methods can be a vertebrate, such as
a mammal, a fish, a bird, a reptile, or an amphibian. Alternatively, the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, or rodent. The term does not denote a particular age or sex, and thus, adult and child subjects, as well as fetuses, whether male or female, are intended to be covered. In an aspect, a subject can be a human patient. In an aspect, a subject can have a disease or disorder, be suspected of having a disease or disorder, or be at risk of developing a disease or disorder (e.g., a genetic disease or disorder). In an aspect, a subject can have an AD or AIF disease and/or disorder. In an aspect, a subject can be in need of one or more transplanted organs. In an aspect, a subject can have received one or more transplanted organs. In an aspect, a subject can have received one or more transplanted organs. In an aspect, a subject can be in need of gene therapy, can be receiving gene therapy, or can have received gene therapy.
[0040] As used herein, the term “diagnosed” means having been subj ected to an examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof, or by one or more of the disclosed methods. For example, “diagnosed with a disease or disorder” means having been subjected to an examination by a person of skill, for example, a physician, and found to have a condition (such as a genetic disease or disorder) that can be treated by one or more of the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof, or by one or more of the disclosed methods. For example, “suspected of having a disease or disorder” can mean having been subjected to an examination by a person of skill, for example, a physician, and found to have a condition (such as a genetic disease or disorder) that can likely be treated by one or more of the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof, or by one or more of the disclosed methods. In an aspect, an examination can be physical, can involve various tests (e.g., blood tests, genotyping, biopsies, etc.) and assays (e.g., enzymatic assay), or a combination thereof.
[0041] A “patient” refers to a subject afflicted with a disease or disorder (e.g., a genetic disease or disorder). In an aspect, a patient can refer to a subject that has been diagnosed with or is suspected of having a disease or disorder. In an aspect, a patient can refer to a subject that has been diagnosed with or is suspected of having a disease or disorder and is seeking treatment or receiving treatment for a disease or disorder. In an aspect, a patient can have an AD or AIF disease and/or disorder. In an aspect, a patient can be in need of one or more transplanted organs. In an
aspect, a patient can have received one or more transplanted organs. In an aspect, a patient can have received one or more transplanted organs. In an aspect, a patient can be in need of gene therapy, can be receiving gene therapy, or can have received gene therapy.
[0042] As used herein, the phrase "‘identified to be in need of treatment for a disease or disorder,” or the like, refers to selection of a subject based upon need for treatment of the disease or disorder. For example, a subject can be identified as having a need for treatment of a disease or disorder (e.g., a genetic disease or disorder, an AD, an AIF disease, transplanted organs) based upon an earlier diagnosis by a person of skill and thereafter subjected to treatment for the genetic disease or disorder. In an aspect, the identification can be performed by a person different from the person making the diagnosis. In an aspect, the administration can be performed by one who performed the diagnosis.
[0043] As discussed herein, humoral immunity is mediated by circulating proteins called antibodies, which are produced by B lymphocytes. Antibodies exist either as membrane-bound antibodies on the surface of B lymphocytes that function as receptors for the antigen or as secreted antibodies that reside in the circulation, tissues, and mucosal sites to neutralize toxins, prevent the entry and spread of pathogens, and eliminate microbes. The activation of B lymphocytes is initiated by the specific recognition of antigens by the surface Ig receptors of these cells. Activation leads to proliferation of antigen-specific cells and their differentiation in cooperation with Th cells, generating memory B lymphocytes and antibody-secreting plasma cells. The type and amount of antibodies produced vary according to the antigen driving the immune response, the involvement of T lymphocytes, a prior history of antigen exposure, and the site where activation occurs. Antibody responses to protein antigens require that the specifically recognized antigen is internalized by B lymphocytes and that a peptide fragment of it is presented to CD4+ helper T lymphocytes that subsequently activate these B lymphocytes. Because of the involvement of helper T lymphocytes, this type of response is called ‘T-dependent antibody response' (TDAR). In contrast, antibody responses to multivalent nonproteinic antigens with repeating determinants, such as polysaccharides, some lipids, and nucleic acids, do not involve antigen-specific helper T lymphocytes and are called ‘T-independent antibody responses.’ In TDARs, plasma cells or their precursors migrate from germinal centers in the peripheral lymphoid organs, where they are produced, to the bone marrow, where they live for many years and ensure specific protection against microbes for long periods of time.
[0044] As used herein, ‘’immune response” refers to the body’s response to foreign agents and infections organisms and includes (i) the body’s innate or non-specific immune system and (ii) the body's adaptive or specific immune system (including B cells, cytotoxic T cells, and helper T cells).
[0045] As used herein, ‘'primary and secondary antibody responses” to protein antigens differ qualitatively and quantitatively. Primary responses result from the activation of naive B lymphocytes that have not been previously stimulated by the antigen, whereas a secondary' immune response is elicited when the same antigen stimulates antigen-specific memory B lymphocytes. In secondary responses as compared to primary responses, antibody production is greater and peak antibody levels attained more rapidly (approximately 2-3 vs. 7 days), the main isotype is IgG instead of IgM, and antibody affinity is much greater. Once released, the various forms of antibodies (Ig) possess a number of effector functions to engage the antigen. Microbes, tumor cells, or foreign proteins can express several types of antigens and multiple copies of these antigens. If the microbial antigen to which an antibody is directed is associated with the toxic portion of a molecule, then the antibody can neutralize the toxin. The production of neutralizing antibodies is frequently a problem in the therapeutic application of biotechnolog -derived recombinant proteins as neutralizing antibodies can become a rate-limiting step during preclinical testing because animals may perceive the recombinant protein, especially when humanized, as non-self.
[0046] Most of the effector functions of humoral immunity are mediated by antibody-activated processes, but they are also key players in innate immunity. For example, the classical activation pathway of the complement cascade is triggered by antigen-antibody complexes and is specifically mediated by the constant region of the Ig molecule. Both IgM and IgG can activate the complement system, which results in the biologically active components identified previously, including the lytic unit, the chemotactic factors, and the complement peptides, which opsonize the microbe to facilitate phagocytosis. IgM and IgG can function to opsonize some microbes independent of complement activation in an antigen-dependent fashion because macrophages and neutrophils have receptors on their surface, which recognize the constant region of Ig (Fc receptors, FcRs). FcRs also play a maj or role in the ability' of IgG to participate in a process known as ‘antibody-dependent cellular cytotoxicity,’ whereby antigen-specific antibody attaches via FcRs to certain types of cells, including NK. cells, enabling these cells to attach intimately to the target cell and trigger cell death. Finally, FcRs are also the primary effector mechanism for IgE, which is the principal immune defense against certain types of parasitic infections (most notably, helminths) and is produced primarily by the external immune system along secretory surfaces. IgE binds to FcR on the surface of mast cells and basophils. Once bound to FcR, IgE can sen e as an antigen-specific receptor to trigger the release of proinflammatory factors, including vasoactive amines (e.g., histamine) and products of the arachidonic cascade (e.g., leucotrienes and prostaglandins). Systemic immunity is mediated by IgM and IgG, the latter being the major form of Ig found in the blood. Local immunity is mediated primarily by IgA and IgE.
[0047] As known to the skilled person in the art, autoimmune disease (AD) originates in the adaptive immune system. AD occurs when adaptive immune cells lose their ability to maintain self-tolerance of human cells. As a result, the immune system begins attacking healthy tissues as though they were infectious agents. Some ADs are organ-specific, whereas others can affect multiple parts of the body. Recurrent fever and chronic inflammation can be attributed to autoimmune disease. However, many possible symptoms are unique to AD, including hair loss, dry mouth, temperature sensitivity’, muscle weakness, reproductive issues, and more. A variety of conditions including environment, hormones, injury', infection, and genes can all play a role in initiating autoimmunity. AD is thought to be triggered by a combination of multiple factors not limited to genetics. Although the exact causes remain unknown, researchers believe that a variety of conditions including environment, hormones, injury, infection, and genes could all play a role in initiating autoimmunity. Autoimmune conditions are quite common. Current data estimates that ADs affect at least 14 million people in the U.S. alone. There are 80-100 known autoimmune and autoimmune-related conditions, including Hashimoto’s thyroiditis. Type 1 diabetes, Sjogren’s, and celiac disease. Gender prevalence in AD is well documented. In fact, around 80% of those diagnosed are women. While ADs can affect anyone at any age, the majority' tend to appear during adulthood.
[0048] Autoinflammatory (AIF) diseases only involve the innate immune system. AIFs occur when innate immune cells are activated without an infection or injury being present. This mishap kickstarts the release of cytokines and other immune responses, causing fever and inflammation. Recurring episodes of high fever are the primary' symptom of AIF. Similar to some autoimmune diseases, autoinflammatory symptoms can be widespread, affecting the joints, gastrointestinal tract, skin, eyes, and internal organs.
[0049] As used herein, a "regulatory element” can refer to promoters, enhancers, internal ribosomal entry' sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Regulatory elements can include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory' sequences).
[0050] As used herein, "inhibit." “inhibiting”, and “inhibition” mean to diminish or decrease an activity, level, response, condition, severity, disease, or other biological parameter (such as the level of circulating IgG and/or circulating IgM or the level of surface-bound IgM on B cells). This can include, but is not limited to, the complete ablation of the activity', level, response, condition, severity', disease, or other biological parameter (such as the level of circulating IgG and/or IgM or the level of surface-bound IgM on B cells). This can also include, for example, a 10% inhibition
or reduction in the activity, level, response, condition, severity, disease, or other biological parameter as compared to the native or control level (e.g., a subj ect not having a disease or disorder such as a genetic disease or disorder). Thus, in an aspect, the inhibition or reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of reduction in between as compared to native or control levels. In an aspect, the inhibition or reduction can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% as compared to native or control levels. In an aspect, the inhibition or reduction can be 0-25%, 25-50%, 50-75%, or 75- 100% as compared to native or control levels. In an aspect, a native or control level can be a predisease or pre-disorder level.
[0051] The words "treat" or “treating’’ or “treatment” include palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. In an aspect, the terms cover any treatment of a subject, including a mammal (e.g., a human), and includes: (i) preventing the undesired physiological change, disease, pathological condition, or disorder from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the physiological change, disease, pathological condition, or disorder, i.e., arresting its development; or (iii) relieving the physiological change, disease, pathological condition, or disorder, i.e., causing regression of the disease. For example, in an aspect, treating a disease or disorder can reduce the severity of an established a disease or disorder in a subject by l%-100% as compared to a control (such as, for example, an individual not having a genetic disease or disorder). In an aspect, treating can refer to a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of a disease or disorder (such as a genetic disease or disorder). For example, treating a disease or disorder can reduce one or more symptoms of a disease or disorder in a subject by 1 %-l 00% as compared to a control (such as, for example, an individual not having a genetic disease or disorder). In an aspect, treating can refer to 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% reduction of one or more symptoms of an established a disease or disorder. It is understood that treatment does not necessarily refer to a cure or complete ablation or eradication of a disease or disorder. However, in an aspect, treatment can refer to a cure or complete ablation or eradication of a disease or disorder.
[0052] As used herein, the term “prevent” or “preventing” or “prevention” refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by
advance action. It is understood that where reduce, inhibit, or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed. In an aspect, preventing a disease or disorder having chromatin deregulation and/or chromatin dysregulation is intended. The words “prevent”, “preventing”, and “prevention” also refer to prophylactic or preventative measures for protecting or precluding a subject (e.g., an individual) not having a given a disease or disorder (such as a genetic disease or disorder) or related complication from progressing to that complication.
[0053] As used herein, the terms “administering” and “administration” refer to any method of providing one or more of the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, the following: oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, in utero administration, intrahepatic administration, intravaginal administration, ophthalmic administration, intraaural administration, otic administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-CSF administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can also include hepatic intra-arterial administration or administration through the hepatic portal vein (HPV). Administration of a disclosed enzy me, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical composition, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed small molecule, a disclosed endonuclease, a disclosed oligonucleotide, and/or a disclosed RNA therapeutic can comprise administration directly into the CNS or the PNS. Administration can be continuous or intermittent. Administration can comprise a combination of one or more route.
[0054] In an aspect, the skilled person can determine an efficacious dose, an efficacious schedule, and an efficacious route of administration for the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof to treat or prevent a disease or disorder (such as genetic disease or disorder). In an aspect, the skilled person can also alter, change, or modify an aspect of an administering step to improve efficacy of the disclosed enzymes, the disclosed recombinant enzy mes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof.
[0055] By '‘determining the amount” is meant both an absolute quantification of a particular analyte (e.g., level of IgG and/or IgM) or a determination of the relative abundance of a particular analyte (e.g., level of IgG and/or IgM compared to a control / reference level). The phrase includes both direct or indirect measurements of abundance or both.
[0056] As used herein. IdeZ is a cysteine protease that inactivates IgG antibodies by cleaving IgG at the lower hinge region of the heavy chain producing one F(ab’)? and one homodimeric Fc fragment.
[0057] As used herein, the term “pharmaceutically acceptable carrier'’ refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. In an aspect, a pharmaceutical carrier employed can be a solid, liquid, or gas. In an aspect, examples of solid carriers can include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. In an aspect, examples of liquid carriers can include sugar syrup, peanut oil, olive oil, and water. In an aspect, examples of gaseous carriers can include carbon dioxide and nitrogen. In preparing a disclosed composition for oral dosage form, any convenient pharmaceutical media can be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like can be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcry stalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like can be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets can be coated by standard aqueous or nonaqueous techniques. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as
polylactide-polygly colide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial -retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
[0058] As used herein, the term '‘excipient” refers to an inert substance which is commonly used as a diluent, vehicle, preservative, binder, or stabilizing agent, and includes, but is not limited to, proteins (e.g., serum albumin, etc.), amino acids (e.g., aspartic acid, glutamic acid, lysine, arginine, glycine, histidine, etc.), fatty acids and phospholipids (e.g., alkyl sulfonates, caprylate, etc.), surfactants (e.g., SDS, polysorbate, nonionic surfactant, etc.), saccharides (e.g., sucrose, maltose, trehalose, etc.) and polyols (e.g., mannitol, sorbitol, etc.). See, also, for reference. Remington’s Pharmaceutical Sciences, (1990) Mack Publishing Co., Easton, Pa., which is hereby incorporated by reference in its entirety.
[0059] As used herein, “concurrently” means (1) simultaneously in time, or (2) at different times during the course of a common treatment schedule.
[0060] The term “contacting” as used herein refers to bringing one or more of the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, the disclosed vectors, the disclosed pharmaceutical formulations, or any combination thereof together with a target area or intended target area (e.g. a cleavage site on IgG (SEQ ID NO: 111 - SEQ ID NO: 118) and/or IgM (SEQ ID NO: 110)) in such a manner that the one or more of the disclosed isolated nucleic acid molecules, disclosed vectors, disclosed pharmaceutical formulations, or a combination thereof exert an effect on the intended target or targeted area either directly or indirectly. A target area can comprise one or more cells, and in an aspect, one or more cells can be in a subject. A target area or intended target area can be one or more of a subject’s organs (e.g., lungs, heart, liver, kidney, brain, etc.). In an aspect, a target area or intended target area can be any organ, tissue, or cells that are affected by a disease or disorder (such as a genetic disease or disorder).
[0061] As used herein, “determining” can refer to measuring or ascertaining the presence and severity of a disease or disorder, such as, for example, a genetic disease or disorder. Methods and techniques used to determine the presence and/or severity of a disease or disorder are ty pically known to the medical arts. For example, the art is familiar with the ways to identify and/or
diagnose the presence, severity, or both of a disease or disorder (such as, for example, a genetic disease or disorder).
[0062] As used herein, “effective amount'’ and “amount effective” can refer to an amount that is sufficient to achieve the desired result such as, for example, the treatment and/or prevention of a disease or disorder (e.g., a genetic disease or disorder) or a suspected disease or disorder. As used herein, the terms “effective amount” and “amount effective” can refer to an amount that is sufficient to achieve the desired an effect on an undesired condition (e.g., a disease or disorder). For example, a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects. In an aspect, “therapeutically effective amount” means an amount of a disclosed enzy me, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation; that (i) treats the particular disease, condition, or disorder (e.g., a genetic disease or disorder), (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder e.g., a genetic disease or disorder), or (iii) delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein (e.g., a genetic disease or disorder). The specific therapeutically effective dose level for any particular patient will depend upon a variety' of factors including the disorder being treated and the severity of the disorder; the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, disclosed vectors, disclosed pharmaceutical formulations employed; the disclosed methods employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the disclosed isolated nucleic acid molecules, disclosed vectors, or disclosed pharmaceutical formulations employed; the duration of the treatment; drugs used in combination or coincidental with the disclosed isolated nucleic acid molecules, disclosed vectors, or disclosed pharmaceutical formulations employed, and other like factors well known in the medical arts. For example, it is within the skill of the art to start doses of the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, disclosed vectors, or disclosed pharmaceutical formulations at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, then the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, a single dose of the disclosed isolated nucleic acid molecules, disclosed vectors, or disclosed pharmaceutical formulations can contain such amounts or submultiples thereof to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance
can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition, such as, for example, a disease or disorder due to a missing, deficient, and/or mutant protein or enzyme.
[0063] As used herein. “RNA therapeutics” can refer to the use of oligonucleotides to target RNA. RNA therapeutics can offer the promise of uniquely targeting the precise nucleic acids involved in a particular disease with greater specificity, improved potency, and decreased toxicity. This could be particularly powerful for genetic diseases where it is most advantageous to aim for the RNA as opposed to the protein. In an aspect, a therapeutic RNA can comprise one or more expression sequences. As known to the art, expression sequences can comprise an RNAi, shRNA, mRNA, non-coding RNA (ncRNA), an antisense such as an antisense RNA, miRNA, morpholino oligonucleotide, peptide-nucleic acid (PNA) or ssDNA (with natural, and modified nucleotides, including but not limited to, LNA, BNA, 2’-O-Me-RNA, 2 -MEO-RNA, 2'-F-RNA), or analog or conjugate thereof. In an aspect, a disclosed therapeutic RNA can comprise one or more long non-coding RNA (IncRNA), such as, for example, along intergenic non-coding RNA (lincRNA), pre-transcript, pre-miRNA, pre-mRNA, competing endogenous RNA (ceRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), pseudo-gene, rRNA, or tRNA. In an aspect, ncRNA can be piwi-interacting RNA (piRNA), primary miRNA (pri-miRNA), or premature miRNA (pre-miRNA). In an aspect, a disclosed therapeutic RNA or an RNA therapeutic can comprise antisense oligonucleotides (ASOs) that inhibit mRNA translation, oligonucleotides that function via RNA interference (RNAi) pathway, RNA molecules that behave like enzymes (ribozymes), RNA oligonucleotides that bind to proteins and other cellular molecules, and ASOs that bind to mRNA and form a structure that is recognized by RNase H resulting in cleavage of the mRNA target. In an aspect, RNA therapeutics can comprise RNAi and ASOs that inhibit mRNA translation. Generally speaking, as know n to the art, RNAi operates sequence specifically and post-transcriptionally by activating ribonucleases which, along with other enzymes and complexes, coordinately degrade the RNA after the original RNA target has been cut into smaller pieces while antisense oligonucleotides bind to their target nucleic acid via Watson-Crick base pairing, and inhibit or alter gene expression via steric hindrance, splicing alterations, initiation of target degradation, or other events.
[0064] As used herein, “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein must contain at least two amino acids and there is no limitation on the maximum number of amino acids that can comprise a protein’s sequence. The term “peptide” can refer to a short chain of amino acids including, for example, natural peptides, recombinant peptides, synthetic
peptides, or any combination thereof. Proteins and peptides can include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, and fusion proteins, among others.
[0065] "Nucleic acid” or "oligonucleotide” or "polynucleotide” as used herein means at least two nucleotides covalently linked together. The depiction of a single strand can also define the sequence of the complementary strand. Thus, a nucleic acid can encompass the complementary strand of a depicted single strand. Many variants of a nucleic acid can be used for the same purpose as a given nucleic acid. Thus, a nucleic acid can encompass substantially identical nucleic acids and complements thereof. A single strand can provide a probe that can hybridize to a target sequence under stringent hybridization conditions. Thus, a nucleic acid can encompass a probe that hybridizes under stringent hybridization conditions. A nucleic acid can be single-stranded, or double-stranded, or can contain portions of both double-stranded and single-stranded sequence. The nucleic acid can be DNA, both genomic and cDN A, RN A, or a hybrid, where the nucleic acid can contain combinations of deoxy ribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine and isoguanine. Nucleic acids can be obtained by chemical synthesis methods or by recombinant methods. Also as used herein, the terms “nucleic acid,” “nucleic acid molecule,” "nucleic acid construct,” "nucleotide sequence”, and "polynucleotide” can refer to RNA or DNA that is linear or branched, single or double stranded, or a hybrid thereof. The term can encompass RNA/DNA hybrids. When dsRNA is produced synthetically, less common bases, such as inosine, 5- methylcytosine, 6-methyladenine. hypoxanthine and others can also be used for antisense, dsRNA, and ribozyme pairing. For example, polynucleotides that contain C-5 propyne analogues of uridine and cytidine have been shown to bind RNA with high affinity and to be potent antisense inhibitors of gene expression. Other modifications, such as modification to the phosphodiester backbone, or the 2'-hy droxy in the ribose sugar group of the RNA can also be made. A "synthetic” nucleic acid or polynucleotide, as used herein, refers to a nucleic acid or polynucleotide that is not found in nature but is constructed by the hand of man and therefore is not a product of nature.
[0066] A “polynucleotide” is a sequence of nucleotide bases, and may be RNA, DNA, or DNA- RNA hybrid sequences (including both naturally occurring and non-naturally occurring nucleotides).
[0067] A "fragment” or "portion” of a nucleotide sequence can be understood to mean a nucleotide sequence of reduced length relative (e.g., reduced by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more nucleotides) to a reference nucleic acid or nucleotide sequence and comprising, consisting essentially of, or consisting of a nucleotide sequence of
contiguous nucleotides identical or almost identical (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical) to the reference nucleic acid or nucleotide sequence. Such a nucleic acid fragment or portion according to the disclosure can be. where appropriate, included in a larger polynucleotide of which it is a constituent. In an aspect, a fragment or portion of a nucleotide sequence or nucleic acid sequence can comprise the sequence encoding an exon having one or more mutations.
[0068] A “fragment’' or “portion” of an amino acid sequence can be understood to mean an amino acid sequence of reduced length relative (e.g., reduced by 1, 2. 3, 4, 5. 6, 7, 8. 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, or more ammo acids) to a reference amino acid sequence and comprising, consisting essentially of, or consisting of an amino acid sequence of contiguous amino acids identical or almost identical (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical) to the reference amino acid sequence. Such an amino acid fragment or portion according to the disclosure can be, where appropriate, included in a larger amino acid sequence of which it is a constituent.
[0069] “Complement” or “complementary” as used herein means a nucleic acid can mean Watson-Crick (e.g., A-T/U and C-G) or Hoogsteen base pairing between nucleotides or nucleotide analogs of nucleic acid molecules. “Complementarity” refers to a property shared between two nucleic acid sequences, such that when they are aligned antiparallel to each other, the nucleotide bases at each position will be complementary.
[0070] As used herein, “operably linked” means that expression of a gene or a transgene is under the control of a promoter with which it is spatially connected. A promoter can be positioned 5’ (upstream) or 3’ (downstream) of a gene under its control. The distance between the promoter and a gene can be approximately the same as the distance between that promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variation in this distance can be accommodated without loss of promoter function.
[0071 ] As used herein, “promoter” or “promoters” are known to the art. Depending on the level and tissue-specific expression desired, a variety of promoter elements can be used. A promoter can be tissue-specific or ubiquitous and can be constitutive or inducible, depending on the pattern of the gene expression desired. A promoter can be native (endogenous) or foreign (exogenous) and can be a natural or a synthetic sequence. By foreign or exogenous, it is intended that the transcriptional initiation region is not found in the wild-type host into which the transcriptional initiation region is introduced.
[0072] '‘Tissue-specific promoters” are known to the art and include, but are not limited to, neuron-specific promoters, muscle-specific promoters, liver-specific promoters, skeletal musclespecific promoters, and heart-specific promoters.
[0073] “Liver-specific promoters” are known to the art and include, but are not limited to, the thyroxin binding globulin (TBG) promoter, the al-microglobulin/bikunin enhancer/thyroid hormone-binding globulin promoter, the human albumin (hALB) promoter, the thyroid hormone- binding globulin promoter, the a- 1 -anti -trypsin promoter, the bovine albumin (bAlb) promoter, the murine albumin (mAlb) promoter, the human al -antitrypsin (hAAT) promoter, the ApoEhAAT promoter comprising the ApoE enhancer and the hAAT promoter, the transthyretin (TTR) promoter, the liver fatty acid binding protein promoter, the hepatitis B virus (HBV) promoter, the DC172 promoter comprising the hAAT promoter and the al -microglobulin enhancer, the DC 190 promoter comprising the human albumin promoter and the prothrombin enhancer, or any other natural or synthetic liver-specific promoter. In an aspect, a liver specific promoter can comprise about 845-bp and comprise the thyroid hormone-binding globulin promoter sequences (2382 to 13), two copies of al-microglobulin/bikunin enhancer sequences (22,804 through 22,704), and a 71-bp leader sequence as described by Ill CR, et al. (1997).
[0074] Ubiquitous/constitutive promoters” are known to the art and include, but are not limited to, a CMV major immediate-early enhancer/chicken beta-actin promoter, a cytomegalovirus (CMV) major immediate-early promoter, an Elongation Factor 1-a (EFl-a) promoter, a simian vacuolating virus 40 (SV40) promoter, an AmpR promoter, a PyK promoter, a human ubiquitin C gene (Ubc) promoter, a MFG promoter, a human beta actin promoter, a CAG promoter, a EGR1 promoter, a FerH promoter, a FerL promoter, a GRP78 promoter, a GRP94 promoter, a HSP70 promoter, a 0-kin promoter, a murine phosphoglycerate kinase (mPGK.) or human PGK (hPGK) promoter, a ROSA promoter, human Ubiquitin B promoter, a Rous sarcoma virus promoter, or any other natural or synthetic ubiquitous/constitutive promoters.
[0075] As used herein, an “inducible promoter” refers to a promoter that can be regulated bypositive or negative control. Factors that can regulate an inducible promoter include, but are not limited to, chemical agents (e g., the metallothionein promoter or a hormone inducible promoter), temperature, and light.
[0076] As used herein, the term “seroty pe” is a distinction used to refer to an AAV having a capsid that is serologically distinct from other AAV serotypes. Serologic distinctiveness can be determined by the lack of cross-reactivity between antibodies to one AAV as compared to another AAV. Such cross-reactivity differences are usually due to differences in capsid protein sequences/antigenic determinants (e.g., due to VP1, VP2, and/or VP3 sequence differences of AAV serotypes).
[0077] As used herein, “tropism’’ refers to the specificity of an AAV capsid protein present in an AAV viral particle, for infecting a particular type of cell or tissue. The tropism of an AAV capsid for a particular type of cell or tissue may be determined by measuring the ability of AAV vector particles comprising the hybrid AAV capsid protein to infect or to transduce a particular type of cell or tissue, using standard assays that are well-known in the art such as those disclosed in the examples of the present application. As used herein, the term “liver tropism” or “hepatic tropism” refers to the tropism for liver or hepatic tissue and cells, including hepatocytes.
[0078] “Sequence identity” and “sequence similarity” can be determined by alignment of two peptide or two nucleotide sequences using global or local alignment algorithms. Sequences may then be referred to as “substantially identical” or “essentially similar” when they are optimally aligned. For example, sequence similarity or identity can be determined by searching against databases such as FASTA, BLAST, etc., but hits should be retrieved and aligned pairwise to compare sequence identity. Two proteins or two protein domains, or two nucleic acid sequences can have “substantial sequence identity” if the percentage sequence identity is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more, preferably 90%, 95%, 98%, 99% or more. Such sequences are also referred to as “variants” herein, e.g., other variants of a missing, deficient, and/or mutant protein or enzyme. It should be understood that sequence with substantial sequence identity do not necessarily have the same length and may differ in length. For example, sequences that have the same nucleotide sequence but of which one has additional nucleotides on the 3’- and/or 5’-side are 100% identical.
[0079] A “heterologous” or a “recombinant” nucleotide or amino acid sequence as used interchangeably herein can refer to a nucleotide or an amino acid sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring nucleotide or amino acid sequence.
[0080] Different nucleic acids or proteins having homology' can be referred to as “homologues”. The term homologue includes homologous sequences from the same and other species and orthologous sequences from the same and other species. “Homology” refers to the level of similarity' betw een two or more nucleic acid and/or amino acid sequences in terms of percent of positional identity (i.e., sequence similarity or identity). Homology' also refers to the concept of similar functional properties among different nucleic acids or proteins. Thus, the disclosed compositions and disclosed methods can comprise homologues to the disclosed nucleotide sequences and/or disclosed polypeptide sequences.
[0081] “Orthologous,” as used herein, can refer to homologous nucleotide sequences and/or amino acid sequences in different species that arose from a common ancestral gene during speciation. A homologue of a disclosed nucleotide sequence or a disclosed polypeptide can have
substantial sequence identity (e.g., at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and/or 100%) to a disclosed nucleotide sequence or a disclosed polypeptide.
[0082] As used herein, “codon optimization” can refer to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing one or more codons or more of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. As contemplated herein, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the “Codon Usage Database.” Many methods and software tools for codon optimization have been reported previously . (See, for example, genomes .urv.es/ OPTIMIZER/) .
[0083] For example, a codon is a sequence of three nucleotides that encodes for a specific amino acid in the synthesis of a protein. There are 64 distinct codons, but only 20 amino acids, leading to the degeneracy of the genetic code. For instance, the amino acid Leucine can be encoded with six synonymous codons CUU, CUC, CUA, CUG, UUA and UUG whereas Cysteine can be encoded with two codons UGU and UGC. Overall, 2 of the 20 amino acids can be encoded with 1 codon, 9 with 2 codons, 1 with 3 codons, 5 with 4 codons and 3 with 6 codons leading to 61 essential codons. The remaining three codons are stop codons and are reserved for termination of protein formation. Codon degeneracy leads to many possible ways of encoding a protein, e.g. a typical 375-amino acid protein in humans can be potentially encoded by 10207 different codon sequences. All possible encodings and resulting sequences are not equally likely to be observed in nature; however, as some synonymous codons are more frequently used than others in encoding a particular amino acid in a particular organism. This phenomenon is called ‘codon usage bias’ or ‘codon bias’. As an example, Leucine is encoded 39.5% of the time with codon CUG in Homo sapiens, whereas the same codon is used 11.1% of the same amino acid’s encoding in Saccharomyces cerevisiae (Nakamura et al., 2000).
[0084] As used herein, “immune tolerance,” “immunological tolerance,” and “immunotolerance” refers to a state of unresponsiveness or blunted response of the immune system to substances (e.g., protein replacement therapy, enzyme replacement therapy, recombinant product, a transplanted organ, a vector protein, etc.) that have the capacity to elicit an immune response in a subject. Immune tolerance is induced by prior exposure to a specific antigen. Immune tolerance can be determined in a subject by measuring antibodies against a particular antigen (such as, for example, to an HLA on a transplanted organ, an enzy me or therapeutic protein as part of replacement
therapy, a viral vector, an AAV capsid protein). Low or absent antibody titers over time is an indicator of immune tolerance or the efficacy of a disclosed enz me or disclosed recombinant enzy me. For example, immune tolerance can be established by having IgG antibody titers of less than or equal to about 12,000, 11,500, 11,000. 10.500, 10,000, 9,500. 9,000, 8,500, 8,000, 7.500, 7,000, 6.500, or 6,000 following gene therapy (such as the administration of the transgene encoding, for example, a missing, deficient, and/or mutant protein or enzyme), protein replacement therapy, enzyme replacement therapy, or a recombinant product.
[0085] As known to the art, antibodies (Abs) can mitigate AAV infection through multiple mechanisms by binding to AAV capsids and blocking critical steps in transduction such as cell surface attachment and uptake, endosomal escape, productive trafficking to the nucleus, or uncoating as well as promoting AAV opsonization by phagocytic cells, thereby mediating their rapid clearance from the circulation. For example, in humans, serological studies reveal a high prevalence of NAbs in the worldwide population, with about 67% of people having antibodies against AAV1, 72% against AAV2, and approximately 40% against AAV serotypes 5 through 9. Vector immunogenicity represents a major challenge in re-administration of AAV vectors.
[0086] In an aspect, also disclosed herein are partial self-complementary7 parvovirus (e.g., a disclosed AAV) genomes, plasmid vectors encoding the parvovirus genomes, and parvovirus (e.g., a disclosed AAV) particles including such genomes. In an aspect, provided herein is a plasmid vector comprising a nucleotide sequence encoding a disclosed parvovirus genome such as for example, a disclosed AAV. In an aspect, provided herein is a partial self-complementary' parvovirus genome including a payload construct, parvovirus ITRs flanking the payload construct, and a self-complementary region flanking one of the ITRs. A self-complementary7 region can comprise a nucleotide sequence that is complementary7 to the payload construct. A disclosed self- complementary region can have a length that is less the entire length of the pay load construct.
[0087] In an aspect, a disclosed self-complementary7 region of a disclosed parvovirus genome can comprise a minimum length, while still having a length that is less the entire length of the payload construct. In an aspect, a disclosed self-complementary region can comprise at least 50 bases in length, at least 100 bases in length, at least 200 in length, at least 300 bases in length, at least 400 bases in length, at least 500 bases in length, at least 600 bases in length, at least 700 bases in length, at least 800 bases in length, at least 900 bases in length, or at least 1,000 bases in length.
[0088] In an aspect, a “self-complementary parvovirus genome” can be a single stranded polynucleotide having, in the 5’ to 3’ direction, a first parvovirus ITR sequence, a heterologous sequence (e.g., payload construct comprising, for example, a desired gene), a second parvovirus ITR sequence, a second heterologous sequence, wherein the second heterologous sequence is complementary to the first heterologous sequence, and a third parvovirus ITR sequence. In
contrast to a self-complementary genome, a "partial self-complementary genome” does not include three parvovirus ITRs and the second heterologous sequence that is complementary to the first heterologous sequence has a length that is less than the entire length of the first heterologous sequence (e.g., payload construct). Accordingly, a partial self-complementary genome is a single stranded polynucleotide having, in the 5’ to 3’ direction or the 3’ to 5’ direction, a first parvovirus ITR sequence, a heterologous sequence (e.g., payload construct), a second parvovirus ITR sequence, and a self-complementary region that is complementary to a portion of the heterologous sequence and has a length that is less than the entire length the heterologous sequence.
[0089] As used herein, “immune-modulating” refers to the ability of a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a disclosed agent to alter (modulate) one or more aspects of the immune system. The immune system functions to protect the organism from infection and from foreign antigens by cellular and humoral mechanisms involving lymphocytes, macrophages, and other antigen-presenting cells that regulate each other by means of multiple cell-cell interactions and by elaborating soluble factors, including lymphokines and antibodies, that have autocrine, paracrine, and endocrine effects on immune cells.
[0090] As used herein, “immune modulator” refers to an agent that is capable of adjusting a given immune response to a desired level (e.g., as in immunopotentiation, immunosuppression, or induction of immunologic tolerance). Examples of immune modulators include but are not limited to, a disclosed immune modulator can comprise aspirin, azathioprine, belimumab, betamethasone dipropionate, betamethasone valerate, bortezomib, bredinin, cyazathioprine, cyclophosphamide, cyclosporine, deoxyspergualin, didemnin B, fluocinolone acetonide, folinic acid, ibuprofen. IL6 inhibitors (such as sarilumab) indomethacin, inebilizumab, intravenous gamma globulin (IVIG), methotrexate, methylprednisolone, mycophenolate mofetil, naproxen, prednisolone, prednisone, prednisolone indomethacin, rapamycin, rituximab, sirolimus, sulindac, synthetic vaccine particles containing rapamycin (SVP-Rapamycin or ImmTOR), thalidomide, tocilizumab, tolmetin, triamcinolone acetonide. anti-CD3 antibodies, anti-CD4 antibodies, anti-CD19 antibodies, anti- CD20 antibodies, anti-CD22 antibodies, anti-CD40 antibodies, anti-FcRN antibodies, anti-IL6 antibodies, anti-IGFIR antibodies, an IL2 mutein, a BTK inhibitor, or a combination thereof. In an aspect, a disclosed immune modulator can comprise one or more Treg (regulatory T cells) infusions (e.g., antigen specific Treg cells to AAV). In an aspect, a disclosed immune modulator can be bortezomib or SVP-Rapamycin. In an aspect, an immune modulator can be administered by any suitable route of administration including, but not limited to, in utero, intra-CSF, intrathecally, intravenously, subcutaneously, trans dermally, intradermally, intramuscularly, orally, trans cutaneously, intraperitoneally (IP), or intravaginally. In an aspect, a disclosed
immune modulator can be administered using a combination of routes. Administration can also include hepatic intra-arterial administration or administration through the hepatic portal vein (HPV). Administration of an immune modulator can be continuous or intermittent, and administration can comprise a combination of one or more routes.
[0091] As used herein, the term "immunotoleranf ’ refers to unresponsiveness to an antigen (e.g., a vector, a therapeutic protein, a transgene product, etc.). An immunotolerant promoter can reduce, ameliorate, or prevent transgene-induced immune responses that can be associated with gene therapy. Assays known in the art to measure immune responses, such as immunohistochemical detection of cytotoxic T cell responses, can be used to determine whether one or more promoters can confer immunotolerant properties.
[0092] As used herein, the term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products.
[0093] As used herein, the term “in combination” in the context of the administration of other therapies (e.g., other agents) includes the use of more than one therapy (e.g., drug therapy). Administration “in combination with” one or more further therapeutic agents includes simultaneous (e.g.. concurrent) and consecutive administration in any order. The use of the term “in combination” does not restrict the order in which therapies are administered to a subject. By way of non-limiting example, a first therapy (e.g., a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof) may be administered prior to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks), concurrently, or after (e.g., 1 minute. 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours. 12 hours, 24 hours, 48 hours, 72 hours, 96 hours. 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 1 1 weeks, or 12 weeks or longer) the administration of a second therapy (e.g., gene therapy, enzyme replacement therapy, protein replacement therapy, recombinant product) to a subject having or diagnosed with a disease or disorder (such as a genetic disease or disorder).
[0094] Disclosed are the components to be used to prepare the disclosed enzymes, the disclosed recombinant enzymes, disclosed isolated nucleic acid molecules, disclosed vectors, or disclosed pharmaceutical formulations as well as the disclosed enzymes, the disclosed recombinant enzymes, the disclosed isolated nucleic acid molecules, disclosed vectors, or disclosed
pharmaceutical formulations used within the methods disclosed herein. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds cannot be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular compound is disclosed and discussed and a number of modifications that can be made to a number of molecules including the compounds are discussed, specifically contemplated is each and every combination and permutation of the compound and the modifications that are possible unless specifically indicated to the contrary. Thus, if a class of molecules A, B. and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered disclosed. Likewise, any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B- F, and C-E would be considered disclosed. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the compositions of the invention. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the methods of the invention.
B. Compositions for Transcriptome Engineering
1. Enzymes
[0095] Disclosed herein is an enzy me having IgM specific protease activity. Disclosed herein is an enzyme having IgG specific protease activity. Disclosed herein is an enzyme having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme having IgM specific protease activity. Disclosed herein is a recombinant enzyme having IgG specific protease activity. Disclosed herein is a recombinant enzyme having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a fusion protein having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme that can bind to and cleave at one or more sequences set forth in SEQ ID NO: 111 - SEQ ID NO: 118 and at the sequence set forth in SEQ ID NO: 110.
[0096] Disclosed herein is an enzy me comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46. Disclosed herein is an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and having IgM specific protease activity and/or IgG specific protease activity.
[0097] Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:01. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:04.
[0098] Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:07. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO: 10. Disclosed herein is an enzy me comprising the sequence set forth in SEQ ID NO: 13.
[0099] Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO: 16. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO: 19.
[0100] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 02 or SEQ IDNO:03 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof and having IgM specific protease activity.
Disclosed herein is a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof and having IgM specific protease activity.
[0101] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity’ to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO: 05 or SEQ IDNO:06 and having IgM specific protease activity'. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID
NO:06 or a fragment thereof and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof and having IgM specific protease activity.
[0102] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity7, or at least 90% identity7 to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme compnsing a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity7 to the sequence set forth in SEQ ID NO: 08 or SEQ ID NO:09 and having IgM specific protease activity'. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity7 to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof and having IgM specific protease activity.
[0103] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 and having IgM specific protease activity. Disclosed herein is a recombinant enzy me comprising the sequence set forth in SEQ ID NO:11 or SEQ ID NO: 12 or a fragment thereof and having IgM specific protease activity. Disclosed herein is a
recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof and having IgM specific protease activity.
[0104] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity’ to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 and having IgM specific protease activity. Disclosed herein is a recombinant enzy me comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof and having IgM specific protease activity.
[0105] Disclosed herein is a recombinant fusion protein comprising a proteolytic domain from a disclosed IgG specific protease linked to a proteolytic domain from a disclosed IgM specific protease. In an aspect of a disclosed recombinant fusion protein, a linker can comprise a flexible linker or a rigid linker. In an aspect, a disclosed linker can comprise the sequence of any one of SEQ ID NO:94 - SEQ ID NO: 104. In an aspect, a disclosed linker can comprise the sequence of SEQ ID NO: 96. In an aspect, a disclosed linker can be a rigid linker.
[0106] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18. Disclosed herein is a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 and having IgM specific
protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
[0107] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NQ:20 or SEQ ID NO:21 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 and having IgM specific protease activity’ and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
[0108] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23. Disclosed herein is a recombinant enzyme com rising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%,
at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
[0109] Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:24. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:27. Disclosed herein is an enzy me comprising the sequence set forth in SEQ ID NO:30. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:33. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO: 36.
[01 10] Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:39. Disclosed herein is an enzyme comprising the sequence set forth in SEQ ID NO:42.
[0111] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%. at least 70%. at least 80%. or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at
least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof and having IgM specific protease activity.
[0112] Disclosed herein is a recombinant enzy me comprising the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%. at least 60%. at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof. Disclosed herein is a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof and having IgM specific protease activity7. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof and having IgM specific protease activity.
[01 13] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 31 or SEQ ID NO:32 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at
least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof and having IgM specific protease activity.
[0114] Disclosed herein is a recombinant enzy me comprising the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%. at least 60%. at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof. Disclosed herein is a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 34 or SEQ ID NO:35 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof and having IgM specific protease activity7. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof and having IgM specific protease activity.
[01 15] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 37 or SEQ IDNO:38 and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof and having IgM specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at
least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof and having IgM specific protease activity.
[0116] Disclosed herein is a recombinant enzy me comprising the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%. at least 60%. at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof. Disclosed herein is a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
[0117] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity’ to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 and having IgM specific protease activity and IgG specific protease activity7. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment
thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
[0118] Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
[0119] In an aspect, a disclosed recombinant enzy me can have IgM specific protease activity'. In an aspect, a disclosed recombinant enzyme can cleave the IgM the heavy chain at the interdomain region between constant domains CLL2 and Cp3. In an aspect, a disclosed recombinant enzyme can cleave human IgM. In an aspect, a disclosed recombinant enzyme can cleave non-human primate IgM. In an aspect, a disclosed recombinant enzy me does not cleave non-human IgM. For example, in an aspect, a disclosed recombinant enzyme does not cleave dog IgM, pig IgM, and mouse IgM. In an aspect, a disclosed IgM specific recombinant enzyme does not cleave human IgA, IgD, IgE, IgG, or any combination thereof.
[0120] In an aspect, a disclosed recombinant enzyme can have a binding domain specific for IgM. In an aspect, a disclosed recombinant enzy me can cleave IgM between position 350 and position
IgM (for example, the substrate). In an aspect, a disclosed recombinant enzyme can have a binding domain capable of specifically binding to one or more amino acid residues 355 through 360 of IgM. In an aspect, a disclosed recombinant enzyme can have an affinity for human IgM. In an aspect, a disclosed IgM can be cleaved at SEQ ID NO: 110. In an aspect, a disclosed IgM can be cleaved at the sequence comprising 355D, 356T. 357A, 3581, 359R. and 360V. In an aspect, a disclosed IgM can be cleaved at position 355 through position 360 of SEQ ID NO: 105.
[0121] In an aspect, a disclosed recombinant enzyme can have IgG and IgM specific protease activity. In an aspect, a disclosed recombinant enzyme can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3 and can cleave the IgG below the hinge region. In an aspect, a disclosed recombinant enzyme can cleave the IgG below the hinge region, thereby yielding Ftab'h and Fc fragments. In an aspect, a disclosed recombinant enzyme can cleave the IgG separating the Cp2 and Cp3 domains from the Cpl domain.
[0122] In an aspect, a disclosed recombinant enzyme can cleave human IgG and human IgM. In an aspect, a disclosed recombinant enz me can cleave non-human primate IgG and non-human primate IgM. In an aspect, a disclosed recombinant enzyme having IgG and IgM protease activity does not cleave IgA, IgD, IgE, or any combination thereof. In an aspect, a disclosed recombinant enzyme having IgG and IgM protease activity does not cleave non-human IgM or non-human IgG. For example, in an aspect, a disclosed recombinant enzyme having IgG and IgM protease activity does not cleave dog IgM, pig IgM, and mouse IgM, or dog IgG, pig IgG, or mouse IgG.
[0123] In an aspect, a disclosed recombinant enzyme can have a binding domain capable of specifically binding to the sequence of SEQ ID NO: 111, SEQ ID NO:112, SEQ ID NO: 113, SEQ ID NO: 114, or any combination thereof. In an aspect, a disclosed recombinant enzyme can have a binding domain capable of specifically binding to the sequence of SEQ ID NO: 1 15, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof. In an aspect, a disclosed recombinant enzyme can cleave IgG at amino acid residues 109 through 124 of the IgG of SEQ ID NO: 106, residues 106 through 120 of the IgG of SEQ ID NO: 107, residues 156 through 171 of the IgG of SEQ ID NO: 108. residues 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, a disclosed recombinant enzyme can cleave IgG at amino acid residues 116 through 122 of the IgG of SEQ ID NO: 106, residues 112 through 118 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108, residues 113 through 119 oflgG of SEQ ID NO: 109, or any combination thereof. In an aspect, a disclosed recombinant enzyme can cleave one or more IgG molecules at SEQ ID NO: 115, SEQ ID NO: 1 16, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
[0124] In an aspect, a disclosed recombinant enzy me can be specific for IgM and IgG, can cleave IgM between position 355 and position 360 of SEQ ID NO: 105, and can cleave at residues 116
through 122 of the IgG of SEQ ID NO: 106, residues 112 through 118 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108, and residues 113 through 119 of IgG of SEQ ID NO: 109. In an aspect, a disclosed recombinant enzyme can be specific for IgM and IgG can recognize and cleave SEQ ID NO: 110 in IgM and cleave SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117. SEQ ID NO: 118 in IgG
[0125] In an aspect, a disclosed recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in a subject. In an aspect, a disclosed recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject. In an aspect, a disclosed recombinant enzyme can cleave and/or degrade circulating IgM and/or IgM and IgG in a subject. In an aspect, a disclosed recombinant enzyme can transiently clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject, or can transiently cleave and/or degrade circulating IgM and/or IgM and IgG in a subject. In an aspect, a disclosed recombinant enzyme can reduce and/or diminish the level of circulating IgM and/or IgG and IgM levels in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM levels in a subject. In aspect, a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
[0126] In an aspect, a disclosed recombinant enzyme can block and/or minimize activation of the complement cascade. In an aspect, a disclosed recombinant enzyme can block and/or minimize activation of the formation of the Cl complex and/or C3 complex. In an aspect, a disclosed recombinant enzyme can block and/or minimize activation of the classical complement pathway. In an aspect, a disclosed recombinant enzyme can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
[0127] In an aspect, a disclosed recombinant enzyme can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells. In an aspect, the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient. In an aspect, a disclosed recombinant enzyme can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells. In an aspect, a disclosed recombinant enzyme can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
[0128] In an aspect, a disclosed recombinant enzyme can reduce and/or minimize vector mediated immunotoxicity in a subject. In an aspect, a disclosed recombinant enzyme can enable and/or allow vector re-dosing in a subject. In an aspect, a disclosed recombinant enzyme can reduce and/or minimize transgene immunogenicity in a subject.
[0129] In an aspect, a disclosed recombinant enzyme can improve and/or enhance transgene efficacy and/or expression in a subj ect. In an aspect, a disclosed recombinant enzyme can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%. 60%. 70%. 80%. 90%. 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed recombinant enzymes). In an aspect, the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40- 50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed recombinant enzymes). In an aspect, an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed recombinant enzymes). In an aspect, an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wild-type or control level.
[0130] In an aspect, a disclosed recombinant enzyme can decrease and/or minimize the severity’ of a rejection event of the one or more transplanted organs. In an aspect, a disclosed recombinant enzyme can prevent the rejection of the one or more transplanted organs. In an aspect, a disclosed rej ection event can be classified a hyperacute rej ection event, an acute rej ection event, or a chronic rejection event. In an aspect, following the administration and/or delivery of a disclosed recombinant enzyme, the one or more transplanted organs are not rejected by the subject. In an aspect, following the administration and/or delivery’ of a disclosed recombinant enzy me, the viability’ of one or more transplanted organs can be improved and/or increased. In an aspect, following the administration and/or delivery of a disclosed recombinant enzyme, the functionality' of one or more transplanted organs can be improved and/or increased. In an aspect, following the administration and/or delivery of a disclosed recombinant enzyme, the functionality of one or more transplanted organs is not decreased and/or diminished. In an aspect, a disclosed recombinant enzyme can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
[0131] In an aspect, a disclosed enzyme can be used to modulate humoral immunity in a subject. In an aspect, modulating humoral immunity in a subject can be an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject's humoral immunity.
[0132] In an aspect, a disclosed enzyme can comprise one or more labels and/or tags. In an aspect, a disclosed label and/or a tag can comprise a fluorescent label and/or a tag. In an aspect, a disclosed label and/or a tag can comprise a carboxy -terminal label and/or tag or an amino-terminal label and/or tag. In an aspect, a disclosed label and/or a tag can comprise a carboxy -terminal fluorescent label and/or tag or an amino-terminal fluorescent label and/or tag. In an aspect, a disclosed label and/or tag can comprise an ALFA tag, an AviTag, a C tag, a Calmodulin-tag, an iCapTag (intein Capture Tag), a polyglutamate tag, a polyarginine tag, an E tag, a FLAG tag, a HA tag, a His tag, a Myc tag, a NE tag, a RholD4 tag, a S tag, a SBP tag, a Softag 1, a Softag 3, a Spot tag, a Strep tag, a T7 tag, a TC tag, a Ty tag, a V5 tag. a VSV-tag, an Xpress tag, an Isopeptag, a Spy tag, a SnoopTag, a SnoopTagJr, a DogTag, a SdyTag, a BCCP (Biotin Carboxyl Carrier Protein), a glutathione-S-transferase tag, a green fluorescent protein tag, a Halo tag, a SNAP -tag, a CLIP tag, a HUH tag, a maltose binding protein tag, a Nus tag, a thioredoxin tag, a Fc tag, a Designed Intrinsically Disordered tags containing disorder promoting amino acids, a Carbohydrate Recognition Domain or CRDSAT tag, a HiBiT-tag, or any combination thereof.
[0133] In an aspect, a disclosed label and/or a tag can comprise a fluorescent label or a fluorescent tag. In an aspect, a disclosed fluorescent label or disclosed fluorophore can comprise enhanced green fluorescent protein (EGFP), mEmerald, enhanced yellow fluorescent protein (EYFP), mApple, TdTomato, mCherry, miRFP670. any known fluorescent label or tag, or any combination thereof. In an aspect, a disclosed fluorescent label or disclosed fluorophore can comprise any fluorescent label or fluorophore that is amendable to analysis via flow cytometry. In an aspect, a pair of disclosed fluorescent labels or disclosed fluorophores can comprise any pair of fluorescent labels or fluorophores that is amendable to analysis via flow cytometry and have excitation and emission spectra that can be isolated or separated from each other, thereby enabling the interrogation of the docking interactions. Fluorophores and fluorescent labels are known in the art.
[0134] In an aspect, a disclosed enzy me or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg body weight to about 100 mg/kg body w eight. In an aspect, a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg,
about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
[0135] Disclosed herein is a recombinant enzy me comprising the sequence of SEQ ID NO:119. Disclosed herein is a recombinant enzy me encoded by the codon-optimized nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a recombinant enzyme encoded by a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity7 to the codon-optimized sequence of SEQ ID NO: 160 or SEQ ID NO: 161.
[0136] Disclosed herein is a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. Disclosed herein is a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 119. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity7 to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
[0137] Disclosed herein is a recombinant enzyme comprising the sequence of SEQ ID NO: 119 and having human and non-human primate IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121 and having human and non-human primate IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159 and having human and non-human primate IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity7 to the sequence of SEQ ID NO: 119 and having human and non-human primate IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity7 to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121 and having human and non-human primate IgG specific protease activity. Disclosed herein is a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159 and having human and non-human primate IgG specific protease activity.
[0138] Disclosed herein is a recombinant enzyme encoded by the codon-optimized nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161 and having human and non-human primate IgG specific protease activity. Disclosed herein is a recombinant enzyme encoded by a nucleic acid
sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the codon-optimized nucleic acid sequence of SEQ ID NO: 1 0 or SEQ ID NO: 161 and having human and non-human primate IgG specific protease activity.
2. Nucleic Acid Molecules
[0139] Disclosed herein is an isolated nucleic acid molecule encoding any disclosed enzyme. Disclosed herein is an isolated nucleic acid molecule encoding any disclosed recombinant enzyme. Disclosed herein is an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO: 92.
[0140] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:01. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:24. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:47. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:70.
[0141] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:04. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:27. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:50. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:73.
[0142] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:07. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:30. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:53. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:76.
[0143] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 10. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:33. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:56. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:79.
[0144] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 13. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:36. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:59. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:82.
[0145] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 16. Disclosed herein is an isolated nucleic acid molecule
encoding the enzyme comprising the sequence set forth in SEQ ID NO:39. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:62. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:85. [0146] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 19. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:42. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:65. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:88. [0147] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO: 02 or SEQ ID NO:03. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 and having IgM specific protease activity'. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof and having IgM specific protease activity7. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03 or a fragment thereof and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:48 or SEQ ID NO: 49. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:71 or SEQ ID NO:72.
[0148] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at
least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 and having IgM specific protease activity'. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity' to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 and having IgM specific protease activity7. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity' to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06 or a fragment thereof and having IgM specific protease activity'. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:51 or SEQ ID NO: 52. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:74 or SEQ ID NO:75.
[0149] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity7, or at least 90% identity7 to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the recombinant enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:08 or SEQ ID
NO:09 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof and having IgM specific protease activity7. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%. at least 70%. at least 80%. or at least 90% identity to the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09 or a fragment thereof and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:54 or SEQ ID NO:55. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:77 or SEQ ID NO: 78.
[0150] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity7, or at least 90% identity to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity7 to the sequence set forth in SEQ ID NO:11 or SEQ ID NO: 12 and having IgM specific protease activity7. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof and having IgM specific protease activity7. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity7 to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12 or a fragment thereof and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:57 or SEQ ID NO: 58. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 80 or SEQ ID NO: 81.
[0151] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity’ to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity’ to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof and having IgM specific protease activity7. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15 or a fragment thereof and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:60 or SEQ ID NO:61. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:83 or SEQ ID NO:84.
[0152] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%. at least 60%. at least 70%, at least 80% identity7, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 and having IgM specific protease activity and IgG specific protease
activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:63 or SEQ ID NO:64. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:86 or SEQ ID NO:87.
[0153] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 20 or SEQ ID NO:21. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NQ:20 or SEQ ID NO:21 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:2I and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity7 to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is
an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ IDNO:66 or SEQ ID NO:67. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 89 or SEQ ID NO:90.
[0154] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO: 22 or SEQ ID NO:23. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme compnsing the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme comprising the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:68 or SEQ ID NO:69. Disclosed herein is an isolated nucleic acid molecule comprising the sequence set forth in SEQ ID NO:91 or SEQ ID NO:92.
[0155] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:24. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:27. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:30. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me having the
sequence set forth in SEQ ID NO:33. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:36.
[0156] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:39. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:42.
[0157] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%. at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having sequence having at least 50%, at least 60%. at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof and having IgM specific protease activity.
[0158] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ
ID NO:28 or SEQ ID NO:29 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity', or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:28 or SEQ ID NO:29 or a fragment thereof and having IgM specific protease activity.
[0159] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me having the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:31 or SEQ ID NO:32 or a fragment thereof and having IgM specific protease activity.
[0160] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity7, or at least 90% identity7 to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme
having the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:34 or SEQ ID NO:35 or a fragment thereof and having IgM specific protease activity.
[0161] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me having the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%. at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me having the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof and having IgM specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:37 or SEQ ID NO:38 or a fragment thereof and having IgM specific protease activity.
[0162] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity’ to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%. at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof and having IgM specific protease activity' and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:40 or SEQ ID NO:41 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
[0163] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity7, or at least 90% identity7 to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzy me having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity7 to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 and having IgM specific protease activity and IgG specific protease activity7. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity7, or at least 90% identity to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 and having IgM specific
protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:43 or SEQ ID NO:44 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
[0164] Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46. Disclosed herein is an isolated nucleic acid molecule encoding the enz me having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%, at least 80% identity, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule encoding the enzyme having a sequence having at least 50%, at least 60%, at least 70%. at least 80%, or at least 90% identity to the sequence set forth in SEQ ID NO:45 or SEQ ID NO:46 or a fragment thereof and having IgM specific protease activity and IgG specific protease activity.
[0165] In an aspect, a disclosed isolated nucleic acid molecule can comprise the nucleic acid sequence for one or more labels and/or tags. In an aspect, a disclosed label and/or a tag can comprise a fluorescent label and/or a tag. In an aspect, a disclosed label and/or a tag can comprise a carboxy -terminal label and/or tag or an amino-terminal label and/or tag. In an aspect, a disclosed label and/or a tag can comprise a carboxy-terminal fluorescent label and/or tag or an aminoterminal fluorescent label and/or tag.
[0166] In an aspect, a disclosed label and/or tag can comprise an ALFA tag, an AviTag, a C tag, a Calmodulin-tag, an iCapTag (intein Capture Tag), a poly glutamate tag, a polyarginine tag, an E tag, a FLAG tag, a HA tag, a His tag, a Myc tag, a NE tag, a RholD4 tag, a S tag, a SBP tag, a Softag 1, a Softag 3, a Spot tag, a Strep tag, a T7 tag, a TC tag, a Ty tag, a V5 tag, a VSV-tag, an Xpress tag. an Isopeptag, a Spy tag. a SnoopTag. a SnoopTagJr. a DogTag. a SdyTag, a BCCP (Biotin Carboxyl Carrier Protein), a glutathione-S-transferase tag, a green fluorescent protein tag, a Halo tag, a SNAP-tag, a CLIP tag, a HUH tag, a maltose binding protein tag, a Nus tag, a thioredoxin tag, a Fc tag, a Designed Intrinsically Disordered tags containing disorder promoting amino acids, a Carbohydrate Recognition Domain or CRDSAT tag, a HiBiT-tag. or any combination thereof.
[0167] In an aspect, a disclosed label and/or a tag can comprise a fluorescent label or a fluorescent tag. In an aspect, a disclosed fluorescent label or disclosed fluorophore can comprise enhanced green fluorescent protein (EGFP), mEmerald. enhanced yellow fluorescent protein (EYFP), mApple, TdTomato, mCherry, miRFP670, any known fluorescent label or tag, or any combination thereof. In an aspect, a disclosed fluorescent label or disclosed fluorophore can comprise any fluorescent label or fluorophore that is amendable to analysis via flow cytometry7. In an aspect, a pair of disclosed fluorescent labels or disclosed fluorophores can comprise any pair of fluorescent labels or fluorophores that is amendable to analysis via flow cytometry and have excitation and emission spectra that can be isolated or separated from each other, thereby enabling the interrogation of interactions. Fluorophores and fluorescent labels are known in the art.
[0168] In an aspect of a disclosed nucleic acid molecule, a disclosed encoded recombinant enzyme can have IgM specific protease activity. In an aspect, a disclosed encoded recombinant enzyme can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3. In an aspect, a disclosed encoded recombinant enzyme can cleave human IgM. In an aspect, a disclosed encoded enzyme can cleave non-human primate IgM. In an aspect, a disclosed encoded recombinant enzyme does not cleave non-human IgM. For example, in an aspect a disclosed encoded recombinant enzyme does not cleave dog IgM, pig IgM, and mouse IgM. In an aspect, a disclosed encoded IgM specific recombinant enzyme does not cleave human IgA, IgD, IgE, IgG, or any combination thereof.
[0169] In an aspect, a disclosed encoded recombinant enzy me can have a binding domain specific for IgM. In an aspect, a disclosed encoded recombinant enzyme can cleave IgM between position 350 and position 365 of SEQ ID NO: 105. In an aspect, SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate). In an aspect, a disclosed encoded recombinant enzy me can have a binding domain capable of specifically binding to one or more amino acid residues 355 through 360 of IgM. In an aspect, a disclosed encoded recombinant enzyme can
have an affinity for human IgM. In an aspect, a disclosed IgM can be cleaved at SEQ ID NO: 110. In an aspect, a disclosed IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, a disclosed IgM can be cleaved at position 355 through position 360 of SEQ ID NO: 105.
[0170] In an aspect, a disclosed encoded recombinant enzyme can have IgG and IgM specific protease activity. In an aspect, a disclosed encoded recombinant enzyme can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3 and can cleave the IgG below the hinge region. In an aspect, a disclosed encoded recombinant enzyme can cleave the IgG below the hinge region, thereby yielding Ftab’fi and Fc fragments. In an aspect, a disclosed encoded recombinant enzyme can cleave the IgG separating the Cp2 and Cp3 domains from the Cpl domain.
[0171] In an aspect, a disclosed encoded recombinant enzyme can cleave human IgG and human IgM. In an aspect, a disclosed encoded recombinant enzyme can cleave non-human primate IgG and non-human primate IgM. In an aspect, a disclosed encoded recombinant enzyme having IgG and IgM protease activity does not cleave IgA, IgD, IgE, or any combination thereof. In an aspect, a disclosed encoded recombinant enzyme having IgG and IgM protease activity does not cleave non-human IgM or non-human IgG. For example, in an aspect, a disclosed encoded recombinant enzyme having IgG and IgM protease activity does not cleave dog IgM, pig IgM, and mouse IgM, or dog IgG, pig IgG, or mouse IgG.
[0172] In an aspect, a disclosed encoded recombinant enzyme can have a binding domain capable of specifically binding to the sequence of SEQ ID NO:111, SEQ ID NO: 112, SEQ ID NO:113, SEQ ID NO: 114, or any combination thereof. In an aspect, a disclosed encoded recombinant enzyme can have a binding domain capable of specifically binding to the sequence of SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof. In an aspect, a disclosed encoded recombinant enzy me can cleave IgG at amino acid residues 109 through 124 of the IgG of SEQ ID NO: 106, residues 106 through 120 of the IgG of SEQ ID NO: 107, residues 156 through 171 of the IgG of SEQ ID NO: 108, residues 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, a disclosed encoded recombinant enzyme can cleave IgG at amino acid residues 116 through 122 of the IgG of SEQ ID NO: 106, residues 112 through 118 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108. residues 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, a disclosed encoded recombinant enzyme can cleave one or more IgG molecules at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
[0173] In an aspect, a disclosed encoded recombinant enzyme can be specific for IgM and IgG, can cleave IgM between position 355 and position 360 of SEQ ID NO: 105, and can cleave at residues 116 through 122 of the IgG of SEQ ID NO: 106, residues 112 through 118 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108, and residues 113 through 119 of IgG of SEQ ID NO: 109. In an aspect, a disclosed encoded recombinant enzyme can be specific for IgM and IgG can recognize and cleave SEQ ID NO: 1 10 in IgM and cleave SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118 m IgG
[0174] In an aspect, a disclosed encoded recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in a subject. In an aspect, a disclosed recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject. In an aspect, a disclosed recombinant enzyme can cleave and/or degrade circulating IgM and/or IgM and IgG in a subject. In an aspect, a disclosed recombinant enzyme can transiently clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject, or can transiently cleave and/or degrade circulating IgM and/or IgM and IgG in a subject. In an aspect, a disclosed recombinant enzyme can reduce and/or diminish the level of circulating IgM and/or IgM and IgG levels in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgM and IgG levels in a subject. In aspect, a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
[0175] In an aspect of a disclosed nucleic acid molecule, a disclosed encoded enzy me can block and/or minimize activation of the complement cascade. In an aspect, a disclosed encoded enzyme can block and/or minimize activation of the formation of the Cl complex and/or C3 complex. In an aspect, a disclosed encoded enzyme can block and/or minimize activation of the classical complement pathway. In an aspect, a disclosed encoded enz me can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
[0176] In an aspect of a disclosed nucleic acid molecule, a disclosed encoded enzyme can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells. In an aspect, the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient. In an aspect, a disclosed encoded enzyme can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells. In an aspect, a disclosed encoded enzyme can remove and/or
cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
[0177] In an aspect of a disclosed nucleic acid molecule, a disclosed encoded enzyme can reduce and/or minimize vector mediated immunotoxicity in a subject. In an aspect of a disclosed nucleic acid molecule, a disclosed encoded enzyme can enable and/or allow vector re-dosing in a subject. In an aspect of a disclosed nucleic acid molecule, a disclosed encoded enzyme can reduce and/or minimize transgene immunogenicity in a subject. In an aspect of a disclosed nucleic acid molecule, a disclosed encoded enzyme can improve and/or enhance transgene efficacy and/or expression in a subject.
[0178] In an aspect, a disclosed nucleic acid molecule can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, a disclosed nucleic acid molecule can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more a disclosed nucleic acid molecules). In an aspect, the amount of improvement and/or enhancement can be 10-20%, 20- 30%. 30-40%, 40-50%, 50-60%. 60-70%, 70-80%, 80-90%. or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more a disclosed nucleic acid molecule). In an aspect, an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more a disclosed nucleic acid molecules). In an aspect, an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wildtype or control level.
[0179] In an aspect, a disclosed nucleic acid molecule and/or a disclosed nucleic acid sequence can be CpG depleted and codon-optimized for expression in a human cell. In an aspect, “CpG- free” can mean completely free of CpGs or partially free of CpGs. In an aspect, “CpG-free” can mean “CpG-depleted”. In an aspect, “CpG-depleted” can mean “CpG-free'’. In an aspect, “CpG- depleted” can mean completely depleted of CpGs or partially depleted of CpGs. In an aspect, “CpG-free” can mean “CpG-optimized” for a desired and/or ideal expression level. CpG depletion and/or optimization is know n to the skilled person in the art.
[0180] In an aspect, a “codon-optimized” gene can be a gene having its frequency of codon usage designed to mimic the frequency of preferred codon usage of the host cell (i.e.. a human cell or a
human subject). In an aspect, a disclosed nucleic acid molecule and/or a disclosed nucleic acid sequence can be codon-optimized, either wholly or in part. Because any one amino acid (except for methionine and tryptophan) is encoded by several codons, the sequence of the nucleic acid molecule can be changed without changing the encoded amino acid. In an aspect, a disclosed nucleic acid sequence can be codon-optimized for expression in a human cell or a human organ or one or more human cells or one or more human organs. In an aspect, a disclosed nucleic acid sequence can be codon-optimized for expression in a human subject.
[0181] In an aspect, a disclosed codon-optimized nucleic acid sequence can comprise SEQ ID NO:48. SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO : 74, SEQ ID NO : 75 , SEQ ID NO : 77, SEQ ID NO : 78, SEQ ID NO : 80, SEQ ID NO : 81 , SEQ ID NO: 83, SEQ ID NO:84, SEQ ID NO: 86. SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, or any combination thereof.
[0182] In an aspect, a disclosed nucleic acid sequence can encode the protein or a portion thereof (such as, for example, Exon 1 or Exon 4, etc.) associated with the following genes: ABCA1, ABCA12, ABCA13, ABCA2, ABCA3, ABCA4, ABCA5, ABCC1, ABCC2, ABCC6, ABCC8, ABCC9, AC AN, ADAMTS13, ADCY10, ADGRV1, AGL. AGRN, AHDC1, ALK, ALMS 1, ALPK3, ALS2, ANAPC 1, ANK.1, ANK2, ANKA, ANKRD11, ANKRD26, APC, APC2, APOB, ARFGEF2, ARHGAP31, ARHGEF10, ARHGEF18, ARID1A, ARID1B, ARID2, ASH1L, ASPM, ASXL1, ASXL2, ASXL3, ATM, ATP7A, ATP7B, ATR, ATRX, BAZ1A, BAZ2B, BCOR. BCORL1, BDP1, BLM, BPTF, BRCA1, BRCA2, BRD4, BRWD3, C2CD3, C3, C5, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1S, CAD, CAMTAI, CARMIL2, CC2D2A, CCDC88A, CCDC88C, CCNB3, CDH23, CDK13, CDK5RAP2, CELSR1, CEMIP2, CENPE, CENPF, CENPJ, CEP152, CEP164, CEP250, CEP290, CFAP43, CFAP44, CFAP65, CFTR/ABCC7, CHD1, CHD2, CHD3, CHD4. CHD7. CHD8, CIC, CIT. CLIP1, CLTC, CNOT1, CNTNAP1. COL11A1. COL11A2, COL12A1, COL17A1, COL18A1, COL1A1 , COL1 A2, COL27A1 , COL2A1 , COL3A1 , COL4A1, COL4A2, COL4A3, COL4A4, COL4A5, COL4A6, COL5A1, COL5A2, COL6A3, COL7A1, CPAMD8, CPLANE1, CPS1, CPSF1, CRB1, CREBBP, CUBN, CUL7, CUX1, DCC, DCHS1, DEPDC5, DICER1, DIP2B, DLC1, DMD. DMXL2, DNAH1, DNAH11, DNAH17, DNAH2, DNAH5, DNAH7, DNAH8, DNAH9, DNMBP, DNMT1, DOCK2, DOCK3, DOCK6, DOCK7, DOCK8, DSCAM, DSP, DST, DUOX2, DYNC1H1, DYNC2H1, DYSF, EIF2AK4, EP300, EPG5, ERCC6, ERCC6L2, EXPH5, EYS, F5, F8, FANCA, FANCD2, FANCM, FAT1, FAT4, FBN1, FBN2, FLG, FLG2, FLNA, FLNB, FLNC, FLT4, FMN2, FN1, FRAS1, FREM1,
FREM2, FSIP2, FYC01, GLI2, GLI3, GPR179, GREB1L, GRIN2A, GRIN2B, GRIN2D, HCFC1, HECW2, HERC1, HERC2, HFM1, HIVEP1, HIVEP2, HMCN1, HSPG2, HTT, HUWE1, HYDIN, IFT140, IFT172, IGF1R, IGF2R, IGSF1, INSR, INTS1, IQSEC2, ITGB4, ITPR1, ITPR2, JMJD1C, KALRN, KANK1, KAT6A, KAT6B, KDM3B, KDM5B, KDM5C, KDM6A, KDM6B, KDR, KIAA0586. KIAA1109, KIAA1549, KIDINS220, KIF14, KIF1A, KIF1B, KIF21A, KIF26B, KIF7, KMT2A, KMT2B, KMT2C, KMT2D, KMT2E, KNL1, LAMA1, LAMA2, LAMA3, LAMA4, LAMA5, LAMB1, LAMB2, LAMC3, LCT, L0XHD1, LPA, LRBA, LRP1, LRP2, LRP4, LRP5, LRP6, LRPPRC, LRRK1, LRRK2, LTBP2, LTBP4, LYST, MACF1, MADD, MAGI2, MAP1B, MAP3K1, MAPK8IP3. MAPKBPL MAST1, MBD5, MCM3AP, MED12, MED12L, MED13, MED13L, MED23, MEGF8, MET, MLH3, MPDZ, MSH6, MTOR, MYH10, MYH11, MYH14, MYH2, MYH3, MYH6, MYH7, MYH7B, MYH8, MYH9, MYLK, MYO15A, MYO18B, MYO3A, MYO5A, MYO5B, MYO7A, MYO9A, NALCN. NBAS, NBEA, NBEAL2, NCAPD2, NCAPD3, NEB, NEXMIF, NEXMIF. NF1, NFASC, NHS, NIN, N1PBL, NLRP1, NOTCH1, NOTCH2. NOTCH3. NPHP4. NRXN1, NRXN3, NSD1, NSD2, NUP155, NUP188, NUP205, OBSCN, OBSL1, OTOF, OTOG, OTOGL, PARD3, PBRM1, PCDH15, PCLO, PCNT, PHIP, PI4KA, PIEZO1, PIEZO2, PIK3C2A, PIKFYVE, PKD1, PKD1L1, PKHD1, PLCE1, PLEC. PLEKHG2, PNPLA6, POGZ, POLA1, POLE, POLR1A, POLR2A, POLR3A, PRG4. PRKDC. PRPF8, PRR12, PRX, PTCHI, PTPN23, PTPRF, PTPRJ, PTPRQ, PXDN, QRICH2, RAB3GAP2, RAIL RALGAPA1, RANBP2, RB1CC1, RELN, RERE, REV3L, RIC1, RIMS1, RIMS2, RNF213, ROBO1, ROBO2, ROBO3, ROS 1, RP1, RP1L1, RTTN, RUSC2, RYR1, RYR2, SACS, SAMD9, SAMD9L, SBF2, SCAPER, SCN10A, SCN11A, SCN1A, SCN2A. SCN3A, SCN4A, SCN5A, SCN8A, SCN9A, SETBP1, SETD1A, SETD1B, SETD2, SETD5, SETX, SHANK2, SHANK3, SHROOM4, SI, SIPA1L3, SLIT2, SLX4, SMARCA2, SMARCA4, SMCHD1, SNRNP200, SON, SPEF2, SPEG, SPG11, SPTA1, SPTAN1, SPTB, SPTBN2, SPTBN4, SRCAP, STRC, SVIL, SYNE1, SYNGAP1, SYNJL SZT2. TAF1, TANC2, TCF20, TCOF1, TDRD9, TECPR2. TECTA, TENM3, TENM4, TET3, TEX14, TEX15. TG, THOC2. TMEM94, TNC. TNIK, TNR, TNRC6B, TNXB, TOGARAMI, TONSL, TRIO, TRIOBP, TRIP1 1 , TRIP12, TRPM1 , TRPM6, TRPM7, TRRAP, TSC2, TTC37, TTN, TUBGCP6, UBR1, UNC80, USH2A, USP9X, VCAN, VPS13A, VPS13B, VPS13C, VPS13D, VWF, WDFY3, WDR19, WDR62, WDR81, WNK1, WRN, ZFHX2, ZFYVE26. ZNF142, ZNF292, ZNF335. ZNF407, ZNF462, ZNF469. or a portion thereof.
[0183] In an aspect, a disclosed nucleic acid sequence can encode a gene or a portion thereof (e.g., a specific exon such as an exon having a mutation) with a gene product that is directly or indirectly linked to one or more genetic diseases. Such genes include but are not limited to the following:
dystrophin including mini- and micro-dystrophins (DMD); titin (TTN); titin cap (TCAP) a- sarcoglycan (SGCA), P-sarcoglycan (SGCB), y-sarcoglycan (SGCG) or 8-sarcoglycan (SGCD); alpha- 1 -antitrypsin (Al-AT); myosin heavy chain 6 (MYH6); myosin heavy chain 7 (MYH7); myosin heavy chain 11 (MYH11); myosin light chain 2 (ML2); myosin light chain 3 (ML3); myosin light chain kinase 2 (MYLK2); myosin binding protein C (MYBPC3); desmin (DES); dynamin 2 (DNM2); laminin a2 (LAMA2); lamin A/C (LMNA); lamin B (LMNB); lamin B receptor (LBR); dysferlin (DYSF); emerin (EMD); insulin; blood clotting factors, including but not limited to, factor VIII and factor IX; erythropoietin (EPO); lipoprotein lipase (LPL); sarcoplasmic reticulum Ca2++-ATPase (SERCA2A), S100 calcium binding protein Al (SI 00 Al); myotubularin (MTM); DM1 protein kinase (DMPK); glycogen phosphorylase L (PYGL); glycogen phosphorylase, muscle associated (PYGM); glycogen synthase 1 (GYS I); glycogen synthase 2 (GYS2); a-galactosidase A (GLA); a-N-acetylgalactosaminidase (NAGA); acid a-glucosidase (GAA), sphingomyelinase phosphodiesterase 1 (SMPD1); lysosomal acid lipase (LIPA); collagen type I al chain (COL1A1); collagen type I a2 chain (COL1 A2); collagen type III al chain (COL3A1); collagen type V al chain (COL5A1); collagen type V a2 chain (COL5A2); collagen type VI al chain (COL6A1); collagen type VI a2 chain (COL6A2); collagen type VI a3 chain (COL6A3); procollagen-lysine 2-oxoglutarate 5-dioxygenase (PLOD1); lysosomal acid lipase (LIPA); frataxin (FXN); myostatin (MSTN); P-N-acetyl hexosaminidase A (HEXA); P-N-acetylhexosaminidase B (HEXB); P-glucocerebrosidase (GBA); adenosine monophosphate deaminase 1 (AMPD1); P-globin (HBB); iduronidase (IDUA); iduronate 2- sulfate (IDS); troponin 1 (TNNI3); troponin T2 (TNNT2); troponin C (TNNC1); tropomyosin 1 (TPM1); tropomyosin 3 (TPM3); N-acetyl-a-glucosaminidase (NAGLU); N-sulfoglucosamine sulfohydrolase (SGSH); heparan-a-glucosaminide N-acetyltransferase (HGSNAT); integrin a 7 (IGTA7); integrin a 9 (IGTA9); glucosamine(N-acetyl)-6-sulfatase (GNS); galactosamine(N- acetyl)-6-sulfatase (GALNS); P-galactosidase (GLB1); P-glucuronidase (GUSB); hyaluronoglucosaminidase 1 (HYAL1); acid ceramidase (ASAHI); galactosylcermidase (GALC); cathepsin A (CTSA); cathepsin D (CTSA); cathepsin K (CTSK); GM2 ganglioside activator (GM2A); arylsulfatase A (ARSA); arylsulfatase B (ARSB); formylglycine-generating enzyme (SUMFI); neuraminidase 1 (NEU1); N-acetylglucosamine-1 -phosphate transferase a (GNPTA); N-acetylglucosamine-1 -phosphate transferase P (GNPTB); N-acetylglucosamine-l-phosphate transferase y (GNPTG); mucolipin-1 (MCOLN1); NPC intracellular transporter 1 (NPC1); NPC intracellular transporter 2 (NPC2); ceroid lipofuscinosis 5 (CLN5); ceroid lipofuscinosis 6 (CLN6); ceroid lipofuscinosis 8 (CLN8); palmitoyl protein thioesterase 1 (PPT1); tripeptidyl peptidase 1 (TPP1); battenin (CLN3); DNAJheat shock protein family 40 member C5 (DNAJC5); major facilitator superfamily domain containing 8 (MFSD8); mannosidase a class 2B member 1
(MAN2B 1); mannosidase R (MANBA); aspartylglucosaminidase (AGA); a-L-fucosidase (FUCA1); cystinosin, lysosomal cysteine transporter (CTNS); sialin; solute carrier family 2 member 10 (SLC2A10); solute carrier family 17 member 5 (SLC17A5); solute carrier family 6 member 19 (SLC6A19); solute carrier family 22 member 5 (SLC22A5); solute carrier family 37 member 4 (SLC37A4); lysosomal associated membrane protein 2 (LAMP2); sodium voltagegated channel a subunit 4 (SCN4A); sodium voltage-gated channel P subunit 4 (SCN4B); sodium voltage-gated channel a subunit 5 (SCN5A); sodium voltage-gated channel a subunit 4 (SCN4A); calcium voltage-gated channel subunit ale (CACNA1C); calcium voltage-gated channel subunit als (CACNA1S); phosphoglycerate kinase 1 (PGK1); phosphoglycerate mutase 2 (PGAM2); amylo-a-l,6-glucosidase,4-a-glucanotransferase (AGL); potassium voltage-gated channel ISK- related subfamily member 1 (KCNE1); potassium voltage-gated channel ISK-related subfamily member 2 (KCNE2); potassium voltage-gated channel subfamily J member 2 (KCNJ2); potassium voltage-gated channel subfamily J member 5 (KCNJ5); potassium voltage-gated channel subfamily H member 2 (KCNH2); potassium voltage-gated channel KQT-like subfamily member 1 (KCNQ1); hyperpolarization-activated cyclic nucleotide-gated potassium channel 4 (HCN4); chloride voltage-gated channel 1 (CLCN1); carnitine palmitoyltransferase 1A (CPT1A); ryanodine receptor 1 (RYR1); ryanodine receptor 2 (RYR2); bridging integrator 1 (BINI); LARGE xylosyl- and glucuronyltransferase 1 (LARGE1); docking protein 7 (D0K7); fukutin (FKTN); fukutin related protein (FKRP); selenoprotein N (SELENON); protein O- mannosyltransferase 1 (POMT1); protein O-mannosyltransferase 2 (POMT2); protein O-linked mannose N-acetylglucosaminyltransferase 1 (POMGNT1); protein O-linked mannose N- acetylglucosaminyltransferase 2 (POMGNT2); protein-O-mannose kinase (POMK); isoprenoid synthase domain containing (ISPD); plectin (PLEC); cholinergic receptor nicotinic epsilon subunit (CHRNE); choline O-acetyltransferase (CHAT); choline kinase |3 (CHKB); collagen like tail subunit of asymmetric acetylcholinesterase (COLQ); receptor associated protein of the synapse (RAPSN); four and a half LIM domains 1 (FHL1); [3- 1 A-glucuron l transferase 1 (B4GAT1); P-l,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2); dystroglycan 1 (DAGI); transmembrane protein 5 (TMEM5); transmembrane protein 43 (TMEM43); SECIS binding protein 2 (SECISBP2); glucosamine (UDP-N-acety l)-2-epimerase/N-acety lmannosamine kinase (GNE); anoctamin 5 (ANO5); structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1); lactate dehydrogenase A (LDHA); lactate dehydrogenase B (LHDB); calpain 3 (CAPN3); caveolin 3 (CAV3); tripartite motif containing 32 (TRIM32); CCHC-type zinc finger nucleic acid binding protein (CNBP); nebulin (NEB); actin, al, skeletal muscle (ACTA1); actin, al, cardiac muscle (ACTC1); actinin a2 (ACTN2); poly(A)-binding protein nuclear 1 (PABPN1); LEM domain-containing protein 3 (LEMD3); zinc metalloproteinase
STE24 (ZMPSTE24); microsomal triglyceride transfer protein (MTTP); cholinergic receptor nicotinic al subunit (CHRNA1); cholinergic receptor nicotinic a2 subunit (CHRNA2); cholinergic receptor nicotinic a3 subunit (CHRNA3); cholinergic receptor nicotinic a4 subunit (CEIRNA4); cholinergic receptor nicotinic a5 subunit (CHRNA5); cholinergic receptor nicotinic a6 subunit (CHRNA6); cholinergic receptor nicotinic a7 subunit (CHRN A7); cholinergic receptor nicotinic a8 subunit (CHRNA8); cholinergic receptor nicotinic a9 subunit (CHRNA9); cholinergic receptor nicotinic alO subunit (CHRNA10); cholinergic receptor nicotinic pi subunit (CHRNB1); cholinergic receptor nicotinic P2 subunit (CHRNB2); cholinergic receptor nicotinic P3 subunit (CHRNB3); cholinergic receptor nicotinic P4 subunit (CHRNB4); cholinergic receptor nicotinic y subunit (CHRNG1); cholinergic receptor nicotinic a subunit (CHRND); cholinergic receptor nicotinic E subunit (CHRNE1); ATP binding cassette subfamily A member 1 (ABCA1); ATP binding cassette subfamily C member 6 (ABCC6); ATP binding cassette subfamily C member 9 (ABCC9); ATP binding cassette subfamily D member 1 (ABCD1); ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 (ATP2A1); ATM serine/threonine kinase (ATM); a tocopherol transferase protein (TTP A); kinesin family member 21 A (KIF21A); paired-like homeobox 2a (PH0X2A); heparan sulfate proteoglycan 2 (HSPG2); stromal interaction molecule 1 (STIM1); notch 1 (NOTCHI); notch 3 (N0TCH3); dystrobrevin a (DTNA); protein kinase AMP-activated, noncatalytic y2 (PRKAG2); cysteine- and glycine-rich protein 3 (CSRP3); viniculin (VCL); myozenin 2 (MyoZ2); myopalladin (MYPN); junctophilin 2 (JPH2); phospholamban (PLN); calreticulin 3 (CALR3); nexilin F-actin-binding protein (NEXN); LIM domain binding 3 (LDB3); eyes absent 4 (EYA4); huntingtin (HTT); androgen receptor (AR); protein tyrosine phosphate non-receptor type 11 (PTPN11); junction plakoglobin (JUP); desmoplakin (DSP); plakophilin 2 (PKP2); desmoglein 2 (DSG2); desmocollin 2 (DSC2); catenin a3 (CTNNA3); NK2 homeobox 5 (NKX2-5); A-kinase anchor protein 9 (AKAP9); A-kinase anchor protein 10 (AKAP10); guanine nucleotide-binding protein a-inhibiting activity polypeptide 2 (GNAI2); ankyrin 2 (ANK2); syntrophin a-1 (SNTAT); calmodulin 1 (CALM1); calmodulin 2 (CALM2); HTRA serine peptidase 1 (HTRA1); fibrillin 1 (FBN1); fibrillin 2 (FBN2); xylosyltransferase 1 (XYLT1); xylosyltransferase 2 (XYLT2); tafazzin (TAZ); homogentisate 1 ,2-dioxygenase (HGD); glucose-6-phosphatase catalytic subunit (G6PC); 1,4- alpha-glucan enzyme 1 (GBE1); phosphofructokinase, muscle (PFKM); phosphorylase kinase regulatory subunit alpha 1 (PHKA1); phosphorylase kinase regulatory subunit alpha 2 (PHKA2); phosphorylase kinase regulator}' subunit beta (PHKB); phosphorylase kinase catalytic subunit gamma 2 (PHKG2); phosphoglycerate mutase 2 (PGAM2); cystathionine-beta-synthase (CBS); methylenetetrahydrofolate reductase (MTHFR); 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR); 5-methyltetrahydrofolate-homocysteine methyltransferase reductase
(MTRR); methylmalonic aciduria and homocystinuria, cblD type (MMADHC); mitochondrial DNA, including, but not limited to mitochondrially encoded NADH: ubiquinone oxidoreductase core subunit 1 (MT-ND1); mitochondrially encoded NADH: ubiquinone oxidoreductase core subunit 5 (MT-ND5); mitochondrially encoded tRNA glutamic acid (MT-TE); mitochondrially encoded tRNA histadine (MT-TH); mitochondrially encoded tRNA leucine 1 (MT-TL1); mitochondrially encoded tRNA lysine (MT-TK); mitochondrially encoded tRNA serine 1 (MT- TS1); mitochondrially encoded tRNA valine (MT-TV); mitogen-activated protein kinase 1 (MAP2K1); B-Raf proto-oncogene, serine/threonine kinase (BRAF); raf-1 proto-oncogene, serine/threonine kinase (RAFI); growth factors, including, but not limited to insulin growth factor 1 (IGF-1); transforming growth factor 03 (TGF03); transforming growth factor 0 receptor, type I (TGF0R1); transforming growth factor 0 receptor, type II (TGF0R2), fibroblast growth factor 2 (FGF2), fibroblast growth factor 4 (FGF4), vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B): vascular endothelial growth factor C (VEGF-C), vascular endothelial growth factor D (VEGF-D), vascular endothelial growth factor receptor 1 (VEGFR1), and vascular endothelial growth factor receptor 2 (VEGFR2), or any combination thereof.
[0184] In an aspect, a disclosed nucleic acid sequence can encode an RNA. In an aspect, a disclosed encoded RNA can comprise ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), micro RNA (miRNA), Piwd-interacting RNA (piRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), singe guide RNA (sgRNA), non-coding RNA (ncRNA), long non-coding RNA (IncRNA), 7SL, Xist, short enhancer RNA (eRNA), circular RNA, intergenic RNA, or any combination thereof. In an aspect, a disclosed encoded RNA can comprise IncRNA, siRNA, shRNA, sgRNA, circular RNA, snoRNA, miRNA, or any combination thereof. [0185] In an aspect, a disclosed encoded RNA can comprise a functional non-coding RNA element. In an aspect, a disclosed nucleic acid molecule can comprise the sequence for one or more regulatory elements. In an aspect, a disclosed regulatory element can be a promoter, an enhancer, an internal ribosomal entry site (IRES), or another expression control element (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Regulatory elements can include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). In an aspect, a disclosed promoter can be tissue-specific or ubiquitous and can be constitutive or inducible, depending on the pattern of the gene expression desired. A promoter can be native or foreign and can be a natural or a synthetic sequence. By foreign, it is intended that the transcriptional initiation region is not found
in the w ild-type host into which the transcriptional initiation region is introduced. In an aspect, a disclosed promoter can be a promoter/enhancer. In an aspect, a disclosed promoter can be an endogenous promoter. In an aspect, a disclosed endogenous promoter can be an endogenous promoter/enhancer. In an aspect, a disclosed endogenous promoter or a disclosed endogenous promoter/enhancer can generally be obtained from anon-coding region upstream of a transcription initiation site of a gene of interest. In an aspect, a disclosed endogenous promoter or a disclosed endogenous promoter/enhancer can be used for constitutive and efficient expression of a disclosed gene. In an aspect, a disclosed promoter can be a CMV promoter or a CMV promoter/enhancer. CMV promoters and CMV promoters/enhancers are well known to the art. In an aspect, a disclosed promoter can be any eukaryotic RNA polymerase II promoter.
[0186] In an aspect, a disclosed nucleic acid molecule can be in an expression cassette. Expression cassettes are know n to the art and can comprise a promoter sequence, an open reading frame (for the transgene of interest), and a 3’ UTR (typically containing a polyA in eukaryotes). [0187] In an aspect, a disclosed isolated nucleic acid molecule can restore one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation. In an aspect, a disclosed isolated nucleic acid molecule can restore the functionality and/or structural integrity7 of a missing, deficient, and/or mutant protein or enzy me.
[0188] In an aspect, upon expression, a disclosed isolated nucleic acid molecule can decrease and/or minimize the severity' of a rejection event of the one or more transplanted organs. In an aspect, upon expression, a disclosed isolated nucleic acid molecule can prevent the rejection of the one or more transplanted organs. In an aspect, a disclosed rejection event can be classified a hyperacute rejection event, an acute rejection event, or a chronic rejection event. In an aspect, upon expression, a disclosed isolated nucleic acid molecule, the one or more transplanted organs are not rejected by' the subject. In an aspect, upon expression, a disclosed isolated nucleic acid molecule, the viability7 of one or more transplanted organs can be improved and/or increased. In an aspect, upon expression, a disclosed isolated nucleic acid molecule, the functionality of one or more transplanted organs can be improved and/or increased. In an aspect, upon expression, a disclosed isolated nucleic acid molecule, the functionality of one or more transplanted organs is not decreased and/or diminished. In an aspect, a disclosed encoded recombinant enzyme can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
[0189] Disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzyme of SEQ ID NO: 119. Disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzyme of any7 one of SEQ ID NO: 120 - SEQ ID NO: 121. Disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzyme of any one of SEQ ID
NO: 122 - SEQ ID NO: 159. Disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzyme of SEQ ID NO: 119, which has IgG specific protease activity. Disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzy me of any one of SEQ ID NO: 120 - SEQ ID NO: 121, which has IgG specific protease activity’. Disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the recombinant enzyme of any one of SEQ ID NO: 122 - SEQ ID NO: 159, which has IgG specific protease activity7.
[0190] Disclosed herein is an isolated nucleic acid molecule encoding a recombinant enzyme comprising the nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a nucleic acid sequence encoding a recombinant enzyme and having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity7 to the nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a nucleic acid sequence encoding a recombinant enzyme having human and non-human primate IgG specific protease activity and having the nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a recombinant enzyme encoded by a nucleic acid sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity7 to the codon-optimized nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161 and having human and non-human primate IgG specific protease activity.
[0191] Disclosed herein is an expression cassette comprising a disclosed nucleic acid sequence. Disclosed herein is an expression cassette comprising an isolated nucleic acid molecule encoding any disclosed enzyme. Disclosed herein is an expression cassette comprising an isolated nucleic acid molecule encoding any disclosed recombinant enzyme. Disclosed herein is an expression cassette comprising an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92. Disclosed herein is an expression cassette comprising an isolated nucleic acid molecule comprising the sequence of SEQ ID NO: 160 or SEQ ID NO: 161.
3. Vectors
[0192] Disclosed herein is a vector comprising a disclosed isolated nucleic acid molecule. Disclosed herein is a vector comprising one or more disclosed isolated nucleic acid molecules. Disclosed herein is a vector comprising a disclosed isolated nucleic acid molecule have IgM specific protease activity7. Disclosed herein is a vector comprising a disclosed isolated nucleic acid molecule having IgM and IgG specific protease activity. Disclosed herein is a vector comprising a disclosed isolated nucleic acid molecule having IgM specific protease activity. Disclosed herein is a vector comprising a disclosed isolated nucleic acid molecule have IgM and IgG specific protease activity7. Disclosed herein is a vector comprising a nucleic acid sequence encoding the enzyme of any one of SEQ ID NO: 01 - SEQ ID NO: 46 or a fragment thereof.
Disclosed herein is a vector comprising a nucleic acid sequence encoding the recombinant enzyme of any one of SEQ ID NO:02, SEQ ID NO:03, SEQ ID NO:05, SEQ ID NO:06, SEQ ID NO:08, SEQ ID NO: 09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:21. SEQ ID NO:22, SEQ ID NO 23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29. SEQ ID NO:31, SEQ ID NO:32. SEQ ID NO:34, SEQ ID NO 35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO 41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, and SEQ ID NO:46. Disclosed herein is a vector comprising a nucleic acid sequence encoding the enzyme of any one of SEQ ID NO:01, SEQ ID NO:04, SEQ ID NO:07, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:39, and SEQ ID NO:42. Disclosed herein is a vector comprising a disclosed expression cassette.
[0193] Disclosed herein is a vector comprising a nucleic acid sequence comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92 or a fragment thereof. Disclosed herein is a vector comprising a nucleic acid sequence of any one of SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO 52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO 58, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:72. SEQ ID NO:74, SEQ ID NO 75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:81. SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:86, and SEQ ID NO:87. Disclosed herein is a vector comprising a nucleic acid sequence of any one of SEQ ID NO:01, SEQ ID NO:47, SEQ ID NO:50, SEQ ID NO:53, SEQ ID NO:56, SEQ ID NO:59, SEQ ID NO:62, SEQ ID NO:65, SEQ ID NO:70, SEQ ID NO 73, SEQ ID NO:76, SEQ ID NO:79, and SEQ ID NO:82.
[0194] Disclosed herein is a vector comprising a nucleic acid sequence comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92 or a fragment thereof. Disclosed herein is a vector comprising a nucleic acid sequence of any one of SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55. SEQ ID NO:57, SEQ ID NO 58, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:64. SEQ ID NO:66, SEQ ID NO:67. SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:71 , SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO 75, SEQ ID NO:77, SEQ ID NO : 78, SEQ ID NO : 80, SEQ ID NO : 81 , SEQ ID NO : 83, SEQ ID NO : 84, SEQ ID NO : 86, and SEQ ID NO:87. Disclosed herein is a vector comprising a nucleic acid sequence of any one of SEQ ID NO:01, SEQ ID NO:47. SEQ ID NO:50, SEQ ID NO:53, SEQ ID NO:56, SEQ ID NO:59, SEQ ID NO:62, SEQ ID NO:65, SEQ ID NO:70, SEQ ID NO:73, SEQ ID NO:76, SEQ ID NO:79, and SEQ ID NO:82.
[0195] Disclosed herein is a vector comprising a nucleic acid sequence encoding the recombinant enzyme of SEQ ID NO: 119. Disclosed herein is a vector comprising a nucleic acid sequence
encoding the recombinant enzyme of SEQ ID NO: 120 or SEQ ID NO: 121. Disclosed herein is a vector comprising a nucleic acid sequence encoding the recombinant enzyme of any one of SEQ ID NO: 122 - SEQ ID NO: 159. Disclosed herein is a vector comprising a nucleic acid sequence encoding the recombinant enzyme of SEQ ID NO: 119 or a fragment thereof. Disclosed herein is a vector comprising a nucleic acid sequence encoding the recombinant enzyme of SEQ ID NO: 120 or SEQ ID NO: 121 or a fragment thereof. Disclosed herein is a vector comprising a nucleic acid sequence encoding the recombinant enzyme of any one of SEQ ID NO: 122 - SEQ ID NO: 159 or a fragment thereof.
[0196] Disclosed herein is a vector comprising a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a vector comprising a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 160 or SEQ ID NO: 161 or a fragment thereof.
[0197] In an aspect, a disclosed vector can restore one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation. In an aspect, a disclosed vector can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
[0198] In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1010 vg/kg to about 2 x 1014 vg/kg. In an aspect, for example, a disclosed vector can be administered at a dose of about 1 x 1011 to about 8 x 1013 vg/kg or about 1 x 1012 to about 8 x 1013 vg/kg. In an aspect, a disclosed vector can be administered at a dose of about 1 x 1013 to about 6 x 1013 vg/kg. In an aspect, a disclosed vector can be administered at a dose of at least about 1 x 1010, at least about 5 x 1010. at least about 1 x 1011, at least about 5 x 1011, at least about 1 x 1012, at least about 5 x 1012, at least about 1 x 1013, at least about 5 x 1013, or at least about 1 x 1014 vg/kg. In an aspect, a disclosed vector can be administered at a dose of no more than about 1 x 1010, no more than about 5 x 1010, no more than about 1 x 1011, no more than about 5 x 1011, no more than about 1 x 1012, no more than about 5 x 1012, no more than about 1 x 1013. no more than about 5 x 1013, or no more than about 1 x 1014 vg/kg. In an aspect, a disclosed vector can be administered at a dose of about 1 x 1012 vg/kg. In an aspect, a disclosed vector can be administered at a dose of about 1 x 1011 vg/kg. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subject total to about 1 x 1017 vg per subject total. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subject total, about 1 x 1013 vg per subject total, about 1 x 1014 vg per subject total, about 1 x 1015 vg per subject total, about 1 x 1016 vg per subject total, or about 1 x 1017 vg per
subject total. In an aspect, a disclosed vector can be administered in a single dose, or in multiple doses (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses) as needed for the desired therapeutic results. In an aspect, a therapeutically effective amount of disclosed vector can comprise a range determined by a skilled person. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subj ect total to about 1 x 1017 vg per subject total. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subject total, about 1 x 1013 vg per subject total, about 1 x 1014 vg per subject total, about 1 x 1015 vg per subject total, about 1 x 1016 vg per subject total, or about 1 x 1017 vg per subject total.
[01 9] In an aspect, a disclosed nucleic acid sequence can have a coding sequence that is less than about 4.5 kilobases.
[0200] In an aspect, a disclosed vector can be a viral vector or a non-viral vector. In an aspect, a disclosed non-viral vector can be a polymer-based vector, a peptide-based vector, a lipid nanoparticle, a solid lipid nanoparticle, or a cationic lipid-based vector. In an aspect, a disclosed vector can comprise exosomes, extracellular vesicles, and virus like particles. In an aspect, a disclosed viral vector can be an adenovirus vector, an AAV vector, a herpes simplex virus vector, a retrovirus vector, a lentivirus vector, and alphavirus vector, a Flavivirus vector, a rhabdovirus vector, a measles virus vector, a Newcastle disease viral vector, a poxvirus vector, or a picomavirus vector.
[0201] In an aspect, a disclosed viral vector can be an adeno-associated virus (AAV) vector In an aspect, a disclosed AAV vector can include naturally isolated serotypes including, but not limited to, AAV1, AAV2, AAV3 (including 3a and 3b), AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV9, AAV10, AAVrhlO, AAV11, AAV12, AAV13, AAVrh39, AAVrh43, AAVcy.7 as well as bovine AAV, caprine AAV, canine AAV, equine AAV, ovine AAV, avian AAV, primate AAV, non-primate AAV, and any other virus classified by the International Committee on Taxonomy of Viruses (ICTV) as an AAV. In an aspect, an AAV capsid can be a chimera either created by capsid evolution or by rational capsid engineering from a naturally isolated AAV variants to capture desirable serotype features such as enhanced or specific tissue tropism and/or a host immune response escape. Naturally isolated AAV variants include, but not limited to, AAV-DJ, AAV-HAE1, AAV-HAE2, AAVM41, AAV- 1829. AAV2 Y/F, AAV2 T/V, AAV2i8, AAV2.5, AAV9.45, AAV9.61, AAV-B1, AAV-AS, AAV9.45A-Stnng (e.g., AAV9.45-AS), AAV9.45Angiopep, AAV9.47-Angiopep, and AAV9.47-AS, AAV-PHP.B, AAV-PHP.eB, AAV-PHP.S, AAV-F, AAVcc.47, and AAVcc.81. In an aspect, a disclosed AAV vector can be AAV-Rh74 or a related variant (e.g., capsid variants like RHM4-1). In an aspect, a disclosed
AAV vector can be AAV 8. In an aspect, a disclosed AAV vector can be AAVhum.8. In an aspect, a disclosed AAV vector can be a self-complementary AAV as disclosed herein.
[0202] In an aspect, a disclosed vector can comprise one or more promoters operably linked to a disclosed transgene and/or a disclosed nucleic acid sequence. In an aspect, a disclosed promoter can be positioned 5’ (upstream) or 3’ (downstream) of a disclosed transgene and/or a disclosed nucleic acid sequence under its control. As is known in the art, variation in this distance can be accommodated without loss of promoter function.
[0203] In an aspect, a disclosed vector can further comprise one or more regulatory elements. In an aspect, a disclosed "‘regulatory element" can refer to promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Regulatory elements are discussed infra and can include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences).
[0204] In an aspect, a disclosed promoter for the one or more disclosed isolated nucleic acid molecules can be tissue-specific or ubiquitous and can be constitutive or inducible, depending on the pattern of the gene expression desired. A promoter can be native or foreign and can be a natural or a synthetic sequence. By foreign, it is intended that the transcriptional initiation region is not found in the wild-type host into which the transcriptional initiation region is introduced. In an aspect, a disclosed promoter can be a promoter/enhancer. In an aspect, a disclosed promoter for the one or more disclosed isolated nucleic acid molecules can be an endogenous promoter. In an aspect, a disclosed endogenous promoter can be an endogenous promoter/enhancer. In an aspect, a disclosed endogenous promoter or a disclosed endogenous promoter/enhancer can generally be obtained from a non-coding region upstream of a transcription initiation site of a gene of interest. In an aspect, a disclosed endogenous promoter or a disclosed endogenous promoter/enhancer can be used for constitutive and efficient expression of a disclosed gene. In an aspect, a disclosed promoter for the one or more disclosed isolated nucleic acid molecules can be a CMV promoter or a CMV promoter/enhancer. CMV promoters and CMV promoters/enhancers are well known to the art. In an aspect, a disclosed promoter can be any eukaryotic RNA polymerase II promoter.
[0205] In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme having IgM specific protease activity. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave the IgM the heavy chain at the interdomain region betw een constant domains Cp2 and Cp3. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that
can cleave human IgM. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave non-human primate IgM. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzy me that does not cleave non-human IgM. For example, in an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that does not cleave dog IgM, pig IgM, and mouse IgM. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed IgM specific recombinant enzyme that does not cleave human IgA, IgD, IgE, IgG, or any combination thereof.
[0206] In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have a binding domain specific for IgM. In an aspect, a disclosed recombinant enzyme can cleave IgM between position 350 and position 365 of SEQ ID NO: 105. In an aspect, SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate). In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have a binding domain capable of specifically binding to one or more amino acid residues 355 through 360 of IgM. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have an affinity for human IgM. In an aspect, a disclosed IgM can be cleaved at SEQ ID NO: 110. In an aspect, a disclosed IgM can be cleaved at the sequence comprising 355D. 356T, 357A. 3581. 359R, and 360V. In an aspect, a disclosed IgM can be cleaved at position 355 through position 360 of SEQ ID NO: 105. [0207] In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have IgG and IgM specific protease activity. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3 and can cleave the IgG below the hinge region. In an aspect, a disclosed recombinant enzyme can cleave the IgG below the hinge region, thereby yielding F(ab’)2 and Fc fragments. In an aspect, a disclosed recombinant enzyme can cleave the IgG separating the Cp2 and Cp3 domains from the Cpl domain.
[0208] In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave human IgG and human IgM. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave non- human primate IgG and non-human primate IgM. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme having IgG and IgM protease activity' does not cleave IgA, IgD, IgE, or any combination thereof. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme having IgG and IgM protease activity does not cleave non-human IgM or non-human IgG. For example, in an
aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme having IgG and IgM protease activity that does not cleave dog IgM, pig IgM, and mouse IgM, or dog IgG, pig IgG, or mouse IgG.
[0209] In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have a binding domain capable of specifically binding to the sequence of SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO: 114, or any combination thereof. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can have a binding domain capable of specifically binding to the sequence of SEQ ID NO: 115. SEQ ID NO: 116, SEQ ID NO: 117. SEQ ID NO: 118, or any combination thereof. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave IgG at amino acid residues 109 through 124 of the IgG of SEQ ID NO: 106, residues 106 through 120 of the IgG of SEQ ID NO:107, residues 156 through 171 of the IgG of SEQ ID NO: 108, residues 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave IgG at amino acid residues 116 through 122 of the IgG of SEQ ID NO: 106, residues 112 through 118 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108, residues 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, a disclosed vector can comprise the nucleic acid sequence of a disclosed recombinant enzyme that can cleave one or more IgG molecules at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO:118, or any combination thereof.
[0210] In an aspect, a disclosed encoded recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in a subject. In an aspect, a disclosed recombinant enzyme can clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject. In an aspect, a disclosed recombinant enz me can cleave and/or degrade circulating IgM and/or IgM and IgG in a subject. In an aspect, a disclosed recombinant enzyme can transiently clear and/or remove IgM and/or IgM and IgG from circulation in the sera of a subject, or can transiently cleave and/or degrade circulating IgM and/or IgM and IgG in a subject. In an aspect, a disclosed recombinant enzyme can reduce and/or diminish the level of circulating IgM and/or IgM and IgG levels in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgM and IgG levels in a subject. In aspect, a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
[0211] In an aspect, a disclosed vector can block and/or minimize activation of the complement cascade. In an aspect, a disclosed vector can block and/or minimize activation of the formation of the C 1 complex and/or C3 complex. In an aspect, a disclosed vector can block and/or minimize activation of the classical complement pathway. In an aspect, a disclosed vector can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof. [0212] In an aspect, a disclosed vector can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells. In an aspect, the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient. In an aspect, a disclosed vector can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells. In an aspect, a disclosed vector can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
[0213] In an aspect, a disclosed vector can decrease and/or minimize the severity of a rejection event of the one or more transplanted organs. In an aspect a disclosed vector can prevent the rejection of the one or more transplanted organs. In an aspect, a disclosed rejection event can be classified a hyperacute rejection event, an acute rejection event, or a chronic rejection event. In an aspect, following the administration and/or delivery of a disclosed vector, the one or more transplanted organs are not rejected by the subject. In an aspect, following the administration and/or delivery of a disclosed vector, the viability of one or more transplanted organs can be improved and/or increased. In an aspect, following the administration and/or delivery of a disclosed vector, the functionality of one or more transplanted organs can be improved and/or increased. In an aspect, following the administration and/or delivery of a disclosed vector, the functionality7 of one or more transplanted organs is not decreased and/or diminished. In an aspect, a disclosed recombinant enzyme can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
[0214] In an aspect, a disclosed vector can reduce and/or minimize vector mediated immunotoxicity7 in a subject. In an aspect, a disclosed vector can reduce and/or minimize transgene immunogenicity in a subject.
[0215] In an aspect, a disclosed vector can be used to modulate humoral immunity in a subject. In an aspect, modulating humoral immunity in a subject can be an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject’s humoral immunity7.
[0216] In an aspect, a disclosed vector can enable and/or allow vector re-dosing in a subject. In an aspect, a disclosed aspect, a disclosed vector can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, a disclosed vector can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, a disclosed vector can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed vectors). In an aspect, the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed vectors). In an aspect, an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed vectors). In an aspect, an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wild-type or control level.
4. Pharmaceutical Formulations
[0217] Disclosed herein is a pharmaceutical formulation comprising a disclosed enzyme. Disclosed herein is a pharmaceutical formulation comprising a disclosed enzyme and one or more pharmaceutically acceptable carriers and/or excipients. Disclosed herein is a pharmaceutical formulation comprising a disclosed recombinant enzyme. Disclosed herein is a pharmaceutical formulation comprising a disclosed recombinant enzyme and one or more pharmaceutically acceptable carriers and/or excipients. Disclosed herein is a pharmaceutical formulation comprising a disclosed vector. Disclosed herein is a pharmaceutical formulation comprising a disclosed vector and one or more pharmaceutically acceptable carriers and/or excipients. Disclosed herein is a pharmaceutical formulation comprising an enzyme having IgM specific protease activity. Disclosed herein is a pharmaceutical formulation comprising an enzyme having IgG specific protease activity. Disclosed herein is a pharmaceutical formulation comprising an enzyme having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a pharmaceutical formulation comprising a recombinant enz me having IgM specific protease activity7. Disclosed herein is a pharmaceutical formulation comprising a recombinant enzyme having IgG specific protease activity. Disclosed herein is a pharmaceutical formulation comprising a recombinant enz me having IgM specific protease activity and IgG specific protease
activity. Disclosed herein is a pharmaceutical formulation comprising a fusion protein having IgM specific protease activity and IgG specific protease activity. Disclosed herein is a pharmaceutical formulation comprising an enzy me comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46. Disclosed herein is a pharmaceutical formulation comprising an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and having IgM specific protease activity and/or IgG specific protease activity.
[0218] Disclosed herein is a pharmaceutical formulation comprising a disclosed recombinant enzyme having human or non-human primate IgM specific protease activity and a disclosed recombinant enzyme having human or non-human primate IgG specific protease activity. Disclosed herein is a pharmaceutical formulation comprising the recombinant enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and the recombinant enzyme comprising the sequence of SEQ ID NO: 119. Disclosed herein is a pharmaceutical formulation comprising the recombinant enzyme comprising the sequence of any one of SEQ ID NO: 01 - SEQ ID NO:46 and the recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. Disclosed herein is a pharmaceutical formulation comprising the recombinant enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and the recombinant enzy me comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159. [0219] Disclosed herein is a pharmaceutical formulation comprising a recombinant enzyme comprising the sequence of SEQ ID NO: 119. Disclosed herein is a pharmaceutical formulation comprising a recombinant enzy me comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. Disclosed herein is a pharmaceutical formulation comprising a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159. Disclosed herein is a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 119. Disclosed herein is a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. Disclosed herein is a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159. Disclosed herein is a pharmaceutical formulation comprising a recombinant enzyme comprising the sequence of SEQ ID NO: 119 and having human and non-human primate IgG specific protease activity. Disclosed herein is a pharmaceutical formulation comprising a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121 and having human and non- human primate IgG specific protease activity. Disclosed herein is a pharmaceutical formulation
comprising a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159 and having human and non-human primate IgG specific protease activity. Disclosed herein is a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 119 and having human and non-human primate IgG specific protease activity. Disclosed herein is a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121 and having human and non-human primate IgG specific protease activity. Disclosed herein is a pharmaceutical formulation comprising a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159 and having human and non-human primate IgG specific protease activity.
[0220] Disclosed herein is a pharmaceutical formulation comprising a disclosed isolated nucleic acid molecule. Disclosed herein is a pharmaceutical formulation comprising a disclosed isolated nucleic acid molecule and one or more pharmaceutically acceptable carriers and/or excipients. Disclosed herein is a pharmaceutical formulation comprising an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92. Disclosed herein is a pharmaceutical formulation comprising an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92 and one or more pharmaceutically acceptable carriers and/or excipients. Disclosed herein is a pharmaceutical formulation comprising an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a pharmaceutical formulation comprising an isolated nucleic acid molecule comprising the sequence of SEQ ID NO: 160 or SEQ ID NO: 161 and one or more pharmaceutically acceptable carriers and/or excipients.
[0221] In an aspect, a disclosed pharmaceutical formulation can restore one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation. In an aspect, a disclosed pharmaceutical formulation can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
[0222] In an aspect, a disclosed pharmaceutical formulation can have IgM specific protease activity. In an aspect, a disclosed pharmaceutical formulation can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3. In an aspect, a disclosed recombinant enzyme can cleave human IgM. In an aspect, a disclosed pharmaceutical formulation can cleave non-human primate IgM. In an aspect, a disclosed pharmaceutical formulation does not cleave non-human IgM. For example, in an aspect, a disclosed pharmaceutical formulation
does not cleave dog IgM, pig IgM, and mouse IgM. In an aspect, a disclosed IgM specific pharmaceutical formulation does not cleave human IgA, IgD, IgE, IgG, or any combination thereof.
[0223] In an aspect, a disclosed pharmaceutical formulation can have a binding domain specific for IgM. In an aspect, a disclosed pharmaceutical formulation can cleave IgM between position 350 and position 365 of SEQ ID NO: 105. In an aspect, SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate). In an aspect, a disclosed pharmaceutical formulation can have a binding domain capable of specifically binding to one or more amino acid residues 355 through 360 of IgM. In an aspect, a disclosed pharmaceutical formulation can have an affinity for human IgM. In an aspect, a disclosed IgM can be cleaved at SEQ ID NO: 110. In an aspect, a disclosed IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, a disclosed IgM can be cleaved at position 355 through position 360 of SEQ ID NO: 105.
[0224] In an aspect, a disclosed pharmaceutical formulation can have IgG and IgM specific protease activity. In an aspect, a disclosed pharmaceutical formulation can cleave the IgM the heavy chain at the interdomain region between constant domains Cp2 and Cp3 and can cleave the IgG below the hinge region. In an aspect, a disclosed pharmaceutical formulation can cleave the IgG below the hinge region, thereby yielding Ffab'E and Fc fragments. In an aspect, a disclosed pharmaceutical formulation can cleave the IgG separating the Cp2 and Cp3 domains from the Cpl domain.
[0225] In an aspect, a disclosed pharmaceutical formulation can cleave human IgG and human IgM. In an aspect, a disclosed pharmaceutical formulation e can cleave non-human primate IgG and non-human primate IgM. In an aspect, a disclosed pharmaceutical formulation having IgG and IgM protease activity does not cleave IgA, IgD, IgE, or any combination thereof. In an aspect, a disclosed pharmaceutical formulation having IgG and IgM protease activity does not cleave non- human IgM or non-human IgG. For example, in an aspect, a disclosed pharmaceutical formulation having IgG and IgM protease activity does not cleave dog IgM. pig IgM. and mouse IgM, or dog IgG, pig IgG, or mouse IgG.
[0226] In an aspect, a disclosed pharmaceutical formulation can have a binding domain capable of specifically binding to the sequence of SEQ ID NO:111, SEQ ID NO: 112, SEQ ID NO:113, SEQ ID NO: 114. or any combination thereof. In an aspect, disclosed pharmaceutical formulation can have a binding domain capable of specifically binding to the sequence of SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof. In an aspect, disclosed pharmaceutical formulation can cleave IgG at amino acid residues 109 through 124 of the IgG of SEQ ID NO: 106, residues 106 through 120 of the IgG of SEQ ID NO: 107, residues
156 through 171 of the IgG of SEQ ID NO: 108, residues 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, a disclosed pharmaceutical formulation can cleave IgG at amino acid residues 116 through 122 of the IgG of SEQ ID NO:106, residues 112 through 119 of the IgG of SEQ ID NO: 107, residues 163 through 169 of the IgG of SEQ ID NO: 108, residues 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, a disclosed pharmaceutical formulation can cleave one or more IgG molecules at SEQ ID NO:115, SEQ ID NO: 116, SEQ ID NO:117, SEQ ID NO:118, or any combination thereof.
[0227] In an aspect, a disclosed pharmaceutical formulation can clear and/or remove IgM and/or IgG and IgM from circulation in a subject. In an aspect, a disclosed recombinant enzyme can cleave and/or degrade circulating IgM and/or IgG and IgM in a subject. In an aspect, disclosed pharmaceutical formulation can transiently clear and/or remove IgM and/or IgG and IgM from circulation in a subject, or can transiently cleave and/or degrade circulating IgM and/or IgG and IgM in a subject. In an aspect, disclosed pharmaceutical formulation can reduce and/or diminish the level of circulating IgM and/or IgG and IgM levels in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM levels in a subject. In aspect, a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
[0228] In an aspect, a disclosed pharmaceutical formulation can block and/or minimize activation of the complement cascade. In an aspect, a disclosed pharmaceutical formulation can block and/or minimize activation of the formation of the Cl complex and/or C3 complex. In an aspect, a disclosed pharmaceutical formulation can block and/or minimize activation of the classical complement pathway. In an aspect, a disclosed pharmaceutical formulation can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
[0229] In an aspect, a disclosed pharmaceutical formulation can remove and/or cleave surfacebound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells. In an aspect, the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient. In an aspect, a disclosed pharmaceutical formulation can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells. In an aspect, a disclosed pharmaceutical formulation me can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
[0230] In an aspect, a disclosed pharmaceutical formulation can reduce and/or minimize vector mediated immunotoxicity in a subject. In an aspect, a disclosed pharmaceutical formulation can enable and/or allow vector re-dosing in a subject.
[0231] In an aspect, a disclosed pharmaceutical formulation can reduce and/or minimize transgene immunogenicity in a subject. In an aspect, a disclosed pharmaceutical formulation can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed pharmaceutical formulations). In an aspect, the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed pharmaceutical formulations). In an aspect, an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed pharmaceutical formulations). In an aspect, an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wild-type or control level.
[0232] In an aspect, a disclosed pharmaceutical formulation can comprise (i) one or more active agents, (ii) biologically active agents, (iii) one or more pharmaceutically active agents, (iv) one or more immune-based therapeutic agents, (v) one or more clinically approved agents, or (vi) a combination thereof. In an aspect, a disclosed composition can comprise one or more immune modulators. In an aspect, a disclosed composition can comprise one or more proteasome inhibitors. In an aspect, a disclosed composition can comprise one or more immunosuppressives or immunosuppressive agents. In an aspect, an immunosuppressive agent can be anti-thymocyte globulin (ATG), cyclosporine (CSP), mycophenolate mofetil (MMF), or a combination thereof. In an aspect, a disclosed formulation can comprise an anaplerotic agent (such as, for example, C7 compounds like triheptanoin or MCT).
[0233] In an aspect, a pharmaceutical formulation can decrease and/or minimize the severity of a rejection event of the one or more transplanted organs. In an aspect, a pharmaceutical formulation can prevent the rejection of the one or more transplanted organs. In an aspect, a disclosed rejection event can be classified a hyperacute rejection event, an acute rejection event, or a chronic rejection event. In an aspect, following administration of a disclosed pharmaceutical formulation, a
disclosed isolated nucleic acid molecule, the one or more transplanted organs are not rejected by the subject. In an aspect, following administration of a disclosed pharmaceutical formulation, the viability of one or more transplanted organs can be improved and/or increased. In an aspect, following administration of a disclosed pharmaceutical formulation, the functionality of one or more transplanted organs can be improved and/or increased. In an aspect, following administration of a disclosed pharmaceutical formulation, the functionality of one or more transplanted organs is not decreased and/or diminished. In an aspect, a disclosed pharmaceutical formulation can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs. In an aspect, any disclosed pharmaceutical formulation can comprise one or more excipients and/or pharmaceutically acceptable carriers. Excipients and/or pharmaceutically acceptable carriers are known to the art and are discussed supra.
[0234] In an aspect of a disclosed pharmaceutical formulation, a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg body weight to about 100 mg/kg body weight. In an aspect, a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
5. Plasmids
[0235] Disclosed herein is a plasmid comprising one or more disclosed isolated nucleic acid molecules. Disclosed herein is a plasmid comprising one or more disclosed vectors. Disclosed here are plasmids used in methods of making a disclosed composition such as, for example, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. Plasmids and using plasmids are known to the art.
[0236] Disclosed herein is a plasmid comprising the sequence set forth in any one of SEQ ID NO:93 or a fragment thereof. Disclosed herein is a plasmid comprising a sequence having at least 40%, 50%, 60%, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to the sequence set forth in SEQ ID NO:93 or a fragment thereof. Disclosed herein is a plasmid comprising a sequence having at least 40%-60%, at least 60%-80%, at least 80%-90%, or at least 90%-100% identity to the sequence set forth in SEQ ID NO:93 or a fragment thereof.
[0237] Disclosed herein is a plasmid comprising a nucleic acid sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO: 92. Disclosed herein is a plasmid comprising a nucleic acid
molecule that, upon expression, can generate an enzyme comprising the sequence of any one of SEQ ID NO: 01 - SEQ ID NO: 46. Disclosed herein is a plasmid comprising a nucleic acid sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a plasmid comprising a nucleic acid molecule that, upon expression, can generate an enzyme comprising the sequence of any one of SEQ ID NO: 119 - SEQ ID NO: 121.
6. Cells
[0238] Disclosed herein are cells comprising a disclosed isolated nucleic acid molecule, a disclosed vector, and/or a disclosed plasmid. Disclosed herein are cells transduced by one or more disclosed viral vectors. Disclosed herein are cells transduced by one or more disclosed recombinant viral vectors. Disclosed herein are cells transfected with one or more disclosed isolated nucleic acid molecules. In an aspect, a disclosed cell has been transfected or disclosed cells have been transfected with one or more nucleic acid sequences having the sequence set forth in SEQ ID NO 93.
[0239] Disclosed herein are cells that have been transfected by a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO: 92. Disclosed herein are cells that generate a disclosed enzyme or a disclosed recombinant enzyme for harvesting and purification. Disclosed herein are cells that generate an enzyme comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 for harvesting and purification. Disclosed herein are cells that, upon expression of the nucleic acid molecule comprising the sequence of any one of SEQ ID NO:47 - SEQ ID NO:92, can generate an enzyme comprising the sequence of any one of SEQ ID NO: 01 - SEQ ID NO:46 for harvesting and purification.
[0240] Disclosed herein are cells that have been transfected by a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein are cells that generate a disclosed enzyme or a disclosed recombinant enz me for harvesting and purification. Disclosed herein are cells that generate an enzy me comprising the sequence of any one of SEQ ID NO: 119 - SEQ ID NO: 121 for harvesting and purification. Disclosed herein are cells that generate an enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159 for harvesting and purification. Disclosed herein are cells that, upon expression of the nucleic acid molecule comprising the sequence of SEQ ID NO:160 or SEQ ID NO: 161, can generate an enzyme comprising the sequence of SEQ ID NO: 119 for harvesting and purification.
[0241] In an aspect, a disclosed cell or disclosed cells can be humanized. Techniques to achieve transfection and transduction are known to the art and using transfected or transduced cells are known to the art. In an aspect, disclosed herein are human immortalized cells lines transduced by one or more disclosed viral vectors or transfected with one or more disclosed isolated nucleic acids or disclosed plasmids. In an aspect, disclosed herein are human immortalized cells lines
contacted with one or more disclosed pharmaceutical formulations. Disclosed herein are cells obtained for a subject treated with one or more disclosed isolated nucleic acid molecule, one or more disclosed vectors, one or more disclosed plasmids, or one or more disclosed pharmaceutical formulations.
7. Animals
[0242] Disclosed herein are animals treated with one or more disclosed enzymes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, and/or one or more disclosed plasmids. Transgenic animals are known to the art as are the techniques to generate transgenic animals.
C. Methods of Cleaving IgM and/or IgG
[0243] Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with one or more disclosed enzymes or disclosed recombinant enzymes. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid molecules. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with one or more disclosed vectors. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with one or more disclosed pharmaceutical formulations. [0244] Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in any one of SEQ ID NO:24 - SEQ ID NO:38. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with an enzy me comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method
comprising contacting one or more IgM molecules with an enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15.
[0245] Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in any one of SEQ ID NO:70 - SEQ ID NO:84. Disclosed herein is a method of cleaving immunoglobulin M (IgM). the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO:48 or SEQ ID NO:49. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO:51 or SEQ ID NO:52. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO:54 or SEQ ID NO:55. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58. Disclosed herein is a method of cleaving immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO: 60 or SEQ ID NO:61.
[0246] Disclosed herein is a method of cleaving immunoglobulin G (IgG), the method comprising contacting one or more IgG molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO: 160 - SEQ ID NO: 161. Disclosed herein is a method of cleaving immunoglobulin G (IgG), the method comprising contacting one or more IgG molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a method of cleaving immunoglobulin G (IgG), the method comprising contacting one or more IgG molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a method of cleaving immunoglobulin G (IgG), the method comprising contacting one or more IgG molecules with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a method of cleaving immunoglobulin G (IgG), the method comprising contacting one or more IgG molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a method of cleaving immunoglobulin G (IgG),
the method comprising contacting one or more IgG molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161. Disclosed herein is a method of cleaving immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
[0247] Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed enzymes or disclosed recombinant enzy mes. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed nucleic acid molecules. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed vectors. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed pharmaceutical formulations. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with an enzy me comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with an enzy me comprising the sequence set forth in any one of SEQ ID NO: 39 - SEQ ID NO:46. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with an enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with an enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with an enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising
contacting one or more IgM molecules and IgG molecules with an enzyme comprising the sequence set forth in any one of SEQ ID NO: 119 - SEQ ID NO: 121.
[0248] Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:62 - SEQ ID NO:69. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO: 85 - SEQ ID NO:92. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:63 or SEQ ID NO:64. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:66 or SEQ ID NO:67. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:68 or SEQ ID NO:69. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 86 or SEQ ID NO: 87. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 89 or SEQ ID NQ:90. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:91 or SEQ ID NO:92.
[0249] In an aspect, the IgM molecule and/or the IgG molecule that is cleaved can be in the sera of a subject. In an aspect, the IgM molecule and/or the IgG molecule that is cleaved can be circulating in a subject. In an aspect, a disclosed IgM molecule and/or the IgG molecule can be neutralizing against an exogenously administered protein. In an aspect, a disclosed IgM molecule and/or the IgG molecule can be neutralizing against enzyme replacement therapy or protein replacement therapy or recombinant product. In an aspect, a disclosed IgM molecule and/or the IgG molecule can be neutralizing against a non-viral vector or a viral vector. In an aspect, a disclosed IgM molecule and/or the IgG molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector. For example, in an aspect, a disclosed IgM molecule
and/or a disclosed IgG molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein).
[0250] In an aspect, a disclosed method can further comprise diagnosing a subject as being in need of one or more disclosed enzymes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0251] In an aspect of a disclosed method, there is at least a 10% reduction, at least a 20% reduction, at least a 30% reduction, at least a 40% reduction, at least a 50% reduction, at least a 60% reduction, at least a 70% reduction, at least an 80% reduction, at least a 90% reduction, or at least a 99% reduction in the level of circulating intact IgM and/or intact IgG.
[0252] In an aspect, a disclosed IgM molecule and/or the IgG molecule can be neutralizing against one or more transplanted organs. In an aspect, a disclosed method can decrease and/or can minimize the severity’ of a rejection event of the one or more transplanted organs. In an aspect, a disclosed method can prevent the rejection of the one or more transplanted organs. In an aspect, a disclosed rejection event can be classified ahyperacute rejection event, an acute rejection event, or a chronic rejection event. In an aspect, a disclosed method can reduce the risk of rejection of the one or more transplanted organs. In an aspect, a disclosed method can reduce or diminish the subject's need for long-term immunosuppression. In an aspect, a disclosed method can improve and/or increase the viability of one or more transplanted organs. In an aspect, a disclosed method can improve and/or increase the functionality of one or more transplanted organs. In an aspect, a disclosed method does not decrease and/or diminish the functionality of one or more transplanted organs. In an aspect, a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
[0253] In an aspect, a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800). In an aspect, a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof. In an aspect, after the contacting step, a disclosed HSAT can be reduced and/or eliminated. In an aspect, after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed. In an aspect, after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed with one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one
or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
[0254] In an aspect, a disclosed method can comprise modifying one or more of the disclosed steps. For example, modifying one or more of steps of a disclosed method can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method. For example, in an aspect, a method can be altered by changing the amount of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof administered to a subj ect. or by changing the frequency of administration of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof to a subject, or by changing the duration of time one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof are administered to a subject.
[0255] In an aspect, a disclosed method can further comprise measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
[0256] In an aspect, a disclosed method of cleaving IgM and/or IgG can clear and/or remove IgM and/or IgG from circulation in a subject. In an aspect, a disclosed method of cleaving IgM and/or IgG can leave and/or degrade circulating IgM and/or IgG in a subject. In an aspect, a disclosed method can transiently clear and/or remove IgM and/or IgG from circulation in a subject, or can transiently cleave and/or degrade circulating IgM and/or IgG in a subject. In an aspect, a disclosed method of cleaving IgM and/or IgG can reduce and/or diminish the level of circulating IgM and/or IgG levels in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG levels in a subject. In aspect, a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
[0257] In an aspect, a disclosed method of cleaving IgM and/or IgG can block and/or minimize activation of the complement cascade. In an aspect, a disclosed method of cleaving IgM and/or IgG can block and/or minimize activation of the formation of the Cl complex and/or C3 complex. In an aspect, a disclosed method of cleaving IgM and/or IgG can block and/or minimize activation of the classical complement pathway. In an aspect, a disclosed method can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize
activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
[0258] In an aspect, a disclosed method of cleaving IgM and/or IgG can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells. [0259] In an aspect, the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient. In an aspect, a disclosed method of cleaving IgM and/or IgG can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells. In an aspect, a disclosed method can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
[0260] In an aspect, a disclosed method of cleaving IgM and/or IgG can reduce and/or minimize vector mediated immunotoxicity in a subject. In an aspect, a disclosed method of cleaving IgM and/or IgG can enable and/or allow vector re-dosing in a subject.
[0261] In an aspect, a disclosed method of cleaving IgM and/or IgG can modulate humoral immunity in a subject. In an aspect, modulating humoral immunity in a subject can be an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject's humoral immunity.
[0262] In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy. In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein. In an aspect of a disclosed method, the intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
[0263] In an aspect, a disclosed method of cleaving IgM and/or IgG can reduce and/or minimize transgene immunogenicity in a subject. In an aspect, a disclosed method of cleaving IgM and/or IgG can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%. 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level
such as a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wildtype or control level.
[0264] In an aspect of a disclosed method, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered prior to, concurrent, or after the delivery and/or administration of enz me replacement therapy, protein replacement, gene therapy, a recombinant product, or any combination thereof.
[0265] In an aspect, a disclosed method of cleaving IgM and/or IgG can further comprise reducing and/or minimizing vector-mediated immunotoxicity and/or transgene immunogenicity (e.g., the ability to induce specific immunity). In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the efficacy of the recombinant product encoded by the transgene. In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof. In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with gene therapy, enzyme replacement therapy, protein replacement, recombinant product, or any combination thereof.
[0266] In an aspect of a disclosed method of cleaving IgM and/or IgG, IgM can be cleaved in the heavy chain at the interdomain region between constant domains Cp2 and Cp3. In an aspect, IgM can be cleaved between position 350 and position 365 of SEQ ID NO: 105. In an aspect, SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate). In an aspect, IgM can be cleaved between positions 355 through 360 of IgM. In an aspect, IgM can be cleaved at SEQ ID NO: 110. In an aspect, IgM can be cleaved at the sequence comprising 355D, 356T,
357 A, 3581, 359R, and 360V. In an aspect IgM can be cleaved at position 355 through position 360 of the IgM of SEQ ID NO: 105. In an aspect, IgG can be cleaved below the hinge region, thereby yielding F(ab’)2 and Fc fragments. In an aspect, IgG can be cleaved to separate the Cu2 and Cp3 domains from the Cpl domain. In an aspect, IgG can be cleaved at SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 1 13, SEQ ID NO: 114. or any combination thereof. In an aspect, IgG can be cleaved at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 1 17, SEQ ID NO: 118, or any combination thereof. In an aspect, IgG can be cleaved at positions 109 through 124 of the IgG of SEQ ID NO: 106, positions 106 through 120 of the IgG of SEQ ID NO: 107, positions 156 through 171 ofthe lgG of SEQ ID NO: 108, positions 106 through 121 of lgG of SEQ ID NO: 109, or any combination thereof. In an aspect, IgG can be cleaved at positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107, positions 163 through 169 of the IgG of SEQ ID NO: 108, positions 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, IgG can be cleaved SEQ ID NO: 115. SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
[0267] Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed recombinant enzymes having IgG specific protease activity.
[0268] Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
[0269] Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 11 or SEQ ID NO: 12 and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 11 or SEQ ID NO: 12 and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 1 19. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 14 or SEQ ID NO: 15 and one or more disclosed
recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159. Disclosed herein is a method of cleaving immunoglobulin M (IgM) and immunoglobulin G (IgG), the method comprising contacting one or more IgM molecules and IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 14 or SEQ ID NO: 15 and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO:119.
[0270] In an aspect, a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 119. In an aspect, a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect, a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159. In an aspect, a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 119. In an aspect, a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect, a disclosed method of cleaving IgM and/or IgG can further comprise contacting one or more IgM molecules and IgG molecules with a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159. [0271] In an aspect, a disclosed method can further comprise administering one or more times one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0272] In an aspect, a disclosed method can further comprise measuring and/or determining a subject’s pre-treatment level of circulating IgG and/or IgM and/or a subject’s pre-treatment level of surface bound IgM. In an aspect, a disclosed method can further comprise measuring and/or determining one or more times a subject’s level of circulating IgG and/or IgM and/or a subject’s level of surface bound IgM (e.g., before, during, and after a disclosed administering step).
[0273] In an aspect, a disclosed method can be performed using a singular disclosed enzyme having both IgG and IgM specific protease activity. In an aspect, a disclosed method can be
performed using a disclosed enzyme having IgG specific protease activity and a disclosed enzyme having IgM specific protease activity.
D. Methods of Cleaving Surface Bound IgM
[0274] Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed enzymes or disclosed recombinant enzymes. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid molecules. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed vectors. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed pharmaceutical formulations. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in any one of SEQ ID NO:24 - SEQ ID NO:38. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15.
[0275] Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid molecules comprising the sequence set forth in any one of SEQ ID
NO:47 - SEQ ID N0:61. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid molecules comprising the sequence set forth in any one of SEQ ID NO:70 - SEQ ID NO: 84.
[0276] Disclosed herein is a method of cleaving bound immunoglobulin M (IgM). the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO:48 or SEQ ID NO:49. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid molecules comprising the sequence set forth in SEQ ID NO:51 or SEQ ID NO:52. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO:54 or SEQ ID NO:55. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with one or more disclosed nucleic acid comprising the sequence set forth in SEQ ID NO:60 or SEQ ID NO:61.
[0277] Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO:18. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM). the method comprising contacting one
or more IgM molecules bound to the surface of B cells with an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46.
[0278] Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:62- SEQ ID NO:69. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:85 - SEQ ID NO:92. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM). the method comprising contacting one or more IgM molecules bound to the surface of B cells with anucleic acid molecule comprising the sequence set forth in SEQ ID NO:63 or SEQ ID NO:64. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:66 or SEQ ID NO:67. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells w ith a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:68 or SEQ ID NO:69. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM). the method comprising contacting one or more IgM molecules bound to the surface of B cells with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:86 or SEQ ID NO:87. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 89 or SEQ ID NQ:90. Disclosed herein is a method of cleaving bound immunoglobulin M (IgM), the method comprising contacting one or more IgM molecules bound to the surface of B cells with a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:91 or SEQ ID NO:92.
[0279] In an aspect, disclosed B cells can be in the sera of a subject. In an aspect, disclosed B cells can be circulating in a subject.
[0280] In an aspect, a disclosed surface-bound IgM molecule can be neutralizing against an exogenously administered protein. In an aspect, a disclosed surface-bound IgM molecule can be neutralizing against enzy me replacement therapy or protein replacement therapy or recombinant product. In an aspect, a disclosed surface-bound IgM molecule can be neutralizing against a non- viral vector or a viral vector. In an aspect, a disclosed surface-bound IgM molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector. For example, in an aspect, a disclosed surface-bound IgM molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein).
[0281] In an aspect, a disclosed method can further comprise diagnosing a subject as being in need of one or more disclosed enzymes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0282] In an aspect of a disclosed method, there is at least a 10% reduction, at least a 20% reduction, at least a 30% reduction, at least a 40% reduction, at least a 50% reduction, at least a 60% reduction, at least a 70% reduction, at least an 80% reduction, at least a 90% reduction, or at least a 99% reduction in the level of circulating intact IgM and/or intact IgG.
[0283] In an aspect, a disclosed surface-bound IgM molecule can be neutralizing against one or more transplanted organs. In an aspect, a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
[0284] In an aspect, a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800). In an aspect, a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof. In an aspect, after the contacting step, a disclosed HSAT can be reduced and/or eliminated. In an aspect, after the reduction and/or elimination of one or more HS ATs, a subject can be re-dosed. In an aspect, after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed with one or more exogenously administered proteins or enzy mes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
[0285] In an aspect, a disclosed method can further comprise measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
[0286] In an aspect, a disclosed method of cleaving surface-bound IgM can clear and/or remove IgM from circulation in a subject. In an aspect, a disclosed method of cleaving surface-bound IgM can cleave and/or degrade circulating IgM in a subject. In an aspect, a disclosed method of cleaving surface-bound IgM can transiently clear and/or remove IgM from circulation in a subject, or can transiently cleave and/or degrade circulating IgM in a subject. In an aspect, a disclosed method of cleaving surface-bound IgM can reduce and/or diminish the level of circulating IgM levels in a subj ect, or can transiently7 reduce and/or diminish the level of circulating IgM levels in a subject. In an aspect, a disclosed method can remove and/or cleave surface bound IgM from B
cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
[0287] In aspect, a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
[0288] In an aspect, a disclosed method of cleaving surface-bound IgM can block and/or minimize activation of the complement cascade. In an aspect, a disclosed method of cleaving surface-bound IgM can block and/or minimize activation of the formation of the C 1 complex and/or C3 complex. In an aspect, a disclosed method of cleaving surface-bound IgM can block and/or minimize activation of the classical complement pathway.
[0289] In an aspect, a disclosed method of cleaving surface-bound IgM can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
[0290] In an aspect, a disclosed method of cleaving surface-bound IgM can reduce and/or minimize vector mediated immunotoxicity in a subject. In an aspect, a disclosed method of cleaving surface-bound IgM can enable and/or allow vector re-dosing in a subject. In an aspect, a disclosed method of cleaving surface-bound IgM can enable and/or allow re-dosing of one or more disclosed enzymes or recombinant enzy mes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof in a subject.
[0291] In an aspect, a disclosed method of cleaving surface-bound IgM can reduce and/or minimize transgene immunogenicity in a subject. In an aspect, a disclosed method of cleaving surface-bound IgM can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%. 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules,
one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wildtype or control level.
[0292] In an aspect, a disclosed method of cleaving surface-bound IgM can modulate humoral immunity in a subj ect. In an aspect, modulating humoral immunity' in a subject can be an increase in the functionality of the subject's humoral immunity, or can be a decrease in the functional of the subject’s humoral immunity.
[0293] In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy. In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein. In an aspect of a disclosed method, the intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
[0294] In an aspect, a disclosed method can comprise administering to a subject in need thereof a theoretically effectively amount of one or more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0295] In an aspect, a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body weight. In an aspect, a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
[0296] In an aspect a subject can have or can be suspected of having one of more disclosed autoimmune diseases and/or disorders, one or more autoinflammatory diseases and/or disorders, one or more inflammatory diseases and/or disorders, or any combination thereof.
[0297] In an aspect, a disclosed autoimmune disease and/or disorder can be celiac disease, diabetes mellitus type 1. Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, or any combination thereof.
[0298] In an aspect, a disclosed autoinflammatory diseases and/or disorder can be Familial Mediterranean Fever (FMF), hyper IgD syndrome (HIDS), TNF receptor-associated periodic syndrome (TRAPS), cryopyrin associated periodic syndromes (CAPS), Blau syndrome, pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome (PAPA), or any combination thereof. [0299] In an aspect, a disclosed inflammatory disease and/or disorder can be Encephalitis, Myelitis, Meningitis, Arachnoiditis, Neuritis, Dacryoadenitis, Scleritis, Episcleritis, Keratitis, Retinitis, Chorioretinitis, Blepharitis, Conjunctivitis, Uveitis, Otitis externa, Otitis media, Labyrinthitis, Mastoiditis, Carditis, Endocarditis, Myocarditis, Pericarditis, Vasculitis, Arteritis, Phlebitis, Capillaritis, Sinusitis, Rhinitis, Pharyngitis, Laryngitis Tracheitis, Bronchitis, Bronchiolitis, Pneumonitis, Pleuritis, Mediastinitis, Stomatitis, Gingivitis, Gingivostomatitis, Glossitis, Tonsillitis, Sialadenitis/Parotitis, Cheilitis, Pulpitis, Gnathitis, Esophagitis, Gastritis, Gastroenteritis. Enteritis, Colitis, Enterocolitis, Duodenitis. Ileitis. Caecitis, Appendicitis, Proctitis, Hepatitis, Ascending cholangitis, Cholecystitis, Pancreatitis, Peritonitis, Dermatitis, Folliculitis, Cellulitis, Hidradenitis, Arthritis, Dermatomyositis, Myositis, Synovitis/Tenosynovitis, Bursitis, Enthesitis, Fasciitis, Capsulitis, Epicondylitis, Tendinitis, Panniculitis, Osteochondritis, Spondylitis. Periostitis, Chondritis. Nephritis, Glomerulonephritis, Pyelonephritis, Ureteritis, Cystitis, Urethritis, Oophoritis, Salpingitis, Endometritis, Parametritis, Cervicitis, Vaginitis, Vulvitis, Mastitis, Orchitis, Epididymitis, Prostatitis, Seminal vesiculitis. Balanitis, Posthitis, Balanoposthitis, Chorioamnionitis, Funisitis, Omphalitis, Insulitis, Hypophysitis, Thyroiditis. Parathyroiditis, Adrenalitis, Lymphangitis, Lymphadenitis, or any combination thereof.
[0300] In an aspect, a subject can be in need of one or more organ transplants. In an aspect, a subj ect can have received one or more organ transplants. In an aspect, a disclosed organ transplant can comprise the heart, one or both kidneys, the liver, one or both lungs, the pancreas, part or all of the colon or the intestines, or any combination thereof.
[0301] In an aspect, a subject can be in need of gene therapy, can have received gene therapy, or can be receiving gene therapy. In an aspect, a subj ect can be treated with gene therapy or can have a disease and/or disorder that can be treated with gene therapy.
[0302] In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. In an aspect, a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
[0303] In an aspect, examples of such genetic diseases and/or disorders or diseases and/or disorders that can be treated with gene therapy include those discussed supra at Part VII(B)(2).
[0304] In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes discussed supra at Part VII(B)(2).
[0305] In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes discussed supra at Part VI(B)(2).
[0306] In an aspect, a disclosed method of cleaving surface-bound IgM can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme delivered by gene therapy. In an aspect, a disclosed method of cleaving surface-bound IgM can comprise restoring one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation.
[0307] In an aspect, restoring one or more aspect of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation comprises restoring the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
[0308] In an aspect, restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise one or more of the following: (i) correcting cell starvation in one or more cell types; (ii) normalizing aspects of the autophagy’ pathway (such as, for example, correcting, preventing, reducing, and/or ameliorating autophagy); (iii) improving, enhancing, restoring, and/or preserving mitochondrial functionality and/or structural integrity; (iv) improving, enhancing, restoring, and/or preserving organelle functionality and/or structural integrity; (v) correcting enzyme dysregulation; (vi) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of the multi-systemic manifestations of a genetic disease or disorder; (vii) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of a genetic disease or disorder, or (viii) any combination thereof. In an aspect, restoring one or more aspects of cellular homeostasis can comprise improving, enhancing, restoring, and/or preserving one or more aspects of cellular structural and/or functional integrity.
[0309] In an aspect, restoring the activity and/or functionality of a missing, deficient, and/or mutant protein or enzyme can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of restoration when compared to a pre-existing level such as, for example, a pre-treatment level. In an aspect, the amount of restoration can be 10-20%, 20-30%, 30-40%,
40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as, for example, a pre-treatment level. In an aspect, restoration can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having a missing, deficient, and/or mutant protein or enzyme). In an aspect, restoration can be a partial or incomplete restoration. In an aspect, restoration can be complete or near complete restoration such that the level of expression, activity, and/or functionality is similar to that of a wild-type or control level.
[0310] In an aspect, a disclosed method of cleaving surface-bound IgM, techniques to monitor, measure, and/or assess the restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise qualitative (or subjective) means as well as quantitative (or objective) means. These means are known to the skilled person. For example, representative regulated variables and sensors relating to systemic homeostasis are provided below.
[0311] In an aspect of a disclosed method of cleaving surface-bound IgM, contacting a cell can comprising methods known to the art. For example, contacting can comprise administering to a subject one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
[0312] In an aspect, administering can comprise intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intra-CSF, intrathecal, intraventricular, intrahepatic. hepatic intraarterial, hepatic portal vein (HPV), or in utero administration. In an aspect, a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via intra-CSF administration in combination with RNAi, antisense oligonucleotides,
miRNA, one or more small molecules, one or more therapeutic agents, one or more proteasome inhibitors, one or more immune modulators, and/or a gene editing system. In an aspect, a disclosed composition, a disclosed enzy me or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via LNP administration. In an aspect, a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be concurrently and/or serially administered to a subject via multiple routes of administration. For example, in an aspect, administering a disclosed nucleic acid molecule, a disclosed enzyme or disclosed recombinant enzyme, a disclosed vector, and/or a disclosed pharmaceutical formulation can comprise intravenous administration and intra-cistem magna (ICM) administration. In an aspect, administering a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can comprise IV administration and intrathecal (ITH) administration. In an aspect, a disclosed method can employ multiple routes of administration to the subject. In an aspect, a disclosed method can employ a first route of administration that can be the same or different as a second and/or subsequent routes of administration.
[0313] In an aspect, a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body weight. In an aspect, a disclosed enzyme or disclosed recombinant enzy me can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
[0314] In an aspect of a disclosed method of cleaving surface-bound IgM, a therapeutically effective amount of disclosed vector can be delivered to a subject via intravenous (IV) administration and can comprise a range of about 1 x 1010 vg/kg to about 2 x 1014 vg/kg. In an aspect, for example, a disclosed vector can be administered at a dose of about 1 x 1011 vg/kg to about 8 x 10° vg/kg or about 1 x 1012 vg/kg to about 8 x 1013 vg/kg. In an aspect, a disclosed vector can be administered at a dose of about I x 1013 vg/kg to about 6 x 1013 vg/kg. In an aspect, a disclosed vector can be administered at a dose of at least about 1 x 1010 vg/kg, at least about 5 x IO10 vg/kg, at least about 1 x 1011 vg/kg, at least about 5 x I011 vg/kg, at least about I x IO12 vg/kg, at least about 5 x 1012 vg/kg, at least about I x 1013 vg/kg, at least about 5 x 1013 vg/kg, or at least about I x 1014 vg/kg. In an aspect, a disclosed vector can be administered at a dose of no more than about 1 x 1010 vg/kg, no more than about 5 x 1010 vg/kg, no more than about 1 x 1011 vg/kg,
no more than about 5 x 1011 vg/kg, no more than about 1 x 1012 vg/kg, no more than about 5 x 1012 vg/kg, no more than about 1 x 1013 vg/kg, no more than about 5 x 1013, or no more than about 1 x 1014 vg/kg. In an aspect, a disclosed vector can be administered to a subject at a dose of about 1 x 1012 vg/kg. In an aspect, a disclosed vector can be administered to a subject at a dose of about 1 x 1011 vg/kg. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subj ect total to about 1 x 1017 vg per subject total. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subject total, about 1 x 1013 vg per subject total, about 1 x 1014 vg per subject total, about 1 x 1015 vg per subject total, about 1 x 1016 vg per subject total, or about 1 x 1017 vg per subject total. In an aspect, a disclosed vector can be administered in a single dose, or in multiple doses (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses) as needed for the desired therapeutic results.
[0315] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise administering to the subject a therapeutically effective amount of a therapeutic agent. A therapeutic agent can be any disclosed agent that effects a desired clinical outcome.
[0316] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise monitoring the subject for adverse effects. In an aspect, in the absence of adverse effects, the method can further comprise continuing to treat the subject. In an aspect, in the presence of adverse effects, the method can further comprise modifying the treating step. Methods of monitoring a subject’s well-being can include both subjective and objective criteria (and are discussed supra). Such methods are known to the skilled person.
[0317] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering to the subject a therapeutically effective amount of an agent that can correct one or more aspects of a dysregulated metabolic or enzymatic pathway. In an aspect, such an agent can comprise an enzyme for enzyme replacement therapy. In an aspect, a disclosed enzyme can replace any enzyme in a dysregulated or dysfunctional metabolic or enzymatic pathway. In an aspect, a disclosed method can comprise replacing one or more enzymes in a dysregulated or dysfunctional metabolic pathway.
[0318] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise administering one or more immune modulators. In an aspect, a disclosed immune modulator can be methotrexate, rituximab, intravenous gamma globulin, or bortezomib, or a combination thereof. In an aspect, a disclosed immune modulator can be bortezomib or SVP-Rapamycin. In an aspect, a disclosed immune modulator can be Tacrolimus. In an aspect, a disclosed immune modulator such as methotrexate can be administered at a transient low to high dose. In an aspect, a disclosed
immune modulator can be administered at a dose of about 0.1 mg/kg body weight to about 0.6 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at a dose of about 0.4 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for 3 to 5 or greater cycles, with up to three days per cycle. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for a minimum of 3 cycles, with three days per cycle. In an aspect, a person skilled in the art can determine the appropriate number of cycles. In an aspect, a disclosed immune modulator can be administered as many times as necessary to achieve a desired clinical effect.
[0319] In an aspect, a disclosed immune modulator can be administered orally about one hour before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered orally about one hour or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof.
[0320] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise administering one or more proteasome inhibitors (e.g., bortezomib, carfilzomib, marizomib, ixazomib, and oprozomib). In an aspect, a proteasome inhibitor can be an agent that acts on plasma cells (e.g., daratumumab). In an aspect, an agent that acts on a plasma cell can be melphalan hydrochloride, melphalan, pamidronate disodium, carmustine, carfilzomib, carmustine, cyclophosphamide, daratumumab, doxorubicin hydrochloride liposome, doxorubicin hydrochloride liposome, elotuzumab, melphalan hydrochloride, panobinostat, ixazomib citrate, carfilzomib, lenalidomide, melphalan, melphalan hydrochloride, plerixafor, ixazomib citrate, pamidronate disodium, panobinostat, plerixafor, pomalidomide, pomalidomide, lenalidomide, selinexor, thalidomide, thalidomide, bortezomib, selinexor, zoledronic acid, or zoledronic acid.
[0321] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise administering one or more proteasome inhibitors or agents that act on plasma cells prior to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can comprise administering one or
more proteasome inhibitors or one or more agents that act on plasma cells concurrently with administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells subsequent to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can further comprise administering one or more proteasome inhibitors more than 1 time. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors repeatedly over time.
[0322] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise administering one or more immunosuppressive agents. In an aspect, an immunosuppressive agent can be, but is not limited to, azathioprine, methotrexate, sirolimus, anti -thymocyte globulin (ATG), cyclosporine (CSP), mycophenolate mofetil (MMF), steroids, or a combination thereof. In an aspect, a disclosed method can comprise administering one or more immunosuppressive agents more than 1 time. In an aspect, a disclosed method can comprise administering one or more one or more immunosuppressive agents repeatedly over time. In an aspect, a disclosed method can comprise administering a compound that targets or alters antigen presentation or humoral or cell mediated or innate immune responses.
[0323] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise administering a compound that exerts a therapeutic effect against B cells and/or a compound that targets or alters antigen presentation or humoral or cell mediated immune response. In an aspect, a disclosed compound can be rituximab, methotrexate, intravenous gamma globulin, anti CD4 antibody, anti CD2, an anti-FcRN antibody, a BTK inhibitor, an anti-IGFIR antibody, a CD19 antibody (e.g., inebilizumab), an anti-IL6 antibody (e.g., tocilizumab), an antibody to CD40, an IL2 mutein, or a combination thereof. Also disclosed herein are Treg infusions that can be administered as a way to help with immune tolerance (e.g., antigen specific Treg cells to AAV). [0324] In an aspect, a disclosed method can further comprise administering lipid nanoparticles (LNPs). In an aspect, LNPs can be organ-targeted. In an aspect, LNPs can be liver-targeted or testes-targeted. For example, in an aspect, mRNA therapy with LNP encapsulation for systemic delivery to a subject has the potential to restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzy me.
[0325] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise plasmapheresis and immunosuppression. In an aspect, a disclosed method can comprise using immunosuppression to decrease the T cell, B cell, and /or plasma cell population, decrease the innate immune response, inflammatory response, and antibody levels in general.
[0326] In an aspect a disclosed method can comprise repeating a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzy me, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell mediated immune response.
[0327] In an aspect, a disclosed method can comprise modifying one or more of the disclosed steps. For example, modifying one or more of steps of a disclosed method can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method. For example, in an aspect, a method can be altered by changing the amount of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof administered to a subject, or by changing the frequency of administration of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof to a subject, or by changing the duration of time one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof are administered to a subject.
[0328] In an aspect, a disclosed method can be altered by changing the amount of one or more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject, or by changing the frequency of administration of one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject.
[0329] In as aspect, a disclosed method can comprise concurrent administration of one or more of the following: one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, one or more disclosed therapeutic agents, one or more disclosed
immune modulators, one or more disclosed proteasome inhibitors, one or more disclosed immunosuppressive agents, one or more disclosed compounds that exert therapeutic effect against B cells, one or more disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response, or any combination thereof.
[0330] In an aspect, a disclosed immune modulator can be administered prior to or after the administration of a disclosed therapeutic agent.
[0331] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise generating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof. For example, in an aspect, a disclosed method of cleaving surface-bound IgM can further comprise generating a disclosed viral or non- viral vector. In an aspect, generating a disclosed viral vector can comprise generating an AAV vector or a recombinant AAV (such as those disclosed herein).
[0332] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise validating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
[0333] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise gene editing one or more relevant genes (such as, for example, a missing, deficient, and/or mutant protein or enzy me), wherein editing includes but is not limited to single gene knockout, loss of function screening of multiple genes at one, gene knockin, or a combination thereof.
[0334] In an aspect, a disclosed method of cleaving surface-bound IgM can further comprise administering an oligonucleotide therapeutic agent. A disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA, noncoding RNA (ncRNA), an antisense molecule, miRNA, a morpholino, a peptide-nucleic acid (PNA), or an analog or conjugate thereof. In an aspect, a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise a CRISPR-based endonuclease. In an aspect, a disclosed endonuclease can be Cas9. In an aspect, a disclosed Cas9 can be from Staphylococcus aureus or Streptococcus pyogenes.
[0335] In an aspect of a disclosed method, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered one or more times. In an aspect, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic
acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered for the duration of the subject’s life, or for the duration of the subject's treatment with, for example, gene therapy, enzy me replacement therapy, protein replacement therapy, and/or recombinant product. In an aspect, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered every' 6 weeks, every' 2 months, every' 3 months, every' 6 months, every' year, year other year, every 3 years, every 5 years, or for any other period deemed necessary by a skilled clinician.
[0336] In an aspect of a disclosed method, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered prior to, concurrent, or after the delivery and/or administration of enzyme replacement therapy, protein replacement, gene therapy, recombinant product, or any combination thereof.
[0337] In an aspect, a disclosed method of cleaving surface bound IgM can further comprise reducing and/or minimizing vector-mediated immunotoxicity' and/or transgene immunogenicity' (e.g., the ability to induce specific immunity). In an aspect, vector-mediated immunotoxicity' and/or transgene immunogenicity can decrease and/or reduce the efficacy of the recombinant product encoded by the transgene. In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability7 and/or likelihood of re-dosing a subject with one or more disclosed enzymes or recombinant enzy mes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof. In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with gene therapy, enzyme replacement therapy, protein replacement, or any combination thereof.
[0338] In an aspect of a disclosed method of cleaving surface bound IgM, IgM can be cleaved in the heavy chain at the interdomain region between constant domains Cp2 and Cp3. In an aspect, IgM can be cleaved between position 350 and position 365 of SEQ ID NO: 105. In an aspect, SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate). In an aspect, IgM can be cleaved between positions 355 through 360 of IgM. In an aspect, IgM can be cleaved at SEQ ID NO: 1 10. In an aspect, IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, IgM can be cleaved at position 355 through position 360 of the IgM of SEQ ID NO: 105. In an aspect, IgG can be cleaved below the hinge region, thereby yielding F(ab’)2 and Fc fragments. In an aspect, IgG can be cleaved to separate the Cp2
and Cp3 domains from the Cpl domain. In an aspect, IgG can be cleaved at SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, or any combination thereof. In an aspect, IgG can be cleaved at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof. In an aspect, IgG can be cleaved at positions 109 through 124 of the IgG of SEQ ID NO: 106. positions 106 through 120 of the IgG of SEQ ID NO: 107. positions 156 through 171 ofthe lgG of SEQ ID NO: 108, positions 106 through 121 of lgG of SEQ ID NO: 109, or any combination thereof. In an aspect, IgG can be cleaved at positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107, positions 163 through 169 ofthe lgG of SEQ ID NO: 108, positions 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, IgG can be cleaved SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO:118, or any combination thereof.
[0339] Disclosed herein is a method of cleaving immunoglobulin M (IgM) bound to the surface of B cells the method comprising contacting one or more IgM molecules with one or more disclosed recombinant enzymes and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
[0340] Disclosed herein is a method of cleaving immunoglobulin M (IgM) bound to the surface of B cells the method comprising contacting one or more IgM molecules with one or more disclosed recombinant enzymes and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
[0341] Disclosed herein is a method of cleaving immunoglobulin M (IgM) bound to the surface of B cells the method comprising contacting one or more IgM molecules with one or more disclosed recombinant enzymes and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 1 19.
[0342] Disclosed herein is a method of cleaving immunoglobulin M (IgM) bound to the surface of B cells the method comprising contacting one or more IgM molecules with one or more disclosed recombinant enzymes and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
[0343] Disclosed herein is a method of cleaving immunoglobulin M (IgM) bound to the surface of B cells the method comprising contacting one or more IgM molecules with one or more disclosed recombinant enzymes and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 119.
[0344] In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 119. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID
NO: 120 or SEQ ID NO: 121. In an aspect a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%. at least 80%. at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 1 19. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
[0345] In an aspect, a disclosed method can further comprise administering one or more times one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0346] In an aspect, a disclosed method can further comprise measuring and/or determining a subject’s pre-treatment level of circulating IgG and/or IgM and/or a subject’s pre-treatment level of surface bound IgM. In an aspect, a disclosed method can further comprise measuring and/or determining one or more times a subject’s level of circulating IgG and/or IgM and/or a subject’s level of surface bound IgM (e.g., before, during, and after a disclosed administering step).
[0347] In an aspect, a disclosed method can be performed using a singular disclosed enzyme having both IgG and IgM specific protease activity. In an aspect, a disclosed method can be performed using a disclosed enzyme having IgG specific protease activity and a disclosed enzyme having IgM specific protease activity.
E. Methods of Reducing Circulating Levels of IgM and/or IgG
[0348] Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzy mes. Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules. Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors.
Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations. Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15. Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:24 - SEQ ID NO:38. Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03. Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06. Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enz me comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09. Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12. Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically^ effective amount of an enzy me comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO:15.
[0349] Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 or SEQ ID NO:70 - SEQ ID NO:84. Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:60, or SEQ ID NO:61. Disclosed herein is a method of reducing the level of circulating intact IgM in the serum of a subject, the method comprising administering to the subject in need thereof a
therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:83, or SEQ ID NO:84.
[0350] Disclosed herein is a method reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzymes. Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules. Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors. Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations.
[0351] Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23. Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46. Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18. Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21 . Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23.
[0352] Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO: 62 - SEQ ID NO: 69 or SEQ ID NO: 85 - SEQ ID NO: 92. Disclosed
herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:63, SEQ ID NO:64. SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, or SEQ ID NO 69. Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90. SEQ ID NO:91, or SEQ ID NO:92.
[0353] Disclosed herein is a method reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity', and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity.
[0354] Disclosed herein is a method reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity (such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15). and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity7 (such as, for example, the enzyme of any one of SEQ ID NO: 119 - SEQ ID NO: 159).
[0355] Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 and (ii) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
[0356] Disclosed herein is a method of reducing the level of circulating intact IgM and IgG in the serum of a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO: 14, or SEQ ID NO: 15, and (ii) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO: 119, SEQ ID NO: 120, or SEQ ID NO: 121.
[0357] Disclosed herein is a method of reducing the level of circulating intact IgG in the serum of a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
[0358] In an aspect, a disclosed IgM molecule can be neutralizing against an exogenously administered protein. In an aspect, a disclosed IgM molecule can be neutralizing against enzyme replacement therapy, protein replacement therapy , and/or recombinant product. In an aspect, a disclosed IgM molecule can be neutralizing against a non-viral vector or a viral vector. In an aspect, a disclosed IgM molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector. For example, in an aspect, a disclosed IgM molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein).
[0359] In an aspect, a disclosed method can further comprise diagnosing a subject as being in need of one or more disclosed enzymes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0360] In an aspect of a disclosed method, there is at least a 10% reduction, at least a 20% reduction, at least a 30% reduction, at least a 40% reduction, at least a 50% reduction, at least a 60% reduction, at least a 70% reduction, at least an 80% reduction, at least a 90% reduction, or at least a 99% reduction in the level of circulating intact IgM and/or intact IgG.
[0361] In an aspect, a disclosed IgM molecule can be neutralizing against one or more transplanted organs. In an aspect, a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
[0362] 'In an aspect, a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800). In an aspect, a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof. In an aspect, after the contacting step, a disclosed HSAT can be reduced and/or eliminated. In an aspect, after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed. In an aspect, after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed with one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
[0363] In an aspect, a disclosed method can further comprise measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
[0364] In an aspect, a disclosed method of reducing circulating levels of IgM and/or IgG and IgM can clear and/or remove IgM and/or IgG and IgM from circulation in a subject. In an aspect, a
disclosed method can cleave and/or degrade circulating IgM and/or IgG and IgM in a subject. In an aspect, a disclosed method can cleave and/or degrade all or nearly all circulating IgM and/or IgG and IgM in a subject. In an aspect, a disclosed method can transiently clear and/or remove IgM and/or IgG and IgM from circulation in a subject, or can transiently cleave and/or degrade circulating IgM and/or IgG and IgM in a subject. In an aspect, a disclosed method can completely or nearly completely clear and/or remove IgM and/or IgG and IgM from circulation in a subject. In an aspect, a disclosed method can reduce and/or diminish the level of circulating IgM and/or IgG and IgM in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM in a subject. In aspect, a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
[0365] In an aspect, a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the complement cascade. In an aspect, a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the formation of the Cl complex and/or C3 complex. In an aspect, a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the classical complement pathway. In an aspect, a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof. In an aspect, a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can reduce and/or minimize vector mediated immunotoxicity in a subject. In an aspect, a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can enable and/or allow vector re-dosing in a subject. In an aspect, a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can enable and/or allow re-dosing of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof in a subject.
[0366] In an aspect, a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells. In an aspect, the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient. In an aspect, a disclosed method of reducing levels of circulating intact IgM or circulating intact IgM and IgG can
transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells.
[0367] In an aspect, a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can reduce and/or minimize transgene immunogenicity in a subject. In an aspect, a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%. 40-50%, 50-60%, 60-70%, 70-80%. 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wildtype or control level.
[0368] In an aspect, a disclosed method reducing the level of circulating intact IgM or circulating intact IgM and IgG can modulate humoral immunity in a subject. In an aspect, modulating humoral immunity7 in a subject can be an increase in the functionality7 of the subject’s humoral immunity7, or can be a decrease in the functional of the subject’s humoral immunity.
[0369] In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy. In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein. In an aspect of a disclosed method, the intact IgM and/or intact IgG can decrease and/or diminish the
effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
[0370] In an aspect, a disclosed method can comprise administering to a subject in need thereof a theoretically effectively amount of one or more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0371] In an aspect, a subject can have or can be suspected of having one of more autoimmune diseases and/or disorders, one or more autoinfl ammatory diseases and/or disorders, one or more inflammatory’ diseases and/or disorders, or any combination thereof. Disclosed autoimmune diseases and/or disorders are known to the art and discussed supra. Disclosed autoinflammatory diseases and/or disorders are known to the art and discussed supra. Disclosed inflammatory' diseases and/or disorders are known to the art and discussed supra.
[0372] In an aspect, a subject can be in need of one or more organ transplants. In an aspect, a subj ect can have received one or more organ transplants. In an aspect, a disclosed organ transplant can comprise the heart, one or both kidneys, the liver, one or both lungs, the pancreas, part or all of the colon or the intestines, or any combination thereof.
[0373] In an aspect, a subject can be in need of gene therapy, can have received gene therapy, or can be receiving gene therapy. In an aspect, a subject can be treated with gene therapy or can have a disease and/or disorder that can be treated with gene therapy. In an aspect, a subject can have or be suspected of having a disclosed disease or disorder that can be treated with gene therapy.
[0374] In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. In an aspect, a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof. In an aspect, a disclosed gene therapy can comprise the delivery' and/or repair of one or more disclosed genes. In an aspect, a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy. Lentiviral gene therapy, or the combination thereof.
[0375] Genetic diseases and/or disorders or diseases and/or disorders that can be treated with gene therapy are known to the art and are discussed supra. In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes known to the art and discussed supra.
[0376] In an aspect, a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the complement cascade. In an aspect, a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the formation of the Cl complex and/or C3
complex. In an aspect, a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can block and/or minimize activation of the classical complement pathway. In an aspect, a disclosed method of reducing the level of circulating intact IgM or circulating intact IgM and IgG can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
[0377] In an aspect, a disclosed method of reducing circulating levels of IgG or circulating intact IgM and IgG can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme delivered by gene therapy. In an aspect, a disclosed method of reducing circulating levels of IgG or circulating intact IgM and IgG can comprise restoring one or more aspects of cellular homeostasis and/or cellular functionality' and/or metabolic dysregulation. In an aspect, restoring one or more aspect of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation comprises restoring the functionality' and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
[0378] In an aspect, restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise one or more of the following: (i) correcting cell starvation in one or more cell types; (ii) normalizing aspects of the autophagy pathway (such as, for example, correcting, preventing, reducing, and/or ameliorating autophagy); (iii) improving, enhancing, restoring, and/or preserving mitochondrial functionality and/or structural integrity; (iv) improving, enhancing, restoring, and/or preserving organelle functionality and/or structural integrity; (v) correcting enzyme dysregulation; (vi) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of the multi-systemic manifestations of a genetic disease or disorder; (vii) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of a genetic disease or disorder, or (viii) any combination thereof. In an aspect, restoring one or more aspects of cellular homeostasis can comprise improving, enhancing, restoring, and/or preserving one or more aspects of cellular structural and/or functional integrity.
[0379] In an aspect, restoring the activity and/or functionality of a missing, deficient, and/or mutant protein or enzyme can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of restoration when compared to a pre-existing level such as, for example, a pre-treatment level. In an aspect, the amount of restoration can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as, for example, a pre-treatment level. In an aspect, restoration can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having a missing, deficient, and/or mutant protein or enzyme). In an aspect, restoration can be a partial or
incomplete restoration. In an aspect, restoration can be complete or near complete restoration such that the level of expression, activity, and/or functionality is similar to that of a wild-type or control level.
[0380] In an aspect of a disclosed method, techniques to monitor, measure, and/or assess the restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise qualitative (or subjective) means as well as quantitative (or objective) means. These means are known to the skilled person. For example, representative regulated variables and sensors relating to systemic homeostasis are discussed supra.
[0381] In an aspect of a disclosed method, contacting a cell can comprising methods known to the art. For example, contacting can comprise administering to a subject one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
[0382] In an aspect, administering can comprise intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intra-CSF, intrathecal, intraventricular, intrahepatic, hepatic intraarterial, hepatic portal vein (HPV), or in utero administration. In an aspect, a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via intra-CSF administration in combination with RNAi, antisense oligonucleotides, miRNA, one or more small molecules, one or more therapeutic agents, one or more proteasome inhibitors, one or more immune modulators, and/or a gene editing system. In an aspect, a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via LNP administration. In an aspect, a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be concurrently and/or serially administered to a subject via multiple routes of administration. For example, in an aspect, administering a disclosed nucleic acid molecule, a disclosed vector, and/or a disclosed pharmaceutical formulation can comprise intravenous administration and intra-cistem magna (ICM) administration. In an aspect, administering a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can comprise IV administration and intrathecal (ITH) administration. In an aspect, a disclosed method can employ multiple routes of administration to the subject. In an aspect, a disclosed method can employ a first route of administration that can be the same or different as a second and/or subsequent routes of administration.
[0383] In an aspect, a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body
weight. In an aspect, a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg. about 75 mg/kg. about 80 mg/kg. about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
[0384] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG, a therapeutically effective amount of disclosed vector can be delivered to a subject via intravenous (IV) administration and can comprise a range of about 1 x 1010 vg/kg to about 2 x 1014 vg/kg. In an aspect, for example, a disclosed vector can be administered at a dose of about 1 x 1011 vg/kg to about 8 x 1013 vg/kg or about 1 x 1012 vg/kg to about 8 x 1013 vg/kg. In an aspect, a disclosed vector can be administered at a dose of about 1 x 1013 vg/kg to about 6 x 1013 vg/kg. In an aspect, a disclosed vector can be administered at a dose of at least about 1 x 1010 vg/kg, at least about 5 x IO10 vg/kg, at least about 1 x 1011 vg/kg, at least about 5 x 1011 vg/kg, at least about 1 x 1012 vg/kg, at least about 5 x 1012 vg/kg, at least about 1 x 1013 vg/kg, at least about 5 x 1013 vg/kg, or at least about 1 x 1014 vg/kg. In an aspect, a disclosed vector can be administered at a dose of no more than about 1 x 1010 vg/kg, no more than about 5 x 1010 vg/kg. no more than about 1 x 1011 vg/kg, no more than about 5 x 1011 vg/kg. no more than about 1 x 1012 vg/kg, no more than about 5 x 1012 vg/kg, no more than about 1 x 1013 vg/kg, no more than about 5 x 1013, or no more than about 1 x 1014 vg/kg. In an aspect, a disclosed vector can be administered to a subject at a dose of about 1 x 1012 vg/kg. In an aspect, a disclosed vector can be administered to a subject at a dose of about 1 x 1011 vg/kg. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subject total to about 1 x 1017 vg per subject total. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subject total, about 1 x 1013 vg per subject total, about 1 x 1014 vg per subject total, about 1 x 1015 vg per subject total, about 1 x 1016 vg per subject total, or about 1 x 1017 vg per subject total. In an aspect, a disclosed vector can be administered in a single dose, or in multiple doses (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses) as needed for the desired therapeutic results.
[0385] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering to the subject a therapeutically effective amount of a therapeutic agent. A therapeutic agent can be any disclosed agent that effects a desired clinical outcome.
[0386] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise monitoring the subject for adverse effects. In an aspect, in the absence of adverse effects, the method can further comprise continuing to treat the subject. In an aspect, in the presence of adverse effects, the method can further comprise modifying the treating step. Methods of monitoring a subject’s well-being can include both subjective and objective criteria (and are discussed supra). Such methods are known to the skilled person.
[0387] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering to the subject a therapeutically effective amount of an agent that can correct one or more aspects of a dysregulated metabolic or enzymatic pathway. In an aspect, such an agent can comprise an enzyme for enzyme replacement therapy. In an aspect, a disclosed enzyme can replace any enzyme in a dysregulated or dysfunctional metabolic or enzy matic pathway. In an aspect, a disclosed method can comprise replacing one or more enzymes in a dysregulated or dysfunctional metabolic pathway.
[0388] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering one or more immune modulators. In an aspect, a disclosed immune modulator can be methotrexate, rituximab, intravenous gamma globulin, or bortezomib, or a combination thereof. In an aspect, a disclosed immune modulator can be bortezomib or SVP-Rapamycin. In an aspect, a disclosed immune modulator can be Tacrolimus. In an aspect, a disclosed immune modulator such as methotrexate can be administered at a transient low to high dose. In an aspect, a disclosed immune modulator can be administered at a dose of about 0.1 mg/kg body weight to about 0.6 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at a dose of about 0.4 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for 3 to 5 or greater cycles, with up to three days per cycle. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body w eight for a minimum of 3 cycles, with three days per cycle. In an aspect, a person skilled in the art can determine the appropriate number of cycles. In an aspect, a disclosed immune modulator can be administered as many times as necessary to achieve a desired clinical effect.
[0389] In an aspect, a disclosed immune modulator can be administered orally about one hour before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered orally about one hour or a few' days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune
modulator can be administered subcutaneously about 15 minutes before or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof.
[0390] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering one or more proteasome inhibitors (e.g., bortezomib, carfilzomib, marizomib, ixazomib, and oprozomib). In an aspect, a proteasome inhibitor can be an agent that acts on plasma cells (e.g., daratumumab). In an aspect, an agent that acts on a plasma cell can be melphalan hydrochloride, melphalan, pamidronate disodium, carmustine, carfilzomib, carmustine, cyclophosphamide, daratumumab, doxorubicin hydrochloride liposome, doxorubicin hydrochloride liposome, elotuzumab, melphalan hydrochloride, panobinostat. ixazomib citrate, carfilzomib, lenalidomide, melphalan, melphalan hydrochloride, plerixafor, ixazomib citrate, pamidronate disodium, panobinostat, plerixafor, pomalidomide, pomalidomide, lenalidomide, selinexor, thalidomide, thalidomide, bortezomib, selinexor, zoledronic acid, or zoledronic acid.
[0391] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering one or more proteasome inhibitors or agents that act on plasma cells prior to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells concurrently with administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells subsequent to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can further comprise administering one or more proteasome inhibitors more than 1 time. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors repeatedly over time.
[0392] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering one or more immunosuppressive agents. In an aspect, an immunosuppressive agent can be, but is not limited to, azathioprine, methotrexate, sirolimus, anti -thymocyte globulin (ATG), cyclosporine (CSP), my cophenolate mofetil (MMF), steroids, or a combination thereof. In an aspect, a disclosed method can comprise administering one or more immunosuppressive agents more than 1 time. In an aspect, a disclosed method can
comprise administering one or more one or more immunosuppressive agents repeatedly over time. In an aspect, a disclosed method can comprise administering a compound that targets or alters antigen presentation or humoral or cell mediated or innate immune responses.
[0393] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise administering a compound that exerts a therapeutic effect against B cells and/or a compound that targets or alters antigen presentation or humoral or cell mediated immune response. In an aspect, a disclosed compound can be rituximab, methotrexate, intravenous gamma globulin, anti CD4 antibody, anti CD2, an anti-FcRN antibody, a BTK inhibitor, an anti-IGFIR antibody, a CD 19 antibody (e.g.. inebilizumab). an anti-IL6 antibody (e.g., tocilizumab), an antibody to CD40, an IL2 mutein, or a combination thereof. Also disclosed herein are Treg infusions that can be administered as a way to help with immune tolerance (e.g., antigen specific Treg cells to AAV).
[0394] In an aspect, a disclosed method can further comprise administering lipid nanoparticles (LNPs). In an aspect. LNPs can be organ-targeted. In an aspect, LNPs can be liver-targeted or testes-targeted. For example, in an aspect, mRNA therapy with LNP encapsulation for systemic delivery to a subject has the potential to restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
[0395] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise plasmapheresis and immunosuppression. In an aspect, a disclosed method can comprise using immunosuppression to decrease the T cell, B cell, and /or plasma cell population, decrease the innate immune response, inflammatory response, and antibody levels in general.
[0396] In an aspect, a disclosed method can comprise repeating a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell mediated immune response.
[0397] In an aspect, a disclosed method can comprise modifying one or more of the disclosed steps. For example, modifying one or more of steps of a disclosed method can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method. For example, in an aspect, a method can be altered by changing the amount of one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or
any combination thereof administered to a subject, or by changing the frequency of administration of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof to a subject, or by changing the duration of time one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof are administered to a subject.
[0398] In an aspect, a disclosed method can be altered by changing the amount of one or more disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject, or by changing the frequency of administration of one or more of the disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject.
[0399] In as aspect, a disclosed method can comprise concurrent administration of one or more of the following: one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, one or more disclosed therapeutic agents, one or more disclosed immune modulators, one or more disclosed proteasome inhibitors, one or more disclosed immunosuppressive agents, one or more disclosed compounds that exert therapeutic effect against B cells, one or more disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response, or any combination thereof.
[0400] In an aspect, a disclosed immune modulator can be administered prior to or after the administration of a disclosed therapeutic agent.
[0401] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise generating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof. [0402] For example, in an aspect, a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG can further comprise generating a disclosed viral or non-viral vector. In an aspect, generating a disclosed viral vector can comprise generating an AAV vector or a recombinant AAV (such as those disclosed herein).
[0403] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG, can further comprise gene editing one or more relevant genes (such as, for example, a missing, deficient, and/or mutant protein or enzyme), wherein editing includes but is not limited to single gene knockout, loss of function screening of multiple genes at one, gene knockin, or a combination thereof.
[0404] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG, can further comprise administering an oligonucleotide therapeutic agent. A disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA, non-coding RNA (ncRNA), an antisense molecule, miRNA, a morpholino, a peptide-nucleic acid (PNA), or an analog or conjugate thereof. In an aspect, a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise a CRISPR-based endonuclease. In an aspect, a disclosed endonuclease can be Cas9. In an aspect, a disclosed Cas9 can be from Staphylococcus aureus or Streptococcus pyogenes.
[0405] In an aspect of a disclosed method of reducing circulating levels of IgM or circulating intact IgM and IgG, can further comprise generating and/or validating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0406] In an aspect of a disclosed method, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered one or more times. In an aspect, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered for the duration of the subject’s life, or for the duration of the subject’s treatment with, for example, gene therapy, enzyme replacement therapy, protein replacement therapy, and/or recombinant product. In an aspect, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered every 6 weeks, every’ 2 months, every 3 months, every 6 months, every year, year other year, every 3 years, every 5 years, or for any other period deemed necessary by a skilled clinician.
[0407] In an aspect of a disclosed method, a disclosed enzy me, a disclosed recombinant enzy me, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical
formulation, or any combination thereof can be delivered and/or administered prior to, concurrent, or after the delivery and/or administration of enzyme replacement therapy, protein replacement, gene therapy, a recombinant product, or any combination thereof.
[0408] In an aspect, a disclosed method of circulating levels of IgM and/or IgG can further comprise reducing and/or minimizing vector-mediated immunotoxicity and/or transgene immunogenicity (e.g., the ability to induce specific immunity). In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the efficacy of the recombinant product encoded by the transgene. In an aspect, vector-mediated immunotoxicity and/or trans gene immunogenicity can decrease and/or reduce the ability and/or likelihood of redosing a subject with one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof. In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with gene therapy, enzyme replacement therapy, protein replacement, or any combination thereof.
[0409] In an aspect of a disclosed method of inhibiting complement, IgM can be cleaved in the heavy' chain at the interdomain region between constant domains Cp2 and Cp3. In an aspect, IgM can be cleaved between position 350 and position 365 of SEQ ID NO: 105. In an aspect, SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate). In an aspect, IgM can be cleaved between positions 355 through 360 of IgM. In an aspect, IgM can be cleaved at SEQ ID NO: 110. In an aspect, IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, IgM can be cleaved at position 355 through position 360 of the IgM of SEQ ID NO: 105. In an aspect, IgG can be cleaved below the hinge region, thereby yielding F(ab’)2 and Fc fragments. In an aspect, IgG can be cleaved to separate the CLI2 and Cp3 domains from the Cpl domain. In an aspect, IgG can be cleaved at SEQ ID NO:111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114. or any combination thereof. In an aspect, IgG can be cleaved at SEQ ID NO: 115. SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118. or any combination thereof. In an aspect, IgG can be cleaved at positions 109 through 124 of the IgG of SEQ ID NO: 106, positions 106 through 120 of the IgG of SEQ ID NO: 107, positions 156 through 171 of the IgG of SEQ ID NO: 108, positions 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, IgG can be cleaved at positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107, positions 163 through 169 ofthe lgG of SEQ ID NO: 108, positions 113 through 119 of IgG of SEQ ID NO:109, or any combination thereof. In an aspect, IgG can be cleaved SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
[0410] Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzy mes having IgM specific protease activity' and one or more disclosed enzymes having IgG specific protease activity.
[0411] Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity' and one or more disclosed recombinant enzy mes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
[0412] Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of any one of SEQ ID NO: 01 - SEQ ID NO:46 and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
[0413] Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity' and one or more disclosed recombinant enzy mes comprising the sequence of SEQ ID NO: 119.
[0414] Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed recombinant enzy mes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
[0415] Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 11 or SEQ ID NO: 12 and one or more disclosed recombinant enzy mes comprising the sequence of SEQ ID NO: 119.
[0416] Disclosed herein is method of reducing the level of circulating intact IgM and/or IgG the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 14 or SEQ ID NO: 15 and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 119.
[0417] In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 119. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the
sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159. In an aspect a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzy me comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 119. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity' to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a sequence having at least 50%. at least 60%. at least 70%. at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
[0418] In an aspect, a disclosed method can further comprise administering one or more times one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0419] In an aspect, a disclosed method can further comprise measuring and/or determining a subject’s pre-treatment level of circulating IgG and/or IgM and/or a subject’s pre-treatment level of surface bound IgM. In an aspect, a disclosed method can further comprise measuring and/or determining one or more times a subject’s level of circulating IgG and/or IgM and/or a subject’s level of surface bound IgM (e.g., before, during, and after a disclosed administering step).
[0420] In an aspect, a disclosed method can be performed using a singular disclosed enzyme having both IgG and IgM specific protease activity. In an aspect, a disclosed method can be performed using a disclosed enzyme having IgG specific protease activity and a disclosed enzyme having IgM specific protease activity.
F. Methods of Inhibiting Complement Activation
[0421] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzymes. Disclosed herein is a method of inhibiting complement activation in a subj ect, the method comprising administering to the subj ect in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations.
[0422] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:24 - SEQ ID NO:38.
[0423] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:08 or SEQ ID NO:09. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15.
[0424] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 or SEQ ID NO:70 - SEQ ID NO:84. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:60, or SEQ ID NO:61 . Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:71. SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:83, or SEQ ID NO:84.
[0425] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of
one or more disclosed recombinant enzymes having IgG specific protease activity, and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity.
[0426] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity (such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15), and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity (such as, for example, the enzyme of any one of SEQ ID NO: 119 - SEQ ID NO: 159).
[0427] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity’ (such as, for example, the enzyme of SEQ ID NO: 11. SEQ ID NO: 12, SEQ ID NO: 14. or SEQ ID NO: 15), and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity' (such as, for example, the enzyme of SEQ ID NO: 119).
[0428] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 and (ii) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO:161.
[0429] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15, and (ii) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO: 119, SEQ ID NO: 120. or SEQ ID NO: 121.
[0430] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161. [0431] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzymes. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules.
Disclosed herein is a method of inhibiting complement activation in a subject, the method
comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations.
[0432] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23.
[0433] Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:62 - SEQ ID NO:69 or SEQ ID NO:85 - SEQ ID NO:92. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, or SEQ ID NO:69. Disclosed herein is a method of inhibiting complement activation in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, or SEQ ID NO:92.
[0434] In an aspect of a disclosed method of inhibiting complement activation, the formation of the C 1 complex and/or C3 complex can be blocked and/or minimized. In an aspect of a disclosed method of inhibiting complement activation, the activation of the classical complement pathway can be blocked and/or minimized. In an aspect, a disclosed method can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation
of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof. In an aspect, a disclosed method of inhibiting complement activation can further comprise clearing and/or removing IgM from circulation in a subject. In an aspect, a disclosed method of inhibiting complement activation can further comprise cleaving and/or degrading circulating IgM in a subj ect. In an aspect, a disclosed method of inhibiting complement activation can further comprise cleaving and/or degrading all or nearly all circulating IgM in a subject. In an aspect, a disclosed method of inhibiting complement activation can further comprise transiently clearing and/or removing IgM from circulation in a subject, or transiently clearing and/or degrading circulating IgM in a subject. In an aspect, a disclosed method of inhibiting complement activation can further comprise completely or nearly completely clearing and/or removing IgM from circulation in a subj ect. In an aspect, a disclosed method of inhibiting complement activation can further comprise reducing and/or diminishing the level of circulating IgM in a subject, or transiently reducing and/or diminishing the level of circulating IgM in a subject.
[0435] In an aspect, a disclosed method of inhibiting complement activation can further comprise clearing and/or removing IgM and/or IgG and IgM from circulation in a subject. In an aspect, a disclosed method of inhibiting complement activation can further comprise clearing and/or degrade circulating IgM and/or IgG and IgM in a subject. In an aspect, a disclosed method of inhibiting complement activation can further comprise cleaving and/or degrading all or nearly all circulating IgM and/or IgG and IgM in a subject. In an aspect, a disclosed method of inhibiting complement activation can further comprise transiently clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, or can transiently cleaving and/or degrading circulating IgM and/or IgG and IgM in a subject.
[0436] In an aspect, a disclosed method of inhibiting complement activation can further comprise completely or nearly completely clearing and/or removing IgM and/or IgG and IgM from circulation in a subject. In an aspect, a disclosed method of inhibiting complement activation can further comprise reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM in a subject. In aspect, a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
[0437] In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against an exogenously administered protein. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against enzyme replacement therapy or protein
replacement therapy or recombinant product. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a non-viral vector or a viral vector. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector. For example, in an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein).
[0438] In an aspect of a disclosed method, there is at least a 10% reduction, at least a 20% reduction, at least a 30% reduction, at least a 40% reduction, at least a 50% reduction, at least a 60% reduction, at least a 70% reduction, at least an 80% reduction, at least a 90% reduction, or at least a 99% reduction in the level of circulating intact IgM and/or intact IgG.
[0439] In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against one or more transplanted organs. In an aspect, a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
[0440] In an aspect, a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800). In an aspect, a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof. In an aspect, after the contacting step, a disclosed HSAT can be reduced and/or eliminated. In an aspect, after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed. In an aspect, after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed with one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
[0441] In an aspect, a disclosed method can further comprise measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
[0442] In an aspect, a disclosed method of inhibiting complement activation can enable and/or allow vector re-dosing in a subject. In an aspect, a disclosed method of inhibiting complement activation can enable and/or allow re-dosing of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof in a subj ect.
[0443] In an aspect, a disclosed method of inhibiting complement activation can further comprise reducing and/or minimizing vector mediated immunotoxicity in a subject. In an aspect, a disclosed method of inhibiting complement activation can reduce and/or minimize transgene immunogenicity in a subject.
[0444] In an aspect, a disclosed method of inhibiting complement activation can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40- 50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wild-type or control level.
[0445] In an aspect, a disclosed method inhibiting complement activation can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells. In an aspect, the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient. In an aspect, a disclosed method of inhibiting complement activation can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells. In an aspect, a disclosed method can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
[0446] In an aspect, a disclosed method of inhibiting complement activation can modulate humoral immunity in a subject. In an aspect, modulating humoral immunity in a subject can be
an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject’s humoral immunity.
[0447] In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy. In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein. In an aspect of a disclosed method, the intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
[0448] In an aspect, a disclosed method of inhibiting complement activation can comprise administering to a subject in need thereof a theoretically effectively amount of one or more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0449] In an aspect, a subject can have or can be suspected of having one of more autoimmune diseases and/or disorders, one or more autoinfl ammatory diseases and/or disorders, one or more inflammatory' diseases and/or disorders, or any combination thereof. Disclosed autoimmune diseases and/or disorders are known to the art and discussed supra. Disclosed autoinflammatory diseases and/or disorders are known to the art and discussed supra. Disclosed inflammatory diseases and/or disorders are known to the art and discussed supra.
[0450] In an aspect, a subject can be in need of one or more organ transplants. In an aspect, a subj ect can have received one or more organ transplants. In an aspect, a disclosed organ transplant can comprise the heart, one or both kidneys, the liver, one or both lungs, the pancreas, part or all of the colon or the intestines, or any combination thereof.
[0451] In an aspect, a subject can be in need of gene therapy, can have received gene therapy, or can be receiving gene therapy. In an aspect, a subject can be treated with gene therapy or can have a disease and/or disorder that can be treated with gene therapy. In an aspect, a subject can have or be suspected of having a disclosed disease or disorder that can be treated with gene therapy.
[0452] In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. In an aspect, a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof. In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. In an aspect, a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
[0453] Genetic diseases and/or disorders or diseases and/or disorders that can be treated with gene therapy are known to the art and are discussed supra. In an aspect, a disclosed gene therapy can comprise the delivery' and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes known to the art and discussed supra.
[0454] In an aspect, a disclosed method of inhibiting complement activation can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme delivered by gene therapy.
[0455] In an aspect, a disclosed method of inhibiting complement activation can comprise restoring one or more aspects of cellular homeostasis and/or cellular functionality’ and/or metabolic dysregulation.
[0456] In an aspect, restoring one or more aspect of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation comprises restoring the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
[0457] In an aspect, restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise one or more of the following: (i) correcting cell starvation in one or more cell ty pes; (ii) normalizing aspects of the autophagy' pathway (such as, for example, correcting, preventing, reducing, and/or ameliorating autophagy); (iii) improving, enhancing, restoring, and/or preserving mitochondrial functionality and/or structural integrity; (iv) improving, enhancing, restoring, and/or preserving organelle functionality and/or structural integrity; (v) correcting enzyme dysregulation; (vi) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of the multi-systemic manifestations of a genetic disease or disorder; (vii) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of a genetic disease or disorder, or (viii) any combination thereof. In an aspect, restoring one or more aspects of cellular homeostasis can comprise improving, enhancing, restoring, and/or preserving one or more aspects of cellular structural and/or functional integrity7.
[0458] In an aspect, restoring the activity and/or functionality of a missing, deficient, and/or mutant protein or enzyme can comprise a 10%, 20%, 30%, 40%, 50%, 60%. 70%. 80%, 90%, 100%, or any amount of restoration w'hen compared to a pre-existing level such as, for example, a pre-treatment level. In an aspect, the amount of restoration can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as, for example, a pre-treatment level. In an aspect, restoration can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having a missing, deficient, and/or mutant protein or enzyme). In an aspect, restoration can be a partial or incomplete restoration. In an aspect, restoration can be complete or near complete restoration
such that the level of expression, activity, and/or functionality is similar to that of a wild-type or control level.
[0459] In an aspect of a disclosed method, techniques to monitor, measure, and/or assess the restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise qualitative (or subjective) means as well as quantitative (or objective) means. These means are known to the skilled person. For example, representative regulated variables and sensors relating to systemic homeostasis are discussed supra.
[0460] In an aspect of a disclosed method, contacting a cell can comprising methods known to the art. For example, contacting can comprise administering to a subject one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
[0461] In an aspect, administering can comprise intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intra-CSF, intrathecal, intraventricular, intrahepatic, hepatic intraarterial, hepatic portal vein (HPV), or in utero administration. In an aspect, a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via intra-CSF administration in combination with RNAi, antisense oligonucleotides, miRNA, one or more small molecules, one or more therapeutic agents, one or more proteasome inhibitors, one or more immune modulators, and/or a gene editing system. In an aspect, a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via LNP administration. In an aspect, a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be concurrently and/or serially administered to a subject via multiple routes of administration. For example, in an aspect, administering a disclosed nucleic acid molecule, a disclosed enzyme or disclosed recombinant enzyme, a disclosed vector, and/or a disclosed pharmaceutical formulation can comprise intravenous administration and intra-cistem magna (ICM) administration. In an aspect, administering a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can comprise IV administration and intrathecal (ITH) administration. In an aspect, a disclosed method can employ multiple routes of administration to the subject. In an aspect, a disclosed method can employ a first route of administration that can be the same or different as a second and/or subsequent routes of administration.
[0462] In an aspect, a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body weight. In an aspect, a disclosed enzy me or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg. about 15 mg/kg, about 20 mg/kg, about 25 mg/kg. about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
[0463] In an aspect of a disclosed method of inhibiting complement activation, a therapeutically effective amount of disclosed vector can be delivered to a subject via intravenous (IV) administration and can comprise a range of about 1 x 1010 vg/kg to about 2 x 1014 vg/kg. In an aspect, for example, a disclosed vector can be administered at a dose of about 1 x 1011 vg/kg to about 8 x 1013 vg/kg or about 1 x 1012 vg/kg to about 8 x 1013 vg/kg. In an aspect, a disclosed vector can be administered at a dose of about 1 x 1013 vg/kg to about 6 x 1013 vg/kg. In an aspect, a disclosed vector can be administered at a dose of at least about 1 x 1010 vg/kg, at least about 5 x 1010 vg/kg, at least about 1 x 1011 vg/kg, at least about 5 x 1011 vg/kg, at least about 1 x 1012 vg/kg, at least about 5 x 1012 vg/kg, at least about 1 x 1013 vg/kg, at least about 5 x 1013 vg/kg, or at least about I x 1014 vg/kg. In an aspect, a disclosed vector can be administered at a dose of no more than about 1 x 1010 vg/kg, no more than about 5 x 1010 vg/kg, no more than about 1 x 1011 vg/kg, no more than about 5 x 1011 vg/kg, no more than about 1 x 1012 vg/kg, no more than about 5 x 1012 vg/kg, no more than about 1 x 1013 vg/kg, no more than about 5 x 1013, or no more than about 1 x 1014 vg/kg. In an aspect, a disclosed vector can be administered to a subject at a dose of about 1 x 1012 vg/kg. In an aspect, a disclosed vector can be administered to a subject at a dose of about 1 x 1011 vg/kg. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subject total to about 1 x 1017 vg per subject total. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x I O12 vg per subject total, about 1 x 1013 vg per subject total, about 1 x 1014 vg per subject total, about 1 x 1015 vg per subject total, about 1 x 1016 vg per subject total, or about 1 x 1017 vg per subject total. In an aspect, a disclosed vector can be administered in a single dose, or in multiple doses (such as 2. 3, 4, 5. 6, 7, 8. 9 or 10 doses) as needed for the desired therapeutic results.
[0464] In an aspect, a disclosed method of inhibiting complement activation can further comprise administering to the subject a therapeutically effective amount of a therapeutic agent. A therapeutic agent can be any disclosed agent that effects a desired clinical outcome.
[0465] In an aspect, a disclosed method of inhibiting complement activation can further comprise monitoring the subject for adverse effects. In an aspect, in the absence of adverse effects, the method can further comprise continuing to treat the subject. In an aspect, in the presence of adverse effects, the method can further comprise modifying the treating step. Methods of monitoring a subject’s well-being can include both subjective and objective criteria (and are discussed supra). Such methods are known to the skilled person.
[0466] In an aspect, a disclosed method of inhibiting complement activation can further comprise administering to the subject a therapeutically effective amount of an agent that can correct one or more aspects of a dysregulated metabolic or enzymatic pathway. In an aspect, such an agent can comprise an enzyme for enzyme replacement therapy. In an aspect, a disclosed enzyme can replace any enzy me in a dysregulated or dysfunctional metabolic or enzymatic pathway. In an aspect, a disclosed method can comprise replacing one or more enzymes in a dysregulated or dysfunctional metabolic pathway.
[0467] In an aspect, a disclosed method of inhibiting complement activation can further comprise administering one or more immune modulators. In an aspect, a disclosed immune modulator can be methotrexate, rituximab, intravenous gamma globulin, or bortezomib, or a combination thereof. In an aspect, a disclosed immune modulator can be bortezomib or SVP-Rapamycin. In an aspect, a disclosed immune modulator can be Tacrolimus. In an aspect, a disclosed immune modulator such as methotrexate can be administered at a transient low to high dose. In an aspect, a disclosed immune modulator can be administered at a dose of about 0.1 mg/kg body weight to about 0.6 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at a dose of about 0.4 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for 3 to 5 or greater cycles, with up to three days per cycle. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for a minimum of 3 cycles, with three days per cycle. In an aspect, a person skilled in the art can determine the appropriate number of cycles. In an aspect, a disclosed immune modulator can be administered as many times as necessary to achieve a desired clinical effect.
[0468] In an aspect, a disclosed immune modulator can be administered orally about one hour before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered orally about one hour or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune
modulator can be administered subcutaneously about 15 minutes before or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof.
[0469] In an aspect, a disclosed method of inhibiting complement activation can further comprise administering one or more proteasome inhibitors (e.g., bortezomib, carfilzomib, marizomib, ixazomib, and oprozomib). In an aspect, a proteasome inhibitor can be an agent that acts on plasma cells (e.g.. daratumumab). In an aspect, an agent that acts on a plasma cell can be melphalan hydrochloride, melphalan, pamidronate disodium, carmustine, carfilzomib, carmustine, cyclophosphamide, daratumumab, doxorubicin hydrochloride liposome, doxorubicin hydrochloride liposome, elotuzumab, melphalan hydrochloride, panobinostat, ixazomib citrate, carfilzomib, lenalidomide, melphalan, melphalan hydrochloride, plerixafor, ixazomib citrate, pamidronate disodium, panobinostat, plerixafor, pomalidomide, pomalidomide, lenalidomide, selinexor, thalidomide, thalidomide, bortezomib, selinexor, zoledronic acid, or zoledronic acid.
[0470] In an aspect, a disclosed method of inhibiting complement activation can further comprise administering one or more proteasome inhibitors or agents that act on plasma cells prior to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells concurrently with administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells subsequent to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can further comprise administering one or more proteasome inhibitors more than 1 time. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors repeatedly over time.
[0471 ] In an aspect, a disclosed method of inhibiting complement activation can further comprise administering one or more immunosuppressive agents. In an aspect, an immunosuppressive agent can be, but is not limited to, azathioprine, methotrexate, sirolimus, anti -thymocyte globulin (ATG). cyclosporine (CSP), mycophenolate mofetil (MMF), steroids, or a combination thereof. In an aspect, a disclosed method can comprise administering one or more immunosuppressive agents more than 1 time. In an aspect, a disclosed method can comprise administering one or more one or more immunosuppressive agents repeatedly over time. In an aspect, a disclosed
method can comprise administering a compound that targets or alters antigen presentation or humoral or cell mediated or innate immune responses.
[0472] In an aspect, a disclosed method of inhibiting complement activation can further comprise administering a compound that exerts a therapeutic effect against B cells and/or a compound that targets or alters antigen presentation or humoral or cell mediated immune response. In an aspect, a disclosed compound can be rituximab, methotrexate, intravenous gamma globulin, anti CD4 antibody, anti CD2, an anti-FcRN antibody, a BTK inhibitor, an anti-IGFIR antibody, a CD19 antibody (e.g., inebilizumab), an anti-IL6 antibody (e.g., tocilizumab), an antibody to CD40, an IL2 mutein, or a combination thereof. Also disclosed herein are Treg infusions that can be administered as a way to help with immune tolerance (e.g., antigen specific Treg cells to AAV). [0473] In an aspect, a disclosed method can further comprise administering lipid nanoparticles (LNPs). In an aspect, LNPs can be organ-targeted. In an aspect, LNPs can be liver-targeted or testes-targeted. For example, in an aspect, mRNA therapy with LNP encapsulation for systemic delivery to a subject has the potential to restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
[0474] In an aspect, a disclosed method of inhibiting complement activation can further comprise plasmapheresis and immunosuppression. In an aspect, a disclosed method can comprise using immunosuppression to decrease the T cell, B cell, and /or plasma cell population, decrease the innate immune response, inflammatory response, and antibody levels in general.
[0475] In an aspect, a disclosed method can comprise repeating a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell mediated immune response.
[0476] In an aspect, a disclosed method can comprise modifying one or more of the disclosed steps. For example, modifying one or more of steps of a disclosed method can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method. For example, in an aspect, a method can be altered by changing the amount of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof administered to a subject, or by changing the frequency of administration of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical
formulations, or any combination thereof to a subject, or by changing the duration of time one or more disclosed enzymes or recombinant enzy mes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof are administered to a subject.
[0477] In an aspect, a disclosed method can be altered by changing the amount of one or more disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject, or by changing the frequency of administration of one or more of the disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject.
[0478] In as aspect, a disclosed method can comprise concurrent administration of one or more of the following: one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, one or more disclosed therapeutic agents, one or more disclosed immune modulators, one or more disclosed proteasome inhibitors, one or more disclosed immunosuppressive agents, one or more disclosed compounds that exert therapeutic effect against B cells, one or more disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response, or any combination thereof.
[0479] In an aspect, a disclosed immune modulator can be administered prior to or after the administration of a disclosed therapeutic agent.
[0480] In an aspect, a disclosed method of inhibiting complement activation can further comprise generating one or more disclosed enzy mes or disclosed recombinant enzy mes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed In an aspect, a disclosed method of inhibiting complement activation can further comprise validating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0481] For example, in an aspect, a disclosed method of inhibiting complement activation can further comprise generating a disclosed viral or non-viral vector. In an aspect, generating a disclosed viral vector can comprise generating an AAV vector or a recombinant AAV (such as those disclosed herein).
[0482] In an aspect, a disclosed method of inhibiting complement activation can further comprise gene editing one or more relevant genes (such as, for example, a missing, deficient, and/or mutant protein or enzyme), wherein editing includes but is not limited to single gene knockout, loss of function screening of multiple genes at one, gene knockin, or a combination thereof.
[0483] In an aspect, a disclosed method of inhibiting complement activation can further comprise administering an oligonucleotide therapeutic agent. A disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA, noncoding RNA (ncRNA), an antisense molecule, miRNA. a morpholino, a peptide-nucleic acid (PNA). or an analog or conjugate thereof. In an aspect, a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise a CRISPR-based endonuclease. In an aspect, a disclosed endonuclease can be Cas9. In an aspect, a disclosed Cas9 can be from Staphylococcus aureus or Streptococcus pyogenes.
[0484] In an aspect of a disclosed method, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered one or more times. In an aspect, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered for the duration of the subject’s life, or for the duration of the subject's treatment with, for example, gene therapy, enzyme replacement therapy, protein replacement therapy, and/or recombinant product. In an aspect, a disclosed enz me, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered every' 6 weeks, every' 2 months, every' 3 months, every' 6 months, every year, year other year, every 3 years, every 5 years, or for any other period deemed necessary by a skilled clinician.
[0485] In an aspect of a disclosed method, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered prior to, concurrent, or after the delivery and/or administration of enzyme replacement therapy, protein replacement, gene therapy, a recombinant product, or any combination thereof.
[0486] In an aspect, a disclosed method of inhibiting complement activation can further comprise reducing and/or minimizing vector-mediated immunotoxicity' and/or transgene immunogenicity' (e.g., the ability to induce specific immunity). In an aspect, vector-mediated immunotoxicity’
and/or transgene immunogenicity can decrease and/or reduce the efficacy of the recombinant product encoded by the transgene. In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof. In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with gene therapy, enzyme replacement therapy, protein replacement, or any combination thereof.
[0487] In an aspect of a disclosed method of inhibiting complement activation, IgM can be cleaved in the heavy chain at the interdomain region between constant domains Cp2 and Cp3. In an aspect, IgM can be cleaved between position 350 and position 365 of SEQ ID NO: 105. In an aspect, SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate). In an aspect, IgM can be cleaved between positions 355 through 360 of IgM. In an aspect, IgM can be cleaved at SEQ ID NO:110. In an aspect, IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, IgM can be cleaved at position 355 through position 360 of the IgM of SEQ ID NO: 105. In an aspect, IgG can be cleaved below the hinge region, thereby yielding F(ab')z and Fc fragments. In an aspect. IgG can be cleaved to separate the Cp2 and Cp3 domains from the Cpl domain. In an aspect, IgG can be cleaved at SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO:113, SEQ ID NO:114, or any combination thereof. In an aspect, IgG can be cleaved at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof. In an aspect, IgG can be cleaved at positions 109 through 124 of the IgG of SEQ ID NO: 106, positions 106 through 120 of the IgG of SEQ ID NO: 107, positions 156 through 171 of the IgG of SEQ ID NO: 108, positions 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, IgG can be cleaved at positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107, positions 163 through 169 of the IgG of SEQ ID NO: 108. positions 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, IgG can be cleaved SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO:118, or any combination thereof.
[0488] Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed enzymes having IgG specific protease activity7.
[0489] Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed
recombinant enzymes having IgM specific protease activity and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159. [0490] Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
[0491] Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 119.
[0492] Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 1 19 - SEQ ID NO: 159. [0493] Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 11 or SEQ ID NO: 12 and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 119.
[0494] Disclosed herein is method of inhibiting complement activation the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 14 or SEQ ID NO: 15 and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 119.
[0495] In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 119. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 1 19. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at
least 80%, at least 90%, or more than 90% identify to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identify to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
[0496] In an aspect, a disclosed method can further comprise administering one or more times one or more disclosed enzymes or recombinant enzy mes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0497] In an aspect, a disclosed method can further comprise measuring and/or determining a subject’s pre-treatment level of circulating IgG and/or IgM and/or a subject’s pre-treatment level of surface bound IgM. In an aspect, a disclosed method can further comprise measuring and/or determining one or more times a subject’s level of circulating IgG and/or IgM and/or a subject's level of surface bound IgM (e.g., before, during, and after a disclosed administering step).
[0498] In an aspect, a disclosed method can be performed using a singular disclosed enzyme having both IgG and IgM specific protease activity. In an aspect, a disclosed method can be performed using a disclosed enzy me having IgG specific protease activity and a disclosed enzyme having IgM specific protease activity.
G. Methods of Reducing and/or Minimizing an Immune Response
[0499] Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any' combination thereof.
[0500] Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15 or SEQ ID NO:24 - SEQ ID NO:38. Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subj ect in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:02, SEQ ID NO:03, SEQ ID NO:05, SEQ ID NO:06, SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15.
[0501] Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ
ID NO:47 - SEQ ID N0:61 or SEQ ID NO:70 - SEQ ID NO:84. Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55. SEQ ID NO:57, SEQ ID NO:58. SEQ ID NO:60, or SEQ ID NO:61. Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:74. SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:83, or SEQ ID NO:84.
[0502] Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity, and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity.
[0503] Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity (such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO:12, SEQ ID NO: 14, or SEQ ID NO: 15), and (ii) a therapeutically effective amount of one or more disclosed recombinant enz mes having IgM specific protease activity (such as, for example, the enzyme of any one of SEQ ID NO: 119 - SEQ ID NO: 159).
[0504] Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity (such as, for example, the enzyme of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15). and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity (such as, for example, the enzyme of SEQ ID NO: 119).
[0505] Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 and (ii) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
[0506] Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14. or SEQ ID NO: 15, and (ii) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO: 119, SEQ ID NO: 120, or SEQ ID NO: 121.
[0507] Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
[0508] Disclosed herein is a method of reducing and/or minimizing an immune response in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23 or SEQ ID NO:39 - SEQ ID NO:46. Disclosed herein is method of reducing and/or minimizing an immune response in a subject, the method comprising administenng to the subj ect in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, or SEQ ID NO: 23.
[0509] Disclosed herein is a method of reducing and/or minimizing an immune response, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed recombinant enzy mes having IgM specific protease activity, wherein following the administering step, the level of circulating IgM targeting a recombinant product is reduced when compared to a pre-administering step level.
[0510] Disclosed herein is a method of reducing and/or minimizing an immune response, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity7, wherein following the administering step, the level of circulating IgG targeting a recombinant product is reduced when compared to a pre-administering step level.
[051 1 ] Disclosed herein is a method of reducing and/or minimizing an immune response, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed recombinant enzy mes having IgM specific protease activity7 and IgG specific protease activity, wherein following the administering step, the level of circulating IgM and IgG targeting a recombinant product is reduced when compared to a pre-administering step level.
[0512] Disclosed herein is a method of reducing and/or minimizing an immune response, the method comprising administering to the subject in need thereof a therapeutically effective amount
of one or more disclosed recombinant enzymes having IgG specific protease activity, one or more disclosed recombinant enzymes having IgM specific protease activity, one or more disclosed recombinant enzy me having both IgM and IgG specific protease activity, or any combination thereof wherein following the administering step, the level of circulating IgG and/or IgM targeting a recombinant product is reduced when compared to a pre-administering step level.
[0513] In an aspect, a disclosed method can further comprise re-dosing the subject with the recombinant product. In an aspect, a disclosed recombinant product can comprise a vector or portion thereof. In an aspect, a disclosed recombinant product can comprise an encoded therapeutic protein or enzyme or an encoded gene product. In an aspect, a disclosed recombinant product can comprise a therapeutic protein or a therapeutic enzyme. In an aspect, a disclosed method can further comprise reducing and/or minimizes immunogenicity7 in the subject to the recombinant product. In an aspect, a disclosed method can further comprise improving and/or enhancing transgene efficacy and/or expression in a subject. In an aspect of a disclosed method, transgene efficacy and/or expression in the subject can be improved and/or enhanced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100% when compared to a pre-administering step level.
[0514] In an aspect of a disclosed method of reducing and/or minimizing an immune response, the formation of the Cl complex and/or C3 complex can be blocked and/or minimized. In an aspect of a disclosed method of reducing and/or minimizing an immune response, the activation of the classical complement pathway can be blocked and/or minimized. In an aspect, a disclosed method of reducing and/or minimizing an immune response can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
[0 15] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, can further comprise cleaving and/or degrading circulating IgM and/or IgG and IgM in a subject, can further comprise cleaving and/or degrading all or nearly all circulating IgM and/or IgG and IgM in a subject, or any combination thereof.
[0516] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise transiently clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, or transiently clearing and/or degrading circulating IgM and/or IgG and IgM in a subject.
[0517] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise completely or nearly completely clearing and/or removing IgM and/or IgG and IgM from circulation in a subject. In an aspect, a disclosed method of reducing and/or minimizing
an immune response can further comprise reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, or transiently reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject.
[0518] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, completely or nearly completely clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, clearing and/or degrade circulating IgM and/or IgG and IgM in a subject, cleaving and/or degrading all or nearly all circulating IgM and/or IgG and IgM in a subject, or any combination thereof.
[0519] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise transiently clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, or can transiently cleaving and/or degrading circulating IgM and/or IgG and IgM in a subject. In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, or can transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM in a subject. In aspect, a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
[0520] In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against an exogenously administered protein. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against enzyme replacement therapy or protein replacement therapy. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a non-viral vector or a viral vector. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector. For example, in an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein). In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against any disclosed recombinant product..
[0521] In an aspect, a disclosed method can further comprise diagnosing a subject as being in need of one or more disclosed enzymes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0522] In an aspect of a disclosed method, there is at least a 10% reduction, at least a 20% reduction, at least a 30% reduction, at least a 40% reduction, at least a 50% reduction, at least a
60% reduction, at least a 70% reduction, at least an 80% reduction, at least a 90% reduction, or at least a 99% reduction in the level of circulating intact IgM and/or intact IgG.
[0523] In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against one or more transplanted organs. In an aspect, a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
[0524] In an aspect, a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800). In an aspect, a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof. In an aspect, after the contacting step, a disclosed HSAT can be reduced and/or eliminated. In an aspect, after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed. In an aspect, after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed with one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
[0525] In an aspect, a disclosed method can further comprise measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
[0526] In an aspect, a disclosed method of reducing and/or minimizing an immune response can enable and/or allow vector re-dosing in a subject. In an aspect, a disclosed method of reducing and/or minimizing an immune response can enable and/or allow re-dosing of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof in a subj ect.
[0527] In an aspect, a disclosed method of reducing and/or minimizing an immune response can reduce and/or minimize transgene immunogenicity in a subject, can improve and/or enhance transgene efficacy and/or expression in a subject, or the combination thereof.
[0528] In an aspect, improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%. 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or
any combination thereof). In an aspect, the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wildtype or control level.
[0529] In an aspect, a disclosed method of reducing and/or minimizing an immune response can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells, can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells, or the combination thereof. In an aspect, the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient. In an aspect, a disclosed method can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
[0530] In an aspect, a disclosed method of reducing and/or minimizing an immune response can modulate humoral immunity in a subject. In an aspect, modulating humoral immunity in a subject can be an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject's humoral immunity.
[0531] In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy. In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein. In an aspect of a disclosed method, the intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
[0532] In an aspect, a disclosed method of reducing and/or minimizing an immune response can comprise administering to a subject in need thereof a theoretically effectively amount of one or
more disclosed enzymes or disclosed recombinant enzymes, one or more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0533] In an aspect, a subject can have or can be suspected of having one of more autoimmune diseases and/or disorders, one or more autoinfl ammatory diseases and/or disorders, one or more inflammatory diseases and/or disorders, or any combination thereof.
[0534] Disclosed autoimmune diseases and/or disorders are known to the art and discussed supra. Disclosed autoinflammatory diseases and/or disorders are know n to the art and discussed supra. Disclosed inflammatory diseases and/or disorders are known to the art and discussed supra.
[0535] In an aspect, a subject can be in need of one or more organ transplants. In an aspect, a subj ect can have received one or more organ transplants. In an aspect, a disclosed organ transplant can comprise the heart, one or both kidneys, the liver, one or both lungs, the pancreas, part or all of the colon or the intestines, or any combination thereof. In an aspect, a subject can be in need of gene therapy, can have received gene therapy, or can be receiving gene therapy. In an aspect, a subject can be treated with gene therapy or can have a disease and/or disorder that can be treated with gene therapy. In an aspect, a subject can have or be suspected of having a disclosed disease or disorder that can be treated with gene therapy.
[0536] In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. In an aspect, a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof. In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. In an aspect, a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
[0537] Genetic diseases and/or disorders or diseases and/or disorders that can be treated with gene therapy are known to the art and are discussed supra. In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes known to the art and discussed supra.
[0538] In an aspect, a disclosed method of reducing and/or minimizing an immune response can restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme delivered by gene therapy.
[0539] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise restoring one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation. In an aspect, restoring one or more aspect of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation comprises restoring the functionality' and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
[0540] In an aspect, restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise one or more of the following: (i) correcting cell starvation in one or more cell types; (ii) normalizing aspects of the autophagy' pathway (such as, for example, correcting, preventing, reducing, and/or ameliorating autophagy); (iii) improving, enhancing, restoring, and/or preserving mitochondrial functionality and/or structural integrity; (iv) improving, enhancing, restoring, and/or preserving organelle functionality and/or structural integrity; (v) correcting enzyme dysregulation; (vi) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of the multi-systemic manifestations of a genetic disease or disorder; (vii) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of a genetic disease or disorder, or (viii) any combination thereof. In an aspect, restoring one or more aspects of cellular homeostasis can comprise improving, enhancing, restoring, and/or preserving one or more aspects of cellular structural and/or functional integrity.
[0541] In an aspect, restoring the activity and/or functionality of a missing, deficient, and/or mutant protein or enzyme can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of restoration when compared to a pre-existing level such as, for example, a pre-treatment level. In an aspect, the amount of restoration can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%. 70-80%, 80-90%, or 90-100% more than a pre-existing level such as, for example, a pre-treatment level. In an aspect, restoration can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having a missing, deficient, and/or mutant protein or enzyme). In an aspect, restoration can be a partial or incomplete restoration. In an aspect, restoration can be complete or near complete restoration such that the level of expression, activity, and/or functionality is similar to that of a wild-type or control level.
[0542] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise administering to the subject a therapeutically effective amount of an agent that can correct one or more aspects of a dysregulated metabolic or enzymatic pathway. In an aspect, such an agent can comprise an enzyme for enzyme replacement therapy. In an aspect, a disclosed enzyme can replace any enzyme in a dysregulated or dysfunctional metabolic or enzymatic pathway. In an aspect, a disclosed method can comprise replacing one or more enzymes in a dysregulated or dysfunctional metabolic pathway.
[0543] In an aspect of a disclosed method, techniques to monitor, measure, and/or assess the restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise qualitative (or subjective) means as well as quantitative (or objective) means. These means are known to the skilled person. For example, representative regulated variables and sensors relating to systemic homeostasis are discussed supra.
[0544] In an aspect of a disclosed method, contacting a cell can comprising methods know n to the art. For example, contacting can comprise administering to a subject one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
[0545] In an aspect, administering can comprise intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intra-CSF, intrathecal, intraventricular, intrahepatic, hepatic intraarterial, hepatic portal vein (HPV), or in utero administration. In an aspect, a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via intra-CSF administration in combination with RNAi, antisense oligonucleotides, miRNA, one or more small molecules, one or more therapeutic agents, one or more proteasome inhibitors, one or more immune modulators, and/or a gene editing system. In an aspect, a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via LNP administration. In an aspect, a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be concurrently and/or serially administered to a subject via multiple routes of administration. For example, in an aspect, administering a disclosed nucleic acid molecule, a disclosed enzyme or disclosed recombinant enzyme, a disclosed vector, and/or a disclosed pharmaceutical formulation can comprise intravenous administration and intra-cistem magna (ICM) administration. In an aspect, administering a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can comprise IV administration and intrathecal (ITH) administration. In an aspect, a disclosed method can employ multiple routes of administration to the subject. In an aspect, a disclosed method can employ a first route of administration that can be the same or different as a second and/or subsequent routes of administration.
[0546] In an aspect, a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body weight. In an aspect, a disclosed enzyme or disclosed recombinant enzyme can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
[0547] In an aspect of a disclosed method of reducing and/or minimizing an immune response, a therapeutically effective amount of disclosed vector can be delivered to a subject via intravenous (IV) administration and can comprise a range of about 1 x IO10 vg/kg to about 2 x 1014 vg/kg. In an aspect, for example, a disclosed vector can be administered at a dose of about 1 x 1011 vg/kg to about 8 x 1013 vg/kg or about I x 1012 vg/kg to about 8 x 1013 vg/kg. In an aspect, a disclosed vector can be administered at a dose of about 1 x 1013 vg/kg to about 6 x 1013 vg/kg. In an aspect, a disclosed vector can be administered at a dose of at least about 1 x IO10 vg/kg, at least about 5 x IO10 vg/kg, at least about 1 x 1011 vg/kg, at least about 5 x 1011 vg/kg, at least about 1 x 1012 vg/kg, at least about 5 x 1012 vg/kg. at least about 1 x 1013 vg/kg. at least about 5 x 1013 vg/kg. or at least about 1 x 1014 vg/kg. In an aspect, a disclosed vector can be administered at a dose of no more than about 1 x IO10 vg/kg, no more than about 5 x IO10 vg/kg, no more than about 1 x 1011 vg/kg, no more than about 5 x 1011 vg/kg, no more than about 1 x 1012 vg/kg, no more than about 5 x 1012 vg/kg, no more than about 1 x 1013 vg/kg, no more than about 5 x 1013, or no more than about 1 x 1014 vg/kg. In an aspect, a disclosed vector can be administered to a subject at a dose of about 1 x 1012 vg/kg. In an aspect, a disclosed vector can be administered to a subject at a dose of about 1 x 1011 vg/kg. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subject total to about 1 x 1017 vg per subject total. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subject total, about 1 x 1013 vg per subject total, about 1 x 1014 vg per subject total, about 1 x 1015 vg per subject total, about 1 x 1016 vg per subject total, or about 1 x 1017 vg per subject total. In an aspect, a disclosed vector can be administered in a single dose, or in multiple doses (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses) as needed for the desired therapeutic results.
[0548] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise administering to the subject a therapeutically effective amount of a therapeutic agent. A therapeutic agent can be any disclosed agent that effects a desired clinical outcome.
[0549] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise monitoring the subject for adverse effects. In an aspect, in the absence of adverse effects, the method can further comprise continuing to treat the subject. In an aspect, in the presence of adverse effects, the method can further comprise modifying the treating step. Methods of monitoring a subject’s well-being can include both subjective and objective criteria (and are discussed supra). Such methods are known to the skilled person.
[0550] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise administering one or more immune modulators. In an aspect, a disclosed
immune modulator can be methotrexate, rituximab, intravenous gamma globulin, or bortezomib, or a combination thereof. In an aspect, a disclosed immune modulator can be bortezomib or SVP- Rapamycin. In an aspect, a disclosed immune modulator can be Tacrolimus. In an aspect, a disclosed immune modulator such as methotrexate can be administered at a transient low to high dose. In an aspect, a disclosed immune modulator can be administered at a dose of about 0. 1 mg/kg body weight to about 0.6 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at a dose of about 0.4 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for 3 to 5 or greater cycles, with up to three days per cycle. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for a minimum of 3 cycles, with three days per cycle. In an aspect, a person skilled in the art can determine the appropriate number of cycles. In an aspect, a disclosed immune modulator can be administered as many times as necessary’ to achieve a desired clinical effect.
[0551] In an aspect, a disclosed immune modulator can be administered orally about one hour before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered orally about one hour or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof.
[0552] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise administering one or more proteasome inhibitors (e.g., bortezomib, carfilzomib, marizomib, ixazomib, and oprozomib). In an aspect, a proteasome inhibitor can be an agent that acts on plasma cells (e.g., daratumumab). In an aspect, an agent that acts on a plasma cell can be melphalan hydrochloride, melphalan, pamidronate disodium, carmustine, carfilzomib, carmustine, cyclophosphamide, daratumumab, doxorubicin hydrochloride liposome, doxorubicin hydrochloride liposome, elotuzumab, melphalan hydrochloride, panobinostat, ixazomib citrate, carfilzomib, lenalidomide, melphalan, melphalan hydrochloride, plerixafor, ixazomib citrate, pamidronate disodium, panobinostat, plerixafor, pomalidomide, pomalidomide, lenalidomide, selinexor, thalidomide, thalidomide, bortezomib, selinexor, zoledronic acid, or zoledronic acid.
[0553] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise administering one or more proteasome inhibitors or agents that act on plasma cells prior to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells concurrently with administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells subsequent to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can further comprise administering one or more proteasome inhibitors more than 1 time. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors repeatedly over time.
[0554] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise administering one or more immunosuppressive agents. In an aspect, an immunosuppressive agent can be, but is not limited to, azathioprine, methotrexate, sirolimus, antithymocyte globulin (ATG), cyclosporine (CSP), mycophenolate mofetil (MMF), steroids, or a combination thereof. In an aspect, a disclosed method can comprise administering one or more immunosuppressive agents more than 1 time. In an aspect, a disclosed method can comprise administering one or more one or more immunosuppressive agents repeatedly over time. In an aspect, a disclosed method can comprise administering a compound that targets or alters antigen presentation or humoral or cell mediated or innate immune responses.
[0555] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further compnse administering a compound that exerts a therapeutic effect against B cells and/or a compound that targets or alters antigen presentation or humoral or cell mediated immune response. In an aspect, a disclosed compound can be rituximab, methotrexate, intravenous gamma globulin, anti CD4 antibody, anti CD2, an anti-FcRN antibody, a BTK inhibitor, an anti-IGFIR antibody, a CD19 antibody (e.g., inebilizumab), an anti-IL6 antibody (e.g.. tocihzumab), an antibody to CD40, an IL2 mutein, or a combination thereof. Also disclosed herein are Treg infusions that can be administered as a way to help with immune tolerance (e.g., antigen specific Treg cells to AAV).
[0556] In an aspect, a disclosed method can further comprise administering lipid nanoparticles (LNPs). In an aspect, LNPs can be organ-targeted. In an aspect, LNPs can be liver-targeted or testes-targeted. For example, in an aspect, mRNA therapy with LNP encapsulation for systemic delivery7 to a subject has the potential to restore the functionality and/or structural integrity' of a missing, deficient, and/or mutant protein or enzyme.
[0557] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise plasmapheresis and immunosuppression. In an aspect, a disclosed method can comprise using immunosuppression to decrease the T cell, B cell, and /or plasma cell population, decrease the innate immune response, inflammatory response, and antibody levels in general.
[0558] In an aspect, a disclosed method can comprise repeating a disclosed administering step such as, for example, repeating the administering of a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell mediated immune response.
[0559] In an aspect, a disclosed method can comprise modifying one or more of the disclosed steps. For example, modifying one or more of steps of a disclosed method can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method. For example, in an aspect, a method can be altered by changing the amount of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof administered to a subject, or by changing the frequency of administration of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof to a subject, or by changing the duration of time one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof are administered to a subject.
[0560] In an aspect, a disclosed method can be altered by changing the amount of one or more disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject, or by changing the frequency of administration of one or more of the disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject.
[0561] In as aspect, a disclosed method can comprise concurrent administration of one or more of the following: one or more disclosed enzymes or recombinant enzymes, one or more of the
disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, one or more disclosed therapeutic agents, one or more disclosed immune modulators, one or more disclosed proteasome inhibitors, one or more disclosed immunosuppressive agents, one or more disclosed compounds that exert therapeutic effect against B cells, one or more disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response, or any combination thereof.
[0562] In an aspect, a disclosed immune modulator can be administered prior to or after the administration of a disclosed therapeutic agent.
[0563] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise generating and/or validating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof. [0564] For example, in an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise generating a disclosed viral or non-viral vector. In an aspect, generating a disclosed viral vector can comprise generating an AAV vector or a recombinant AAV (such as those disclosed herein).
[0565] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise gene editing one or more relevant genes (such as. for example, a missing, deficient, and/or mutant protein or enzyme), wherein editing includes but is not limited to single gene knockout, loss of function screening of multiple genes at one, gene knockin, or a combination thereof.
[0566] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise administering an oligonucleotide therapeutic agent. A disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA, non-coding RNA (ncRNA), an antisense molecule, miRNA, a morpholino, a peptide-nucleic acid (PNA), or an analog or conjugate thereof. In an aspect, a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise a CRISPR- based endonuclease. In an aspect, a disclosed endonuclease can be Cas9. In an aspect, a disclosed Cas9 can be from Staphylococcus aureus or Streptococcus pyogenes.
[0567] In an aspect of a disclosed method, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered one or more times. In an aspect, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic
acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered for the duration of the subject’s life, or for the duration of the subject's treatment with, for example, gene therapy, enzy me replacement therapy, protein replacement therapy, and/or recombinant product. In an aspect, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered every' 6 weeks, every' 2 months, every' 3 months, every' 6 months, every' year, year other year, every 3 years, every 5 years, or for any other period deemed necessary by a skilled clinician.
[0568] In an aspect of a disclosed method, a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered prior to, concurrent, or after the delivery and/or administration of enzyme replacement therapy, protein replacement, gene therapy, recombinant product, or any combination thereof.
[0569] In an aspect, a disclosed method of reducing and/or minimizing an immune response can further comprise reducing and/or minimizing vector-mediated immunotoxicity' and/or transgene immunogenicity (e.g., the ability to induce specific immunity). In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the efficacy of the recombinant product encoded by the transgene. In an aspect, vector-mediated immunotoxicity' and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of redosing a subject with one or more disclosed enzy mes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof. In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with gene therapy, enzyme replacement therapy, protein replacement, or any combination thereof.
[0570] In an aspect of a disclosed method of reducing and/or minimizing an immune response, IgM can be cleaved in the heavy chain at the interdomain region between constant domains Cp2 and Cp3. In an aspect, IgM can be cleaved between position 350 and position 365 of SEQ ID NO: 105. In an aspect, SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate). In an aspect, IgM can be cleaved between positions 355 through 360 of IgM. In an aspect, IgM can be cleaved at SEQ ID NO: 110. In an aspect, IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, IgM can be cleaved at position 355 through position 360 of the IgM of SEQ ID NO: 105. In an aspect, IgG can be cleaved below the hinge region, thereby yielding F(ab’)z and Fc fragments. In an aspect, IgG can
be cleaved to separate the Cp2 and Cp3 domains from the Cpl domain. In an aspect, IgG can be cleaved at SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, or any combination thereof. In an aspect, IgG can be cleaved at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof. In an aspect, IgG can be cleaved at positions 109 through 124 of the IgG of SEQ ID NO: 106, positions 106 through 120 of the IgG of SEQ ID NO: 107, positions 156 through 171 of the IgG of SEQ ID NO: 108, positions 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, IgG can be cleaved at positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107. positions 163 through 169 of the IgG of SEQ ID NO: 108, positions 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, IgG can be cleaved SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
[0571] In an aspect, a disclosed method can further comprise administering one or more times one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0572] In an aspect, a disclosed method can further comprise measuring and/or determining a subject's pre-treatment level of circulating IgG and/or IgM and/or a subject’s pre-treatment level of surface bound IgM. In an aspect, a disclosed method can further comprise measuring and/or determining one or more times a subject’s level of circulating IgG and/or IgM and/or a subject’s level of surface bound IgM (e.g., before, during, and after a disclosed administering step).
[0573] In an aspect, a disclosed method can be performed using a singular disclosed enzyme having both IgG and IgM specific protease activity. In an aspect, a disclosed method can be performed using a disclosed enzyme having IgG specific protease activity and a disclosed enzyme having IgM specific protease activity.
H. Methods of Improving and Enhancing Transgene Efficacy and/or Expression
[0574] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzymes or disclosed recombinant enzymes. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors. Disclosed herein is a method of improving
and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations.
[0575] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO: 15. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:24 - SEQ ID NO:38. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:02 or SEQ ID NO:03. Disclosed herein is method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 08 or SEQ ID NO:09. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15.
[0576] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:61 or SEQ ID NO:70 - SEQ ID NO:84. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:60, or SEQ ID NO:61. Disclosed herein is a method of improving
and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:77, SEQ IDNO:78. SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:83, or SEQ ID NO: 84.
[0577] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed enzy mes or disclosed recombinant enzymes. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed nucleic acid molecules. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of one or more disclosed vectors. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subj ect in need thereof a therapeutically effective amount of one or more disclosed pharmaceutical formulations.
[0578] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzy me comprising the sequence set forth in any one of SEQ ID NO: 16 - SEQ ID NO:23. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in any one of SEQ ID NO:39 - SEQ ID NO:46. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression on in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an enzyme comprising the sequence set forth in SEQ ID NO: 22 or SEQ ID NO:23.
[0579] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in any one of SEQ ID NO: 62 - SEQ ID NO: 69 or SEQ ID NO: 85 - SEQ ID NO: 92. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO 67, SEQ ID NO:68, or SEQ ID NO:69. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, or SEQ ID NO:92.
[0580] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity, and (ii) a therapeutically effective amount of one or more disclosed recombinant enzy mes having IgM specific protease activity.
[0581] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity (such as, for example, the enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15). and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity’ (such as, for example, the enzyme of any one of SEQ ID NO: 119 - SEQ ID NO: 159).
[0582] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgG specific protease activity’ (such as, for example, the enzyme of SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15), and (ii) a therapeutically effective amount of one or more disclosed recombinant enzymes having IgM specific protease activity (such as, for example, the enzyme of SEQ ID NO: 119).
[0583] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof (i) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in
any one of SEQ ID NO:47 - SEQ ID N0:61 and (ii) a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161.
[0584] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, method comprising administering to the subject in need thereof (i) a therapeutically effective amount of the recombinant enzyme of SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO:11, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 15, and (ii) a therapeutically effective amount of the recombinant enzy me of SEQ ID NO: 119, SEQ ID NO: 120, or SEQ ID NO: 121.
[0585] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO 161.
[0586] In an aspect of a disclosed method of improving and/or enhancing transgene efficacy and/or expression, the formation of the Cl complex and/or C3 complex can be blocked and/or minimized. In an aspect of a disclosed method of improving and/or enhancing transgene efficacy and/or expression, the activation of the classical complement pathway can be blocked and/or minimized. In an aspect, a disclosed method can transiently block and/or minimize activation of the complement cascade, can transiently block and/or minimize activation of the formation of the Cl complex and/or C3 complex, can transiently block and/or minimize activation of the classical complement pathway, or any combination thereof.
[0587] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, can further comprise cleaving and/or degrading circulating IgM and/or IgG and IgM in a subject, can further comprise cleaving and/or degrading all or nearly all circulating IgM and/or IgG and IgM in a subject, or any combination thereof.
[0588] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise transiently clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, or transiently clearing and/or degrading circulating IgM and/or IgG and IgM in a subject, can further comprise completely or nearly completely clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, can further comprise reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, or transiently reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, or any combination thereof.
[0589] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise clearing and/or removing IgM and/or IgG and IgM from
circulation in a subject, can further comprise clearing and/or degrade circulating IgM and/or IgG and IgM in a subject, can further comprise cleaving and/or degrading all or nearly all circulating IgM and/or IgG and IgM in a subject, can further comprise transiently clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, can further comprise transiently cleaving and/or degrading circulating IgM and IgM in a subject, or any combination thereof.
[0590] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise completely or nearly completely clearing and/or removing IgM and/or IgG and IgM from circulation in a subject, can further comprise reducing and/or diminishing the level of circulating IgM and/or IgG and IgM in a subject, can further transiently reduce and/or diminish the level of circulating IgM and/or IgG and IgM in a subject, or any combination thereof. In aspect, a disclosed transient reduction and/or diminishment can comprise about 6 hours, about 12 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or more than 4 weeks.
[05 1] In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against an exogenously administered protein. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against enzyme replacement therapy or protein replacement therapy or recombinant product. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a non-viral vector or a viral vector. In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a protein associated with a non-viral vector or a viral vector. For example, in an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against a viral vector capsid protein (e.g., an AAV capsid protein).
[0592] In an aspect, a disclosed method can further comprise diagnosing a subject as being in need of one or more disclosed enzy mes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0593] In an aspect of a disclosed method, there is at least a 10% reduction, at least a 20% reduction, at least a 30% reduction, at least a 40% reduction, at least a 50% reduction, at least a 60% reduction, at least a 70% reduction, at least an 80% reduction, at least a 90% reduction, or at least a 99% reduction in the level of circulating intact IgM and/or intact IgG.
[0594] In an aspect, a disclosed IgM molecule and/or a disclosed IgG molecule can be neutralizing against one or more transplanted organs. In an aspect, a disclosed method can degrade one or more anti-HLA antibodies directed at the one or more transplanted organs.
[0595] In an aspect, a subject can have a high sustained antibody titer (HSAT - defined as titers of > 12,800). In an aspect, a subject can have a high sustained antibody titer (HSAT) against one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof. In an aspect, after the contacting step, a disclosed HSAT can be reduced and/or eliminated. In an aspect, after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed. In an aspect, after the reduction and/or elimination of one or more HSATs, a subject can be re-dosed with one or more exogenously administered proteins or enzymes, one or more enzyme replacement therapies, one or more protein replacement therapies, one or more recombinant products, one or more non-viral vectors or viral vectors, one or more proteins associated with a non-viral vector, one or more proteins associated with a viral vector, or any combination thereof.
[0596] In an aspect, a disclosed method can further compnse measuring one or more time the levels of IgM and/or IgG in the subject (such as, for example, in the subject’s sera).
[0597] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise reducing and/or minimizing vector mediated immunotoxicity in a subject. In an aspect, a disclosed method of inhibiting complement activation can reduce and/or minimize transgene immunogenicity in a subj ect.
[0598] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can enable and/or allow vector re-dosing in a subject.
[0599] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can enable and/or allow re-dosing of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof in a subject. In an aspect, a disclosed method of inhibiting complement activation can improve and/or enhance transgene efficacy and/or expression in a subject. In an aspect, improving and/or enhancing transgene efficacy and/or expression in a subject can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of an improvement and/or enhancement when compared to a pre-existing level of transgene efficacy and/or expression such as, for example, a pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, the amount of improvement and/or enhancement can be 10-20%, 20-30%, 30-40%, 40- 50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% more than a pre-existing level such as a
pre-treatment level (prior to administering one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having received or not having been administered one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof). In an aspect, an improvement and/or enhancement can be a partial or incomplete restoration. In an aspect, an improvement and/or enhancement can be complete or near complete such that the level of neutralizing antibodies or neutralizing IgG and/or IgM molecules is similar to that of a wild-type or control level.
[0600] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can remove and/or cleave surface-bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells. In an aspect, the disclosed removal and/or cleavage of IgM from the surface of B cells can be reversible and/or transient. In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can transiently remove and/or cleave surface-bound IgM from B cells and/or can transiently remove and/or cleave IgM from the surface of B cells. In an aspect, a disclosed method can remove and/or cleave surface bound IgM from B cells and/or can remove and/or cleave IgM from the surface of B cells without killing and/or injuring the B cells.
[0601] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further modulate humoral immunity in a subject. In an aspect, modulating humoral immunity in a subject can be an increase in the functionality of the subject’s humoral immunity, or can be a decrease in the functional of the subject’s humoral immunity.
[0602] In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered gene therapy. In an aspect of a disclosed method, intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an administered therapeutic protein or a therapeutic recombinant protein. In an aspect of a disclosed method, the intact IgM and/or intact IgG can decrease and/or diminish the effectiveness and/or efficacy of an encoded therapeutic protein or encoded therapeutic recombinant protein.
[0603] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise administering to a subject in need thereof a theoretically effectively amount of one or more disclosed enzy mes or disclosed recombinant enzymes, one or
more disclosed nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0604] In an aspect, a subject can have or can be suspected of having one of more autoimmune diseases and/or disorders, one or more autoinfl ammatory diseases and/or disorders, one or more inflammatory diseases and/or disorders, or any combination thereof. Disclosed autoimmune diseases and/or disorders are known to the art and discussed supra. Disclosed autoinflammatory diseases and/or disorders are known to the art and discussed supra. Disclosed inflammatory diseases and/or disorders are known to the art and discussed supra.
[0605] In an aspect, a subject can be in need of one or more organ transplants. In an aspect, a subj ect can have received one or more organ transplants. In an aspect, a disclosed organ transplant can comprise the heart, one or both kidneys, the liver, one or both lungs, the pancreas, part or all of the colon or the intestines, or any combination thereof.
[0606] In an aspect, a subject can be in need of gene therapy, can have received gene therapy, or can be receiving gene therapy. In an aspect, a subject can be treated with gene therapy or can have a disease and/or disorder that can be treated with gene therapy. In an aspect, a subject can have or be suspected of having a disclosed disease or disorder that can be treated with gene therapy.
[0607] In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. In an aspect, a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof. In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. In an aspect, a disclosed gene therapy can comprise AAV-based gene therapy, Adenovirus-based gene therapy, Lentiviral gene therapy, or the combination thereof.
[0608] Genetic diseases and/or disorders or diseases and/or disorders that can be treated with gene therapy are known to the art and are discussed supra. In an aspect, a disclosed gene therapy can comprise the delivery and/or repair of one or more disclosed genes. Genetic diseases and/or disorders can be due to a defect in one or more genes known to the art and discussed supra.
[0609] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme delivered by gene therapy. In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise restoring one or more aspects of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation.
[0610] In an aspect, restoring one or more aspect of cellular homeostasis and/or cellular functionality and/or metabolic dysregulation comprises restoring the functionality and/or
structural integrity of a missing, deficient, and/or mutant protein or enzyme. In an aspect, restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise one or more of the following: (i) correcting cell starvation in one or more cell types; (ii) normalizing aspects of the autophagy pathway (such as, for example, correcting, preventing, reducing, and/or ameliorating autophagy); (hi) improving, enhancing, restoring, and/or preserving mitochondrial functionality and/or structural integrity; (iv) improving, enhancing, restoring, and/or preserving organelle functionality and/or structural integrity; (v) correcting enzyme dysregulation; (vi) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of the multi- systemic manifestations of a genetic disease or disorder; (vii) reversing, inhibiting, preventing, stabilizing, and/or slowing the rate of progression of a genetic disease or disorder, or (viii) any combination thereof. In an aspect, restoring one or more aspects of cellular homeostasis can comprise improving, enhancing, restoring, and/or preserving one or more aspects of cellular structural and/or functional integrity.
[0611] In an aspect, restoring the activity and/or functionality of a missing, deficient, and/or mutant protein or enzyme can comprise a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of restoration when compared to a pre-existing level such as, for example, a pre-treatment level. In an aspect, the amount of restoration can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%. 70-80%, 80-90%, or 90-100% more than a pre-existing level such as, for example, a pre-treatment level. In an aspect, restoration can be measured against a control level or a reference level (e.g., determined, for example, using one or more subjects not having a missing, deficient, and/or mutant protein or enzy me). In an aspect, restoration can be a partial or incomplete restoration. In an aspect, restoration can be complete or near complete restoration such that the level of expression, activity, and/or functionality is similar to that of a wild-type or control level.
[0612] In an aspect of a disclosed method, techniques to monitor, measure, and/or assess the restoring one or more aspects of cellular homeostasis and/or cellular functionality can comprise qualitative (or subjective) means as well as quantitative (or objective) means. These means are known to the skilled person. For example, representative regulated variables and sensors relating to systemic homeostasis are discussed supra.
[0613] In an aspect of a disclosed method, contacting a cell can comprising methods known to the art. For example, contacting can comprise administering to a subject one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof .
[0614] In an aspect, administering can comprise intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intra-CSF, intrathecal, intraventricular, intrahepatic, hepatic intraarterial, hepatic portal vein (HPV), or in utero administration. In an aspect, a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via intra-CSF administration in combination with RNAi, antisense oligonucleotides, miRNA, one or more small molecules, one or more therapeutic agents, one or more proteasome inhibitors, one or more immune modulators, and/or a gene editing system. In an aspect, a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be administered via LNP administration. In an aspect, a disclosed composition, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can be concurrently and/or serially administered to a subject via multiple routes of administration. For example, in an aspect, administering a disclosed nucleic acid molecule, a disclosed enzyme or disclosed recombinant enzyme, a disclosed vector, and/or a disclosed pharmaceutical formulation can comprise intravenous administration and intra-cistem magna (ICM) administration. In an aspect, administering a disclosed composition, a disclosed enzyme or disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, and/or a disclosed vector can comprise IV administration and intrathecal (ITH) administration. In an aspect, a disclosed method can employ multiple routes of administration to the subject. In an aspect, a disclosed method can employ a first route of administration that can be the same or different as a second and/or subsequent routes of administration.
[0615] In an aspect, a therapeutically effective amount of a disclosed enzyme or disclosed recombinant enzyme can comprise about 0.01 mg/kg body weight to about 100 mg/kg body weight. In an aspect, a disclosed enzyme or disclosed recombinant enzy me can be therapeutically effective when the dose comprises about 0.01 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg. about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg body weight.
[0616] In an aspect of a disclosed method of improving and/or enhancing transgene efficacy and/or expression, a therapeutically effective amount of disclosed vector can be delivered to a subject via intravenous (IV) administration and can comprise a range of about 1 x 1010 vg/kg to about 2 x 1014 vg/kg. In an aspect, for example, a disclosed vector can be administered at a dose of about 1 x 1011 vg/kg to about 8 x 1013 vg/kg or about 1 x 1012 vg/kg to about 8 x 10lj vg/kg. In
an aspect, a disclosed vector can be administered at a dose of about 1 x 1013 vg/kg to about 6 x 1013 vg/kg. In an aspect, a disclosed vector can be administered at a dose of at least about 1 x IO10 vg/kg, at least about 5 x IO10 vg/kg, at least about 1 x 1011 vg/kg, at least about 5 x 1011 vg/kg, at least about 1 x 1012 vg/kg, at least about 5 x 1012 vg/kg, at least about 1 x 1013 vg/kg, at least about 5 x 1013 vg/kg, or at least about 1 x 1014 vg/kg. In an aspect, a disclosed vector can be administered at a dose of no more than about 1 x IO10 vg/kg, no more than about 5 x IO10 vg/kg, no more than about 1 x 1011 vg/kg, no more than about 5 x 1011 vg/kg, no more than about 1 x 1012 vg/kg, no more than about 5 x 1012 vg/kg, no more than about 1 x 1013 vg/kg, no more than about 5 x 1013, or no more than about 1 x 1014 vg/kg. In an aspect, a disclosed vector can be administered to a subject at a dose of about 1 x 1012 vg/kg. In an aspect, a disclosed vector can be administered to a subject at a dose of about 1 x 1011 vg/kg. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subject total to about 1 x 1017 vg per subject total. In an aspect, a therapeutically effective amount of disclosed vector can be delivered via intravenous (IV) administration and can comprise a range of about 1 x 1012 vg per subject total, about 1 x 1013 vg per subject total, about 1 x 1014 vg per subject total, about 1 x 1015 vg per subject total, about 1 x 1016 vg per subject total, or about 1 x 1017 vg per subject total. In an aspect, a disclosed vector can be administered in a single dose, or in multiple doses (such as 2, 3, 4, 5. 6, 7, 8, 9 or 10 doses) as needed for the desired therapeutic results.
[0617] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise administering to the subject a therapeutically effective amount of a therapeutic agent. A therapeutic agent can be any disclosed agent that effects a desired clinical outcome.
[0618] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise monitoring the subject for adverse effects. In an aspect, in the absence of adverse effects, the method can further comprise continuing to treat the subject. In an aspect, in the presence of adverse effects, the method can further comprise modifying the treating step. Methods of monitoring a subject’s well-being can include both subjective and objective criteria (and are discussed supra). Such methods are known to the skilled person.
[0619] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise administering to the subject a therapeutically effective amount of an agent that can correct one or more aspects of a dysregulated metabolic or enzymatic pathway. In an aspect, such an agent can comprise an enzyme for enzyme replacement therapy. In an aspect, a disclosed enzyme can replace any enzyme in a dysregulated or dysfunctional metabolic or
enzymatic pathway. In an aspect, a disclosed method can comprise replacing one or more enzymes in a dysregulated or dysfunctional metabolic pathway.
[0620] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise administering one or more immune modulators. In an aspect, a disclosed immune modulator can be methotrexate, rituximab, intravenous gamma globulin, or bortezomib, or a combination thereof. In an aspect, a disclosed immune modulator can be bortezomib or SVP-Rapamycin. In an aspect, a disclosed immune modulator can be Tacrolimus. In an aspect, a disclosed immune modulator such as methotrexate can be administered at a transient low to high dose. In an aspect, a disclosed immune modulator can be administered at a dose of about 0.1 mg/kg body weight to about 0.6 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at a dose of about 0.4 mg/kg body weight. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for 3 to 5 or greater cycles, with up to three days per cycle. In an aspect, a disclosed immune modulator can be administered at about a daily dose of 0.4 mg/kg body weight for a minimum of 3 cycles, with three days per cycle. In an aspect, a person skilled in the art can determine the appropriate number of cycles. In an aspect, a disclosed immune modulator can be administered as many times as necessary' to achieve a desired clinical effect.
[0621] In an aspect, a disclosed immune modulator can be administered orally about one hour before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed therapeutic agent. In an aspect, a disclosed immune modulator can be administered orally about one hour or a few days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered subcutaneously about 15 minutes before or a few7 days before a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof. In an aspect, a disclosed immune modulator can be administered concurrently with a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof.
[0622] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise administering one or more proteasome inhibitors (e.g., bortezomib, carfilzomib, marizomib, ixazomib, and oprozomib). In an aspect, a proteasome inhibitor can be an agent that acts on plasma cells (e.g., daratumumab). In an aspect, an agent that acts on a plasma cell can be melphalan hydrochloride, melphalan, pamidronate disodium, carmustine, carfilzomib. carmustine, cyclophosphamide, daratumumab, doxorubicin
hydrochloride liposome, doxorubicin hydrochloride liposome, elotuzumab, melphalan hydrochloride, panobinostat, ixazomib citrate, carfilzomib, lenalidomide, melphalan, melphalan hydrochloride, plerixafor, ixazomib citrate, pamidronate disodium, panobinostat, plerixafor, pomalidomide, pomalidomide, lenalidomide, selinexor, thalidomide, thalidomide, bortezomib, selinexor, zoledronic acid, or zoledronic acid.
[0623] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise administering one or more proteasome inhibitors or agents that act on plasma cells prior to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells concurrently with administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors or one or more agents that act on plasma cells subsequent to administering a disclosed isolated nucleic acid molecule, a disclosed vector, or a disclosed pharmaceutical formulation. In an aspect, a disclosed method can further comprise administering one or more proteasome inhibitors more than 1 time. In an aspect, a disclosed method can comprise administering one or more proteasome inhibitors repeatedly over time.
[0624] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise administering one or more immunosuppressive agents. In an aspect, an immunosuppressive agent can be, but is not limited to, azathioprine, methotrexate, sirolimus, anti -thymocyte globulin (ATG), cyclosporine (CSP), mycophenolate mofetil (MMF), steroids, or a combination thereof. In an aspect, a disclosed method can comprise administering one or more immunosuppressive agents more than 1 time. In an aspect, a disclosed method can comprise administering one or more one or more immunosuppressive agents repeatedly over time. In an aspect, a disclosed method can comprise administering a compound that targets or alters antigen presentation or humoral or cell mediated or innate immune responses.
[0625] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise administering a compound that exerts a therapeutic effect against B cells and/or a compound that targets or alters antigen presentation or humoral or cell mediated immune response. In an aspect, a disclosed compound can be rituximab, methotrexate, intravenous gamma globulin, anti CD4 antibody, anti CD2, an anti-FcRN antibody, a BTK inhibitor, an anti -I GF 1R antibody, a CD 19 antibody (e.g., inebilizumab), an anti-IL6 antibody (e.g., tocilizumab), an antibody to CD40, an IL2 mutein, or a combination thereof. Also disclosed herein are Treg infusions that can be administered as a way to help with immune tolerance (e.g., antigen specific Treg cells to AAV).
[0626] In an aspect, a disclosed method can further comprise administering lipid nanoparticles (LNPs). In an aspect, LNPs can be organ-targeted. In an aspect, LNPs can be liver-targeted or testes-targeted. For example, in an aspect, mRNA therapy with LNP encapsulation for systemic delivery to a subject has the potential to restore the functionality and/or structural integrity of a missing, deficient, and/or mutant protein or enzyme.
[0627] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise plasmapheresis and immunosuppression. In an aspect, a disclosed method can comprise using immunosuppression to decrease the T cell, B cell, and /or plasma cell population, decrease the innate immune response, inflammatory response, and antibody levels in general.
[0628] In an aspect, a disclosed method can comprise repeating a disclosed administering step such as, for example, repeating the administering of a disclosed enzy me, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed immune modulator, a disclosed proteasome inhibitor, a disclosed immunosuppressive agent, a disclosed compound that exerts a therapeutic effect against B cells and/or a disclosed compound that targets or alters antigen presentation or humoral or cell mediated immune response.
[0629] In an aspect, a disclosed method can comprise modifying one or more of the disclosed steps. For example, modifying one or more of steps of a disclosed method can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method. For example, in an aspect, a method can be altered by changing the amount of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof administered to a subject, or by' changing the frequency of administration of one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof to a subject, or by changing the duration of time one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof are administered to a subject.
[0630] In an aspect, a disclosed method can be altered by changing the amount of one or more disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject, or by changing the frequency of
administration of one or more of the disclosed therapeutic agents, disclosed immune modulators, disclosed proteasome inhibitors, disclosed immunosuppressive agents, disclosed compounds that exert therapeutic effect against B cells and/or disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response administered to a subject.
[0631] In as aspect, a disclosed method can comprise concurrent administration of one or more of the following: one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, one or more disclosed therapeutic agents, one or more disclosed immune modulators, one or more disclosed proteasome inhibitors, one or more disclosed immunosuppressive agents, one or more disclosed compounds that exert therapeutic effect against B cells, one or more disclosed compounds that targets or alters antigen presentation or humoral or cell mediated immune response, or any combination thereof.
[0632] In an aspect, a disclosed immune modulator can be administered prior to or after the administration of a disclosed therapeutic agent.
[0633] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise generating one or more disclosed enzymes or disclosed recombinant enzy mes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof. [0634] For example, in an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise generating a disclosed viral or non-viral vector.
[0635] In an aspect, generating a disclosed viral vector can comprise generating an AAV vector or a recombinant AAV (such as those disclosed herein).
[0636] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise gene editing one or more relevant genes (such as, for example, a missing, deficient, and/or mutant protein or enzyme), wherein editing includes but is not limited to single gene knockout, loss of function screening of multiple genes at one, gene knockin, or a combination thereof.
[0637] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise administering an oligonucleotide therapeutic agent. A disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA. non-coding RNA (ncRNA), an antisense molecule, miRNA, a morpholino, a peptide-nucleic acid (PNA), or an analog or conjugate thereof. In an aspect, a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise a CRISPR-
based endonuclease. In an aspect, a disclosed endonuclease can be Cas9. In an aspect, a disclosed Cas9 can be from Staphylococcus aureus or Streptococcus pyogenes.
[0638] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise generating and/or validating one or more disclosed enzymes or disclosed recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0639] In an aspect of a disclosed method, a disclosed enzyme, a disclosed recombinant enzy me, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof can be delivered and/or administered prior to, concurrent, or after the delivery and/or administration of enzyme replacement therapy, protein replacement, gene therapy, a recombinant product, or any combination thereof.
[0640] In an aspect, a disclosed method of improving and/or enhancing transgene efficacy and/or expression can further comprise reducing and/or minimizing vector-mediated immunotoxicity' and/or transgene immunogenicity (e g., the ability to induce specific immunity). In an aspect, vector-mediated immunotoxicity' and/or transgene immunogenicity' can decrease and/or reduce the efficacy of the recombinant product encoded by the transgene. In an aspect, vector-mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability and/or likelihood of re-dosing a subject with one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof. In an aspect, vector- mediated immunotoxicity and/or transgene immunogenicity can decrease and/or reduce the ability’ and/or likelihood of re-dosing a subject with gene therapy, enzyme replacement therapy, protein replacement, or any combination thereof.
[0641] In an aspect of a disclosed method of improving and/or enhancing transgene efficacy and/or expression, IgM can be cleaved in the heavy chain at the interdomain region between constant domains Cp2 and Cp3. In an aspect, IgM can be cleaved between position 350 and position 365 of SEQ ID NO: 105. In an aspect, SEQ ID NO: 105 can represent the linear sequence of an IgM (for example, the substrate). In an aspect, IgM can be cleaved between positions 355 through 360 of IgM. In an aspect, IgM can be cleaved at SEQ ID NO: 110. In an aspect, IgM can be cleaved at the sequence comprising 355D, 356T, 357A, 3581, 359R, and 360V. In an aspect, IgM can be cleaved at position 355 through position 360 of the IgM of SEQ ID NO: 105. In an aspect, IgG can be cleaved below the hinge region, thereby yielding F(ab’)2 and Fc fragments. In an aspect, IgG can be cleaved to separate the Cp2 and Cp3 domains from the Cpl domain. In an aspect, IgG can be cleaved at SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID
NO: 114, or any combination thereof. In an aspect, IgG can be cleaved at SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof. In an aspect, IgG can be cleaved at positions 109 through 124 of the IgG of SEQ ID NO: 106, positions 106 through 120 of the IgG of SEQ ID NO: 107. positions 156 through 171 of the IgG of SEQ ID NO: 108, positions 106 through 121 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, IgG can be cleaved at positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 1 12 through 118 of the IgG of SEQ ID NO: 107, positions 163 through 169 of the IgG of SEQ ID NO: 108, positions 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, IgG can be cleaved SEQ ID NO: 115. SEQ ID NO: 116. SEQ ID NO: 117, SEQ ID NO: 118, or any combination thereof.
[0642] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed enzymes having IgG specific protease activity.
[0643] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzy mes comprising the sequence of any one of SEQ ID NO:01 - SEQ ID NO:46 and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159.
[0644] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 119. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzymes having IgM specific protease activity' and one or more disclosed recombinant enzymes comprising the sequence of any one SEQ ID NO: 119 - SEQ ID NO: 159. [0645] Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzy mes comprising the sequence of SEQ ID NO: 11 or SEQ ID NO: 12 and one or more disclosed recombinant enzymes comprising the sequence of SEQ
ID NO: 1 19. Disclosed herein is a method of improving and/or enhancing transgene efficacy and/or expression the method comprising contacting one or more IgM molecules and/or IgG molecules with one or more disclosed recombinant enzy mes comprising the sequence of SEQ ID NO: 14 or SEQ ID NO: 15 and one or more disclosed recombinant enzymes comprising the sequence of SEQ ID NO: 119.
[0646] In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 119. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity7 to the sequence of SEQ ID NO: 1 19. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a recombinant enzyme comprising a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of SEQ ID NO: 120 or SEQ ID NO: 121. In an aspect, a disclosed method can further comprise contacting one or more IgM molecules and IgG molecules with a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90% identity to the sequence of any one of SEQ ID NO: 122 - SEQ ID NO: 159.
[0647] In an aspect, a disclosed method can further comprise administering one or more times one or more disclosed enzymes or recombinant enzymes, one or more of the disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0648] In an aspect, a disclosed method can further comprise measuring and/or determining a subject’s pre-treatment level of circulating IgG and/or IgM and/or a subject’s pre-treatment level of surface bound IgM. In an aspect, a disclosed method can further comprise measuring and/or determining one or more times a subject’s level of circulating IgG and/or IgM and/or a subject’s level of surface bound IgM (e.g., before, during, and after a disclosed administering step).
I. Kits
[0649] Disclosed herein is a kit comprising a disclosed enzy me, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or any combination thereof. Disclosed herein is a kit comprising one or more
disclosed enzymes, one or more disclosed recombinant enzymes, one or more disclosed isolated nucleic acid molecules, one or more disclosed vectors, one or more disclosed pharmaceutical formulations, or any combination thereof.
[0650] In an aspect, a disclosed kit can comprise one or more enzymes comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO:46. In an aspect, a disclosed kit can comprise one or more enzy mes encoded by the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO:92. In an aspect, a disclosed kit can comprise one or more enzy mes encoded by the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161. In an aspect, a disclosed kit can comprise one or more nucleic acid sequences comprising the sequence set forth in any one of SEQ ID NO:47 - SEQ ID NO: 92 and one or more nucleic acid sequences comprising the sequence set forth in SEQ ID NO: 160 or SEQ ID NO: 161. In In an aspect, a disclosed kit can comprise one or more recombinant enzy mes comprising the sequence set forth in any one of SEQ ID NO: 119 - SEQ ID NO: 159. In an aspect, a disclosed kit can comprise one or more recombinant enzymes having IgG specific protease activity’. In an aspect, a disclosed kit can comprise one or more recombinant enzymes comprising the sequence set forth in any one of SEQ ID NO:01 - SEQ ID NO:46 and one or more recombinant enzy mes comprising the sequence set forth in any one of SEQ ID NO: 119 - SEQ ID NO: 159.
[0651] In an aspect, a disclosed kit can comprise one or more plasmids (e.g., SEQ ID NO: 93).
[0652] In an aspect, a kit can comprise a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed RNA therapeutic, or a combination thereof, and one or more agents. ■'Agents" and ‘“Therapeutic Agents’" are known to the art and are described supra.
[0653] In an aspect, the one or more agents can treat, prevent, inhibit, and/or ameliorate one or more comorbidities in a subject. In an aspect, one or more active agents can treat, inhibit, prevent, and/or ameliorate cellular and/or metabolic complications related to a missing, deficient, and/or mutant protein, enzyme, or gene.
[0654] In an aspect, a disclosed kit can comprise at least two components constituting the kit. Together, the components constitute a functional unit for a given purpose (such as, for example, treating a subject diagnosed with or suspected of having a disease or disorder). Individual member components may be physically packaged together or separately. For example, a kit comprising an instruction for using the kit may or may not physically include the instruction with other individual member components. Instead, the instruction can be supplied as a separate member component, either in a paper form or an electronic form which may be supplied on computer readable memory’ device or downloaded from an internet website, or as recorded presentation. In an aspect, a kit for use in a disclosed method can comprise one or more containers holding a
disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed RNA therapeutic, or a combination thereof, and a label or package insert with instructions for use. In an aspect, suitable containers include, for example, bottles, vials, syringes, blister pack, etc. The containers can be formed from a variety of materials such as glass or plastic. The container can hold a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, or a combination thereof, and can have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The label or package insert can indicate that a disclosed enzyme, a disclosed recombinant enzyme, a disclosed isolated nucleic acid molecule, a disclosed vector, a disclosed pharmaceutical formulation, a disclosed RNA therapeutic, or a combination thereof can be used for treating, preventing, inhibiting, and/or ameliorating a disease or disorder or complications and/or symptoms associated with a disease or disorder. A kit can comprise additional components necessary for administration such as, for example, other buffers, diluents, filters, needles, and syringes.
[0655] In an aspect, a disclosed kit can be used to cleave IgM and/or IgG, to cleave surface bound IgM on B cells, to reduce circulating levels of IgG and/or IgM, can inhibiting complement activation, can reduce and/or minimize vector mediated immunotoxicity and/or transgene immunogenicity, can improve and/or enhance transgene efficacy and/or expression. In an aspect, a disclosed kit can be used to effect these disclosed uses in a subject, such as, for example, a human subject.
J. Miscellaneous
[0656] Disclosed herein is a recombinant enzyme having human and non-human primate IgM specific protease activity and human and non-human primate IgG specific protease activity. In an aspect, a disclosed recombinant enzyme can comprise a sequence having at least 50% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18. In an aspect, a disclosed recombinant enzyme can comprise a sequence having at least 50% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21. (IceMG2) In an aspect, a disclosed recombinant enzyme can cleave human IgM at the heavy chain at the interdomain region between constant domains Cp2 and Cp3. [0657] In an aspect, the IgM specific protease activity can occur between position 350 and position 365 of the IgM of SEQ ID NOTOS. In an aspect, a disclosed recombinant enzyme can cleave human or non-human primate IgG below the hinge region, thereby separating the Cp2 and Cp3 domains from the Cpl domain. In an aspect, the IgG specific protease activity can occur between positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107, positions 163 through 169 of the IgG of SEQ ID NO: 108, positions
113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof. In an aspect, the IgM specific protease activity occurs at the sequence of SEQ ID NO: 110 of the IgM molecule, and wherein the IgG specific protease activity occurs at the sequence of SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, or any combination thereof of ahuman IgG molecule. [0658] Disclosed herein is an isolated nucleic acid molecule comprising a codon-optimized nucleic acid sequence encoding a disclosed recombinant enzyme. In an aspect, a disclosed isolated nucleic acid molecule can comprise the sequence set forth in SEQ ID NO:63 or SEQ ID NO:64. In an aspect, a disclosed isolated nucleic acid molecule can comprise the sequence set forth in SEQ ID NO:66 or SEQ ID NO:67. Disclosed herein is a recombinant enzyme having human and non-human primate IgM specific protease activity. In an aspect, a disclosed recombinant enzyme can comprise a sequence having at least 50% identity to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12. In an aspect, a disclosed recombinant enzy me can comprise a sequence having at least 50% identity to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15. In an aspect, a disclosed recombinant enzyme can cleave the heavy chain at the interdomain region between constant domains Cp2 and Cp3 of human or non-human primate IgM. In an aspect, the IgM specific protease activity can occur between position 350 and position 365 of the IgM of SEQ ID NO: 105. In an aspect, the IgM specific protease activity can occur at the sequence of SEQ ID NO: 110 of an IgM molecule.
[0659] Disclosed herein is an isolated nucleic acid molecule comprising a codon-optimized nucleic acid sequence encoding a disclosed recombinant enzyme. In an aspect, a disclosed isolated nucleic acid molecule can comprise the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58. In an aspect, a disclosed isolated nucleic acid molecule can comprise the sequence set forth in SEQ ID NO:60 or SEQ ID NO:61.
[0660] Disclosed herein is a pharmaceutical formulation comprising a disclosed recombinant enzyme.
[0661] Disclosed herein is a method of reducing the level of circulating IgM or the levels of circulating IgM and IgG in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a disclosed recombinant enzyme, wherein following the administering step, the level of circulating IgM or the levels of circulating IgM and IgG is reduced when compared to a pre-administering step level. In an aspect, the reduction of the level of circulating IgM or the levels of circulating IgM and IgG can be transient. In an aspect, the transient reduction of the level of circulating IgM or the levels of circulating IgM and IgG can persist about 6 hours, about 12 hours, about 18 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, or more than 2 weeks. In an aspect, transient reduction of circulating level of IgM or the
levels of circulating IgM and IgG can comprise at least an 80% reduction when compared to the pre-administering step level. In an aspect, a disclosed subject has received, is receiving, or will receive a recombinant product. In an aspect, a disclosed subject has received, is receiving, or will receive enzyme replacement therapy or protein replacement therapy. In an aspect, a disclosed subject has received, is receiving, or will receive one or more transplanted organs. In an aspect, following the administering step, the severity of a rejection event of the one or more transplanted organs can be reduced and/or minimized. In an aspect, a disclosed subject can have an autoimmune disease or disorder. In an aspect, a disclosed subject has received, is receiving, or will receive gene therapy.
[0662] Disclosed herein is a method of inhibiting the activation of the classical complement pathway in a subject, the method comprising: administering to the subject in need thereof a therapeutically effective amount of a disclosed recombinant enzyme, wherein following the administering step, the formation of the Cl and/or C3 complex is diminished and/or prevented.
[0663] Disclosed herein is a method of reducing and/or minimizing an immune response, the method comprising: administering to the subject in need thereof a therapeutically effective amount of a disclosed recombinant enzyme, wherein following the administering step, the level of circulating IgM or the level of circulating IgM and IgG targeting a recombinant product is reduced when compared to a pre-administering step level.
[0664] Disclosed herein is a method of reducing and/or minimizing an immune response, the method comprising: administering to the subject in need thereof (i) a therapeutically effective amount of a disclosed recombinant enzyme having IgM specific protease activity or IgM and IgG specific protease activity’ and (ii) a therapeutically effective amount of a recombinant enzyme having the sequence set forth in any of SEQ ID NO: 119 - SEQ ID NO: 159, wherein following the administering step, the levels of circulating IgM and IgG targeting a recombinant product is reduced when compared to a pre-administering step level.
[0665] In an aspect, a disclosed method can further comprise re-dosing the subject with the recombinant product. In an aspect, a disclosed recombinant product can comprise a vector or portion thereof. In an aspect, a disclosed recombinant product can comprise an encoded transgene product. In an aspect, a disclosed recombinant product can comprise a therapeutic protein or a therapeutic enzyme. In an aspect, a disclosed method can further comprise reducing and/or minimizing immunogenicity to the recombinant product. In an aspect, a disclosed method can further comprise improving and/or enhancing transgene efficacy and/or expression in a subject. In an aspect, transgene efficacy and/or expression in the subject can be improved and/or enhanced by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100% when compared to a pre-administering step level.
[0666] Table 3 - Table of Sequences
VIII. EXAMPLES
[0667] Bacteria have evolved specific enz mes such as the IgG cleaving enzyme. IdeS from S. Pyogenes, to evade opsonization and immune recognition (Von Pawel-Rammingen U. et al. (2002) EMBO J. 21: 1607; Hulting G, et al. (2009) FEMS Microbiol Lett. 298:44-50; Lannergard
J, et al. (2006) FEMS Microbiol Lett. 262:230-235). These secreted enzymes belong to the papain-like cysteine protease superfamily and selectively cleave IgG at the Fc hinge region (Wenig K, et al. (2004) Proc Natl Acad Sci USA. 101 : 17371-17376).. However, no human IgM degrading enzymes have been reported to date. The work described below characterizes such enzymes.
Materials and Methods
1. IceM Structural Modeling and IceM-IgM Complex Analyses
[0668] Structural models for IceM and IceMG were generated using AlphaFold2-ptm (Jumper J, et al. (2021) Nature. 596(7873):583-589). Molecular graphics and analyses were performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases (Pettersen EF, et al. (2021) Protein Sci. 30(l):70-82). Structural models of IceM-IgM and IceMG-IgM/IgG complexes were generated using AlphaFol d2-multimer v2 using the existing structure of IdeS (PBD 8A47) as a template (Wenig
K, et al. (2004) Proc Natl Acad Sci USA. 101: 17371-17376). Contact residues analyses were performed using the select contacts command in ChimeraX with atomic distance < 5 Ang. For image rendering of complexes, superposition of AlphaFold2 prediction to PDB 2RCJ was performed using the matchmaker command in ChimeraX (Perkins SJ, et al. (1991) J Mol Biol. 221(4):1345-1366).
2. Plasmid Constructs and Recombinant Protein Expression
[0669] For expression of recombinant His-tagged Idessuis, IceM, or IceMG, coding sequences were synthesized by Twist Bioscience and cloned into the pET-21a expression vector. E. coli strain BL21 star was transformed with recombinant IceM-pET-21a or IceMG-pET-21a. A single colony was inoculated into Terrific Broth (TB) medium containing ampicillin and incubated in 37 °C at 200 rpm. When the OD600 reached ~4, the bacterial culture was induced with 1 mM isopropyl-P-d-thiogalactoside at 37 °C for 4 hr. Cells were harvested by centrifugation and lysed with lysis buffer (50 mM Tris-HCl, 150 mMNaCl, 1% TritonX-100, cocktail, pH 8.0). The target protein was obtained by 2-step purification. Proteins were purified from cell lysate supernatant using Ni-NTA resin followed by Superdex 200 column purification. Recombinant protein was stored in 50 mM Tris-HCl, 150 mM NaCl, and 10% glycerol, pH 8.0 and sterilized by 0.22 pm filter before being stored in aliquots. Endotoxin was removed from recombinant protein using High-Capacity Endotoxin Removal Spin Columns following the manufacturer’s instructions (Thermo Fisher Scientific, 88274). The concentration was determined by Bradford protein assay with BSA as standard. The protein purity and molecular weight of IceM (41.6 kDa) and IceMG (70.4k Da) were determined by standard SDS-PAGE followed by Coomassie staining with 2 pg BSA used as a standard.
3. Tissue Culture
[0670] Human peripheral blood mononuclear cells (ATCC, PCS-800-011) or Daudi cells (ATCC, CCL-213) were maintained at 37 °C and 5% CO2 in RPMI 1640 medium (Gibco, 11875119) supplemented with 10% fetal bovine serum (MilliporeSigma. F0926) according to vendor instructions.
4. SDS-PAGE and Western Blot Analysis
[0671] Samples were incubated at 95 °C for 5 min in LDS loading buffer supplemented with 2.5% P-Mercaptoethanol, separated by SDS-PAGE, and either stained using coomassie blue (Themo Fisher Scientific, 24590) or transferred to PVDF membrane. Membranes were blocked with 5% milk powder in Tris buffered saline with 0.1 % TWEEN 20 (TBST) and incubated for 1 hr at room temperature with horseradish peroxi dase-conjugated primary antibodies for human IgM (1:5000; Proteintech, HRP-66484), porcine IgM (1:5000; Novus, NBP2-42699H), mouse IgM (1: 10,000; Invitrogen. 62-6820) IgG (1: 10.000; Invitrogen, 31423), IgA (1: 1000; Invitrogen. A18781) IgE (1 : 1000; Invitrogen, A18793), IgD (1 :5000; Proteintech, 16489-1-AP), or 6xHistidine (1 : 10,000; Proteintech, HRP-66005). Membranes were then washed 3x with TBST and incubated for 3 min with enhanced chemiluminescence substrate (Thermo Fisher Scientific, 34049). Coomassie- stained gels and immunoblots were visualized on a Bio-Rad ChemiDoc imaging system, and where applicable, quantitated using Bio-Rad Image Lab Version 6.1.0.
5. In Vitro Cleavage Assays
[0672] IgM cleavage was assessed by treating 10 jag of purified human IgM (MilliporeSigma 18260) with 10 pg mL’1 IceM, IceMG, or PBS and incubated at 37 °C for 1 hr. Enzy matic reactions were halted by adding LDS loading buffer, separated by SDS-PAGE, and stained with Coomassie blue as described above. For serum samples, 25 pL of sera were treated with IceM at the concentration indicated for 1 hr at 37 °C. Sera samples were diluted 1 :10 or 1 :50 for IgM or IgG immunoblots, respectively. Western blots were completed as described above and probed using anti-IgM, anti-IgG, anti-IgA, anti-IgE, or anti-IgD antibodies. Human sera were purchased from BioIVT; pig, dog and mouse serum samples were obtained from in-house lab stocks. Nonhuman primate sera were gifts from Alice Tarantal (UCD, Davis, California, USA).
6. Microscopy and Immunofluorescence
[0673] Daudi cells incubated with PBS, recombinant IceM at the concentration indicated for 1 hr at 37 °C. Cells were washed 3x with ice cold PBS and then cytocentrifuged onto Lab-Tek II Chamber Slides (Thermo Fisher Scientific 154453) coated with Poly-L-lysine. Cells were washed with PBS supplemented with 1 mM CaCh and 1 mM MgCb and then fixed using 10% formalin for 30 min. Cells were blocked with 5% normal goal serum in PBS with for 30 min and then incubated with F(ab)-specific anti-human IgM antibody conjugated to FITC for 1 hr at room temperature. Following three washes with PBS and slides were mounted with Prolong Gold Antifade Reagent with DAPI (Invitrogen P36930). Immunofluorescence was visualized using 10X or 20X Olympus objectives on a Zeiss 880 Airyscan Fast Inverted Confocal microscope.
7. Flow Cytometry Analysis
[0674] For surface bound IgM cleavage analysis, 3e5 PBMCs or 5e4 Daudi cells were incubated with PBS, recombinant IceM, or recombinant IceMG at the concentration indicated for 1 hr at 37 °C. Cells were washed 3x with ice cold PBS and then incubated with F(ab)-specific anti-human IgM antibody conjugated to FITC (LSBio. LS-C536848), anti-CD19 conjugated to APC (Abeam, AB 18224), and Zombie Violet (BioLegend, 77477) to assess cell viability per manufacturer recommendations in PBS supplemented with 3% BSA on ice for 1 hr. Cells were then washed 3x with ice cold PBS and analyzed using a BD Biosciences Fortessa X-20 flow cytometer. Flow data were gated on live cells and then CD19+ (APC+) to analyze the IgM+ (FITC+) cohort. Experiments were performed in triplicate. Data were analyzed using FlowJo v. 10.8.1 (BD Biosciences) and graphs w ere generated using GraphPad Prism version 9.5.
8. Complement Assays
[0675] Complement activation assays were adapted from Khandelwal et al., 2018 (Blood. 132:2431-2440). To assess the effect of IceM on complement activation, 25 .L of complement preserved human sera (BioIVT, HUMANSRM-01017110) w ere incubated with PBS or 20 pg mL"
1 of recombinant IceM, or recombinant IceMG for 1 hr at 37 °C. Samples were then treated with PBS, 5el0 vector genomes AAV9, 25 pg mL-1:0.25 U mL'1 Platelet Factor 4 (PF4):Heparin, or 10 mM EDTA + Platelet Factor 4 (PF4): Heparin for 1 hr at 37 °C. Complement activation was evaluated by assessing complement protein C3a levels by commercial ELISA kit (Thermo Fisher Scientific, BMS2089) and absorbance was read using a Victor X3 microplate reader (PerkinElmer) per manufacturer specifications.
9. In Vivo Mouse and Non-Human Primate Studies
[0676] All animal care and procedures were conducted in accordance with National Institutes of Health (NIH) guidelines and approved by the Duke University Institutional Animal Care and Use Committee (Duke IACUC# Al 86-22-10 and Al 13-21-05). For mouse studies, 12-wk-old female C57BL/6J mice were purchased from Jackson Laboratories and injected intraperitoneally with pooled 200 pL of pooled human sera (MilliporeSigma, H4522). After 24 hr, 200 pL of PBS or IceM was administered intravenously by tail vein injection at the dose indicated. Blood samples were taken by submental bleeds at 24 hr post-IceM injection, allowed to coagulate for 30 min, and serum was separated by centrifugation. Mouse sera was diluted 1 : 10 in LDS loading buffer with 2.5% [3-Mercaptoethanol, incubated at 95 °C for 5 min prior to SDS-PAGE, and western blots for anti-IgM were performed as described above. 5 mice (numbered 1-5) were tested per experimental condition. Human sera positive control was included with the PBS samples. For nonhuman primate studies, two male rhesus macaques (macaca mulatta) obtained from Alphagenesis, Inc (Y emassee, SC, USA), animal IDs N303 (6.7kg) and M741 (8.2 kg), were selected for the study. All animals received two doses of IceM at 0.5 mg kg-1 (one month apart) to evaluate the effects of the IgM endopeptidase post-infusion. To assess enzyme activity, blood was collected on the following days: 0, 1, 4, 7, 14, 21, 28 post-IceM treatment. Animals were re-dosed on day 28 and blood was collected on the following days: 29, 32, 35, 42, and 49. NHP sera was diluted 1 : 10 in LDS loading buffer with 2.5% P-Mercaptoethanol, incubated at 95 °C for 5 min prior to SDS- PAGE, and western blots for anti-IgM, anti-IgG, and anti-6xHistidine were performed as described above. Western blots were quantitated using Bio-Rad Image Lab Version 6.1.0. Schematics w ere created with BioRender.com.
10. Statistical Analyses
[0677] Error bars denote mean ± standard deviation. All experiments were completed in at least biological triplicate. Statistical significance w as determined using unpaired, two-tailed Student’s /-test (FIG. 2B and FIG. 2F) or two-way ANOVA with Sidak’s correction for multiple comparisons (FIG. 2D). Analyses were performed with GraphPad Prism version 9.5 with P values less than 0.05 being significant.
Example 1 Characterization of Candidate Human IgM Proteases
[0678] Candidate human IgM proteases were selected and evaluated. The core protease domain was identified and engineered to exclude elaborations such as cell wall binding and excretion motifs to enhance recombinant protein production and then expressed by an IPTG inducible promoter in E. coll (FIG. 1A). Of the candidates tested, two from Lachnoanaerobaciiltim saburreum (Protein 2; NCBI txid: 467210) and Lachnoanaerobaculum umeaense (Protein 6; NCBI txid: 617123) were identified as human IgM cleaving proteases (herein IceM and IceM2) that produced bands consistent with separation of Cp3 and Cp4 domains from the remainder of IgM heavy chain (FIG. IB - FIG. IE). IceM and IceM2 have 76% sequence identity excluding consideration of insertions (246/322 residues) and 75% identity when considering insertions (246/328 residues), within the portion synthesized for testing.
[0679] To further characterize enzymatic activity, recombinant IceM expression in E. coli and purification by Nickel column affinity resin was confirmed via SDS-PAGE (FIG. IE). Treatment of purified human IgM with IceM generated two cleavage products at 41 kDa and 32 kDa indicating hydrolysis of the IgM heavy chain at the interdomain region between constant domains Cp.2 and Cp3 consistent with predictive structural modeling (FIG. ID, FIG. IF). IceM efficiently and specifically cleaved IgM with an ECso of ~0.16 nM, but did not cleave isotypes IgG, IgA, IgE or IgD (FIG. 1G, FIG. 1H) Further, IceM cleaves human and non-human primate IgM in vitro, but not IgM from other species such as dog, pig, or mouse (FIG. II). This high level of specificity is due to specific residues Asp 355, Thr 356, Ala 357, He 358, Arg 359, and Vai 360 (amino acid numbering based on IgM Sequence in Accession No. QBK47415.1) that surround the cleavage site and are unique to human and nonhuman primate IgM (FIG. 1 J).
[0680] Recently the structure of IdeS. another highly specific IgG cleaving papain-like protease superfamily member, was determined in complex with human IgG and demonstrated that human IgG binds to a major pocket adjacent to the enzyme active site (Sudol A S L, et al. (2022) Nature Commun. 13: 1-11) . Next, the high specificity of IceM for IgM was examined. Utilizing AlphaFold2, the structure of this human IgM cleaving enzymes in complex with two human IgM heavy chains was predicted, and then the best ranked structure was used for the interpretation. In the determined structures, the the human IgM heavy chains were bind within the same pocket as determined for the IdeS/IgG Complex (FIG. 2A - FIG. 2C). As a result, the specificity of these enzymes for human IgM w as determined to be due to differences in amino acid composition of the major binding pocket adjacent to the cleavage site for specific Igs. Further, absolute placement of this Ig domain likely contributes a major factor in the specific cleavage product observed within the Ig hinge. Similar amino acid positions were responsible for human IgM binding in the outer
active site clefts of both IgM proteases (FIG. 2B, FIG. 2C). Of residues that directly interact within 5 Angstroms of the IgM, 76% identity was observed among residues in common between both IceM and IceM2 (51/67 residues); among all contact residues 70% identity between both was observed, where inserted residues were counted as mismatched (65/93 residues) (Table 1). In Table 1. the list of amino acid residues in the outer active site clefts of IceM and IceM2 that directly interact within 5 Angstroms of the corresponding human IgM residue (as represented in SEQ ID NO: 105 // QBK47415.1). Homologous positions from IceM and IceM2 are indicated in bold. These numbers were lower than for the proteins overall, likely because enzyme core domains generally are more conserved than enzyme surface.
Example 2 Construction of Recombinant Fusion Protein
[0682] Next, various linkers varying in length and flexibility were designed to engineer a recombinant fusion protein comprising IceM and IdeZ proteolytic domains (FIG. 3A, top). Plasmids for three different fusion protein linkers (rigid linker, flexible linker 1 , and flexible linker 2) were each constructed and expressed using E. coli. After incubation, bacteria were collected,
lysed, and pre- and post-induction samples were analyzed by western blot for anti-His. Significantly greater protein expression for the rigid linker was observed when compared to the flexible linkers indicated by the bands at approximately 70 kDa (FIG. 3A, bottom). Enzy mesubstrate docking analyses indicated the rigid fusion protein, hereinafter termed IceMG, maintained the ability to tightly bind human IgM and IgG within their respective catalytic pocket (FIG. 3B, FIG. 3C) Recombinant IceMG expression in E.Coli and purification by Nickel column affinity resin was confirmed via SDS-PAGE (FIG. 4A). Treatment of purified human IgM with IceMG generated two cleavage products at 41 kDa and 32 kDa consistent with hydrolysis of the IgM heavy chain at the interdomain region between constant domains Cp2 and Cp.3 and with predictive structural modeling of previous IceM cleavage analysis (FIG. 4B). Treatment of purified human IgG with IceMG generated cleavage products at 25 kDa slightly above the light chain representing hydrolysis at a single site below the hinge region, yielding F(ab')2 and Fc fragments, consistent with prior reports of IdeZ (Hulting G, et al. (2009) FEMS Microbiol Lett. 298:44-50). . Treatment of IceMG efficiently and specifically cleaved IgM and IgG with an EC so of -0.07 and 4.7 nM, respectively, but did not cleave isotypes IgA, IgE, IgD (FIG. 4E -FIG. 4G). Further, IceMG cleaved human and non-human primate IgM and IgG in vitro, but not IgM or IgG from other species such as dog, pig, or mouse (FIG. 4H). For IceMG, the specificity for IgG is listed in FIG. 4J and detailed in Table 2 with amino acid numbering based on sequence accession number noted for each subtype. In Table 2, amino acid sequences for IgG subtypes with the cleavage site indicated by backslash. Specific IgG residues immediately within the cleavage are listed. Amino acid numbering is relative to the IgG sequence accession number noted.
[0683] Table 2 - Critical Amino Acid Residues Within the Cleavage Site for IgGl, IgG2, IgG3, and IgG4.
Example 3 Removal of Surface Bound IgM From B Cells
[0684] The ability for IceM and IceMG to remove surface-bound IgM (BCR) from B cells was examined. IceM completely removed IgM from the surface of the B lymphoblast cell line Daudi within 1 hr (FIG. 5A FIG. 5D). Further, IceM robustly cleaved IgM BCR from the surface of CD19+ sub-population in human peripheral blood mononuclear cells (PBMCs) at an EC 50 ~70 nM (FIG. 5E - FIG. 5G). Importantly, surface IgM baseline levels were restored ~12 hr posttreatment - indicating that BCR inactivation is transient and reversible (FIG 5E, FIG. 5F) with no adverse impact on cell viability after 24 hr (97.9% and 97.8% for PBS-treated PBMCs and IceMtreated PBMCs, respectively). Given that IgM is a potent activator of the classical complement pathway triggered by binding Clq, the ability of IceM and IceMG to block complement activation was examined. Using Adeno-associated virus 9 or an in vitro platelet factor-based assay (Khandelwal S, et al. (2018) Blood. 132:2431-2440) mimicking heparin induced thrombocytopenia (FIG. 6A), the pre-treatment of human sera with IceM, and to greater extent, IceMG was determined to block the IgM-triggered complement cascade at levels comparable to EDTA (FIG. 6B, FIG. 6C). These unique properties of IceM and IceMG corroborate the notion that selective IgM cleavage can potentially be leveraged to inactivate B cell sensing and signaling leading to antigen-induced Ig class switching as well as blocking complement activation.
Example 4 Clearance of IgG in Human Sera
[0685] To evaluate Ig clearance in vivo, mice were passively immunized w ith pooled human sera and w ere then administered IceM or IceMG intravenously at doses of 0.25 mg kg’1, 1.0 mg kg’1, or 2.5 mg kg’1 (FIG. 7A). Rapid (within 24 hr) and near-complete clearance of circulating human IgM and IgG at all doses was observed when compared to control animals for IceM (FIG. 7B - FIG. 7E) and IceMG (FIG. 7F - FIG. 71). Based on these results, whether pretreatment wdth IceM or IceMG could rescue AAV transduction in mice passively immunized with human sera and IVIg containing neutralizing antibodies in vivo was evaluated (FIG. 7 J). In animals treated with only sera/IVIg, approximately a log decrease in AAV8-mediated(FIG. 7K, FIG. 7L) and AAV9- (FIG. 7M, FIG. 7N) mediated luciferase expression in heart and liver tissue was observed. In animals treated wdth IceM, a partial rescue in transduction from neutralizing antibodies was observed. In animals treated with IceMG, a complete rescue of luciferase expression in heart and liver tissue was observed (FIG. 7K - FIG. 7N). Interestingly, serotypespecific differences in the level of rescue for animals treated with IceM were observed. These differences could likely be due to timing at which the serum donor was exposed to AAV or seroty pe-specific differences in prevalence or neutralizing ability7 of IgM. The ability7 of IceM and
IceMG to effectively degrade anti-AAV neutralizing antibodies in vivo may present a new paradigm for expanding the patient cohort, reducing vector mediated immunotoxicity and potential redosing of AAV based gene therapies.
Example 5 Evaluation of Protease Activity in Non-Human Primates
[0686] These enzy mes were next evaluated in nonhuman primates in vivo. First, two rhesus macaques (animal ID: N303 & M741) were dosed with recombinant IceM at a dose of 0.5 mg kg" 1 and the kinetics of IgM clearance in serum were monitored at different time intervals (FIG. 8A). Pharmacokinetics of IceM in monkey sera revealed rapid clearance of the recombinant enzyme, with detectable levels at day 1 post-administration, but not subsequent time intervals (FIG. 8B, FIG. 8C). N303 and M741 exhibited 95.4 % and 91.4 % IgM clearance, respectively, at 24 hr post-administration with restoration of baseline levels within ~2 weeks post-treatment (FIG. 8D - FIG. 8F). In addition, repeat dosing of IceM at day 28 yielded similar results with no loss in IgM cleavage activity or any detectable change in pharmacokinetics (FIG. 8D - FIG. 8F).
Example 6 Characterization of Kinetics in Non-Human Primates
[0687] Next, ine macaques were dosed in two separate studies (animal ID: 49873, 49813, 49682, 36725, 37662, 35788, 38131, 38718, 38721) at 0.25 mg kg 1, 0.5 mg kg 1, 1.0 mg kg , or 2.5 mg kg"1 IceMG, and then monitored for kinetics of IgM and IgG clearance at the time intervals indicated (FIG 9A and FIG. 10A). Pharmacokinetics of IceMG in monkey sera revealed rapid, clearance of the recombinant enzyme, with detectable levels up to 24 hr post-administration, but not subsequent time intervals (FIG. 9B - FIG. 9D, top panel). Majority of recombinant IceM was cleared between 6 hr and 24 hr post-administration. Animals exhibited near complete clearance of circulating IgM in both studies with IgM levels returning close to or at baseline between 7-14 days post-treatment (FIG. 9B - FIG. 9G, middle panel; FIG. 10B FIG. 10G, top panel). IgG levels for most animals exhibited significant, yet not complete clearance FIG. 10A - FIG. 10F). Notably, complement activation elicited by AAV9 was blocked in vitro in sera from animals 49873, 49813, 49682 following pre-treatment with IceMG (FIG. 9E). These results corroborated the high degree of selectivity and robust enzymatic cleavage of primate IgM and IgG by these enzy mes in vivo.
Summary of Examples
[0688] The Examples describe highly specific endoproteases that can rapidly cleave human and NHP IgM or both IgM and IgG. The data demonstrate the ability to enzymatically remove IgM BCR in vitro and degrade circulating IgM in vivo in both mice and nonhuman primates. Notably, pretreatment with IceM and IceMG prevented complement activation in human and nonhuman primate sera which may have therapeutic implications. One example would be kidney transplant
recipients who are sensitized to human leukocyte antigens (HLAs) expressed in the transplanted organ have significantly increased rates of acute antibody mediated rejection (AMR) (Lefaucheur C, et al. (2010) J Am Soc Nephrol. 21 : 1398-1407; Bentall A, et al. (2013) Am J Transplant. 13: 76- 85). These donor-specific antibodies cause acute AMR largely through the activation of the complement cascade (Stegall M D, et al. (2012) Nat Rev Nephrol. 8:670-678). IgM is the predominant driver of complement activation and increased donor-specific IgM levels has been associated with organ rejection (Schmitz R, et al. (2021) Nat Commun. 12(1): 5456). Therefore, targeting donor-specific IgM antibodies using IceM in concert with current strategies may represent a viable option to further decrease AMR in sensitized transplant recipients.
[0689] Another example where targeting IgM would be appealing is AAV-mediated gene therapy. While it has been well known that preexisting and neutralizing antibodies prevent the broader application of therapeutic gene transfer, recent clinical trials have show n that antibody response and complement activation can lead to serious adverse events including death, particularly in high dose cohorts (Ertl HCJ, et al. (2022) Front Immunol. 13:985382; Shen W, et al. (2022) Front Immunol. 13: 1001263) . Further, it is well-documented that AAV administration triggers a swift and robust rise in IgM, that after class switching, can lead to immune memory' (Gross DA, et al. (2022) Front Immunol. 13:857276). Therefore, targeting neutralizing antibodies and the complement cascade with IceM and IceMG may decrease toxicity associated with complement activation and may enable AAV redosing by addressing memory immune response.
[0690] The degradation of IgM and IgG could also have profound implications in autoimmune disease as well. It is estimated that over 2.5% of the world’s population has an autoantibody driven autoimmune disease (Edna Au et al., Frontiers in Med. 2022). More specifically, elevated levels of IgM and IgG autoantibodies are associated with multiple autoimmune diseases including systemic lupus ery thematosus, rheumatoid arthritis and multiple sclerosis just to name a few'. Currently, there are no available therapeutics that directly address pathogenic IgM antibodies.
[0691] To this end, IceM and IceMG provide a powerful therapeutic solution with 3 key defining characteristics. First, IceM and IceMG cleared IgM and IgG from circulation in vivo. Second, IceM and IceMG were able to inactivate the antibody driven classical complement pathway by clearing IgM and IgG antibody complexes deposited on tissues such as the kidney. Lastly, IceM and IceMG effectively cleave the IgM BCR providing a potential solution to prevent the generation of class switched IgG autoantibodies.
[0692] Taken together, IceM and IceMG are promising candidates for modulating humoral immunity' in primates and therapeutic removal of IgM or both IgM and IgG in pathophysiological settings that may present in autoimmune disorders, organ transplantation, and AAV gene therapy.
Claims
1. A recombinant enzyme having human and non-human primate IgM specific protease activity and human and non-human primate IgG specific protease activity7.
2. The recombinant enzyme of Claim 1 comprising a sequence having at least 50% identity to the sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18.
3. The recombinant enzyme of Claim 1 comprising a sequence having at least 50% identity to the sequence set forth in SEQ ID NO:20 or SEQ ID NO:21.
4. The recombinant enzyme of any one of Claims 1 - 3, wherein the recombinant enzy me cleaves human IgM at the heavy chain at the interdomain region between constant domains Cp2 and Cp3.
5. The recombinant enzyme of any7 one of Claims 1 - 4, wherein the IgM specific protease activity7 occurs between position 350 and position 365 of the IgM of SEQ ID NO:105.
6. The recombinant enzyme of any one of Claims 1 - 5, wherein the recombinant enzyme cleaves human or non-human primate IgG below the hinge region, thereby separating the Cp2 and Cp3 domains from the Cpl domain.
7. The recombinant enzy me of any one of Claims 1 - 6, wherein the IgG specific protease activity7 occurs between positions 116 through 122 of the IgG of SEQ ID NO: 106, positions 112 through 118 of the IgG of SEQ ID NO: 107, positions 163 through 169 of the IgG of SEQ ID NO: 108, positions 113 through 119 of IgG of SEQ ID NO: 109, or any combination thereof.
8. The recombinant enzy me of any one of Claims 1 - 6, wherein the IgM specific protease activity7 occurs at the sequence of SEQ ID NO: 110 of the IgM molecule, and wherein the IgG specific protease activity occurs at the sequence of SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 1 13, SEQ ID NO: 1 14, or any combination thereof of a human IgG molecule.
9. An isolated nucleic acid molecule comprising a codon-optimized nucleic acid sequence encoding the recombinant enzy me of any one of Claims 1 -8.
10. The isolated nucleic acid molecule of Claim 9 comprising the sequence set forth in SEQ ID
NO:63 or SEQ ID NO:64.
11. The isolated nucleic acid molecule of Claim 9 comprising the sequence set forth in SEQ ID
NO: 66 or SEQ ID NO: 67.
12. A recombinant enzyme having human and non-human primate IgM specific protease activity.
13. The recombinant enzyme of Claim 12 comprising a sequence having at least 50% identity to the sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12.
recombinant enzyme of Claim 12 comprising a sequence having at least 50% identity to the sequence set forth in SEQ ID NO: 14 or SEQ ID NO: 15. recombinant enzyme of any one of Claims 12 - 14, wherein the recombinant enzy me cleaves the heavy chain at the interdomain region between constant domains Cp2 and CLI3 of human or non-human primate IgM. recombinant enzyme of any one of Claims 12 - 15, wherein the IgM specific protease activity7 occurs between position 350 and position 365 of the IgM of SEQ ID NO: 105. recombinant enzyme of any one of Claims 12 - 15, wherein the IgM specific protease activity occurs at the sequence of SEQ ID NO: 110 of an IgM molecule. isolated nucleic acid molecule comprising a codon-optimized nucleic acid sequence encoding the recombinant enzy me of any one of Claims 12 - 17. isolated nucleic acid molecule of Claim 18 comprising the sequence set forth in SEQ ID
NO:57 or SEQ ID NO:58. isolated nucleic acid molecule of Claim 18 comprising the sequence set forth in SEQ ID
NO:60 or SEQ ID NO:61. harmaceutical formulation, comprising: the recombinant enzyme of any one of Claims 1 -
8 or Claims 12 - 17. ethod of reducing the level of circulating IgM or the levels of circulating IgM and IgG in a subject, the method comprising: administering to the subject in need thereof a therapeutically effective amount of the recombinant enzyme of any one of Claims 1 - 8 or Claims 12 - 17, wherein following the administering step, the level of circulating IgM or the levels of circulating IgM and IgG is reduced when compared to a pre-administering step level. method of Claim 22, wherein the reduction of the level of circulating IgM or the levels of circulating IgM and IgG is transient. method of Claim 23. wherein the transient reduction of the level of circulating IgM or the levels of circulating IgM and IgG persists about 6 hours, about 12 hours, about 18 hours, about 24 hours, about 36 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, or more than 2 weeks. method of Claim 24, wherein the transient reduction of circulating level of IgM or the levels of circulating IgM and IgG comprises at least an 80% reduction when compared to the pre-administering step level. method of any one of Claims 22 - 25, wherein the subject has received, is receiving, or will receive a recombinant product.
method of any one of Claims 22 - 25, wherein the subject has received, is receiving, or will receive enzyme replacement therapy or protein replacement therapy. method of any one of Claims 22 - 25, wherein the subject has received, is receiving, or will receive one or more transplanted organs. method of Claim 28. wherein, following the administering step, the severity of a rejection event of the one or more transplanted organs is reduced and/or minimized. method of any one of Claims 22 - 25, wherein the subject has an autoimmune disease or disorder. method of any one of Claims 22 - 25, wherein the subject has received, is receiving, or will receive gene therapy. ethod of inhibiting the activation of the classical complement pathway in a subject, the method comprising: administering to the subject in need thereof a therapeutically effective amount of the recombinant enzymes of any one of Claims 1 - 8 or Claims 12 - 17, wherein following the administering step, the formation of the Cl and/or C3 complex is diminished and/or prevented. ethod of reducing and/or minimizing an immune response, the method comprising: administering to the subject in need thereof a therapeutically effective amount of the recombinant enzyme of any one of Claims 1 - 8 or Claims 12 - 17, wherein following the administering step, the level of circulating IgM or the level of circulating IgM and IgG targeting a recombinant product is reduced when compared to a pre-administering step level. ethod of reducing and/or minimizing an immune response, the method comprising: administering to the subject in need thereof (i) a therapeutically effective amount of the recombinant enzyme of any one of Claims 1 - 8 or Claims 12 - 17 and (ii) a therapeutically effective amount of a recombinant enzy me having the sequence set forth in any of SEQ ID NO: 119 - SEQ ID NO: 159, wherein following the administering step, the levels of circulating IgM and IgG targeting a recombinant product is reduced when compared to a pre-administering step level. method of Claim 33 or Claim 34, further comprising re-dosing the subject with the recombinant product. method of Claim 33 or Claim 34, wherein the recombinant product comprises a vector or portion thereof. method of Claim 33 or Claim 34, wherein the recombinant product comprises an encoded transgene product.
method of Claim 33 or Claim 34, wherein the recombinant product comprises a therapeutic protein or a therapeutic enzyme. method of any one of Claims 33 - 38, further comprising reducing and/or minimizing immunogenicity to the recombinant product. method of Claim 37, further comprising improving and/or enhancing transgene efficacy and/or expression in a subject. method of Claim 40, wherein transgene efficacy and/or expression in the subject is improved and/or enhanced by about 10%, 20%, 30%, 40%, 50%, 60%. 70%, 80%, 90%, 100%, or more than 100% when compared to a pre-administering step level.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263421996P | 2022-11-22 | 2022-11-22 | |
US63/421,996 | 2022-11-22 | ||
US202363492985P | 2023-03-29 | 2023-03-29 | |
US63/492,985 | 2023-03-29 | ||
US202363502920P | 2023-05-17 | 2023-05-17 | |
US63/502,920 | 2023-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024112492A1 true WO2024112492A1 (en) | 2024-05-30 |
Family
ID=91196570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/078407 WO2024112492A1 (en) | 2022-11-22 | 2023-11-01 | Compositions comprising antibody cleaving enzymes and method of using the same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024112492A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130236469A1 (en) * | 2010-05-26 | 2013-09-12 | Intervacc Ab | Vaccine against streptococcal infections based on recombinant proteins |
US20170209561A1 (en) * | 2014-05-30 | 2017-07-27 | Idt Biologika Gmbh | Vaccine composition against streptococcus suis infection |
US20180170974A1 (en) * | 2015-07-09 | 2018-06-21 | Intervacc Ab | Vaccine against s. suis infection |
WO2022020232A1 (en) * | 2020-07-20 | 2022-01-27 | Genentech, Inc. | Methods for middle down antibody characterization |
US20220133864A1 (en) * | 2020-11-04 | 2022-05-05 | Selecta Biosciences, Inc. | Methods and compositions for reducing immune responses against immunoglobulin proteases |
-
2023
- 2023-11-01 WO PCT/US2023/078407 patent/WO2024112492A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130236469A1 (en) * | 2010-05-26 | 2013-09-12 | Intervacc Ab | Vaccine against streptococcal infections based on recombinant proteins |
US20170209561A1 (en) * | 2014-05-30 | 2017-07-27 | Idt Biologika Gmbh | Vaccine composition against streptococcus suis infection |
US20180170974A1 (en) * | 2015-07-09 | 2018-06-21 | Intervacc Ab | Vaccine against s. suis infection |
WO2022020232A1 (en) * | 2020-07-20 | 2022-01-27 | Genentech, Inc. | Methods for middle down antibody characterization |
US20220133864A1 (en) * | 2020-11-04 | 2022-05-05 | Selecta Biosciences, Inc. | Methods and compositions for reducing immune responses against immunoglobulin proteases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2909733C (en) | Effective delivery of large genes by dual aav vectors | |
KR20200051011A (en) | Modified closed-terminated DNA (CEDNA) | |
US11660353B2 (en) | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems | |
EP3403675B1 (en) | Adeno-associated virus virion for use in treatment of epilepsy | |
EP3254702B1 (en) | Aav/xbp1s-ha virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities | |
US20230075314A1 (en) | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF | |
JP2023527556A (en) | Engineered coronavirus spike (S) proteins and methods of their use | |
US20210395781A1 (en) | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems | |
US20220324943A1 (en) | Multimeric protein domains for multifunctionality and enhanced secretion of therapeutic proteins | |
JP2021501137A (en) | Use of Syncitin for Targeted Drugs and Gene Delivery to Regenerated Muscle Tissue | |
US20220333136A1 (en) | Aav capsid variants targeting human glioblastoma cells | |
US11795476B2 (en) | AAV/UPR-plus virus, UPR-plus fusion protein, genetic treatment method and its use in the treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, among others | |
KR20220140537A (en) | Gene therapy to treat CDKL5 deficiency disorder | |
KR20220107243A (en) | APOE gene therapy | |
TW202332767A (en) | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease | |
EP3360580B1 (en) | Method for genetic treatment using the aav-xbp1s/gfp virus and use thereof in the prevention and treatment of amyotrophic lateral sclerosis | |
US20240131197A1 (en) | Compositions For and Methods of Improving Gene Therapy | |
WO2022121860A1 (en) | Methods and kits for inducing immunotolerance to gene delivering target vehicle | |
WO2024112492A1 (en) | Compositions comprising antibody cleaving enzymes and method of using the same | |
US20240124878A1 (en) | Compositions for and methods of engineering the transcriptome | |
JP2020533313A (en) | Methods and compositions for treating neuropathic pain | |
EP4297802A1 (en) | Compositions for and methods of editing the genome | |
WO2022232575A1 (en) | Compositions comprising adeno-associated virus chimera capsid proteins and methods of using the same | |
US20240139329A1 (en) | Targets for Receptor-Mediated Control of Therapeutic Biodistribution and Efficacy | |
RU2816963C2 (en) | Modified closed circular dna (ccdna) containing symmetric modified inverted end repeated sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23895235 Country of ref document: EP Kind code of ref document: A1 |